{"title": "PDF", "author": "PDF", "url": "https://www.espaciosanitario.com/uploads/s1/14/63/93/9/guia-de-farmaciencia-sobre-evidencia-de-tratamientos-en-dolores-menores.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n \n \nRelaci\u00f3n de autores por orden alfab\u00e9tico:\n \nAlonso Garre, Carlos\n \nBaquero Navarro, Ricardo\n \nCal Seijas, Roi\n \nEiras Espi\u00f1o, Abel\n \nHern\u00e1ndez Ramos, Jos\u00e9 Antonio\n \nJusto Hern\u00e1ndez, Alicia\n \nLafuente G\u00f3mez, Nuria\n \nMart\u00ednez, Gemma\n \nMu\u00f1oz Mu\u00f1oz, Nuria\n \nParis Fern\u00e1ndez de la Puente, Juan Luis\n \nRodr\u00edguez \u00c1lvarez, Ram\u00f3n\n \nSantamar\u00eda Ugarte, Ander\n \nSelvi Sabater, Pablo\n \n \nCoordinaci\u00f3n y revisi\u00f3n:\n \nRoi Cal Seijas\n \nEdici\u00f3n:\n \nJaime Borrego Jim\u00e9nez\n \n \n2\n \n \u00cdndice\n \n \n \nPR\u00d3LOGO\n5\n \nACN\u00c9\n7\n \nHERPES LABIAL\n11\n \nESTOMATITIS AFTOSA\n14\n \nFARINGOAMIGDALITIS\n16\n \nTOS AGUDA\n19\n \nCONGESTI\u00d3N NASAL\n22\n \nRINITIS AL\u00c9RGICA\n25\n \nCONJUNTIVITIS\n27\n \nBLEFARITIS\n29\n \nORZUELO\n30\n \nOJO SECO\n32\n \nDEGENERACI\u00d3N MACULAR ASOCIADA A LA EDAD\n36\n \nACIDEZ DE EST\u00d3MAGO\n38\n \nN\u00c1USEAS Y V\u00d3MITOS\n43\n \nDIARREA AGUDA\n45\n \nESTRE\u00d1IMIENTO\n48\n \nINSUFICIENCIA VENOSA: VARICES EXTERNAS Y HEMORROIDES\n51\n \nINSOMNIO\n54\n \nCEFALEA\n58\n \nBIBLIOGRAF\u00cdA\n62\n \n \n \n \n3\n \n  \n \n4\n \n PR\u00d3LOGO\n \nLa\nhistoria\nde\nla\nmedicina\nle\notorga\na\nJames\nLind\nel\nprivilegio\nde\nser\nel\nprimero\nen\nrealizar\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nun\nensayo\ncl\u00ednico\nall\u00e1\npor\nel\na\u00f1o\n1747\na\nbordo\nun\nbarco\nde\nla\nRoyal\nNavy.\nHasta\naquel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmomento,\npara\nun\nmarinero\nera\nm\u00e1s\nprobable\nfallecer\na\ncausa\ndel\nescorbuto\nque\nahogado\no\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nconflictos\narmados\ny,\ncomo\nes\nnatural,\nproliferaron\nentonces\ntoda\nsuerte\nde\nremedios\n \n \n \n \n \n \n \n \n \n \n \n \n \navalados\npor\nlas\nautoridades\nm\u00e9dicas\nde\nla\n\u00e9poca:\nsangr\u00edas,\nagua\nde\nmar,\nvinagre,\nmercurio\no\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\u00e1cido\nsulf\u00farico\ny\nclorh\u00eddrico,\nentre\notros.\nEstos\nextra\u00f1os\nremedios\nno\ns\u00f3lo\neran\nin\u00fatiles,\nsino\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nen\nmuchos\ncasos\nacababan\ncon\nla\nvida\nde\nlos\ndesdichados\nmarineros.\nGracias\na\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsencillo\nensayo\nen\nel\nque\nLind\ncompar\u00f3\nla\neficacia\nde\nvarios\nremedios\npopulares\ncontra\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nescorbuto,\npudo\ndemostrar\nque\nsimplemente\nel\nzumo\nde\nc\u00edtricos\nera\neficaz\npara\nprevenir\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratar\nla\nenfermedad.\nEsto\ncambi\u00f3\nla\nhistoria\nde\nla\nnavegaci\u00f3n\npara\nsiempre.\nSin\nembargo,\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nuso\nde\nensayos\ncl\u00ednicos\nno\nse\npopulariz\u00f3\nhasta\nmuchos\na\u00f1os\ndespu\u00e9s\ny\nla\nmedicina\nsigui\u00f3\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nbas\u00e1ndose\nen\ntradiciones\ny\nopiniones\nde\nciertos\nm\u00e9dicos\nconsiderados\ncomo\n\u00abeminencias\u00bb.\n \n \n \n \n \n \n \n \n \n \n \nSirva\ncomo\notro\nejemplo\nilustrativo\nel\nuso\ncontinuo\nde\nlas\nsangr\u00edas\no\nflebotom\u00edas,\nusadas\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicina\ndurante\nm\u00e1s\nde\n2000\na\u00f1os\n(hasta\nbien\nentrado\nel\nsiglo\nXIX)\ny\nque\nhan\nsido\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nresponsables de millones de muertes.\n \n \nAfortunadamente,\nla\nmedicina\nha\navanzado\nmucho\ndesde\nel\nsiglo\nXIX\ngracias\nal\navance\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncient\u00edfico\nen\notros\ncampos\ny\nal\nmejorado\ndise\u00f1o\nde\nlos\nensayos\ncl\u00ednicos,\ncon\nla\ninclusi\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nherramientas\ncomo\nel\nensayo\ndoble\nciego,\nla\naleatorizaci\u00f3n\nde\npacientes\no\nla\nestad\u00edstica.\nSin\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nembargo,\nla\neste\nprogreso\nha\nsido\nlento\ny\ngradual;\nde\nhecho,\nhasta\nla\nsegunda\nmitad\ndel\nsiglo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nXX\nno\nera\nobligatorio\ndemostrar\nemp\u00edricamente\nque\nlos\nf\u00e1rmacos\nempleados\neran\na\nla\nvez\n \n \n \n \n \n \n \n \n \n \n \n \n \n \neficaces\ny\nseguros.\nLa\ntragedia\nocurrida\ncon\nel\nf\u00e1rmaco\ntalidomida\n\u200b\nfue\nel\ndetonante\n\u200b\npara\n\u200b\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlas agencias reguladoras creasen normativas mucho m\u00e1s exigentes.\n \nEsta\ngu\u00eda,\nenfocada\ntanto\npara\nfarmac\u00e9uticos\ncomo\npara\notros\nprofesionales\nsanitarios,\n \n \n \n \n \n \n \n \n \n \n \ntiene\ncomo\nobjetivo\nofrecer\nalgo\nde\nluz,\nen\nbase\na\nlos\nestudios\npublicados,\npara\nintentar\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmejorar\nla\nfarmacoterapia\nde\nlos\npacientes\ny\nreducir\nel\nriesgo\nde\nefectos\nsecundarios\n \n \n \n \n \n \n \n \n \n \n \n \n \ninnecesarios.\nSu\npretensi\u00f3n\nes\nde\nservir\nde\norientaci\u00f3n\nen\nla\nindicaci\u00f3n\no\nprescripci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\ndestinados\na\ntratar\no\naliviar\npatolog\u00edas\nmenores.\nDescubriremos\na\nlo\nlargo\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nella\nque\nalgunos\nde\nlos\nmedicamentos\nm\u00e1s\nempleados\ny\nque\nmuchos\nconsideran\nefectivos,\n \n \n \n \n \n \n \n \n \n \n \n \n \nno\nsiempre\ncuentan\ncon\npruebas\nque\nrespalden\nsu\nuso,\no\nincluso\nque\nseg\u00fan\nlos\nensayos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncl\u00ednicos no tienen mayor efectividad que el placebo.\n \nEsta\ngu\u00eda\nha\nsido\nredactada\npor\nfarmac\u00e9uticos\npertenecientes\na\nFarmaCiencia,\nasociaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \nsin\n\u00e1nimo\nde\nlucro,\nrevisando\nla\nbibliograf\u00eda\nexistente\nen\ncada\nuno\nde\nlos\n19\ntemas.\nNo\nexiste\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconflicto\nalguno\nde\nintereses\nya\nque\nno\nse\nha\nrecibido\naporte\necon\u00f3mico\nni\npresiones\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nning\u00fan tipo por parte de la industria farmac\u00e9utica.\n \n \nRoi Cal Seijas\n \n \n \n5\n \n  \n \n6\n \n ACN\u00c9\n \nParis Fern\u00e1ndez, JL.\n \nEl\nacn\u00e9\nvulgar\nes\nuna\npatolog\u00eda\nde\nla\npiel\nque\nhabitualmente\nse\nasocia\na\nun\ncomponente\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npsicol\u00f3gico.\n\u200b\nConstituye\nel\ndiagn\u00f3stico\nm\u00e1s\ncom\u00fan\npor\nparte\nde\ndermat\u00f3logos,\ny\nes\n \n \n \n \n \n \n \n \n \n \n \n \ndiagnosticado\nhabitualmente\ntambi\u00e9n\npor\nm\u00e9dicos\nde\notras\nespecialidades\n(1).\nEl\nacn\u00e9\nes\n \n \n \n \n \n \n \n \n \n \n \n \nmuy\ncom\u00fan\ny\nafecta\naproximadamente\na\nun\n85%\nde\nlos\nadolescentes;\nsu\nprevalencia\ntras\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nadolescencia\ndisminuye\ncon\nla\nedad.\nPor\notra\nparte,\nel\nacn\u00e9\nadolescente\nes\nm\u00e1s\nhabitual\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla\npoblaci\u00f3n\nmasculina,\ntendencia\nque\nse\nrevierte\ncon\nla\nedad,\nsiendo\nel\nacn\u00e9\ndel\nadulto\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncom\u00fan\nen\nlas\nmujeres.\nLa\nforma\nadulta\nde\nla\nenfermedad\ntiende\na\nser\nconsecuencia\nde\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nforma\ncr\u00f3nica\nmantenida\ndesde\nla\nadolescencia\nm\u00e1s\nque\na\nuna\nnueva\naparici\u00f3n\nen\nla\nedad\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nadulta (1).\n \nLa\npatog\u00e9nesis\ndel\nacn\u00e9\nes\nel\nresultado\nde\nm\u00faltiples\nprocesos\nque\ntienen\nlugar\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nunidad\npiloseb\u00e1cea\n(formada\npor\nel\ntallo\ndel\npelo,\nel\nfol\u00edculo\npiloso,\nla\ngl\u00e1ndula\nseb\u00e1cea\ny\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nm\u00fasculo\nerector\ndel\npelo),\ny\nque\ndan\nlugar\na\nsobrecrecimiento\nbacteriano\ne\ninflamaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \nlocal.\nLa\ndistribuci\u00f3n\ncorporal\ndel\nacn\u00e9\nest\u00e1\nasociada\ncon\nla\ndensidad\nde\ngl\u00e1ndulas\nseb\u00e1ceas,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nes\nmayor\nen\ncara,\ntorso,\ncuello\ny\nespalda\n(1).\nEl\ncomienzo\nde\nla\npatolog\u00eda\nsuele\ncoincidir\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncon\nla\npubertad\ndebido\na\nuna\nalteraci\u00f3n\nen\nla\nfunci\u00f3n\nde\nlas\ngl\u00e1ndulas\nseb\u00e1ceas\ncomo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconsecuencia de cambios hormonales (2).\n \nInicialmente\nse\nproduce\nla\nestimulaci\u00f3n\nde\nla\nunidad\npiloseb\u00e1cea\npor\nparte\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nandr\u00f3genos\ncirculantes,\nlo\nque\nprovoca\nuna\nsobreproducci\u00f3n\nde\ngrasa\nque\nda\nlugar\na\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nhiperqueratosis.\nAl\nbloquearse\nel\nfol\u00edculo\npiloso\nse\ngeneran\ncomedones,\nque\npueden\nser\n \n \n \n \n \n \n \n \n \n \n \n \nabiertos\n(puntos\nnegros)\no\ncerrados\n(puntos\nblancos)\n(2).\nCabe\ndestacar\nque\nla\ncoloraci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\ncomedones\nabiertos\nse\ndebe\na\nla\noxidaci\u00f3n\nde\nla\nmelanina\ny\nno\na\nla\nacumulaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsuciedad\n(1).\nEste\nbloqueo\npiloso\njunto\ncon\nla\ncolonizaci\u00f3n\nbacteriana\npor\nparte\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nPropionibacterium\nacnes\ninduce\nla\nliberaci\u00f3n\nde\nmediadores\ninflamatorios\nen\nla\npiel,\nlo\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \nproduce\nla\nacumulaci\u00f3n\nde\nneutr\u00f3filos\ny\nlinfocitos,\ndando\nlugar\na\nla\naparici\u00f3n\nde\np\u00e1pulas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(irregularidades\nrojas\ny\npeque\u00f1as),\np\u00fastulas\n(p\u00e1pulas\ncon\npus\nen\nla\npunta),\nn\u00f3dulos\n(bultos\n \n \n \n \n \n \n \n \n \n \n \n \n \ns\u00f3lidos\ny\ndolorosos\nbajo\nla\nsuperficie\ncut\u00e1nea)\ny\nquistes\n(bultos\ndolorosos\ncon\npus,\ntambi\u00e9n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nbajo la superficie de la piel) (2).\n \nCon\nobjeto\nde\nproporcionar\nrecomendaciones\nterap\u00e9uticas\nen\nfunci\u00f3n\ndel\ngrado\nde\n \n \n \n \n \n \n \n \n \n \n \nafectaci\u00f3n,\nun\ncomit\u00e9\nde\nla\nUni\u00f3n\nEuropea\n(UE)\npropone\nla\nsiguiente\nclasificaci\u00f3n\ncl\u00ednica\ncon\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nniveles crecientes de afectaci\u00f3n (3):\n \n\u25cf\nAcn\u00e9 comedoniano.\n \n\u25cf\nAcn\u00e9 p\u00e1pulo-pustuloso leve-moderado.\n \n\u25cf\nAcn\u00e9 p\u00e1pulo-pustuloso grave, acn\u00e9 nodular moderado.\n \n\u25cf\nAcn\u00e9 nodular grave, acn\u00e9 qu\u00edstico.\n \n \n \n7\n \n Factores relacionados con la patolog\u00eda\n \nEl\nacn\u00e9\nes\nuna\npatolog\u00eda\nmultifactorial,\nde\nmanera\nque\nciertos\nfactores\npueden\nmodificar\n \n \n \n \n \n \n \n \n \n \n \n \n \nel\nriesgo\nde\nsufrirla.\nEl\nconsumo\nde\ntabaco\nse\nasocia\ncon\nun\nmayor\nriesgo\nde\nacn\u00e9,\ncuya\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ngravedad\ntambi\u00e9n\nparece\nseguir\nun\npatr\u00f3n\ndosis-dependiente\ncon\nel\nn\u00famero\nde\ncigarrillos\n \n \n \n \n \n \n \n \n \n \n \n \nconsumidos\nal\nd\u00eda\n(1).\nCon\nrespecto\nal\nimpacto\nde\nla\ndieta,\nsi\nbien\nhoy\nparece\nclaro\nque\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconsumo\nde\nchocolate\nno\npresenta\nasociaci\u00f3n\ncon\nla\nprevalencia\nde\nla\nenfermedad,\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \nconsumo\nde\nproductos\nl\u00e1cteos\npodr\u00eda\npresentar\nuna\ncierta\ncorrelaci\u00f3n\n(aunque\nla\ncalidad\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nevidencia\nde\ndicha\nrelaci\u00f3n\nes\nlimitada)\n(1).\nEl\nuso\nde\nproductos\ncosm\u00e9ticos\ncon\ngran\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncantidad\nde\naceites\nen\nsu\ncomposici\u00f3n\npuede\nconducir\ntambi\u00e9n\na\nun\nempeoramiento\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlesiones\n(1).\nPor\notra\nparte,\nla\nevidencia\nsobre\nla\nefectividad\ndel\nuso\nde\nproductos\nde\nlavado\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npara\nel\nacn\u00e9\nes\nmuy\nlimitada\ny\ngeneralmente\nde\nbaja\ncalidad,\npor\nlo\nque\nes\ndif\u00edcil\nestablecer\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomendaciones\nen\neste\naspecto\n(4).\nLa\nmayor\nprevalencia\nen\npacientes\ncuyos\npadres\n \n \n \n \n \n \n \n \n \n \n \n \nsufrieron\nacn\u00e9\nen\nla\nadolescencia\nindica\ntambi\u00e9n\nla\nposible\nexistencia\nde\nfactores\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \npredisposici\u00f3n gen\u00e9ticos (1, 2).\n \nEs\nimportante\ndesterrar\nciertos\nmitos\nestablecidos\nen\nla\nsociedad\ncon\nrespecto\nal\nacn\u00e9.\nEl\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconsenso\nactual\ndescarta\nsu\nasociaci\u00f3n\ncon\nel\nconsumo\nde\nchocolate\ne\nindica\nla\nprobable\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nineficacia\nde\nla\nexposici\u00f3n\na\nla\nluz\nsolar\nen\nlos\ns\u00edntomas,\nas\u00ed\ncomo\nla\nfalta\nde\npruebas\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrelacionen\nsu\naparici\u00f3n\ncon\nalguna\ndeficiencia\nen\nlos\nh\u00e1bitos\nhigi\u00e9nicos\n(5).\nSeguir\n \n \n \n \n \n \n \n \n \n \n \n \nasumiendo\nla\nveracidad\nde\nestos\nmitos\nacarrea\nasimismo\nuna\nserie\nde\nriesgos,\ntales\ncomo\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nexposici\u00f3n\ndirecta\na\nluz\nsolar\nsin\nprotecci\u00f3n\n(con\nel\nriesgo\nasociado\nde\npatolog\u00edas\ncomo\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmelanoma,\nadem\u00e1s\ndel\nefecto\nfotosensibilizador\nde\nalgunos\nf\u00e1rmacos\nempleados\npara\nel\n \n \n \n \n \n \n \n \n \n \n \ntratamiento\ndel\nacn\u00e9,\ncomo\nlas\ntetraciclinas\no\nla\nisotretino\u00edna),\nla\npr\u00e1ctica\nde\nlavados\nfaciales\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nobsesivos\n(que\npueden\ndesencadenar\nuna\nrespuesta\ninflamatoria\nque\nllegue\na\nagravar\nlos\n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas)\no\nla\nculpabilizaci\u00f3n\ndel\npaciente\n(con\nimportantes\nconsecuencias\nen\nel\n \n \n \n \n \n \n \n \n \n \n \ncomponente psicol\u00f3gico asociado) (5).\n \n \nTratamiento\n \nDada\nsu\ngran\nrelevancia\nsocial\ny\nsu\nelevada\nprevalencia,\nse\nhan\nrealizado\nuna\ngran\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmultitud\nde\nestudios\ny\nrevisiones\npara\nevaluar\ndistintas\nintervenciones\nterap\u00e9uticas\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \nacn\u00e9\n(23\u201329).\nComo\nfuente\nde\nespecial\nrelevancia\npodemos\ndestacar\nla\n\u200b\nGu\u00eda\neuropea\nbasada\n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nla\nevidencia\npara\nel\ntratamiento\ndel\nacn\u00e9,\nrealizada\npor\nun\ncomit\u00e9\nde\nexpertos\nen\nel\na\u00f1o\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2012,\ny\nactualizada\nen\n2016\n(3,\n30,\n31).\nLas\nrecomendaciones\nincluidas\nen\ndicha\ngu\u00eda\nfueron\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndivididas\nen\nvarios\nniveles\nde\nrecomendaci\u00f3n:\nalta,\nmedia\ny\nbaja\n(seg\u00fan\nel\nnivel\nde\nevidencia\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ny\nconsenso),\nrecomendaci\u00f3n\nnegativa\n(cuando\nel\ntratamiento\nen\ncuesti\u00f3n\nest\u00e1\nactivamente\n \n \n \n \n \n \n \n \n \n \n \nno\nrecomendado)\ny\nrecomendaci\u00f3n\nabierta\n(cuando\nel\nnivel\nde\nevidencia\nactual\nimpide\n \n \n \n \n \n \n \n \n \n \n \n \nposicionarse\nclaramente\na\nfavor\no\nen\ncontra\nde\nuna\nintervenci\u00f3n\nconcreta)\n(30).\nLa\ncalidad\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\ncada\nestudio\nempleado\npara\nel\ndesarrollo\nde\nesta\ngu\u00eda\nfue\ntenida\nen\ncuenta\npara\ninformar\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nel\nnivel\nde\nrecomendaci\u00f3n,\nsiendo\nconsiderados\ncomo\nde\n\u00f3ptima\ncalidad\nlos\ndatos\n \n \n \n \n \n \n \n \n \n \n \n \nprovenientes de ensayos cl\u00ednicos aleatorizado y controlados con doble ciego.\n \n \n8\n \n \u25cf\nRetinoides\nt\u00f3picos.\nLos\nretinoides\nson\nderivados\nde\nvitamina\nA\nque\npueden\nprevenir\n \n \n \n \n \n \n \n \n \n \n \n \nla\nformaci\u00f3n\nde\ncomedones\nmediante\nla\nnormalizaci\u00f3n\nde\nla\ndescamaci\u00f3n\ndel\nepitelio\n \n \n \n \n \n \n \n \n \n \n \n \nfolicular.\nLos\nprincipales\nretinoides\nde\nuso\nt\u00f3pico\nson\ntretino\u00edna,\nadapaleno\ny\n \n \n \n \n \n \n \n \n \n \n \ntazaroteno\n(6).\nLa\ninformaci\u00f3n\nproveniente\nde\nensayos\ncl\u00ednicos\naleatorizados\ny\n \n \n \n \n \n \n \n \n \n \ncontrolados\ncon\ndoble\nciego\nindica\nque\nlos\nretinoides\nt\u00f3picos\nson\ncapaces\nde\nreducir\n \n \n \n \n \n \n \n \n \n \n \n \n \nel\nn\u00famero\nde\ncomedones\ny\nlesiones\ninflamatorias,\nsiendo\nel\nadapaleno\nel\nf\u00e1rmaco\n \n \n \n \n \n \n \n \n \n \n \n \nmejor\ntolerado\n(6,7).\nSon\nla\nopci\u00f3n\nmejor\nvalorada\nla\nutilizaci\u00f3n\nde\nretinoides\nt\u00f3picos\n \n \n \n \n \n \n \n \n \n \n \n \n \npara\nel\ntratamiento\ndel\nacn\u00e9\ncomedoniano,\ncon\nun\nnivel\nde\nrecomendaci\u00f3n\nmedio\n \n \n \n \n \n \n \n \n \n \n \n \n(30).\n \n\u25cf\nAntimicrobianos\nt\u00f3picos:\nEntre\nlos\nantimicrobianos\nt\u00f3picos\nque\nse\nhan\nempleado\n \n \n \n \n \n \n \n \n \n \npara\nel\ntratamiento\ndel\nacn\u00e9\nse\nencuentran\nclindamicina,\neritromicina,\ntetraciclina\ny\n \n \n \n \n \n \n \n \n \n \n \nper\u00f3xido\nde\nbenzo\u00edlo\n(6,\n8).\nEl\n\u00e1cido\nazelaico\ntambi\u00e9n\npodr\u00eda\nconsiderarse\nen\neste\n \n \n \n \n \n \n \n \n \n \n \n \n \ngrupo,\ndado\nque\nha\ndemostrado\ncapacidad\nantibacteriana\nfrente\na\n\u200b\nP.\nacnes\n \n \n \n \n \n \n \n \n \n \n \nintrafolicular\n(6).\nEl\nconsenso\nactual\ndesaconseja\nel\ntratamiento\ncon\nantibi\u00f3ticos\n \n \n \n \n \n \n \n \n \n \nt\u00f3picos\nde\nforma\naislada,\ndebido\na\nla\naparici\u00f3n\npotencial\nde\nresistencias\n(9,\n10).\nSin\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nembargo,\nno\nse\nhan\nobservado\nresistencias\nal\nper\u00f3xido\nde\nbenzo\u00edlo\nni\nal\n\u00e1cido\n \n \n \n \n \n \n \n \n \n \n \n \n \nazelaico\n(6).\nEn\nel\ntratamiento\nde\nacn\u00e9\np\u00e1pulo-pustuloso\nleve-moderado\nse\nconsidera\n \n \n \n \n \n \n \n \n \n \n \ncomo\nrecomendaci\u00f3n\nde\nnivel\nalto\nel\nempleo\nde\ntratamientos\nt\u00f3picos\ncombinados\nde\n \n \n \n \n \n \n \n \n \n \n \n \nper\u00f3xido de benzo\u00edlo con adapaleno o clindamicina (30).\n \n\u25cf\nAntibi\u00f3ticos\norales.\nLos\nantibi\u00f3ticos\norales\nse\nhan\nempleado\ncon\nel\nobjetivo\nde\n \n \n \n \n \n \n \n \n \n \n \n \nreducir\nla\ncarga\nde\n\u200b\nP.\nacnes\nen\nlos\nfol\u00edculos.\nLos\nprincipales\nantibi\u00f3ticos\norales\n \n \n \n \n \n \n \n \n \n \n \n \n \nempleados\npara\nel\ntratamiento\ndel\nacn\u00e9\nson\ntetraciclina,\ndoxiciclina,\nminociclina,\n \n \n \n \n \n \n \n \n \n \nclindamicina\ny\neritromicina\n(6,\n11).\nLos\nantibi\u00f3ticos\norales\nhan\nmostrado\nser\nuna\n \n \n \n \n \n \n \n \n \n \n \n \nopci\u00f3n\neficaz\npara\nel\ntratamiento\ndel\nacn\u00e9,\naunque\nno\nexiste\ninformaci\u00f3n\nde\ncalidad\n \n \n \n \n \n \n \n \n \n \n \n \n \nque\npermita\nla\nselecci\u00f3n\nde\nun\nantibi\u00f3tico\no\npauta\nconcreta\ncomo\nla\nm\u00e1s\neficaz,\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nforma\nque\nla\nelecci\u00f3n\nsuele\nbasarse\nen\nel\nperfil\nde\nseguridad\ndel\nf\u00e1rmaco\n(6).\nDe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnuevo,\nla\naparici\u00f3n\nde\nresistencia\nantibi\u00f3tica\nobliga\na\nacudir\na\ncombinaciones\nde\n \n \n \n \n \n \n \n \n \n \n \n \ndistintos agentes terap\u00e9uticos (12).\n \n\u25cf\nTerapia\nhormonal.\nEl\ntratamiento\nhormonal\ndel\nacn\u00e9\nse\nplantea\nexclusivamente\nen\n \n \n \n \n \n \n \n \n \n \n \nmujeres.\nEl\nobjetivo\nes\nlograr\nuna\ndisminuci\u00f3n\nen\nla\nactividad\nandrog\u00e9nica,\ndebido\na\n \n \n \n \n \n \n \n \n \n \n \n \n \nsu\nasociaci\u00f3n\ncon\nla\npatolog\u00eda.\nEntre\nlos\nf\u00e1rmacos\nempleados\nest\u00e1n\nlos\n \n \n \n \n \n \n \n \n \n \n \nanticonceptivos\norales\ny\nf\u00e1rmacos\nque\nbloquean\nreceptores\nde\nandr\u00f3genos,\ncomo\nla\n \n \n \n \n \n \n \n \n \n \n \nflutamida\no\nla\nespironolactona\n(6).\nVarios\nensayos\ncl\u00ednicos\naleatorizados\ny\n \n \n \n \n \n \n \n \n \n \ncontrolados\nhan\nmostrado\nla\neficacia\ndel\nuso\nde\nanticonceptivos\norales\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\ndel\nacn\u00e9\n(13).\nUna\nrevisi\u00f3n\nsistem\u00e1tica\nCochrane\npublicada\nen\n2012\n \n \n \n \n \n \n \n \n \n \n \nconcluy\u00f3\nla\neficacia\nde\nla\nterapia\nanticonceptiva\ncombinada\nen\nla\nreducci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \nlesiones cut\u00e1neas inflamatorias y no inflamatorias asociadas al acn\u00e9 (14).\n \n\u25cf\nIsotretino\u00edna\noral.\nLa\nisotretino\u00edna\nes\nun\nmetabolito\nde\nla\nvitamina\nA\nque\ninhibe\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nproliferaci\u00f3n\nde\nlas\ngl\u00e1ndulas\nseb\u00e1ceas,\nreduce\nsu\ntama\u00f1o,\nsuprime\nla\nproducci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \nsebo y normaliza la descamaci\u00f3n del epitelio folicular (6).\n \n \n \nLa\nisotretino\u00edna\nes\nun\nconocido\nterat\u00f3geno,\nde\nforma\nque\nson\nnecesarias\nmedidas\n \n \n \n \n \n \n \n \n \n \n \n \n9\n \n anticonceptivas\nen\nlas\npacientes\nhasta\n6\nsemanas\ntras\nla\nsuspensi\u00f3n\ndel\ntratamiento,\n \n \n \n \n \n \n \n \n \n \n \n \ny\nla\ndispensaci\u00f3n\ndel\ntratamiento\ndebe\nir\nacompa\u00f1ada\nde\ntest\nde\nembarazo\n(6).\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nisotretino\u00edna\nes\nconsiderada\nen\nla\npr\u00e1ctica\ncl\u00ednica\nactual\ncomo\nel\ntratamiento\nde\n \n \n \n \n \n \n \n \n \n \n \n \nprimera\nl\u00ednea\nen\nacn\u00e9\nnodular\nmoderado/grave\ny\nen\nacn\u00e9\nque\nno\nresponde\na\notras\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nterapias.\nUna\nrevisi\u00f3n\nsistem\u00e1tica\nCochrane\nde\n2018\nconcluy\u00f3\nque\nlas\npruebas\n \n \n \n \n \n \n \n \n \n \n \ndisponibles\nparecen\nno\ncontradecir\nesta\nrecomendaci\u00f3n\n(15).\nSin\nembargo,\nse\n \n \n \n \n \n \n \n \n \n \nconsider\u00f3\nque\nfaltaban\ndatos\nde\nelevada\ncalidad\nmetodol\u00f3gica\npara\nconcluir\nde\n \n \n \n \n \n \n \n \n \n \n \nforma\ndefinitiva\nen\ndos\naspectos\nconcretos:\nla\neficacia\nde\nisotretino\u00edna\noral\nen\n \n \n \n \n \n \n \n \n \n \n \n \nmonoterapia\nfrente\na\nla\ncombinaci\u00f3n\nde\nantibi\u00f3ticos\norales\ncon\ntratamientos\nt\u00f3picos,\n \n \n \n \n \n \n \n \n \n \n \ny\nla\nselecci\u00f3n\nde\nuna\npauta\nposol\u00f3gica\nconcreta\nde\nisotretino\u00edna\noral\n(15,\n16).\nLas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npruebas\ndisponibles\ntampoco\npermitieron\nconfirmar\nni\nrechazar\nde\nforma\n \n \n \n \n \n \n \n \n \nconcluyente\nlos\npotenciales\nefectos\nsecundarios\na\nnivel\npsicol\u00f3gico\nen\nel\nuso\nde\n \n \n \n \n \n \n \n \n \n \n \n \nisotretino\u00edna oral (15).\n \n\u25cf\nTerapias\nlum\u00ednicas.\nConsisten\nen\ndiferentes\nterapias\nbasadas\nen\nm\u00e9todos\n\u00f3pticos,\n \n \n \n \n \n \n \n \n \n \nbien\nempleando\nirradiaci\u00f3n\nl\u00e1ser\n(con\ndistintas\nfuentes\nlum\u00ednicas\na\ndiferentes\n \n \n \n \n \n \n \n \n \n \nlongitudes\nde\nonda),\nbien\nutilizando\nterapia\nfotodin\u00e1mica\n(fotoactivaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \nf\u00e1rmacos\ncomo\nel\n\u00e1cido\naminolevul\u00ednico)\n(6,\n17\u201320).\nEl\nmecanismo\nde\nacci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \nsupuesto\npara\neste\ntipo\nde\nterapias\nes\nel\ncalentamiento\nfotot\u00e9rmico\nde\nlas\ngl\u00e1ndulas\n \n \n \n \n \n \n \n \n \n \n \n \n \nseb\u00e1ceas\ny\nla\ninactivaci\u00f3n\nfotoqu\u00edmica\nde\n\u200b\nP.\nacnes\n(que\nproduce\ncoproporfirinas\ny\n \n \n \n \n \n \n \n \n \n \n \n \nprotoporfirinas)\n(6).\nAunque\nalgunos\ndatos\ndisponibles\nparecen\nindicar\nun\ncierto\n \n \n \n \n \n \n \n \n \n \npotencial\nterap\u00e9utico\nen\nestas\nestrategias\n(especialmente\nen\nel\ncaso\nde\nla\nterapia\n \n \n \n \n \n \n \n \n \n \n \n \nfotodin\u00e1mica),\nla\nfalta\nde\ndatos\nprocedentes\nde\nestudios\nde\nelevada\ncalidad\n \n \n \n \n \n \n \n \n \n \n \nmetodol\u00f3gica\nimpide\ndeterminar\nde\nforma\nconcluyente\nel\npotencial\nde\nlas\nmismas\n(6,\n \n \n \n \n \n \n \n \n \n \n \n \n21).\nActualmente\nno\nconstituyen\nla\nprimera\nl\u00ednea\nterap\u00e9utica\nen\nninguna\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \npresentaciones\ncl\u00ednicas\nde\nla\nenfermedad\n(6).\nExiste\nuna\nrecomendaci\u00f3n\nabierta,\nsin\n \n \n \n \n \n \n \n \n \n \n \nposibilidad\nde\nconcluir\na\nfavor\no\nen\ncontra\nde\nuso\npara\nning\u00fan\ntipo\nde\nacn\u00e9,\ndebido\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla baja calidad de las pruebas disponibles (30).\n \n \n\u25cf\nTerapias\ncomplementarias.\nUna\nrevisi\u00f3n\nsistem\u00e1tica\nCochrane\nde\n2015\nconcluy\u00f3\nque\n \n \n \n \n \n \n \n \n \n \nexisten\nalgunas\npruebas\nde\nbaja\ncalidad\nde\nensayos\nindividuales\nde\nque\nla\ndieta\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nbaja\ncarga\ngluc\u00e9mica,\nel\naceite\ndel\n\u00e1rbol\ndel\nt\u00e9\ny\nel\nveneno\nde\nabeja\npodr\u00edan\nreducir\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlas\nlesiones\ntotales\nde\nla\npiel\nen\nel\nacn\u00e9\nvulgar,\npero\nno\nencontr\u00f3\npruebas\npara\napoyar\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nel\nuso\nde\notras\nterapias\nalternativas\ncomo\nplantas\nmedicinales\no\nacupuntura\npara\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento de esta afecci\u00f3n (22).\n \n\u25cf\nTerapias\ncombinadas.\nEn\nla\npr\u00e1ctica\ncl\u00ednica\nes\nhabitual\nla\ncombinaciones\nde\ndistintas\n \n \n \n \n \n \n \n \n \n \n \n \nestrategias\nterap\u00e9uticas,\ntanto\nen\nterapias\nt\u00f3picas\ncombinadas\n(p.\nej.:\nadapaleno\ny\n \n \n \n \n \n \n \n \n \n \n \nper\u00f3xido\nde\nbenzo\u00edlo)\ncomo\nen\ncombinaci\u00f3n\nde\ntratamientos\nt\u00f3picos\ny\nsist\u00e9micos\n(p.\n \n \n \n \n \n \n \n \n \n \n \n \nej.:\ncombinaci\u00f3n\nde\nantibi\u00f3ticos\norales\ncon\nretinoides\nt\u00f3picos,\nper\u00f3xido\nde\nbenzo\u00edlo\no\n \n \n \n \n \n \n \n \n \n \n \n \n\u00e1cido azelaico) (3,6).\n \n \n \n10\n \n HERPES LABIAL\n \nHern\u00e1ndez Ramos, JA\n \nEl\nherpes\nlabial\nes\nuna\nforma\ncl\u00ednica\nde\nla\nenfermedad\nque\nsurge\ntras\nla\ninfecci\u00f3n\npor\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nvirus\ndel\nherpes\nsimple\ntipo\n1\n(VHS-1),\naunque\nel\ntipo\n2\ntambi\u00e9n\npuede\nprovocar\nlesiones\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \norales\nmuy\nsimilares.\nEl\nVHS-1\nes\nun\nmicroorganismo\nque\nse\ntransmite\nprincipalmente\na\n \n \n \n \n \n \n \n \n \n \n \n \n \ntrav\u00e9s\nde\nla\nsaliva,\ntanto\npor\ncontacto\ndirecto\n(besos)\ncomo\nindirecto\n(uso\ncompartido\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncubiertos,\ncepillos\nde\ndientes,\ncuchillas,\netc.).\nDe\nesta\nmanera,\ninfecta\ntanto\nc\u00e9lulas\n \n \n \n \n \n \n \n \n \n \n \n \nmucoepiteliales\ncon\nlas\nque\nentra\nen\ncontacto,\ncomo\nneuronas\nque\nlas\ninervan,\nen\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nganglios\ntrig\u00e9minos.\nEs\nah\u00ed\ndonde\nel\nvirus\npermanece\nen\nestado\nlatente\nde\nmanera\n \n \n \n \n \n \n \n \n \n \n \n \n \nindefinida,\ncon\ncapacidad\nde\nreactivarse\ny\nregresar\na\nlas\nc\u00e9lulas\nmucoepiteliales,\ndonde\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \nmultiplica\ny\nocasiona\nda\u00f1os\norofaciales.\nExisten\nnumerosas\ncausas\nque\npromueven\nla\n \n \n \n \n \n \n \n \n \n \n \nreactivaci\u00f3n\ndel\nVHS,\nentre\nlas\nque\ndestacan:\nfr\u00edo,\nestr\u00e9s,\nmenstruaci\u00f3n,\nfiebre,\nradiaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \nUVB y alimentos irritantes\n\u200b\n \n\u200b\no a los que el paciente tiene alergia (1, 2).\n \n \nFormas cl\u00ednicas\n \n \nEl\nVHS\nno\nsolo\nprovoca\nlesiones\nmucocut\u00e1neas\na\nnivel\nlabial\ny\nperilabial.\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \nprimoinfecci\u00f3n\nse\npresenta\nprincipalmente\ndurante\nla\ninfancia\nbajo\nla\nforma\nde\nun\ns\u00edndrome\n \n \n \n \n \n \n \n \n \n \n \n \n \nfebril\nacompa\u00f1ado\nde\ngingivoestomatitis\no\nfaringoamigdalitis,\naunque\nsi\nse\nda\nen\nreci\u00e9n\n \n \n \n \n \n \n \n \n \n \n \n \nnacidos\ne\ninmunocomprometidos\npueden\naparecer\ns\u00edndromes\noculares\no\ncerebrales\ngraves.\n \n \n \n \n \n \n \n \n \n \nA\nesta\nprimera\nfase\nsobreviene\nel\nestado\nde\nlatencia,\ndurante\nel\ncual\nse\nproducen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecurrencias\ncon\nla\nconsiguiente\naparici\u00f3n\nde\nda\u00f1o\na\nnivel\nmucocut\u00e1neo.\nPor\nsu\nincidencia\n \n \n \n \n \n \n \n \n \n \n \n \n \ndestaca\nel\nherpes\nlabial,\naunque\nlas\nlesiones\ntambi\u00e9n\npueden\naparecer\nen\notras\n \n \n \n \n \n \n \n \n \n \n \n \nlocalizaciones.\nEn\neste\ncaso,\nprimero\nsuele\naparecer\neritema,\nprurito\no\nparestesias\nen\nla\nzona\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nafectada\n(calenturas)\ny\nposteriormente\nse\ndesarrolla\nla\nves\u00edcula,\ncuyo\naspecto\nes\nel\nde\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nampolla\npeque\u00f1a\ny\ntrasl\u00facida\nformada\nsobre\nuna\nbase\neritematosa.\nR\u00e1pidamente\nevoluciona\n \n \n \n \n \n \n \n \n \n \n \na\np\u00fastula\ny\ntras\nliberar\nsu\ncontenido\nse\nforma\nuna\ncostra.\nEstas\nlesiones\nson\ndolorosas\ny\nsu\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncontenido es capaz de infectar a otras personas (1, 2, 3).\n \n \nEntre\notras\nlocalizaciones\ndonde\nel\nVHS\nes\ncapaz\nde\nproducir\nafecciones\nmucocut\u00e1neas\n \n \n \n \n \n \n \n \n \n \n \n \ndestacan\nel\nherpes\ngenital\ny\nel\npanadizo\nherp\u00e9tico.\nEl\nprimero\nest\u00e1\nespecialmente\nasociado\nal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nVHS-2\ny\ncobra\nmayor\nimportancia\nen\nembarazadas\nque\npueden\ncontagiar\nal\nreci\u00e9n\nnacido\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntrav\u00e9s\ndel\ncanal\ndel\nparto,\nya\nque\nla\ninfecci\u00f3n\ndel\nneonato\nsuele\nser\nmortal.\nEl\npanadizo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nherp\u00e9tico\nse\npresenta\na\nnivel\ndactilar\ny\naparece\nt\u00edpicamente\nen\npersonas\nque\nest\u00e1n\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncontacto\ncon\nun\nfoco\ncontagioso\n(personas\nque\ntratan\ncon\ninfectados\npor\nVHS,\npacientes\ncon\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nherpes genital y ni\u00f1os que padecen formas herp\u00e9ticas orales y se chupan los dedos).\n \n \nTratamiento\n \n \nEl\ntratamiento\nde\nuna\ninfecci\u00f3n\npor\nVHS\ndepende\nde\nla\nforma\ncl\u00ednica\ny\nla\ngravedad\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncaso,\ndebiendo\niniciarse\nsiempre\nlo\nantes\nposible\n(1).\nLos\nantivirales\nactivos\nfrente\na\nVHS\npor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nv\u00eda\noral\ncomo\naciclovir,\nvalaciclovir\ny\nfamciclovir\nest\u00e1n\nindicados\nen\nlas\nformas\nmucocut\u00e1neas\n \n \n \n \n \n \n \n \n \n \n \n \n \n(3) y necesitan receta m\u00e9dica para su dispensaci\u00f3n.\n \n \n11\n \n En\ncuanto\nal\nherpes\nlabial,\naunque\nse\npodr\u00eda\nutilizar\nla\nv\u00eda\noral\n(4),\nse\nprefiere\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \naplicaci\u00f3n\nt\u00f3pica\nde\nun\nantiviral\nespec\u00edfico,\nexistiendo\ntres\nposibilidades:\naciclovir,\n \n \n \n \n \n \n \n \n \n \npenciclovir\ny\ndocosanol.\nLos\ntres\nse\ncomercializan\nen\npresentaciones\nde\nventa\nlibre.\nTanto\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncrema\nde\naciclovir/hidrocortisona\n50mg/g\n+\n10mg/g\ncomo\nla\nde\naciclovir\n50mg/g\n(sin\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ncorticoide)\ndeben\naplicarse\ncada\n4\nhoras\ndurante\n4\no\n5\nd\u00edas\n(3,\n5,\n6).\nEl\naciclovir\nes\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nf\u00e1rmaco\ncon\nactividad\nantiviral\nque\npuede\nreducir\ntanto\nla\nintensidad\nde\nlos\nsignos\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas\ncomo\nla\nduraci\u00f3n\ndel\nepisodio\n(4,\n5,\n6).\nLa\nasociaci\u00f3n\nde\naciclovir\ne\nhidrocortisona\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nno ha demostrado ser m\u00e1s eficaz que el antiviral en monoterapia.\n \nExisten\ndatos\ncontradictorios\nacerca\nde\nesta\ncomparaci\u00f3n\n(4,\n7,\n8),\naunque\nde\nmomento,\n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\nestudios\ncon\nmayor\nnivel\nde\nevidencia\nse\u00f1alan\nque\nlas\ndiferencias\nen\nresultados\ncl\u00ednicos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nentre\nestas\ndos\nopciones\nno\nson\nestad\u00edsticamente\nsignificativas\n(8).\nY\npor\notro\nlado,\nno\nest\u00e1\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nclaro\nsi\nel\nuso\nprofil\u00e1ctico\nde\naciclovir\nt\u00f3pico\nes\nm\u00e1s\nefectivo\nque\nun\nplacebo\nen\nrecurrencias\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprecipitadas por exposici\u00f3n a la luz solar (9).\n \n \nA\npesar\nde\nque\nel\naciclovir\nprobablemente\nsea\nel\nantiherp\u00e9tico\nde\nuso\nm\u00e1s\nextendido,\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npenciclovir\nha\ndemostrado\nuna\nmayor\neficacia\nreduciendo\nel\nn\u00famero\nde\nlesiones,\nel\n\u00e1rea\n \n \n \n \n \n \n \n \n \n \n \n \n \nafectada\ny\nel\nt\u00edtulo\nviral.\nSin\nembargo,\nsus\nefectos\nsolo\nmejoran\nmoderadamente\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \nresultados\nobtenidos\npor\nuna\ncrema\ncontrol\nsin\nprincipio\nactivo\n(10).\nLa\ncrema\nde\npenciclovir\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n10mg/g debe aplicarse cada 2 horas durante 4 d\u00edas (11).\n \n \nEn\ncuanto\na\nla\ncrema\nde\ndocosanol\n100mg/g,\n\u00fanicamente\nest\u00e1\nindicada\npara\nlas\nprimeras\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfases\nde\nla\nrecurrencia,\npuesto\nque\nno\nha\ndemostrado\nser\neficaz\ntras\nla\naparici\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nves\u00edculas.\nEsta\ncrema\ndebe\naplicarse\ncada\n3\nhoras\ndurante\n4\na\n6\nd\u00edas.\nDe\nlos\ntres\nantivirales\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nt\u00f3picos,\nel\ndocosanol\nes\nel\nque\nha\ndemostrado\nmenor\neficacia,\npues\nse\nbasa\n\u00fanicamente\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla\nreducci\u00f3n\nde\nla\nduraci\u00f3n\ndel\nepisodio\n(12).\nAdem\u00e1s,\nestudios\nque\ncomparaban\nel\nn\u00famero\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nlesiones,\nel\n\u00e1rea\nafectada\ny\nel\nt\u00edtulo\nviral\nno\nencontraron\ndiferencias\nestad\u00edsticamente\n \n \n \n \n \n \n \n \n \n \n \n \n \nsignificativas\nentre\nel\ntratamiento\ncon\ndocosanol,\ncon\nun\nplacebo\no\nla\nausencia\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\n(10).\nTampoco\nse\nconoce\nsu\nmecanismo\nde\nacci\u00f3n\ny\nno\nhay\ndatos\nsobre\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninteracciones con otros f\u00e1rmacos (12).\n \nEl\ntratamiento\ndel\nherpes\nlabial\nno\nse\nlimita\na\nlos\nantivirales,\nsino\nque\ntambi\u00e9n\nexisten\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nproductos\nque\na\u00edslan\nla\nlesi\u00f3n\ny\nfavorecen\nel\nproceso\nde\ncicatrizaci\u00f3n.\nEntre\nellos,\ndestacan\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\nparches\nde\nhidrocoloide\ncomercializados\npor\ndiferentes\nlaboratorios\ny\nque\nofrecen\n \n \n \n \n \n \n \n \n \n \n \nbeneficios\ninteresantes\npara\nel\npaciente.\nEstos\nproductos\ndelimitan\nla\nzona\nafectada,\n \n \n \n \n \n \n \n \n \n \n \nreduciendo\nla\ncontagiosidad,\ny\nla\nrecubren\nde\nun\nambiente\nh\u00famedo,\nlo\nque\nproduce\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nefecto\ncalmante\ny\nacelera\nla\ncicatrizaci\u00f3n.\nAdem\u00e1s,\ndisimulan\nla\nlesi\u00f3n,\nlo\nque\nsupone\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nventaja\nest\u00e9tica.\nDel\nmismo\nmodo,\nexisten\notros\nproductos\nbajo\nla\nforma\nde\nsoluci\u00f3n\no\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ns\u00e9rum\nlabial\nque,\nal\naplicarlos,\ncrean\nuna\npel\u00edcula\noclusiva\nque\nsolidifica\ncon\nla\nmisma\nfunci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque los parches de hidrocoloide.\n \n \n \n12\n \n Por\n\u00faltimo,\nalgunos\nproductos\ncontienen\nsales\nde\nzinc,\ncomo\nel\nsulfato\nde\nzinc\no\nel\n\u00f3xido\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nzinc.\nEl\nsulfato\nde\nzinc\ndiluido\nes\nampliamente\nutilizado\nen\nel\ntratamiento\ndel\nherpes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nz\u00f3ster\n(reactivaci\u00f3n\ndel\nvirus\nde\nla\nvaricela\nque\nproduce\nampollas\nmuy\ndolorosas\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndermatoma\nafectado)\npara\nestimular\nla\nformaci\u00f3n\nde\ncostra\ny\nevitar\nposibles\n \n \n \n \n \n \n \n \n \n \n \nsobreinfecciones\n(13).\nAdem\u00e1s,\nlas\nsales\nde\nzinc\ninhiben\nla\nreplicaci\u00f3n\ndel\nVHS\nin\nvitro\n\u200b\n(14).\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSin\nembargo,\nlos\nresultados\nque\narrojan\nlos\nestudios\nsobre\neficacia\nen\nel\ntratamiento\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nherpes\nlabial\nen\nhumanos\nson\ncontradictorios,\npor\nlo\nque\nlas\nsales\nde\nzinc\nno\nrepresentan\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmejor opci\u00f3n en el tratamiento del herpes labial.\n \n \nDurante\nel\ntranscurso\nde\nla\nrecurrencia\nno\nse\naconsejan\nb\u00e1lsamos\nlabiales\ncalmantes,\n \n \n \n \n \n \n \n \n \n \n \n \nreparadores\no\nfotoprotectores\nque\nno\ncuenten\ncon\nindicaci\u00f3n\npara\nel\ntratamiento\ndel\nherpes\n \n \n \n \n \n \n \n \n \n \n \n \n \nlabial.\nEste\ntipo\nde\nproductos\nse\ndeben\nrelegar\na\nla\nfase\nde\ndesaparici\u00f3n\nde\nla\nlesi\u00f3n,\npuesto\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\npueden\npropagar\nla\ninfecci\u00f3n\ny\ntambi\u00e9n\nretrasar\nla\nresoluci\u00f3n\ndel\nepisodio\ndebido\na\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npresencia de componentes irritantes (15).\n \nConclusiones\n \nEl\nuso\nde\nantivirales\npor\nv\u00eda\noral\ndeber\u00eda\nreservarse\ns\u00f3lo\npara\npresentaciones\ncl\u00ednicas\n \n \n \n \n \n \n \n \n \n \n \n \n \ngraves\npor\nmotivos\nde\nseguridad.\nLos\nantivirales\nt\u00f3picos\ncomo\naciclovir\no\npenciclovir\nhan\n \n \n \n \n \n \n \n \n \n \n \n \n \ndemostrado\nsu\nefectividad,\naunque\nla\nutilidad\ncl\u00ednica\nde\nlos\nmismos\nes\nlimitada.\nDebe\n \n \n \n \n \n \n \n \n \n \n \n \n \nevitarse\nel\nuso\nde\npomadas\no\nb\u00e1lsamos\nno\nespec\u00edficos\nque\npodr\u00edan\nayudar\na\nextender\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlesiones.\n \n \n \n13\n \n ESTOMATITIS AFTOSA\n \nEiras, A.\n \nLas\naftas\nse\ndefinen\ncomo\nun\ntipo\nde\nlesiones\nen\nla\ncavidad\noral\nen\nforma\nde\n\u00falceras\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nblanquecinas.\nSon\nmuy\ndolorosas,\nespecialmente\ndurante\nla\nmasticaci\u00f3n,\ny\nsuelen\nproducir\n \n \n \n \n \n \n \n \n \n \n \nrecidivas.\nSe\ninician\ncon\nuna\nsensaci\u00f3n\nde\npicor\no\nescozor\ny\naparece\nuna\nmancha\nrojiza.\nEn\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \napenas\nunas\nhoras,\naparece\nla\n\u00falcera\nblanca,\nredonda\nu\novalada,\nde\n1-10\nmm\nde\ndi\u00e1metro\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncon\nun\nhalo\neritematoso.\nPueden\naparecer\ntanto\nde\nforma\naislada\ncomo\nen\nm\u00faltiples\n \n \n \n \n \n \n \n \n \n \n \n \n \nlocalizaciones\nal\nmismo\ntiempo.\nEn\nla\nmayor\u00eda\nde\nlos\ncasos\nse\ntrata\nde\nun\nproceso\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nautolimitado\nque\ndura\nentre\nuna\ny\ndos\nsemanas\n(1).\nActualmente\nse\ndesconoce\nla\ncausa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \netiol\u00f3gica\nde\nesta\npatolog\u00eda.\nSe\ncree\nque\nes\nmultifactorial\ny\nque\nentre\nestos\nfactores\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nencuentran\nfactores\ngen\u00e9ticos,\ninmunol\u00f3gicos\ny\nhormonales,\nenfermedades\nde\nbase\n(liquen\n \n \n \n \n \n \n \n \n \n \nplano,\np\u00e9nfigo,\npenfigoide,\nneoplasias\n\u2026\n)\no\nd\u00e9ficits\nnutricionales.\nEn\nmuchas\nocasiones,\nlos\n \n \n \n \n \n \n \n \n \n \n \ncasos\nde\naftas\nque\nvemos\nen\nla\nfarmacia\npueden\ndeberse\na\ntraumatismos,\nuna\npr\u00f3tesis\nu\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nortodoncia mal adaptada, t\u00e9cnicas de cepillado inadecuadas, etc. (2).\n \nTratamiento\n \nAunque\nremiten\nde\nforma\nnatural,\nexisten\nnumerosas\nopciones\nde\ntratamiento\ncuyo\n \n \n \n \n \n \n \n \n \n \n \nobjetivo\nes\nreducir\nel\ndolor\ny\nla\ninflamaci\u00f3n,\nfavorecer\nla\ncicatrizaci\u00f3n\nacortando\nsu\nduraci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ny prevenir la sobreinfecci\u00f3n y la recidiva.\n \nTratamiento t\u00f3pico\n \nEntre\nlos\ntratamientos\nt\u00f3picos\nque\ncuentan\ncon\npruebas\nconcluyentes\na\nsu\nfavor\n \n \n \n \n \n \n \n \n \n \n \n \ndestacamos:\n \n\u25cf\nAntis\u00e9pticos: clorhexidina al 0,12% en gel o colutorio, triclos\u00e1n en gel o colutorio.\n \n\u25cf\nAntiinflamatorios:\nacet\u00f3nido\nde\ntriamcionlona\n0,05-0,5%\nen\nsoluci\u00f3n\no\norabase\n(con\n \n \n \n \n \n \n \n \n \n \nprescripci\u00f3n),\npropionato\nde\nclobetasol\nal\n0,025%\nen\nsoluci\u00f3n\no\norabase\n(con\n \n \n \n \n \n \n \n \n \n \n \nprescripci\u00f3n), hidrocortisona en comprimidos para chupar.\n \n\u25cf\nAntibi\u00f3ticos: doxiciclina (con prescripci\u00f3n).\n \n\u25cf\nAnest\u00e9sicos: lidoca\u00edna, benzoca\u00edna, tetraca\u00edna.\n \n\u25cf\nCicatrizantes:\n\u00e1cido hialur\u00f3nico al 0,2% en gel, colutorio o aerosol.\n \nDurante\nel\ntratamiento\nt\u00f3pico\nes\nimportante\nrecordar\nal\npaciente\nque\nse\nlave\nbien\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmanos\nantes\nde\naplicar\nel\ntratamiento\ny\nque\nevite\nbeber\no\ncomer\nhasta\npasado\nun\ntiempo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npara no arrastrar el medicamento de la zona a tratar (2).\n \nEn\ncasos\nm\u00e1s\ngraves,\nen\nlos\nque\nla\nv\u00eda\nt\u00f3pica\nes\nineficaz,\nel\nm\u00e9dico\npodr\u00eda\nprescribir\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nglucocorticoides\ncomo\nla\nprednisona,\nque\nha\ndemostrado\naliviar\nel\ndolor\ny\nconseguir\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nreepitelizaci\u00f3n de las lesiones (1, 3, 4).\n \n \n \n14\n \n Medidas no farmacol\u00f3gicas\n \nTanto\ndurante\nel\ntratamiento\nde\nlas\naftas\ncomo\nen\nsu\nprevenci\u00f3n,\ndebemos\nrecomendar\n \n \n \n \n \n \n \n \n \n \n \n \n \na\ntodos\nnuestros\npacientes\nunas\npautas\nde\nhigiene\nbucodental\nadecuadas:\nutilizar\ncepillos\n \n \n \n \n \n \n \n \n \n \n \n \nsuaves,\nrenovarlos\ncada\n3\nmeses,\nutilizar\nsedas\ndentales,\nvisitar\nal\nodont\u00f3logo\nde\nforma\n \n \n \n \n \n \n \n \n \n \n \n \n \nregular,\netc.\nLa\nt\u00e9cnica\nde\ncepillado\nes\nespecialmente\nimportante\npara\nprevenir\nulceraciones\n \n \n \n \n \n \n \n \n \n \n \n \npor\ntraumatismos.\nOtras\nmedidas\naconsejables\nser\u00edan\nmantener\nla\nmucosa\nhidratada,\nevitar\n \n \n \n \n \n \n \n \n \n \n \nlos\nalimentos\n\u00e1cidos\ny\nlas\ncomidas\npicantes\no\nmuy\ncalientes,\nllevar\nuna\ndieta\nequilibrada\ny,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsobre todo, eliminar sustancias nocivas como el tabaco (2, 4).\n \nEn\nla\nb\u00fasqueda\nbibliogr\u00e1fica\npodemos\nencontrar\nrevisiones\nde\nmultitud\nde\nestudios\n \n \n \n \n \n \n \n \n \n \n \nsobre\ntratamientos\nalternativos.\nEn\nla\nmayor\u00eda,\nlos\nautores\nse\u00f1alan\nla\nfalta\nde\nhomogeneidad\n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nlos\nm\u00e9todos\ny\nprotocolos\nde\nlos\nestudios,\npor\nlo\nque\nno\npueden\ndemostrar\nde\nforma\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconcluyente\nsu\neficacia\n(5-7).\nLa\nadministraci\u00f3n\nde\ncomplejos\nmultivitam\u00ednicos\ncomo\nposible\n \n \n \n \n \n \n \n \n \n \n \ntratamiento\npreventivo\nde\nlas\naftas\nno\nha\nconseguido\ndemostrar\nmayor\neficacia\nque\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \nplacebo (8).\n \nDerivaci\u00f3n\n \nSi\nnos\nencontramos\ncon\nun\npaciente\nque\nha\nsufrido\nrecidivas\no\ncuyo\nproceso\nde\ncuraci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nse\nalarga\nm\u00e1s\nde\ndos\nsemanas,\ndebemos\nremitirlo\nal\nm\u00e9dico.\nEn\nestos\npacientes\nes\nnecesario\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrealizar\nun\ndiagn\u00f3stico\ndiferencial\ndel\ntipo\nde\n\u00falcera\npara\ndescartar\n\u00falceras\nneopl\u00e1sicas\n(m\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \n \nfrecuentes\nen\npacientes\nmayores\nde\n50\na\u00f1os),\n\u00falceras\npor\nvirus\nEpstein-Barr,\nherpes\no\n \n \n \n \n \n \n \n \n \n \n \n \n \nvaricela-z\u00f3ster,\netc.\nAdem\u00e1s,\nel\nm\u00e9dico\nsuele\npedir\nuna\nanal\u00edtica\nen\nbusca\nde\nestados\n \n \n \n \n \n \n \n \n \n \n \n \n \ncarenciales que aumentan la incidencia de las aftas, como puede ser la anemia (1, 2).\n \nConclusi\u00f3n\n \nAunque\nning\u00fan\ntratamiento\nfarmacol\u00f3gico\nresulta\ncurativo,\nexisten\nvarios\ntratamientos,\n \n \n \n \n \n \n \n \n \n \nt\u00f3picos\nu\norales,\neficaces\npara\nel\nalivio\nde\nlos\ns\u00edntomas\nde\nla\nestomatitis\naftosa\n(9).\nDe\ntodos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nellos,\nlos\ncorticoides\nson\nel\ntratamiento\nm\u00e1s\neficaz,\npero\nexisten\notras\nopciones\ncomo\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\u00e1cido\nhialur\u00f3nico\no\nla\nclorhexidina\npara\nevitar\nsobreinfecciones.\nEn\nel\ncaso\nde\naftas\n \n \n \n \n \n \n \n \n \n \n \n \n \nrecurrentes\nse\ndebe\npreguntar\npor\nposibles\nfactores\ndesencadenantes,\ncomo\nantecedentes\n \n \n \n \n \n \n \n \n \n \nde\ntraumatismos,\ntoma\nde\nmedicamentos\no\ningesta\nde\nalimentos\nirritantes,\nas\u00ed\ncomo\n \n \n \n \n \n \n \n \n \n \n \n \ninvestigar\nun\nposible\nd\u00e9ficit\nnutricional\n(hierro,\n\u00e1cido\nf\u00f3lico,\nvitaminas\ndel\ngrupo\nB\ny\nzinc)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(10).\n \n \n \n15\n \n FARINGOAMIGDALITIS\n \nCal Seijas, R.\n \nLa\nfaringoamigdalitis\naguda\n(FAA)\nes\nuna\npatolog\u00eda\ninfecciosa\nde\norigen\nv\u00edrico\n(m\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \nfrecuente)\no\nbacteriano.\nLa\ncl\u00ednica\nno\npermite\ndistinguir\ncon\nprecisi\u00f3n\nentre\nFAA\nv\u00edrica\no\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nbacteriana,\npero\nhay\nciertos\ns\u00edntomas\nque\npueden\norientar\nel\ndiagn\u00f3stico.\nLa\nFAA\nbacteriana\n \n \n \n \n \n \n \n \n \n \n \n \n \nestreptoc\u00f3cica\nsuele\ncomenzar\nde\nforma\nbrusca\ny\ncursar\ncon\nfiebre,\ndolor\nde\ngarganta,\ndolor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\ncabeza,\nmialgias,\nn\u00e1useas,\nv\u00f3mitos\ny\ndolor\nabdominal.\nNormalmente\ntambi\u00e9n\nse\nobserva\n \n \n \n \n \n \n \n \n \n \n \n \neritema,\ninflamaci\u00f3n\nde\nfaringe\ny\n\u00favula\ne\nhipertrofia\ndel\ntejido\nlinfoide;\nlas\nam\u00edgdalas\nsuelen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nestar\neritematosas,\ninflamadas\ny\ncon\nexudado\nblanquecino-amarillento\n(50-90%\nde\nlos\n \n \n \n \n \n \n \n \n \n \ncasos).\nLa\nadenopat\u00eda\ncervical\nanterior,\ndolorosa\nal\ntacto,\ntambi\u00e9n\nse\npresenta\nen\nun\n30-60%\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nlos\ncasos.\nEs\nimportante\ndescartar\nel\nposible\norigen\nbacteriano,\nya\nque\nen\neste\ncaso\nser\u00e1\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnecesario\ninstaurar\ntratamiento\nantibi\u00f3tico,\nsiendo\namoxicilina\no\npenicilina\nconsiderados\n \n \n \n \n \n \n \n \n \ncomo de primera elecci\u00f3n (1).\n \nLas\nFAA\nv\u00edricas\nson\nmayoritarias\n(65-85%)\ny\ngeneralmente\nest\u00e1n\ncausadas\npor\n \n \n \n \n \n \n \n \n \n \n \nadenovirus.\nSuceden\nen\nel\ntranscurso\nde\nun\ncuadro\ncatarral,\nla\nfiebre\n\u2014si\nse\nproduce\u2014\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsuele\nser\nalta\ny\nla\npresencia\nde\nexudado\nno\nes\ntan\nfrecuente\ncomo\nen\nlas\nFAA\nbacterianas.\nSu\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nes\nmeramente\nsintom\u00e1tico\npara\ntratar\nde\naliviar\nel\ndolor\ny\nla\nirritaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ngarganta que sufre el paciente.\n \nNos\ncentraremos\nen\neste\napartado\nen\nla\nrevisi\u00f3n\nde\nlos\ndiferentes\ntratamientos\n \n \n \n \n \n \n \n \n \n \n \n \nsintom\u00e1ticos\ndisponibles\npara\nel\nalivio\ndel\ndolor\nen\nla\nfaringitis\naguda,\nya\nsea\nsu\norigen\nv\u00edrico\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \no bacteriano.\n \n \nTratamiento\n \nAntiinflamatorios no esteroideos (AINE) por v\u00eda oral\n \nLos\nAINE\npor\nv\u00eda\noral\ny\nel\nparacetamol\nson\nefectivos\npara\nel\nmanejo\ndel\ndolor\nen\nla\nFAA.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nNo\ntodos\nlos\nAINE\nse\nhan\nestudiado\npara\nesta\nindicaci\u00f3n,\npero\nsabemos\nque\nel\n\u200b\nibuprofeno\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndosis\nde\n400\nmg/8\nhoras\nes\neficaz\nen\nla\ndisminuci\u00f3n\ndel\ndolor\n(2,\n3),\nincluso\nm\u00e1s\nque\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nparacetamol\na\ndosis\nde\n1\ng/8\nhoras.\nNo\nobstante,\nalgunas\ngu\u00edas\nsiguen\nindicando\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nparacetamol\ncomo\nprimera\nelecci\u00f3n.\nNo\nse\nobservaron\ndiferencias\nsignificativas\nen\nla\n \n \n \n \n \n \n \n \n \n \n \nincidencia de efectos secundarios entre ambos.\n \nCorticoides\n \nLos\ncorticoides\norales\no\nintramusculares\naumentan\nla\nprobabilidad\nde\nresoluci\u00f3n\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \nFAA\ny\nmejoran\nel\ndolor\nen\nlos\npacientes\ncon\nfaringitis\nbacteriana\ncuando\nse\nasocian\nal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nantibi\u00f3tico\n(4).\nHar\u00edan\nfalta\nensayos\nespec\u00edficos\npara\nsaber\nsi\nobtienen\nel\nmismo\n \n \n \n \n \n \n \n \n \n \n \n \n \nresultado en las FAA v\u00edricas.\n \n \n \n16\n \n Antiinflamatorios t\u00f3picos\n \nOtra\nopci\u00f3n\npara\naliviar\nel\ndolor\ny\nla\nirritaci\u00f3n\ncuando\nno\nse\ndesea\nusar\nf\u00e1rmacos\npor\nv\u00eda\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsist\u00e9mica\nes\nemplear\nla\nv\u00eda\nt\u00f3pica.\nLos\nAINE\nt\u00f3picos\npueden\nadministrarse\nen\nforma\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \naerosol,\ncaramelos,\ncomprimidos\npara\nchupar,\netc.\nUno\nde\nlos\nm\u00e1s\nempleados\nes\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \nflurbiprofeno.\nLos\nestudios\ncl\u00ednicos\nrealizados,\naunque\npeque\u00f1os,\ndemuestran\nla\neficacia\ndel\n \n \n \n \n \n \n \n \n \n \n \nflurbiprofeno en el alivio del dolor de garganta (5).\n \nPreparados bucofar\u00edngeos con combinaci\u00f3n de principios activos\n \nPara\nel\nalivio\ndel\ndolor\nen\nlas\nFAA\nagudas\nes\nfrecuente\nel\nuso\nde\npreparados\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nbucofar\u00edngeos\nque\ncombinan\ndiferentes\nf\u00e1rmacos\ncon\nacciones\nantiinfecciosas,\nanalg\u00e9sicas\ny\n \n \n \n \n \n \n \n \n \n \nantiinflamatorias.\nUna\nde\nlas\nm\u00e1s\npopulares\nes\nla\nasociaci\u00f3n\nde\nbacitracina,\nlisozima\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \npapa\u00edna.\nPara\nesta\ncombinaci\u00f3n\nhay\npublicados\nestudios\na\ndoble\nciego\nque\ndemuestran\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \ndisminuci\u00f3n\ndel\ndolor,\ndel\nenrojecimiento\ny\nde\nla\ninflamaci\u00f3n\n\u200b\n(6).\nDiferentes\ncombinaciones\n \n \n \n \n \n \n \n \n \n \n \n \nsimilares\n(tirotricina,\ncloruro\nde\nbenzalconio\ny\nbenzoca\u00edna)\nhan\ndemostrado\nmayor\neficacia\n \n \n \n \n \n \n \n \n \n \n \nfrente\nal\nplacebo\nen\nFAA\n(7).\nOtros\nprincipios\nactivos\ncom\u00fanmente\nempleados\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nde\nla\nFAA\nsobre\nlos\nque\npodemos\nencontrar\nensayos\ncl\u00ednicos\nque\nrespalden\nsu\n \n \n \n \n \n \n \n \n \n \n \n \n \n \neficacia\nson\nla\necto\u00edna\n(8)\ny\nel\nambroxol\n(9).\nLos\npreparados\nbucofar\u00edngeos\nson\nen\ngeneral\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nbien\ntolerados\ny\nno\npresentan\nefectos\nsecundarios\nsignificativos.\nDado\nsu\nperfil\nde\neficacia\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nseguridad\npueden\nconsiderarse\nuna\nbuena\nopci\u00f3n\nterap\u00e9utica\nen\ntratamiento\nde\nla\nFAA\n \n \n \n \n \n \n \n \n \n \n \n \nv\u00edrica o bacteriana, solos o en combinaci\u00f3n con otros tratamientos.\n \n \nDemulcentes\n \nLos\ndemulcentes\ntradicionales\ncomo\nla\nmiel\no\nlos\ncaramelos\nayudan\na\nformar\nuna\npel\u00edcula\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsobre\nlas\nmembranas\nmucosas\nque\nproporciona\nalivio\ndel\ndolor\ndurante\nun\nbreve\nper\u00edodo\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntiempo\n(30\nminutos).\nCuando\nestos\ndemulcentes\nse\ncombinan\ncon\nanest\u00e9sicos\nlocales\ncomo\n \n \n \n \n \n \n \n \n \n \n \n \nla lidoca\u00edna, la duraci\u00f3n del efecto puede ser algo mayor (10, 11).\n \nMedicina tradicional china\n \nEn\nuna\nrevisi\u00f3n\nCochrane\nde\n7\nensayos\ncl\u00ednicos\naleatorizados\nacerca\nde\nremedios\n \n \n \n \n \n \n \n \n \n \n \n \nherbales\nchinos\npara\nel\ndolor\nde\ngarganta,\nno\nse\npudo\nllegar\na\nuna\nconclusi\u00f3n\nfirme\ncon\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque poder recomendar su uso debido a la mala calidad de la metodolog\u00eda empleada (2).\n \nProp\u00f3leo\n \nEl\nprop\u00f3leo\nha\nsido\nampliamente\ninvestigado\npor\nsus\npropiedades\nantibacterianas,\n \n \n \n \n \n \n \n \n \n \nantivirales\ny\nantiinflamatorias.\nExisten\ndiferentes\ntipos\nde\nprop\u00f3leo,\ncon\ndiferentes\n \n \n \n \n \n \n \n \n \n \ncomposiciones\nqu\u00edmicas\ny\npor\nlo\ntanto\ndiferentes\npropiedades\nfarmacol\u00f3gicas,\nlo\nque\n \n \n \n \n \n \n \n \n \n \n \ndificulta\nel\nestudio\ny\nla\ninterpretaci\u00f3n\nde\nlos\nresultados.\nEl\nprop\u00f3leo\ntiene\nproblemas\n \n \n \n \n \n \n \n \n \n \n \n \n \nconocidos\nde\nsolubilidad,\nabsorci\u00f3n\ny\nbiodisponibilidad,\naunque\npodr\u00eda\nconsiderarse\nun\n \n \n \n \n \n \n \n \n \n \ntratamiento\ncomplementario\nv\u00e1lido\npara\naliviar\nel\ndolor\nen\nla\nfaringitis\naguda,\npero\nnunca\n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo \u00fanico tratamiento en FAA bacteriana (13).\n \n \n \n17\n \n Zinc\n \nSe\nha\ndemostrado\nque\nel\nzinc\nno\nreduce\nlos\ns\u00edntomas\nni\nla\nduraci\u00f3n\nde\nlas\nfaringitis\n(12),\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npor lo que su uso en algunos bucofar\u00edngeos no estar\u00eda justificado.\n \n \nVitamina A\n \nLas\ninfecciones\nagudas\nde\nlas\nv\u00edas\nrespiratorias\ninferiores\ny\nla\ncarencia\nde\nla\nvitamina\nA\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nson\nafecciones\ncomunes\nen\nlos\nni\u00f1os\nde\nhasta\nsiete\na\u00f1os\nde\nedad,\nespecialmente\nen\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npa\u00edses\nen\nv\u00edas\nde\ndesarrollo\ny\nen\nni\u00f1os\ncon\ndificultades\npara\nacceder\na\nuna\nalimentaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nadecuada.\nSin\nembargo,\nno\nse\nhan\nencontrado\npruebas\nde\nque\nlos\nsuplementos\ncon\nretinol\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npuedan\ndisminuir\nel\nn\u00famero\nde\ninfecciones;\nde\nhecho,\nalgunos\nestudios\nmostraron\nun\n \n \n \n \n \n \n \n \n \n \n \n \nincremento\nde\nlas\nmismas.\nLas\nhipervitaminosis\nA\npueden\ncausar\nefectos\nsecundarios,\npor\nlo\n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nno\nse\naconseja\nsu\nuso\na\nno\nser\nque\nse\ndemuestren\nniveles\ns\u00e9ricos\nbajos\nde\nvitamina\nA\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(14).\n \nActuaci\u00f3n del farmac\u00e9utico\n \nAnte\nuna\nconsulta\npor\ndolor\nde\ngarganta\ny\nantes\nde\nindicar\nun\ntratamiento,\nes\nnecesario\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nverificar\nque\nno\nexistan\ncriterios\nde\nderivaci\u00f3n\n\u200b\n(brote\ncomunitario,\ninmunodepresi\u00f3n,\n \n \n \n \n \n \n \n \n \n \nantecedentes\nde\nfiebre\nreum\u00e1tica,\nsintomatolog\u00eda\ngrave)\n\u200b\no\nque\nnos\npudieran\nhacer\n \n \n \n \n \n \n \n \n \n \n \nsospechar\nde\nuna\nFAA\nbacteriana\n(fiebre\nsuperior\na\n38\n\u00baC,\nadenopat\u00edas\ndolorosas,\npresencia\n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nexudado...).\nUna\nvez\ndescartados\nlos\ncriterios\nde\nderivaci\u00f3n\ny\nlos\nsignos\nsospechosos\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninfecci\u00f3n\nbacteriana,\npodremos\nindicar\ncon\nconfianza\nAINE\nv\u00eda\noral\n(ibuprofeno\n400\nmg),\n \n \n \n \n \n \n \n \n \n \n \n \npreparados bucofar\u00edngeos o combinaciones de ambos.\n \n \n \n \n18\n \n TOS AGUDA\n \n \nCal Seijas, R.\n \nCabe\naclarar\nque\nexisten\nmuchos\ntipos\nde\ntos,\npor\nlo\nque\nvamos\na\ncentrarnos\nen\nlos\ntipos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nm\u00e1s\ncomunes\nen\nla\ncomunidad.\nLos\ndatos\nno\nson\nextrapolables\na\nla\ntos\nasociada\na\nasma,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nEPOC, ERGE, procesos oncol\u00f3gicos, goteo nasal posterior, etc.\n \nTos productiva\n \nLa\ntos\nproductiva\nes\nun\nmecanismo\nfisiol\u00f3gico\nde\ndefensa,\npor\nlo\nque,\naunque\ninc\u00f3moda,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nresulta\nimprescindible\npara\nque\nel\n\u00e1rbol\nrespiratorio\npueda\neliminar\nel\nexceso\nde\nmucosidad\n \n \n \n \n \n \n \n \n \n \n \n \n \ny\notros\nresiduos\nque\nse\nproducen\ndurante\ninfecciones\nrespiratorias.\nLos\nmedicamentos\n \n \n \n \n \n \n \n \n \n \n \nempleados\npara\neste\ntipo\nde\ntos\nse\ndividen\nen\nmucol\u00edticos\ny\nexpectorantes,\naunque\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npr\u00e1ctica\nesta\ndistinci\u00f3n\nno\nes\nevidente\ny\nser\u00eda\nm\u00e1s\nadecuado\nhablar\nde\n\u200b\nmucosecretol\u00edticos\no\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmucoexpectorantes.\n \n \nNo\nexiste\nevidencia\ncient\u00edfica\ns\u00f3lida\nque\nrespalde\nque\nninguno\nde\nlos\nmedicamentos\n \n \n \n \n \n \n \n \n \n \n \n \n \nmucosecretol\u00edticos\npueda\nacortar\nla\nduraci\u00f3n,\nprevenir\nlas\ncomplicaciones\no\nreducir\nla\n \n \n \n \n \n \n \n \n \n \n \nintensidad\nde\nla\ntos\naguda\nproductiva.\nLa\nacetilciste\u00edna\ny\nla\ncarbociste\u00edna\nson\nlas\nmol\u00e9culas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nm\u00e1s\nestudios\nacumulan;\nsin\nembargo,\ndebido\na\nla\nmala\ncalidad\nde\nlos\nensayos\ny\na\nsu\nbaja\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsignificancia,\nla\nutilidad\ncl\u00ednica\nde\nestos\nf\u00e1rmacos\nes\na\nd\u00eda\nde\nhoy\nm\u00e1s\nque\ndudosa\n(1,\n2,\n3).\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAunque\nen\ngeneral\nson\nf\u00e1rmacos\nbien\ntolerados,\nen\nmenores\nde\ndos\na\u00f1os\nsu\nuso\nest\u00e1\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncontraindicado por el riesgo de obstrucci\u00f3n bronquial.\n \nDado\nel\ncar\u00e1cter\nautolimitado\ny\nbanal\nde\neste\ntipo\nde\ntos,\nno\nparece\nque\nexistan\nmotivos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npara recomendar de forma rutinaria mucosecretol\u00edticos a los pacientes con tos productiva.\n \n \nTos seca\n \nEntendemos\npor\ntos\nseca\no\nirritativa\na\nla\ntos\nque\ncursa\nsin\nexpectoraci\u00f3n\n(tos\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nproductiva).\nEsta\ntos\npuede\ndurar\nhasta\nun\nmes\ndespu\u00e9s\nde\nresuelta\nla\ninfecci\u00f3n\nrespiratoria.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAdem\u00e1s,\npuede\nllegar\na\nproducir\nv\u00f3mitos\no\ninterferir\ncon\nel\nsue\u00f1o,\npor\nlo\nque\nse\njustifica\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnecesidad\nde\nun\ntratamiento.\nSin\nembargo,\na\npesar\ndel\nuso\nextendido\nde\nlos\nf\u00e1rmacos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nantitusivos,\nsu\nefectividad\nha\nsido\npuesta\nen\nentredicho.\nVarios\nestudios\nde\nalta\ncalidad\nhan\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nse\u00f1alado\nque\nalgunos\nde\nlos\nantitusivos\nm\u00e1s\nempleados\nno\nhan\nlogrado\ndemostrar\nmayor\n \n \n \n \n \n \n \n \n \n \n \n \n \neficacia que el placebo.\n \nTratamiento\n \n\u25cf\nLa\ncode\u00edna\nes\nun\nopioide\nque\ncl\u00e1sicamente\nse\nha\nconsiderado\nel\narquetipo\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nantitusivos.\nEn\nlos\nlibros\nde\nfarmacolog\u00eda\ny\ngu\u00edas\nterap\u00e9uticas\nes\nconsiderado,\nadem\u00e1s\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nanalg\u00e9sico,\ncomo\nel\nantitusivo\nm\u00e1s\neficaz.\nA\npesar\nde\nello,\nlos\nensayos\ncl\u00ednicos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrealizados\ndemuestran\nsu\nfalta\nde\neficacia\nen\ncuanto\nal\nalivio\nde\nla\ntos\naguda\nproducida\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npor\ngripe\no\nresfriados.\nTampoco\nen\nel\ntest\nde\nprovocaci\u00f3n\nde\nla\ntos\ncon\ncapsaicina\nha\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconseguido\nmayor\neficacia\nque\nel\nplacebo.\nSu\nuso\nest\u00e1\ncontraindicado\nen\nmenores\nde\n12\n \n \n \n \n \n \n \n \n \n \n \n \n \n \na\u00f1os (4, 5, 6).\n \n19\n \n \u25cf\nEl\ndextrometorfano\nes\nun\nopioide\nsint\u00e9tico\nutilizado\n\u00fanicamente\ncomo\nantitusivo.\nA\n \n \n \n \n \n \n \n \n \n \n \npesar\nde\nser\nunos\nde\nlos\nantitusivos\nm\u00e1s\nempleados,\nexisten\npruebas\ncontradictorias\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nsu\neficacia.\nSu\nacci\u00f3n\nantitusiva\nes\nde\npoca\no\nninguna\nutilidad\ncuando\nse\nutiliza\npara\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratar\nla\ntos\nprimaria\nproducida\nen\nel\ncontexto\nde\ninfecciones\nrespiratorias.\nLos\nensayos\n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nadultos\nson\nescasos\ny\nde\nbaja\ncalidad,\npero\nparecen\nindicar\ncierta\neficacia\nen\nel\nalivio\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nla\ntos\naguda\ny\ncr\u00f3nica.\nEn\npediatr\u00eda\nhay\nconstancia\nde\nsu\nineficacia\nen\nel\ntratamiento\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nla\ntos\ndebida\na\nresfriados,\ndonde\nninguno\nde\nlos\nestudios\npublicados\nle\notorgan\nmayor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nefectividad\nque\nel\nplacebo\n(7,\n8).\nLos\nefectos\nsecundarios\nm\u00e1s\nfrecuentemente\n \n \n \n \n \n \n \n \n \n \n \nobservados\nson\nn\u00e1useas,\nv\u00f3mitos\ny\ndolor\nabdominal.\nNo\ndebe\nusarse\nen\nmenores\nde\n2\n \n \n \n \n \n \n \n \n \n \n \n \n \n \na\u00f1os.\n \n\u25cf\nLa\ncloperastina\nes\nun\nantitusivo\nde\nacci\u00f3n\ncentral\nno\nopi\u00e1ceo\nrelacionado\nqu\u00edmicamente\n \n \n \n \n \n \n \n \n \n \n \n \ncon\nla\nfamilia\nde\nlos\nantihistam\u00ednicos.\nSu\nmecanismo\nde\nacci\u00f3n\nno\nes\ndel\ntodo\nconocido,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npero\nse\ncree\nque\nact\u00faa\ntanto\na\nnivel\ncentral\ncomo\nperif\u00e9rico.\nDe\ntodos\nlos\nantitusivos,\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncloperastina\nes\nla\nque\nposee\nmejores\nensayos\nque\nrespalden\nsu\neficacia\n(9).\nEs\nbien\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntolerada\ny\nposee\nun\nligero\nefecto\nsedante,\npor\nlo\nque\nes\nde\nespecial\nindicaci\u00f3n\nen\ntos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnocturna. Solo debe emplearse en ni\u00f1os mayores de dos a\u00f1os que cursen con tos seca.\n \n\u25cf\nLos\nf\u00e1rmacos\nantihistam\u00ednicos\npueden\nser\nde\nutilidad\nen\nalgunos\ntipos\nde\ntos,\ncomo\nla\ntos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncr\u00f3nica\nde\norigen\nasm\u00e1tico\no\nal\u00e9rgico.\nNo\nobstante,\ny\na\npesar\nde\nsu\nempleo\nregular,\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nexisten\npruebas\nque\navalen\nsu\neficacia\nen\ntos\nprimaria\ninespec\u00edfica\n(10).\nLa\ncombinaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nantihistam\u00ednicos\ncon\ndescongestivos,\ncomo\nocurre\nen\nalgunos\npreparados\npedi\u00e1tricos,\n \n \n \n \n \n \n \n \n \n \nno\nsupone\nninguna\nmejora\nen\nla\nefectividad\ny\naumenta\nel\nriesgo\nde\nefectos\nsecundarios.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nLa\nmayor\u00eda\nde\nefectos\nsecundarios\nsuelen\nser\nleves\n(irritabilidad\ny\nmalestar\n \n \n \n \n \n \n \n \n \n \n \ngastrointestinal), pero se han registrado algunos casos graves de sedaci\u00f3n en ni\u00f1os.\n \n\u25cf\nEl\nsalbutamol\nes\nun\nbroncodilatador\nde\nacci\u00f3n\nr\u00e1pida\nmuy\nutilizado\npor\nv\u00eda\ninhalatoria\n \n \n \n \n \n \n \n \n \n \n \n \n \npara\nel\ntratamiento\ndel\nasma.\nTambi\u00e9n\nexiste\nuna\npresentaci\u00f3n\npor\nv\u00eda\noral\nen\nforma\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \njarabe\nque\nse\nusa\npara\ntratar\nla\ntos\ninespec\u00edfica\ncon\ncomponente\nesp\u00e1stico.\nEsta\nforma\n \n \n \n \n \n \n \n \n \n \n \n \n \n \noral\nha\ndemostrado\n\u00abno\nser\nefectiva\u00bb\nen\nbronquitis\naguda\n(11);\nadem\u00e1s,\npuede\nprovocar\n \n \n \n \n \n \n \n \n \n \n \n \n \nefectos\nsecundarios\ncomo\ntemblor,\nestremecimientos,\nnerviosismo\ny\nalteraciones\n \n \n \n \n \n \n \n \ncardiacas, especialmente en poblaci\u00f3n pedi\u00e1trica.\n \n\u25cf\nLa\nmepifilina\no\nmepiramina\nes\nun\nderivado\nde\netilendiamina\nque\nbloquea\nde\nforma\n \n \n \n \n \n \n \n \n \n \n \n \n \ncompetitiva,\nreversible\ne\ninespec\u00edfica\na\nlos\nreceptores\nH1,\ndisminuyendo\nlos\nefectos\n \n \n \n \n \n \n \n \n \n \n \nsist\u00e9micos\nde\nla\nhistamina.\nProduce\nun\nligero\nefecto\nbroncodilatador\nque\npuede\nser\n\u00fatil\n \n \n \n \n \n \n \n \n \n \n \n \n \nen\ncaso\nde\nafecciones\nbronquiales;\nsin\nembargo,\na\npesar\nde\nsu\nuso\ngeneralizado\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnuestro\npa\u00eds\nen\npoblaci\u00f3n\npedi\u00e1trica\ny\nadulta,\nno\nexiste\nevidencia\nalguna\nque\nrespalde\nsu\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nuso como antitusivo o como mucol\u00edtico en el contexto de afecciones respiratorias.\n \n\u25cf\nLa\nlevodropropizina\nes\nun\nf\u00e1rmaco\ncon\nactividad\nantitusiva.\nSu\nmecanismo\nde\nacci\u00f3n\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \nest\u00e1\nclaro\npero\nparece\nactuar\na\nnivel\nperif\u00e9rico\ntraqueobronquial,\nejerciendo\nefectos\n \n \n \n \n \n \n \n \n \n \n \nantial\u00e9rgicos\ny\nantiespasm\u00f3dicos.\nUn\nmetaan\u00e1lisis\nfinanciado\npor\nun\nfabricante\nde\n \n \n \n \n \n \n \n \n \n \nlevodroperizina\n(12)\napoya\nsu\neficacia\ncomo\nantitusivo\nen\ntos\nseca\ny\nsu\nseguridad\na\npartir\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde los dos a\u00f1os. Otros estudios obtienen conclusiones similares (13).\n \n\u25cf\nLos\ndescongestivos\npor\nv\u00eda\noral,\nsolos\no\nen\ncombinaci\u00f3n\ncon\notros\nmedicamentos\npara\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntos\ny\nel\nresfriado,\nson\nlos\nque\nentra\u00f1an\nmayor\nriesgo\npara\nla\npoblaci\u00f3n\npedi\u00e1trica\n(14).\nNo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n20\n \n deben\nusarse\nen\nning\u00fan\ncaso\nen\nni\u00f1os\nmenores\nde\ndos\na\u00f1os\ny\nse\nrecomienda\nevitarlos\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmenores\nde\nsiete\na\u00f1os.\nAdem\u00e1s,\nno\nhan\npodido\ndemostrar\nser\nm\u00e1s\neficaces\nque\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nplacebo\npara\nninguna\nindicaci\u00f3n\n(15),\npor\nlo\nque\nsu\nadici\u00f3n\na\npreparados\nantitusivos\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nest\u00e1 justificada.\n \n\u25cf\nLa\nmiel\nse\nha\nusado\ntradicionalmente\ncomo\nremedio\nnatural\npara\nel\nalivio\nde\nla\ntos.\nEs\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\npocos\nproductos\nnaturales\npara\nlos\nque\nencontramos\nuna\nevidencia\ncient\u00edfica\nde\n \n \n \n \n \n \n \n \n \n \n \n \nbuena\ncalidad\nque\nrespalde\nsu\neficacia\n(16,\n17).\nSer\u00eda\ndeseable\nrealizar\nmejores\nestudios\n \n \n \n \n \n \n \n \n \n \n \n \n \npara\nsaber\ncu\u00e1l\nser\u00eda\nla\ndosis\neficaz,\nsi\nes\nque\nrealmente\nlo\nes.\nSu\nmecanismo\nde\nacci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npodr\u00eda\nser\nmec\u00e1nico\n(demulcente)\nm\u00e1s\nque\nfarmacol\u00f3gico.\nSolo\ndebe\nemplearse\nen\nni\u00f1os\n \n \n \n \n \n \n \n \n \n \n \n \nmayores de un a\u00f1o por riesgo de botulismo.\n \n \n\u25cf\nHiedra\n(\n\u200b\nHedera\nhelix\n\u200b\n).\nAunque\nhay\nnumerosos\nestudios\nindividuales\nque\nconcluyen\nque\n \n \n \n \n \n \n \n \n \n \n \nlos\nextractos\nde\nhiedra\nson\nefectivos\npara\nreducir\nlos\ns\u00edntomas\nde\nlas\ninfecciones\n \n \n \n \n \n \n \n \n \n \n \n \n \nrespiratorias\nagudas,\nsu\nefectividad\nno\nest\u00e1\nclaramente\nestablecida\n(18).\nLos\nestudios\n \n \n \n \n \n \n \n \n \n \n \nrevisados\n\u200b\u200b\nmuestran\nfallos\nmetodol\u00f3gicos\ngraves;\npor\nejemplo,\nno\nse\nhan\ncomparado\n \n \n \n \n \n \n \n \n \n \n \nfrente\na\nplacebo\nni\nse\nha\nempleado\nel\ndoble\nciego.\nPor\nahora\nsu\nuso\nsigue\nsiendo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntradicional\ny\nno\nse\npuede\napoyar\nsu\nutilizaci\u00f3n\nhasta\nque\nse\nrealicen\nmejores\nestudios.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nUso recomendado s\u00f3lo a partir de los dos a\u00f1os.\n \nConclusiones\n \nEl\ntratamiento\nde\nla\ntos\naguda\ninespec\u00edfica\ncarece\nde\nbuenas\nalternativas\nde\ntratamiento,\n \n \n \n \n \n \n \n \n \n \n \n \n \nespecialmente\nsi\nviene\nacompa\u00f1ada\nde\nmucosidad.\nLa\nmayor\u00eda\nde\nf\u00e1rmacos\nempleados\nhoy\n \n \n \n \n \n \n \n \n \n \n \n \nen\nd\u00eda\nno\nposee\npruebas\ncient\u00edficas\ns\u00f3lidas\na\nfavor\nde\nsu\nuso;\nde\nhecho,\nalgunos\ntienen\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfuerte\nevidencia\ncient\u00edfica\nen\nsu\ncontra.\nPara\nel\ntratamiento\nde\nla\ntos\nseca\nen\nmayores\nde\ndos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \na\u00f1os las mejores opciones ser\u00edan la cloperastina y la levodropropizina.\n \nEn\npediatr\u00eda\nno\nexisten\nmedicamentos\nseguros\ny\neficaces\npara\nlos\nmenores\nde\ndos\na\u00f1os\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nedad.\nLos\nefectos\nsecundarios,\naunque\nsean\nmuy\npoco\nfrecuentes,\nhacen\nque,\nal\ntratarse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nprocesos\nbanales\ny\nautolimitados,\nel\nbalance\nbeneficio-riesgo\nde\nalgunos\nde\nestos\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos sea desfavorable.\n \nLa\ngran\nmayor\u00eda\nde\nproductos\nnaturales\nque\nse\nemplean\npara\nel\nalivio\nde\nla\ntos\nlo\nhacen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nbase\na\nsu\nuso\ntradicional,\nsin\ncontar\ncon\npruebas\nque\napoyen\nsu\neficacia.\nLa\nmiel\no\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \njarabes\nque\nla\nincluyan\npodr\u00edan\nser\nuna\nopci\u00f3n\nen\nmayores\nde\n1\na\u00f1o.\nLa\ntos\naguda,\nal\ntratarse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nun\nproceso\nautolimitado\nque\nsolemos\nempezar\na\ntratar\nen\nsu\nmomento\n\u00e1lgido\n(cuando\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsintomatolog\u00eda\ncomienza\na\nremitir),\nes\nnormal\nque\nlos\npacientes\nperciban\nuna\nfalsa\n \n \n \n \n \n \n \n \n \n \n \n \nsensaci\u00f3n de eficacia del tratamiento.\n \n \n \n21\n \n CONGESTI\u00d3N NASAL\n \nSantamar\u00eda Ugarte, A.\n \nLa\ncongesti\u00f3n\nnasal\nes\nla\ninflamaci\u00f3n\nde\nla\nmucosa\nnasal\nproducida\npor\nla\ndilataci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\nvasos\nsangu\u00edneos\nnasales,\nlo\nque\nprovoca\nun\naumento\ndel\nflujo\nsangu\u00edneo\ny\nel\nllenado\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsinusoides.\nComo\nresultado,\nhay\nun\nestrechamiento\nde\nlos\nconductos\nnasales\nque\nsupone\n \n \n \n \n \n \n \n \n \n \n \n \nuna\nobstrucci\u00f3n\ndel\nflujo\nde\naire\ny\nuna\nsensaci\u00f3n\nde\n\u00abnariz\ntapada\u00bb.\nLa\nobstrucci\u00f3n\nnasal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npuede\nser\ntodav\u00eda\nmayor\ncuando\na\nla\ninflamaci\u00f3n\nde\nla\nmucosa\nse\nune\nla\npresencia\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nabundante\nmucosidad.\nSin\nembargo,\nes\nun\nerror\nampliamente\nextendido\npensar\nque\nel\n \n \n \n \n \n \n \n \n \n \n \n \norigen\nde\nuna\nnariz\ncongestionada\nes\nel\nexceso\nde\nmoco.\nEn\nel\ncaso\nde\nlos\nreci\u00e9n\nnacidos,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\ntienden\na\nrespirar\npor\nla\nnariz,\nla\ncongesti\u00f3n\nnasal\npuede\ncausarles\nuna\ndificultad\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrespiratoria mortal (1,2).\n \nEtiolog\u00eda\n \nLos\nsinusoides\nnasales\nson\nlos\nresponsables\nde\nlos\ncambios\nde\nla\nmucosa\nnasal\ny\nest\u00e1n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nregulados\npor\nreceptores\n\u03b1\n-adren\u00e9rgicos\n(sistema\nsimp\u00e1tico).\nLa\nactivaci\u00f3n\nde\nestos\n \n \n \n \n \n \n \n \n \n \nreceptores\n\u03b1\n1\ny\n\u03b1\n2\nproduce\nla\ncontracci\u00f3n\nde\nlas\nc\u00e9lulas\nmusculares\nvasculares\ny\nreduce\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncontenido\nde\nsangre\nde\nla\nmucosa,\ncon\nlo\nque\nse\nconsigue\nla\ndescongesti\u00f3n\ny\nel\naumento\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nflujo\na\u00e9reo.\nDe\nlos\ndos\ntipos\nde\nreceptores,\nlos\n\u03b1\n2\nson\nlos\nprincipales\nresponsables\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncontrol del proceso (2, 5).\n \nLos\ns\u00edndromes\ncl\u00ednicos\nm\u00e1s\ncomunes\nque\ncursan\ncon\ncongesti\u00f3n\nnasal\nson\nlas\nafecciones\n \n \n \n \n \n \n \n \n \n \n \n \n \nagudas\ndel\ntracto\nrespiratorio\nsuperior\n(sobre\ntodo\nel\nresfriado\ncom\u00fan),\nla\nrinitis\n(al\u00e9rgica,\n \n \n \n \n \n \n \n \n \n \n \n \n \nvasomotora\no\nmedicamentosa)\ny\nla\nsinusitis\ncr\u00f3nica.\nLa\ncongesti\u00f3n\nnasal,\na\nsu\nvez,\npuede\ndar\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlugar\na\nsecuelas\ncomo\nsinusitis\n(inflamaci\u00f3n\nde\nla\nmucosa\nde\nlos\nsenos\nparanasales),\notitis\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmedia y trastornos del sue\u00f1o, incluida la apnea obstructiva del sue\u00f1o (3, 4, 5).\n \nTratamiento\n \nEl\ntratamiento\nfarmacol\u00f3gico\nde\nla\ncongesti\u00f3n\nnasal\nse\nbasa\nen\nel\nempleo\nde\nf\u00e1rmacos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\naumenten\nla\npermeabilidad\nde\nlas\nmembranas\nmucosas\npara\nas\u00ed\ndescongestionar\nla\n \n \n \n \n \n \n \n \n \n \n \n \nzona.\nLos\ndescongestivos\n\u03b1\n-adren\u00e9rgicos,\ntambi\u00e9n\nllamados\nsimpaticomim\u00e9ticos,\npueden\n \n \n \n \n \n \n \n \nadministrarse\npor\nv\u00eda\nt\u00f3pica\n(oximetazolina,\nxilometazolina,\nnafazolina)\no\nsist\u00e9mica\n \n \n \n \n \n \n \n \n \n(fenilefrina,\npseudoefedrina).\nAunque\nno\nse\nhayan\nrealizado\nestudios\ncomparativos,\nse\n \n \n \n \n \n \n \n \n \n \nacepta\nque\nlos\nf\u00e1rmacos\nt\u00f3picos\nson\nm\u00e1s\neficaces\nque\nlos\nf\u00e1rmacos\nsist\u00e9micos\nfrente\na\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncongesti\u00f3n nasal (6, 7).\n \n\u25cf\nDescongestivos\nt\u00f3picos.\nLos\nm\u00e1s\nempleados\nson\nlos\nagonistas\n\u03b1\n2,\nque\nproducen\n \n \n \n \n \n \n \n \n \n \n \nefectos\nm\u00e1s\npotentes,\nduraderos\ny\nselectivos\nque\nlos\ndescongestivos\norales.\nSuelen\n \n \n \n \n \n \n \n \n \n \n \npresentarse\nen\nforma\nde\naerosoles\no\ngotas\ny\nel\nf\u00e1rmaco\nde\nreferencia\nes\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \noximetazolina.\nEn\ngeneral,\ntienen\nun\ncomienzo\nde\nacci\u00f3n\nlento\npero\nprolongado\n \n \n \n \n \n \n \n \n \n \n \n(oximetazolina\ny\nxilometazolina,\ncon\n8-12\nh,\nfrente\na\nlas\n4-6\nh\nde\nnafazolina).\nAunque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsu\nactividad\nes\nmuy\nparecida,\nuna\ndiferencia\na\ntener\nen\ncuenta\nes\nla\nduraci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nacci\u00f3n.\n \n \n22\n \n El\nprincipal\nefecto\nadverso\ndel\nabuso\nde\ndescongestivos\nt\u00f3picos\nes\nla\nrinitis\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentosa,\nque\nconsiste\nen\nuna\nreaparici\u00f3n\nde\nlos\ns\u00edntomas\nuna\nvez\nsuspendido\n \n \n \n \n \n \n \n \n \n \n \n \nel\nf\u00e1rmaco\n(\u00abefecto\nrebote\u00bb).\nNo\nhay\nque\nconfundir\nesta\ncongesti\u00f3n\ncon\nuna\nreca\u00edda\n \n \n \n \n \n \n \n \n \n \n \n \n \ny\nvolver\na\nusar\nel\nmedicamento,\nporque\nse\nentrar\u00eda\nen\nun\nc\u00edrculo\nvicioso.\nPara\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprevenir\nel\nefecto\nrebote\nhay\nque\nevitar\nel\nuso\nprolongado\nde\nlos\nagentes\n \n \n \n \n \n \n \n \n \n \n \n \n \nadren\u00e9rgicos\nt\u00f3picos:\nno\nm\u00e1s\nde\n2\no\n3\nd\u00edas.\nPara\ntratamientos\nprolongados,\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \npreferible utilizar descongestivos orales (2, 5, 8, 9, 10).\n \n\u25cf\nDescongestivos\norales.\nSon\naminas\nsimpaticomim\u00e9ticas\nque\nse\nadministran\npor\nv\u00eda\n \n \n \n \n \n \n \n \n \n \noral\ny\nque\ndespu\u00e9s\nde\nsu\ndistribuci\u00f3n\nsist\u00e9mica\nllegan\na\nla\nmucosa\nnasal,\ndonde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nejercen\nsu\nacci\u00f3n\nvasoconstrictora.\nEntre\nlos\nm\u00e1s\nutilizados\nse\nencuentran\nla\n \n \n \n \n \n \n \n \n \n \n \nfenilefrina\ny\nla\npseudoefedrina,\nque\npodemos\nencontrar\nen\nmedicamentos\nasociados\n \n \n \n \n \n \n \n \n \n \na\ncorticoides\no\nantihistam\u00ednicos.\nA\ndiferencia\nde\nlos\ndescongestivos\nt\u00f3picos,\nprovocan\n \n \n \n \n \n \n \n \n \n \n \nuna\nmenor\nirritaci\u00f3n\nlocal\ny\nno\nproducen\ncongesti\u00f3n\nde\nrebote\nal\nsuspender\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento.\nSe\nhan\ndescrito\nreacciones\nadversas\npoco\nfrecuentes\npero\ngraves,\na\n \n \n \n \n \n \n \n \n \n \n \nmenudo\nrelacionadas\ncon\nuna\nsobredosificaci\u00f3n:\ninsomnio,\ntemblor,\nhiperactividad,\n \n \n \n \n \n \n \n \npalpitaciones\ne\nhipertensi\u00f3n\npor\nla\nvasoconstricci\u00f3n\nperif\u00e9rica\nque\nproducen.\nPor\nello\n \n \n \n \n \n \n \n \n \n \n \nest\u00e1n\ncontraindicadas\nen\npacientes\nhipertensos\no\ncon\ntrastornos\ncardiacos,\n \n \n \n \n \n \n \n \n \nhipertiroideos,\ndiab\u00e9ticos\ny\npacientes\ncon\nglaucoma.\nAdem\u00e1s,\nno\ndeben\n \n \n \n \n \n \n \n \n \nadministrarse\nen\npacientes\ntratados\ncon\nIMAO\npor\nla\nposible\naparici\u00f3n\nde\nuna\ncrisis\n \n \n \n \n \n \n \n \n \n \n \n \n \nhipertensiva\ngrave.\nNo\nse\nrecomienda\nsu\nuso\nen\nmujeres\nembarazadas\nni\nlactantes\n(1,\n \n \n \n \n \n \n \n \n \n \n \n \n \n2, 5, 9, 11).\n \n\u25cf\nCorticoides\nintranasales.\nInhiben\nla\ninflamaci\u00f3n\nde\nla\nmucosa\nde\nlas\nfosas\nnasales\n \n \n \n \n \n \n \n \n \n \n \n \nactuando\nen\nm\u00faltiples\npuntos\nde\nla\ncascada\ninflamatoria.\nLos\nnuevos\ncorticoides\n \n \n \n \n \n \n \n \n \n \n \ninhalados,\ncomo\nmometasona\ny\nfluticasona,\ntienen\nuna\nbiodisponibilidad\nsist\u00e9mica\n \n \n \n \n \n \n \n \n \nmuy\nbaja\nen\ncomparaci\u00f3n\ncon\nbudesonida\no\ntriamcinolona.\nSeg\u00fan\nalgunos\nestudios,\n \n \n \n \n \n \n \n \n \n \n \nla\nbeclometasona\npuede\nproducir\nsupresi\u00f3n\ndel\neje\nhipot\u00e1lamo-hipofisario\ny\nretraso\n \n \n \n \n \n \n \n \n \n \nen\nel\ncrecimiento.\nUtilizados\na\nlas\ndosis\nrecomendadas\npueden\nproducir\nefectos\n \n \n \n \n \n \n \n \n \n \n \nadversos\nde\ncar\u00e1cter\nleve\ncomo\nsequedad,\nirritaci\u00f3n\ny\nhemorragia\nnasal,\nlos\ncuales\n \n \n \n \n \n \n \n \n \n \n \n \npueden\nser\ncausados\npor\nuna\nt\u00e9cnica\nde\nadministraci\u00f3n\ninapropiada.\nA\npesar\nde\nser\n \n \n \n \n \n \n \n \n \n \n \n \n \nunos\nf\u00e1rmacos\nmuy\nseguros,\nla\nmayor\u00eda\nde\nestudios\nson\nde\ncorta\nduraci\u00f3n,\npor\nlo\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nse necesitan investigaciones a largo plazo para evaluar su seguridad (16, 17, 18).\n \n\u25cf\nAntihistam\u00ednicos.\nSon\nantagonistas\nH1\ny\nsuelen\nincluirse\nen\nlas\nformulaciones\nde\n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\npor\nsus\nefectos\nanticolin\u00e9rgicos.\nNo\ntienen\nefectos\ncl\u00ednicamente\n \n \n \n \n \n \n \n \n \nsignificativos\nsobre\nla\ncongesti\u00f3n\nnasal.\nNo\nhay\npruebas\nsuficientes\npara\napoyar\nla\n \n \n \n \n \n \n \n \n \n \n \n \nprescripci\u00f3n\no\nla\nadquisici\u00f3n\nsin\nprescripci\u00f3n\nde\nantihistam\u00ednicos\npara\naliviar\nla\n \n \n \n \n \n \n \n \n \n \n \ncongesti\u00f3n nasal (9, 12, 13).\n \n \n \n23\n \n \u25cf\nSuero\nsalino\ny\nagua\nde\nmar.\nAyudan\na\neliminar\nlas\nsecreciones\ny\na\ndescongestionar\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmucosas.\nSon\nel\ntratamiento\nde\nelecci\u00f3n\nen\nni\u00f1os\npeque\u00f1os\npor\nser\nuna\nopci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \nsegura\nfrente\nal\nuso\nde\ndescongestivos.\nSeg\u00fan\nuna\nrevisi\u00f3n\nCochrane\nde\n2015,\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nirrigaci\u00f3n\ncon\nsoluci\u00f3n\nsalina\nposiblemente\ntenga\nbeneficios\npara\naliviar\nlos\ns\u00edntomas\n \n \n \n \n \n \n \n \n \n \n \nde\nlas\ninfecciones\nrespiratorias\nagudas\ndel\ntracto\nsuperior.\nSin\nembargo,\nlos\nensayos\n \n \n \n \n \n \n \n \n \n \n \n \nincluidos\nfueron\ndemasiado\npeque\u00f1os\ny\ntuvieron\nun\nalto\nriesgo\nde\nsesgo,\nlo\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \nredujo\nla\nconfianza\nen\nlas\npruebas\nque\nlo\nrespaldan.\nEn\nlos\npocos\nestudios\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncomparan\nla\nirrigaci\u00f3n\ncon\nsuero\nsalino\nfrente\na\nla\npulverizaci\u00f3n\ncon\nagua\nde\nmar,\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconcluye\nque\nla\nefectividad\nde\nla\nsoluci\u00f3n\nsalina\nes\nmayor\nque\nla\ndel\nagua\nde\nmar\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nel\nalivio\nde\nlos\ns\u00edntomas\nnasales,\npero\nhar\u00edan\nfalta\nm\u00e1s\nestudios\nsobre\nesta\nmateria\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(14, 15, 19).\n \n\u25cf\nFitoterapia.\nEl\neucalipto\nes\nuna\nplanta\ncom\u00fanmente\nutilizada\npara\naliviar\nla\n \n \n \n \n \n \n \n \n \n \n \ncongesti\u00f3n\nnasal.\nSuele\npresentarse\nen\nforma\nde\nhoja\ntriturada\npara\nla\npreparaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \nde\nuna\ninfusi\u00f3n\npara\nbeber\no\ninhalar\no\ncomo\nun\nl\u00edquido\npara\ningerir\npor\nv\u00eda\noral.\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAgencia\nEuropea\ndel\nMedicamento\n(EMA)\naprueba\nel\nuso\ntradicional\nde\nla\nhoja\ny\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \naceite\nesencial\nde\neucalipto\npara\nel\nalivio\nde\nla\ntos\nasociada\na\nlos\nresfriados.\nSeg\u00fan\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nuna\nrevisi\u00f3n\ndel\n2017\nsobre\nel\nuso\nde\nla\nfitoterapia\nen\notorrinolaringolog\u00eda,\nse\nha\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nvisto\nque\nel\neucalipto\n(entre\notras\nplantas)\nmuestra\nsuperioridad\nsobre\nel\nplacebo\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\ns\u00edntomas\nde\nla\nrinosinusitis\ny\nrinitis\nal\u00e9rgica.\nA\npesar\nde\nello,\nla\nevidencia\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlimitada,\npor\nlo\nque\nno\nse\npodr\u00eda\nrecomendar\npara\nel\ntratamiento\nde\nla\ncongesti\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnasal (20, 21).\n \nConclusiones\n \nLos\ndescongestivos\nadren\u00e9rgicos,\ntanto\nnasales\ncomo\norales,\nhan\ndemostrado\nser\n \n \n \n \n \n \n \n \n \n \neficaces\nante\nla\ncongesti\u00f3n\nnasal.\nLos\ncorticoides\nintranasales,\na\npesar\nde\nser\nefectivos\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmayor\u00eda\nde\npacientes,\nno\ndemostraron\nuna\nmejor\u00eda\nsignificativa\nde\nlos\ns\u00edntomas\nen\n \n \n \n \n \n \n \n \n \n \n \n \nsubgrupos\nimportantes,\npor\nlo\nque\nse\nrequieren\nm\u00e1s\nestudios.\nPor\nel\ncontrario,\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \nantihistam\u00ednicos\nno\ntienen\nning\u00fan\nefecto\nsignificativo\nsobre\nla\ncongesti\u00f3n\nnasal.\nTanto\nel\n \n \n \n \n \n \n \n \n \n \n \n \nsuero salino como la fitoterapia necesitan m\u00e1s estudios para demostrar su efectividad.\n \n \n \n24\n \n RINITIS AL\u00c9RGICA\n \nCal Seijas, R.\n \nSe\ndefine\nla\nrinitis\nal\u00e9rgica\n(RA)\ncomo\nun\ntrastorno\nsintom\u00e1tico\nde\nla\nnariz\ncausado\npor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nuna\ninflamaci\u00f3n\nde\nlas\nmembranas\nmediada\npor\nIgE\ntras\nla\nexposici\u00f3n\na\nun\ndeterminado\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nal\u00e9rgeno\n(1).\n\u200b\nCl\u00ednicamente\nse\ncaracteriza\npor\nestornudos\nen\nserie,\nrinorrea,\nobstrucci\u00f3n\nnasal\n \n \n \n \n \n \n \n \n \n \n \n \ny\nprurito.\nEs\nmuy\nfrecuente\nsu\npresentaci\u00f3n\ncl\u00ednica\ncomo\nrinoconjuntivitis.\nActualmente\nse\n \n \n \n \n \n \n \n \n \n \n \n \nconsidera\nla\nrinitis\ny\nel\nasma\nal\u00e9rgica\ncomo\ndiferentes\nexpresiones\ncl\u00ednicas\nde\nuna\nmisma\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nenfermedad\ninflamatoria\nmediada\npor\nIgE\nque\nafecta\na\ntoda\nla\nv\u00eda\nrespiratoria\n(3).\nEs\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nimprescindible\nel\nadecuado\ndiagn\u00f3stico\npara\ndiferenciar\nentre\nRA\ny\notros\ntipos\nde\nrinitis\n(5)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\ncursan\ncon\nmanifestaciones\ncl\u00ednicas\nmuy\nsimilares\ncomo\nrinitis\ninfecciosa,\ninducida\npor\n \n \n \n \n \n \n \n \n \n \n \n \nf\u00e1rmacos, NARES (s\u00edndrome de rinitis no al\u00e9rgica con eosinofilia nasal), etc.\n \nLa\nrinitis\nal\u00e9rgica\nes\nuna\nenfermedad\nde\nelevada\nprevalencia\n(>\n20%),\nespecialmente\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninfancia\ny\nadolescencia.\nEn\nlos\n\u00faltimos\na\u00f1os\nse\nha\nobservado\nun\naumento\nde\nsu\nincidencia\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npa\u00edses\nen\ndesarrollo\n(2).\nEs\npor\nello\nque\nconstituye\nuno\nde\nlos\nprincipales\nmotivos\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconsulta\nen\nalergolog\u00eda\ny\nes\ncausa\nfrecuente\nde\nconsultas\ny\nsolicitudes\nde\nindicaci\u00f3n\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfarmacia\ncomunitaria.\nLos\nagentes\ndesencadenantes\ninvolucrados\nen\nla\nRA\nm\u00e1s\nhabituales\n \n \n \n \n \n \n \n \n \n \n \nson\np\u00f3lenes\nde\ndiferentes\nespecies\nvegetales\n(gram\u00edneas,\ncipr\u00e9s,\nolivo,\nmalezas\n\u2026\n),\nmohos\n \n \n \n \n \n \n \n \n \n \n \n(\n\u200b\nAlternaria,\nCladosporium,\nAspergillus\n\u200b\ny\nPenicilium\n\u200b\n),\n\u00e1caros\ndel\npolvo\ndom\u00e9stico\n \n \n \n \n \n \n \n \n \n(\n\u200b\nDermatophagoides\npteronyssinus\n\u200b\n,\n\u200b\nD.\nfarinae\n\u200b\n)\ny\nanimales\ndom\u00e9sticos\n(perros,\ngatos,\n \n \n \n \n \n \n \n \n \nratones\n\u2026\n) (4).\n \nLa\nrinitis\nal\u00e9rgica\npuede\nclasificarse\ncomo\nRA\nestacional\no\nRA\nperenne\nen\nfunci\u00f3n\nde\nsi\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas\nse\nproducen\nen\nuna\n\u00e9poca\nconcreta\no\nsi\nest\u00e1n\npresentes\nla\nmayor\nparte\ndel\na\u00f1o.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nQuiz\u00e1\nsea\nm\u00e1s\nadecuada\nla\nclasificaci\u00f3n\npropuesta\nen\nel\ndocumento\nARIA\n(5),\nque\nclasifica\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nRA\nen\nfunci\u00f3n\nde\nsu\nduraci\u00f3n\nen\nintermitente\ny\npersistente,\ny\nen\nfunci\u00f3n\nde\nsu\ngravedad\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nleve, moderada o grave.\n \nTratamiento\n \nAntihistam\u00ednicos\n \nLos\nantihistam\u00ednicos\norales\n(cetirizina,\nloratadina\no\nmizolastina)\nconstituyen\nuno\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \ntratamientos\nm\u00e1s\nempleados\nen\nla\nRA.\nSon\neficaces\naliviando\nalgunos\nde\nlos\ns\u00edntomas\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nRA\nestacional\n(6),\n\u200b\npero\nse\nconsidera\nque\nson\nmenos\neficaces\nque\nlos\ncorticoides.\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nefectividad\nde\nlos\nantihistam\u00ednicos\nintranasales\ncomo\nlevocabastina\no\nazelastina\nha\nsido\n \n \n \n \n \n \n \n \n \n \n \ndemostrada\nen\nel\nalivio\nde\nlos\ns\u00edntomas\nde\nla\nRA\nestacional\n(7);\nde\nhecho,\nalgunos\nestudios\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmuestran ventajas de la administraci\u00f3n intranasal frente a la v\u00eda oral (8).\n \nNo\nse\nrecomienda\nel\nuso\ncombinado\nde\nantihistam\u00ednicos\ny\ncorticoides\nnasales\nen\nni\u00f1os\n \n \n \n \n \n \n \n \n \n \n \n \n \ndebido\na\nla\nausencia\nde\npruebas\nde\nque\nla\ncombinaci\u00f3n\nsea\nmejor\nque\nlos\ncorticoides\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmonoterapia,\nadem\u00e1s\nde\nsuponer\nun\naumento\ndel\ncoste\ny\nuna\nmayor\nprobabilidad\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nefectos\nsecundarios\n(9).\nLos\nefectos\nsecundarios\nm\u00e1s\nfrecuentes\nson\nsomnolencia\ny\nsedaci\u00f3n,\n \n \n \n \n \n \n \n \n \n \n \n \nespecialmente con los antihistam\u00ednicos de primera generaci\u00f3n.\n \n25\n \n Corticoides\n \nLos\ncorticoides\nintranasales\nson\nla\nmejor\nopci\u00f3n\nterap\u00e9utica\nen\nel\ntratamiento\nde\nla\nRA\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nadultos\ny\nen\nni\u00f1os\na\npartir\nde\n6\na\u00f1os,\ny\nson\nespecialmente\neficaces\nen\nel\nalivio\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncongesti\u00f3n\nnasal\n(10).\nNo\nse\nha\nobservado\nretraso\nen\nel\ncrecimiento\nen\nni\u00f1os\ncon\nRA\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nperenne\ny\ntratamiento\ncon\ncorticoides\nintranasales\nde\n\u00faltima\ngeneraci\u00f3n\n(propionato\nde\n \n \n \n \n \n \n \n \n \n \n \nfluticasona\no\nfuroato\nde\nmometasona)\n(11).\nNo\nse\naconseja\nla\nutilizaci\u00f3n\nde\ncorticoides\n \n \n \n \n \n \n \n \n \n \n \n \n \norales\nexcepto\nen\ncasos\nde\nobstrucci\u00f3n\nnasal\ngrave\no\ncomo\nmedicaci\u00f3n\nde\nrescate\nen\ncasos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndonde los s\u00edntomas no puedan ser controlados con tratamientos de primera elecci\u00f3n (12).\n \nFitoterapia\n \nAlgunas\ndrogas\nvegetales\nse\nasocian\ncon\nefectos\nantial\u00e9rgicos,\nantiinflamatorios\ne\n \n \n \n \n \n \n \n \n \n \ninmunomoduladores.\nA\npesar\nde\nque\nvarios\nestudios\napuntan\na\nque\nalgunas\nplantas\n \n \n \n \n \n \n \n \n \n \n \n \nmedicinales\npodr\u00edan\nser\n\u00fatiles\npara\naliviar\nlos\ns\u00edntomas\nde\nla\nRA,\nla\nbaja\ncalidad\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninvestigaciones impide poder realizar ninguna recomendaci\u00f3n sobre su uso (13).\n \n \n Lavados nasales\n \nLa\nirrigaci\u00f3n\ncon\nsuero\nsalino\npodr\u00eda\nser\nuna\nopci\u00f3n\neficaz,\nsegura\ny\necon\u00f3mica\nfrente\nal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nuso\nde\ncorticoides\no\nantihistam\u00ednicos.\nNo\nobstante,\nla\ncalidad\nde\nla\nevidencia\npara\nhacer\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomendaci\u00f3n\nes\nbaja.\nHar\u00edan\nfalta\nmejores\nestudios\nsobre\nesta\nmateria\ny\nque\ncomparasen\n \n \n \n \n \n \n \n \n \n \n \n \n \nlos distintos tipos de soluciones salinas (14).\n \nDescongestivos\n \nLos\ndescongestivos\norales\n(fenilefrina,\npseudoefedrina),\nsolos\no\ncombinados\ncon\n \n \n \n \n \n \n \n \n \nantihistam\u00ednicos\norales,\nmejoran\nlos\ns\u00edntomas\nde\nla\nRA\nestacional\ny\nsu\ncombinaci\u00f3n\nresulta\n \n \n \n \n \n \n \n \n \n \n \n \n \nm\u00e1s\neficaz\nque\nambos\nf\u00e1rmacos\npor\nseparado.\nEn\nraras\nocasiones\npueden\nocasionar\n \n \n \n \n \n \n \n \n \n \n \n \ninsomnio,\ntemblor,\nxerostom\u00eda,\nhiperactividad,\npalpitaciones\ne\nhipertensi\u00f3n,\npor\nlo\nque\nno\n \n \n \n \n \n \n \n \n \n \n \nse\naconseja\nsu\nuso\nen\npacientes\ncon\narritmias,\nenfermedad\ncoronaria,\nhipertensi\u00f3n,\n \n \n \n \n \n \n \n \n \n \n \nhipertiroidismo, glaucoma, diabetes o disfunci\u00f3n urinaria (15).\n \nLos\ndescongestivos\nnasales\ndisminuyen\nr\u00e1pidamente\nla\nobstrucci\u00f3n\nnasal,\npero\nno\nse\n \n \n \n \n \n \n \n \n \n \n \naconseja\nsu\nuso\nprolongado\npor\nel\nefecto\nrebote\nque\nse\nproduce\nsi\nse\nusan\nm\u00e1s\nde\n3-4\nd\u00edas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(16).\nTambi\u00e9n\npreocupa\nsu\nseguridad\nen\nla\npoblaci\u00f3n\npedi\u00e1trica\n(17):\nel\nuso\npor\nv\u00eda\noral\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npseudoefedrina\nest\u00e1\ncontraindicado\nen\nmenores\nde\n12\na\u00f1os.\nLos\ndescongestivos\nen\naerosol\n \n \n \n \n \n \n \n \n \n \n \n \n(xilometazolina) tampoco deben usarse en menores de 6 a\u00f1os.\n \nInmunoterapia\n \nLa\ninmunoterapia\ncon\nadministraci\u00f3n\nde\nal\u00e9rgenos\nespec\u00edficos\nreduce\nde\nforma\n \n \n \n \n \n \n \n \n \n \nsignificativa\nlos\ns\u00edntomas\nde\nla\nRA\nestacional,\nreduciendo\nla\nnecesidad\nde\ntratamiento\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \npresentando escasos efectos secundarios (18).\n \nComo\nvemos,\nla\nrinitis\nal\u00e9rgica\nes\nuna\npatolog\u00eda\ncon\nalta\nprevalencia.\nHay\ndiferentes\ntipos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nrinitis\ncon\ncl\u00ednicas\nmuy\nsemejantes,\npor\nlo\nque\nes\nindispensable\nrealizar\nun\ndiagn\u00f3stico\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndiferencial.\nEs\nimportante\nque\nel\npaciente\nconozca\nel\nagente\ndesencadenante\nde\nsu\n \n \n \n \n \n \n \n \n \n \n \n \npatolog\u00eda para, en la medida de lo posible, evitar la exposici\u00f3n.\n \n26\n \n CONJUNTIVITIS\n \nSelvi Sabater, P.\n \nLa\nconjuntivitis\nse\ndefine\ncomo\nuna\ninflamaci\u00f3n\nde\nla\nconjuntiva\nsin\nafecci\u00f3n\ncorneal\n(1).\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nLa\nconjuntiva\nes\nla\nmembrana\nmucosa\nque\nrecubre\nla\nsuperficie\ninterna\nde\nlos\np\u00e1rpados\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(conjuntiva\npalpebral)\ny\nla\nesclera\nanterior\nhasta\nel\nlimbo\nesclerocorneal\n(conjuntiva\nbulbar).\n \n \n \n \n \n \n \n \n \n \n \n \nLa conjuntiva, generalmente transparente, se torna de color rosa-rojo al estar inflamada.\n \nSe\ntrata\nde\nla\nenfermedad\nocular\nm\u00e1s\nfrecuente\ny\nsuele\nser\nautolimitada\ny\nsin\nsecuelas.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nLas\nconjuntivitis\nse\npueden\nclasificar\nen\ninfecciosas\ny\nno\ninfecciosas.\nA\nsu\nvez,\nlas\ninfecciosas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npueden\ndividirse\nen\nbacterianas\ny\nv\u00edricas\ny\nlas\nno\ninfecciosas\nen\nal\u00e9rgicas\ny\nno\nal\u00e9rgicas.\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprevalencia\nde\nla\nconjuntivitis\ndifiere\nen\nfunci\u00f3n\nde\nsu\netiolog\u00eda,\nsiendo\nla\ninfecciosa\nla\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncom\u00fan en ni\u00f1os, y la v\u00edrica m\u00e1s com\u00fan que la bacteriana tanto en ni\u00f1os como en adultos (2).\n \nIndependientemente\nde\nsu\netiopatolog\u00eda,\nsuelen\ncursar\ncon\nuno\no\nvarios\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \nsiguientes\ns\u00edntomas:\nojo\nrojo,\nsensaci\u00f3n\nde\ncuerpo\nextra\u00f1o,\nfotosensibilidad,\nlagrimeo\ny\n \n \n \n \n \n \n \n \n \n \n \npicor.\nNo\nsuelen\ncursar\ncon\ndolor\nni\ncon\np\u00e9rdida\nde\nvisi\u00f3n.\nAunque\nes\ndif\u00edcil\npoder\ndistinguir\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\ntipos\nde\nconjuntivitis,\npodemos\nobservar\ndiferencias\nen\nel\ntipo\nde\nsecreci\u00f3n,\nla\npresencia\n \n \n \n \n \n \n \n \n \n \n \n \n \n \no no de lagrimeo y prurito, etc. (3)\n \n \nLa\nconjuntivitis\nal\u00e9rgica\nsuele\nestar\ndesencadenada\npor\nal\u00e9rgenos\nque,\nen\ncontacto\ncon\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \nojo,\nproducen\ndesgranulaci\u00f3n\nde\nmastocitos\nmediada\npor\nIgE,\nliberando\nhistamina\ny\notros\n \n \n \n \n \n \n \n \n \n \n \n \nmediadores.\nUno\nde\nlos\nprincipales\ns\u00edntomas\nen\neste\ntipo\nde\nconjuntivitis\nes\nel\npicor,\ny\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndebe tener precauci\u00f3n, puesto que rascarse el ojo puede empeorar los s\u00edntomas.\n \nLa\nconjuntivitis\nno\nal\u00e9rgica\n(y\nno\ninfecciosa)\npuede\nestar\ncausada\npor\nproductos\nqu\u00edmicos\n \n \n \n \n \n \n \n \n \n \n \n \n \no\nenfermedades\nsist\u00e9micas\ncon\nmanifestaci\u00f3n\nocular\n(generalmente,\nenfermedades\n \n \n \n \n \n \n \n \ninmunomediadas).\n \nLa\nconjuntivitis\nv\u00edrica,\nt\u00edpicamente\nproducida\npor\nadenovirus\n(aunque\ntambi\u00e9n\npor\n \n \n \n \n \n \n \n \n \n \nherpes\nvirus),\npuede\nestar\nacompa\u00f1ada\nde\ninfecciones\nde\nzonas\ncercanas\ncomo\notitis\no\n \n \n \n \n \n \n \n \n \n \n \n \n \ninfecciones\ndel\ntracto\nrespiratorio\nsuperior.\nSe\ntrata\nde\nuna\ninfecci\u00f3n\nmuy\ncontagiosa,\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \nsuele afectar al segundo ojo tras 24-48 h de la infecci\u00f3n del primero.\n \nLa\nconjuntivitis\nbacteriana\nsuele\nestar\nproducida\npor\n\u200b\nStaphylococcus\naureus\n(el\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \ncom\u00fan\nen\nadultos),\n\u200b\nStreptococcus\npneumoniae\ny\n\u200b\nHaemophilus\ninfluenzae\n\u200b\n.\n(4)\nPodemos\n \n \n \n \n \n \n \n \n \n \ndistinguir\nun\nsubtipo\nque\nser\u00eda\nla\nconjuntivitis\nbacteriana\nhiperaguda,\ncausada\npor\n\u200b\nNeisseria\n\u200b\n,\n \n \n \n \n \n \n \n \n \n \n \n \nsobre\ntodo\n\u200b\nN.\ngonorrhoeae\n\u200b\n,\nque\nse\ntransmite\npor\ncontacto\nsexual\ny\npresenta\nun\ncurso\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nenfermedad r\u00e1pido.\n \n \n \n27\n \n Tratamiento de la conjuntivitis bacteriana\n \nA\npesar\nde\nser\nuna\nenfermedad\nautolimitada,\nel\nuso\nde\nantibi\u00f3ticos\nt\u00f3picos\ndisminuye\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntiempo hasta la recuperaci\u00f3n.\n \n \nLa\nColaboraci\u00f3n\nCochrane\nrealiz\u00f3\nuna\nrevisi\u00f3n\nen\n2012\nde\nlos\ntratamientos\nde\n \n \n \n \n \n \n \n \n \n \n \n \nantibi\u00f3ticos\nt\u00f3picos,\ndonde\nse\nlocalizaron\n11\nensayos\ncl\u00ednicos\naleatorios\n(dos\nde\nalta\ncalidad\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nel\nresto\nclasificados\ncomo\ncalidad\ndeficiente)\nque\nreclutaban\nun\ntotal\nde\n3673\npacientes.\nLos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmetan\u00e1lisis\nde\nlos\ndatos\nsobre\ntasa\nde\nremisi\u00f3n\ncl\u00ednica\ny\nmicrobiol\u00f3gica\nmostraron\nbeneficio\n \n \n \n \n \n \n \n \n \n \n \n \n \nen remisi\u00f3n temprana y tard\u00eda (5).\n \nLos\nantibi\u00f3ticos\nt\u00f3picos\nde\nelecci\u00f3n\nson\neritromicina\ny\ntrimetoprim-polimixina\nB,\naunque\n \n \n \n \n \n \n \n \n \n \n \n \ntambi\u00e9n\nes\nposible\nutilizar\notros\ncomo\nfluoroquinolonas,\nbacitracina\no\ncloranfenicol.\nEn\nni\u00f1os\n \n \n \n \n \n \n \n \n \n \n \n \nes\npreferible\nel\nuso\nde\npomadas\noft\u00e1lmicas,\ndebido\na\nla\ncomplejidad\nde\npoder\nadministrar\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ngotas\noculares.\nEn\nel\ncaso\nde\nconjuntivitis\nen\npacientes\nque\nusen\nlentillas\ny\nante\nel\nriesgo\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninfecci\u00f3n\npor\n\u200b\nPseudomonas\naeruginosa\n\u200b\n,\nse\nrecomienda\nel\nuso\npreferente\nde\n \n \n \n \n \n \n \n \n \n \nfluoroquinolonas (6).\n \nLos\ncorticoides\nt\u00f3picos\nno\ndeben\nutilizarse\nde\nmanera\nrutinaria\nen\nla\nconjuntivitis\n \n \n \n \n \n \n \n \n \n \n \n \nbacteriana\ndebido\na\nque\nse\nasocian\na\ncomplicaciones\ncomo\nda\u00f1o\ncorneal\no\nperforaci\u00f3n.\n \n \n \n \n \n \n \n \n \n \n \n \n \nAdem\u00e1s, el tratamiento cr\u00f3nico se asocia a glaucoma y caratas.\n \nFitoterapia\n \nA\npesar\ndel\nuso\nextendido\nde\ncolirios\na\nbase\nde\nplantas\npara\nel\ntratamiento\nde\ndiferentes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntipos\nde\nconjuntivitis,\nno\nexisten\nensayos\ncl\u00ednicos\nadecuados\nque\nrespalden\nel\nuso\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nproductos\na\nbase\nde\n\u200b\nEuphrasia\nofficinalis\n\u200b\n(7),\nagua\nde\n\u200b\nHammamelis\no\nde\nmanzanilla.\nSe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnecesitan\nestudios\nespec\u00edficos\nen\nhumanos\nque\ndemuestren\nbeneficios\nfrente\nal\nlavado\ncon\n \n \n \n \n \n \n \n \n \n \n \n \nsuero fisiol\u00f3gico.\n \n \nAtenci\u00f3n farmac\u00e9utica\n \nCabe\nrecalcar\nque\ntodos\nlos\ncolirios\ncon\nantibi\u00f3ticos\no\ncorticoides\nrequieren\nreceta\n \n \n \n \n \n \n \n \n \n \n \n \nm\u00e9dica.\nAnte\nun\ncaso\nde\nojo\nrojo\nsospechoso\nde\nuna\nposible\nconjuntivitis\ninfecciosa,\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnecesario\nderivar\nal\npaciente\na\nsu\nm\u00e9dico\npara\nque\nse\npueda\nrealizar\nun\ndiagn\u00f3stico\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndiferencial\ne\ninstaurar\nel\ntratamiento\nde\nelecci\u00f3n.\nSe\ndebe\nprestar\nespecial\natenci\u00f3n\na\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmedidas\nhigi\u00e9nicas,\nya\nque\nson\n\u00fatiles\npara\neliminar\ncontaminantes,\nal\u00e9rgenos\ny\npara\nreducir\n \n \n \n \n \n \n \n \n \n \n \n \n \ny prevenir infecciones.\n \nDesde\nla\nfarmacia\nhay\nque\ninsistir\nen\nun\nuso\nadecuado\nde\ncolirios\ny\npomadas\noft\u00e1lmicas,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecordando su correcta forma de administraci\u00f3n y conservaci\u00f3n.\n \n \nDebe\nrecomendarse\nevitar\nel\nuso\nde\nremedios\ncaseros\ncomo\nlos\nlavados\ncon\nagua\ny\nsal\no\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncon\nmanzanilla,\nya\nque\naumentan\nlos\nposibles\nefectos\nsecundarios\nsin\nhaber\ndemostrado\n \n \n \n \n \n \n \n \n \n \n \n \nbeneficio alguno.\n \n \n \n28\n \n BLEFARITIS\n \nCal Seijas, R.\n \nLa\nblefaritis\nes\nuna\ninflamaci\u00f3n\ndifusa\ndel\nborde\npalpebral,\ncr\u00f3nica\ny\ncon\nexacerbaciones\n \n \n \n \n \n \n \n \n \n \n \n \n \nocasionales\n(1).\nLos\ns\u00edntomas\nque\nprovoca\nson\nquemaz\u00f3n\ny\nprurito\npalpebral.\nEn\nocasiones\n \n \n \n \n \n \n \n \n \n \n \n \n \npuede\nobservarse\ndescamaci\u00f3n\nseca\nen\nla\nbase\nde\nlas\npesta\u00f1as\ny\nla\npresencia\nde\ncostras\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \namarillentas.\nPuede\nestar\nasociada\na\notros\ntrastornos\nde\nla\npiel\ncomo\nros\u00e1cea,\ndermatitis\n \n \n \n \n \n \n \n \n \n \n \n \n \nseborreica\no\npsoriasis.\nEs\nfrecuente\nsu\nrelaci\u00f3n\ncon\nla\nenfermedad\ndel\nojo\nseco,\nya\nque\nsuele\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprovocar\nun\nempeoramiento\nde\nla\ncalidad\nde\nla\nl\u00e1grima.\nEl\nuso\nde\nlentes\nde\ncontacto,\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconjuntivitis\nal\u00e9rgica\no\nel\ntabaco\npueden\nagravar\nla\nblefaritis.\nAlgunos\nestudios\nrecientes\nhan\n \n \n \n \n \n \n \n \n \n \n \n \n \nencontrado\nrelaci\u00f3n\nentre\nel\ns\u00edndrome\nmetab\u00f3lico\ny\nla\nblefaritis,\nsugiriendo\nque\n\u00e9sta\npodr\u00eda\n \n \n \n \n \n \n \n \n \n \n \n \n \nservir como un indicador temprano de la enfermedad (2).\n \nEn funci\u00f3n del \u00e1rea afectada se distinguen tipos de blefaritis:\n \n\u25cf\nBlefaritis\ncr\u00f3nica\nposterior\no\nmarginal:\nes\nla\nm\u00e1s\nfrecuente\ny\nafecta\na\nlos\norificios\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsalida\nde\nlas\ngl\u00e1ndulas\nde\nMeibomio.\nLa\ndisfunci\u00f3n\nde\nestas\ngl\u00e1ndulas\npuede\ncausar\n \n \n \n \n \n \n \n \n \n \n \n \n \nsu obstrucci\u00f3n, destrucci\u00f3n o un aumento de la secreci\u00f3n grasa.\n \n\u25cf\nBlefaritis\ncr\u00f3nica\nanterior:\nafecta\na\nla\nbase\nde\nlas\npesta\u00f1as\ny\nse\nsospecha\nque\npueda\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntener\nun\norigen\ninfeccioso\n(Staphylococcus\naureus)\no\nser\ncausada\npor\nun\nproceso\n \n \n \n \n \n \n \n \n \n \n \n \nseborreico\nque\norigina\nuna\nmayor\nproliferaci\u00f3n\nbacteriana.\nLa\ninfestaci\u00f3n\npor\n\u00e1caros\n \n \n \n \n \n \n \n \n \n \n \ncomo\nDemodex\nfolliculorum\ny\nDemodex\nbrevis\npueden\nser\nun\nfactor\netiol\u00f3gico\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nblefaritis anterior cr\u00f3nica (3).\n \n\u25cf\nBlefaritis mixta: comparte caracter\u00edsticas comunes a las anteriores.\n \nEs\nimportante\ndistinguir\nentre\nla\nblefaritis\ny\nla\ndisfunci\u00f3n\nde\nla\ngl\u00e1ndulas\nMeibomio\n \n \n \n \n \n \n \n \n \n \n \n \n \n(MGD)\ndel\nojo\nseco\nacuodeficiente.\nEl\nagravamiento\nde\nlos\ns\u00edntomas\npor\nla\nma\u00f1ana\nes\nt\u00edpico\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nla\nblefaritis,\nmientras\nque\nel\nagravamiento\nde\nlos\ns\u00edntomas\nhacia\nel\nfinal\ndel\nd\u00eda\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncaracter\u00edstico del ojo seco.\n \nTratamiento\n \nA\nd\u00eda\nde\nhoy\nno\nexisten\ntratamientos\nque\ncuren\nla\nblefaritis,\npero\ns\u00ed\ntratamientos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nefectivos\npara\naliviar\nlos\ns\u00edntomas.\nEs\nnecesario\nque\nse\nestablezca\nun\ndiagn\u00f3stico\nadecuado\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nse\ndistinga\nentre\nlos\ndiferentes\ntipos\nde\nblefaritis\npara\npoder\ninstaurar\nel\ntratamiento\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nid\u00f3neo.\n \n\u25cf\nAntibi\u00f3ticos.\nEn\nla\nblefaritis\nanterior\nlos\nantibi\u00f3ticos\nt\u00f3picos\nson\nefectivos\npara\nel\n \n \n \n \n \n \n \n \n \n \n \n \nalivio\nde\nlos\ns\u00edntomas\ny\npara\neliminar\nlas\nbacterias\nde\nlos\nbordes\npalpebrales.\nNo\nhay\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndiferencias\nsignificativas\nentre\nlos\ndiferentes\nantibi\u00f3ticos\nt\u00f3picos\nestudiados:\n \n \n \n \n \n \n \n \neritromicina,\nbacitracina,\ntetraciclina\ny\ndoxiciclina\n(4).\nEl\nuso\nde\nantibi\u00f3ticos\npor\nv\u00eda\n \n \n \n \n \n \n \n \n \n \n \n \noral\ncomo\nlos\nmacr\u00f3lidos\no\nlas\ntetraciclinas\nes\ntambi\u00e9n\nefectivo\n(5);\nsin\nembargo,\n \n \n \n \n \n \n \n \n \n \n \n \n \npreocupa su seguridad y la creaci\u00f3n de resistencias bacterianas.\n \n\u25cf\nCorticoides.\nLos\nesteroides\nt\u00f3picos\nson\neficaces\nen\nel\nalivio\nde\nlos\ns\u00edntomas,\npero\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nson efectivos a la hora de eliminar bacterias (4,5).\n \n29\n \n \u25cf\nLimpieza\npalpebral.\nLa\nhigiene\ndel\np\u00e1rpado\ncon\nproductos\nespec\u00edficos\ncomo\nlociones\n \n \n \n \n \n \n \n \n \n \n \no\ntoallitas\ny\nel\nuso\nde\ncompresas\ncalientes\nparecen\nser\nefectivos\npara\nel\nalivio\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsintom\u00e1tico en la blefaritis anterior y posterior (2).\n \n\u25cf\n\u00c1cidos\ngrasos\nomega-3.\nEl\n\u200b\nInternational\nMGD\nWorkshop\naconsej\u00f3\nun\naumento\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \ningesta\ndiet\u00e9tica\nde\nlos\n\u00e1cidos\ngrasos\nomega-3\ndebido\na\nsus\npropiedades\n \n \n \n \n \n \n \n \n \n \n \nantiinflamatorias\ny\nla\nreducci\u00f3n\nde\nlos\ns\u00edntomas\ndel\nojo\nseco\n(6).\nSin\nembargo,\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nexiste\nevidencia\nconcluyente\nde\nque\nlos\nsuplementos\nde\nomega-3\npuedan\naliviar\nlos\n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas del ojo seco o de la blefaritis (7).\n \n\u25cf\nManzanilla.\nA\npesar\nde\nque\nes\nhabitual\nla\nrecomendaci\u00f3n,\nincluso\npor\nparte\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nprofesionales\nsanitarios,\nde\naplicar\nbolsas\nde\nmanzanilla\ncaliente\nsobre\nel\np\u00e1rpado,\nno\n \n \n \n \n \n \n \n \n \n \n \n \nhemos\nencontrado\npruebas\nde\nsu\nefectividad.\nPor\nel\ncontrario,\nla\nmanzanilla\npor\ns\u00ed\n \n \n \n \n \n \n \n \n \n \n \n \n \nmisma\npuede\ncausar\nconjuntivitis\ny\nreacciones\nal\u00e9rgicas\nen\npersonas\nsensibles\n(8).\nNo\n \n \n \n \n \n \n \n \n \n \n \n \nse debe aconsejar su uso en blefaritis.\n \n\u25cf\n\u00c1rbol\ndel\nt\u00e9.\nDada\nla\nactividad\nbactericida,\nantimic\u00f3tica\ny\nacaricida\nde\n\u200b\nMelaleuca\n \n \n \n \n \n \n \n \n \n \n \n \nalternifolia\n\u200b\n,\nel\naceite\ndel\n\u00e1rbol\ndel\nt\u00e9\npuede\nser\nun\ntratamiento\nefectivo\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nde\nciertos\ntipos\nde\nblefaritis,\nsiendo\naltamente\neficaz\nen\nlos\ncasos\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \ninfestaci\u00f3n por \n\u200b\nDemodex\n\u200b\n spp. (9,10).\n \nORZUELO\n \nMart\u00ednez, G.\n \nEl\norzuelo\n(tambi\u00e9n\nllamado\ninflamaci\u00f3n\nde\nlas\ngl\u00e1ndulas\nde\nZeiss\no\nde\nMoll)\nse\ntrata\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nuna\ninfecci\u00f3n\naguda\nprincipalmente\nproducida\npor\nestafilococos\nprocedentes\nde\nla\nflora\n \n \n \n \n \n \n \n \n \n \n \nnormal\nde\nla\npiel\n(Staphylococcus\nepidermidis\ny\nStaphylococcus\naureus)\n(1).\nSe\npuede\n \n \n \n \n \n \n \n \n \n \n \n \ndistinguir entre orzuelo interno y externo.\n \n\u25cf\nOrzuelo\nexterno:\nSe\norigina\nen\nlas\ngl\u00e1ndulas\npiloseb\u00e1ceas\nde\nZeiss\ny\nen\nlas\ngl\u00e1ndulas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsudor\u00edparas\nde\nMoll;\nambas\nse\nlocalizan\nen\nel\nborde\nlibre\nde\nlos\np\u00e1rpados\ny\nen\nla\nbase\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nlas\npesta\u00f1as\n(2).\nEn\ncuanto\na\nlos\nsignos\ny\ns\u00edntomas,\nse\nobserva\ninflamaci\u00f3n,\ndolor,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nhipersensibilidad\nlocalizada,\nlagrimeo,\nfotofobia,\nsensaci\u00f3n\nde\ncuerpo\nextra\u00f1o\ne\n \n \n \n \n \n \n \n \n \ninduraci\u00f3n\nredondeada\ncon\nzona\namarillenta\n(que\nindica\nque\nterminar\u00e1\nsupurando)\n \n \n \n \n \n \n \n \n \n \n(3).\n \n\u25cf\nOrzuelo\ninterno:\nEn\neste\ncaso,\nlas\ngl\u00e1ndulas\nafectadas\nson\nlas\nde\nMeibomio,\nque\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nencuentran\nen\nla\nzona\nanat\u00f3mica\ndel\ntarso\nocular\n(2),\npor\nlo\nque\nlos\npacientes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrefieren\nm\u00e1s\ndolor\nque\ncon\nlos\norzuelos\nexternos\n(3).\nSe\npuede\nnotar\nuna\nelevaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nla\nzona\nde\nla\ngl\u00e1ndula\ninfectada,\ncreando\nun\nabsceso\nque\nen\nocasiones\ntermina\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsupurando.\nSin\nembargo,\nrara\nvez\nse\nrompe\nespont\u00e1neamente\n(4).\nSe\nproduce\ncon\n \n \n \n \n \n \n \n \n \n \n \n \nmenos frecuencia que el externo y tiene m\u00e1s probabilidades de recidivas (3).\n \nNo\nhay\nque\nconfundir\norzuelo\nexterno\ncon\nchalaci\u00f3n,\nya\nque\n\u00e9ste\nse\ntrata\nde\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nobstrucci\u00f3n\ncompleta\nsin\ninfecci\u00f3n\nbacteriana\nde\nlas\ngl\u00e1ndulas\nde\nMeibomio\ny\nes\nnecesaria\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nincisi\u00f3n y posterior drenaje (4). Un orzuelo externo puede acabar en chalaci\u00f3n (5).\n \n30\n \n Tratamiento\n \nRecientemente,\nuna\nrevisi\u00f3n\nde\nlos\ndiferentes\nestudios\nrealizados\ndurante\na\u00f1os\npor\n \n \n \n \n \n \n \n \n \n \n \ndiferentes\ninvestigadores\nindic\u00f3\nque\nla\nevidencia\nsobre\nla\nefectividad\nde\nlas\nintervenciones\n \n \n \n \n \n \n \n \n \n \n \n \nno\nquir\u00fargicas\npara\nel\ntratamiento\ndel\norzuelo\nes\ninsuficiente,\nrefiri\u00e9ndose\na\nantibi\u00f3ticos\n \n \n \n \n \n \n \n \n \n \n \n \norales\ny\nt\u00f3picos,\ngasas\ncalientes,\ntoallitas\nexfoliantes\npara\np\u00e1rpados\ny\ncorticoesteroides\n \n \n \n \n \n \n \n \n \n \n \nt\u00f3picos\n(5).\nDe\nhecho,\nen\nun\nestudio\nrealizado\nen\n2012\ncon\n79\npacientes,\nse\ndetect\u00f3\nque,\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndeterminados\ncasos,\nS.\nepidermidis\ny\nS.\naureus\n(las\nprincipales\nespecies\ncausantes\nde\nesta\n \n \n \n \n \n \n \n \n \n \n \n \n \npatolog\u00eda)\npresentaban\nresistencia\na\nla\nterramicina\n(antibi\u00f3tico\nt\u00f3pico\ncom\u00fanmente\nutilizado\n \n \n \n \n \n \n \n \n \n \npara estos casos) (1).\n \nEn\nun\nestudio\nen\nel\nque\nse\ninvestig\u00f3\nla\nefectividad\nde\neste\nantibi\u00f3tico\npara\ntodo\ntipo\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npatolog\u00edas\ninfecciosas\noculares\nse\ncomprob\u00f3\nque\nla\nterramicina\nno\ntuvo\nning\u00fan\nefecto\npara\n \n \n \n \n \n \n \n \n \n \n \n \n \nlos orzuelos internos y externos en los 19 pacientes que participaron (6).\n \nAdem\u00e1s\nde\nlas\nposibles\nresistencias,\nen\ndeterminadas\nsituaciones\nen\nlas\nque\nla\nzona\nest\u00e1\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndemasiado\ninflamada,\nel\nf\u00e1rmaco\nno\npuede\npenetrar\nen\nla\nmasa\nocular\npara\ninhibir\n \n \n \n \n \n \n \n \n \n \n \n \n \neficazmente\nel\ncrecimiento\nde\nbacterias\n(1).\nPor\ntanto,\nseg\u00fan\nestos\nestudios,\nexiste\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nposibilidad\nde\nque\nse\nprescriban\nantibi\u00f3ticos\nde\nforma\ninnecesaria\nal\nno\nproducir\nning\u00fan\n \n \n \n \n \n \n \n \n \n \n \n \n \nefecto (1, 5, 6), dando lugar a pat\u00f3genos resistentes o a efectos secundarios (1).\n \nEn\nla\nmayor\u00eda\nde\ncasos\nse\ntrata\nde\nun\nproceso\npatol\u00f3gico\nautolimitado\nque\ndesaparece\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nespont\u00e1neamente\nen\nuna\no\ndos\nsemanas\nsin\nnecesidad\nde\nning\u00fan\ntipo\nde\ntratamiento,\n \n \n \n \n \n \n \n \n \n \n \n \n \nmientras\nque\nen\notros\ncasos\nes\nnecesaria\nuna\nintervenci\u00f3n\nquir\u00fargica\nque\nconsiste\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \nincisi\u00f3n y drenaje (1, 5).\n \nAtenci\u00f3n farmac\u00e9utica\n \nExplicaremos\na\nlos\npacientes\nque\nen\nla\nmayor\u00eda\nde\nocasiones\nlos\norzuelos\nson\nprocesos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npatol\u00f3gicos\nautorresolutivos\ny,\nsi\nsobrepasa\nlas\ndos\nsemanas\nde\nduraci\u00f3n,\nser\u00eda\nnecesario\n \n \n \n \n \n \n \n \n \n \n \n \nderivarle\nal\nm\u00e9dico\npor\nlas\ncomplicaciones\nque\npodr\u00edan\ngenerarse\ncomo\nproblemas\nde\nvisi\u00f3n,\n \n \n \n \n \n \n \n \n \n \n \n \n \nblefaritis o ros\u00e1cea (5).\n \nDeberemos\nrecordarles\nque,\nbajo\nning\u00fan\nconcepto,\nintenten\npor\nellos\nmismos\ndrenar\nlas\n \n \n \n \n \n \n \n \n \n \n \n \ngl\u00e1ndulas\ninfectadas,\npor\npeligro\nde\nprovocarse\nda\u00f1os\nmayores.\nAnte\nla\npetici\u00f3n\nde\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \nantibi\u00f3tico\nde\nuso\noft\u00e1lmico\nsin\nreceta,\nles\nexplicaremos\nque\nel\nuso\nde\nantibi\u00f3ticos\npara\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\ndel\norzuelo\nha\ndemostrado\nser\ninefectivo,\nadem\u00e1s\nde\npoder\nocasionar\n \n \n \n \n \n \n \n \n \n \n \nresistencias bacterianas.\n \n \n \n \n31\n \n OJO SECO\n \nCal Seijas, R., Alonso Garre, C., Rodr\u00edguez \u00c1lvarez, R.\n \nSeg\u00fan\nel\ninforme\nde\n2017\n\u200b\nDry\nEye\nWorkshop\n(DEWS\nII)\nde\nla\n\u200b\nTear\nFilm\nand\nOcular\nSurface\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSociety\n(TFOS),\nse\ndefine\nla\nenfermedad\ndel\nojo\nseco\n(EOS)\ncomo\n\u00abuna\nenfermedad\n \n \n \n \n \n \n \n \n \n \n \n \n \nmultifactorial\nde\nla\nsuperficie\nocular,\nque\nse\ncaracteriza\npor\nuna\np\u00e9rdida\nde\nla\nhomeostasis\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nla\npel\u00edcula\nlagrimal\ny\nque\nva\nacompa\u00f1ada\nde\ns\u00edntomas\noculares,\nen\nla\nque\nla\ninestabilidad\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ne\nhiperosmolaridad\nde\nla\nsuperficie\nocular,\nla\ninflamaci\u00f3n\ny\nel\nda\u00f1o\nde\nla\nsuperficie\nocular,\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlas anomal\u00edas neurosensoriales desempe\u00f1an papeles etiol\u00f3gicos\u00bb (1).\n \nLa\nEOS\nes\nla\nalteraci\u00f3n\nm\u00e1s\nfrecuente\nde\nla\nsuperficie\nocular\no\nsistema\nlagrimal\n(2),\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconsidera\nla\nmayor\u00eda\nde\nlas\nveces\ncomo\nuna\ndolencia\nmenor\n(aunque\nen\nalgunos\ncasos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npueden\nsurgir\ncomplicaciones\nimportantes)\ny\nsu\nsintomatolog\u00eda\npuede\nvariar\ndesde\nuna\n \n \n \n \n \n \n \n \n \n \n \nsimple\nirritaci\u00f3n\nhasta\ndolor\nintenso.\nLa\ngravedad\nde\nlos\ns\u00edntomas\npuede\nfluctuar\na\nlo\nlargo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndel d\u00eda y suelen empeorar hacia la tarde-noche (3).\n \nLa\np\u00e9rdida\nde\nla\nfunci\u00f3n\no\nla\ndestrucci\u00f3n\nde\nlas\ngl\u00e1ndulas\nlacrimales\nes\nm\u00e1s\nprevalente\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npersonas\nde\nedad\navanzada\ny\nen\nmujeres,\nya\nque\nse\nve\ninfluida\npor\nel\ntratamiento\nhormonal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsustitutivo,\nel\nembarazo\ny\nla\nmenopausia\n(4).\nEn\nmujeres\nposmenop\u00e1usicas,\nel\nojo\nseco\nsuele\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npresentarse\njunto\ncon\nsequedad\nde\notras\nmucosas\n(nariz,\nboca,\nvagina);\na\neste\ns\u00edndrome\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nle\nconoce\ncomo\nde\nSj\u00f6gren\ntipo\nI.\nSi\nadem\u00e1s\neste\ns\u00edndrome\nviene\nacompa\u00f1ado\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nenfermedades\nsist\u00e9micas\ncomo\nla\nartritis\nreumatoide\no\nel\nlupus\neritematoso,\nse\ndenomina\n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edndrome de Sj\u00f6gren tipo II.\n \nLos\nf\u00e1rmacos\ndescongestivos,\nantihistam\u00ednicos,\nansiol\u00edticos,\nantidepresivos,\n \n \n \n \n \n \nantipsic\u00f3ticos,\nanticolin\u00e9rgicos,\ndiur\u00e9ticos,\nantiparkinsonianos\ny\nlos\ntratamientos\ncon\n \n \n \n \n \n \n \n \nretinoide-antibi\u00f3tico\npara\nel\nacn\u00e9\npueden\ninducir\ntambi\u00e9n\nla\nsequedad\nocular\nal\ndisminuir\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nproducci\u00f3n\nlacrimal\n(5).\nPersonas\ncon\nalergia,\ndiabetes,\nmigra\u00f1a,\nalteraciones\ndel\nsue\u00f1o\no\n \n \n \n \n \n \n \n \n \n \n \n \nd\u00e9ficit de vitamina A son m\u00e1s propensas a sufrir EOS (6).\n \nLa\ninflamaci\u00f3n\nde\nlos\nbordes\ndel\np\u00e1rpado\nen\nuna\nblefaritis\nprovoca\nque\nla\nsecreci\u00f3n\ngrasa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nlas\ngl\u00e1ndulas\nde\nMeibomio\nno\nproteja\nde\nla\nevaporaci\u00f3n\na\nla\npel\u00edcula\nlagrimal,\npor\nlo\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nal\nhaber\nuna\nmayor\nevaporaci\u00f3n\nse\nproduce\nuna\nconcentraci\u00f3n\nde\nsales\ndisueltas\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \npueden da\u00f1ar el epitelio corneal y conjuntival (7).\n \nTanto\nel\nuso\nde\ndispositivos\nde\npantalla\nplana\n(ordenador,\n\u200b\ntablet\n\u200b\n,\ntelevisi\u00f3n,\ntel\u00e9fono\n \n \n \n \n \n \n \n \n \n \n \n \nm\u00f3vil,\netc.)\no\nde\nlentes\nde\ncontacto\ncomo\ndeterminadas\ncondiciones\nambientales\n(viento,\n \n \n \n \n \n \n \n \n \n \n \n \nhumo,\nfr\u00edo,\naire\nacondicionado,\ncontaminaci\u00f3n\natmosf\u00e9rica)\ntienen\nuna\ninfluencia\nnegativa\n \n \n \n \n \n \n \n \n \n \nen la EOS (6).\n \n \n \n32\n \n Funci\u00f3n y estructura de la l\u00e1grima\n \nLas\nfunciones\nde\nla\nl\u00e1grima\nson\nmantener\nla\nhidrataci\u00f3n\nde\nla\nsuperficie\nocular,\nas\u00ed\ncomo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmantener\nel\npoder\nde\nrefracci\u00f3n\n(una\ndisminuci\u00f3n\nde\nla\npel\u00edcula\nlagrimal\nafecta\na\nla\nagudeza\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nvisual).\nAdem\u00e1s\nde\nestas\ndos\nfunciones\nfundamentales\ny\nprincipales,\ntambi\u00e9n\nposee\n \n \n \n \n \n \n \n \n \n \n \nfunciones\naccesorias,\ncomo\nson\nla\nde\nprotecci\u00f3n\n(ayuda\na\nproteger\nel\nojo\ny\nlas\nmucosas\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlas\ninfecciones),\nnutrici\u00f3n\n(favorece\nel\nintercambio\ngaseoso\nde\nO\n\u200b\n2\nen\nla\nc\u00f3rnea)\ne\nhigiene\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(ayuda a eliminar impurezas).\n \nLa l\u00e1grima es una pel\u00edcula fluida que recubre todo el ojo con tres fases diferenciadas:\n \n\u25cf\nCapa\nlip\u00eddica:\nsecretada\npor\nlas\ngl\u00e1ndulas\nde\nMeibonio\ny\nlas\ngl\u00e1ndulas\nde\nZeiss\ny\ncuya\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfunci\u00f3n principal es la de evitar la evaporaci\u00f3n de la l\u00e1grima (2).\n \n\u25cf\nCapa\nacuosa:\nes\nel\ncomponente\nprincipal\nde\nla\nl\u00e1grima\ncon\nun\nporcentaje\nsuperior\nal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n90%\nde\nla\nmisma.\nSe\nsecreta\npor\nlas\ngl\u00e1ndulas\nlagrimales\naccesorias\nde\nKrausse\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nWolfring (8).\n \n\u25cf\nCapa\nde\nmucina:\nes\nla\ncapa\nque\nest\u00e1\nen\ncontacto\ncon\nlos\nepitelios,\nsecretada\npor\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nc\u00e9lulas\ncaliciformes\ny\nlas\ngl\u00e1ndulas\nde\nHenle\ny\nManz,\nformando\nun\ngel\nrico\nen\nhidratos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde carbono que se disuelven progresivamente en la capa acuosa.\n \n \nEl\n\u00faltimo\ninforme\nTFOS\nDEWS\nII\nha\nunido\nlas\ncapas\nacuosa\ny\nmuc\u00ednica\nen\nuna\nsola,\nla\ncapa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmucoacuosa,\ncon\nun\ngradiente\nde\nconcentraci\u00f3n\ndecreciente\nde\nmucinas\ndesde\nla\nsuperficie\n \n \n \n \n \n \n \n \n \n \n \n \ncorneal hacia el exterior (1).\n \nFisiopatolog\u00eda\n \nLas\nalteraciones\nde\nla\npel\u00edcula\nlagrimal\npueden\ndeberse\na\ncambios\nen\nsu\ncomposici\u00f3n\no\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla\ndisminuci\u00f3n\nen\nla\nproducci\u00f3n\nde\nl\u00e1grimas\ndebido\na\ninflamaci\u00f3n\nde\nlas\ngl\u00e1ndulas\nlagrimales,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nsucede\nen\nel\ns\u00edndrome\nde\nSj\u00f6gren.\nEl\nmantenimiento\nde\nla\nhomeostasis\nde\nla\npel\u00edcula\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlagrimal\ndepende\ndel\ncorrecto\nfuncionamiento\nde\nla\nunidad\nfuncional\nlagrimal,\ntanto\ndesde\n \n \n \n \n \n \n \n \n \n \n \n \nel\npunto\nde\nvista\nanat\u00f3mico\ncomo\nfisiol\u00f3gico.\nLa\np\u00e9rdida\nde\neste\nequilibrio\nu\nhomeostasis\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla base del desarrollo de EOS (9).\n \nHiperosmolaridad\nde\nla\nl\u00e1grima:\nel\naumento\nde\nla\nosmolaridad\n(concentraci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \nsolutos)\npuede\ndeberse\na\nun\nd\u00e9ficit\nen\nla\nsecreci\u00f3n\nlagrimal\no\nbien\na\nun\naumento\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nevaporaci\u00f3n\ncon\nconsiguiente\nreducci\u00f3n\ndel\ncomponente\nacuoso.\nEste\naumento\nde\nla\n \n \n \n \n \n \n \n \n \n \n \nosmolaridad es el mecanismo central de la EOS.\n \nInestabilidad\nde\nla\npel\u00edcula\nlagrimal:\nse\nproduce\npor\nuna\nruptura\nprematura\nde\nla\npel\u00edcula\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlagrimal\na\nconsecuencia\nde\nla\nhiperosmolaridad\no\npor\notras\ncausas\ncomo\nla\npresencia\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsustancias qu\u00edmicas (conservantes) o por el uso de lentes de contacto.\n \n \n \n33\n \n Clasificaci\u00f3n\n \nLa\nclasificaci\u00f3n\nconvencional\ndivide\nla\nEOS\nen\ndos\ntipos:\nacuodeficiente\no\ncuantitativa\n \n \n \n \n \n \n \n \n \n \n \n \n(disminuci\u00f3n\nde\nla\ncantidad\nde\nl\u00e1grimas)\ny\nevaporativa\no\ncualitativa\n(alteraci\u00f3n\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \ncomposici\u00f3n\nde\nla\nl\u00e1grima).\nNo\nobstante,\nno\npueden\nconsiderarse\ncomo\nentidades\naisladas,\n \n \n \n \n \n \n \n \n \n \n \n \nsino\nm\u00e1s\nbien\ncomo\ncontinuaci\u00f3n\nuna\nde\nla\notra.\nEl\n\u00faltimo\ninforme\nTFOS\nDEWS\nII\na\u00f1ade\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nEOS mixta, con caracter\u00edsticas comunes de ambos tipos.\n \n\u25cf\nEOS\nacuodeficiente:\nS\u00edndrome\nde\nSj\u00f6gren\n(enfermedad\nautoinmune\nsist\u00e9mica\nque\n \n \n \n \n \n \n \n \n \nafecta\na\nlas\ngl\u00e1ndulas\nexocrinas)\no\nno\nSj\u00f6gren,\nm\u00e1s\nleve\ny\ncom\u00fan\nen\npersonas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmayores\ndebido\na\ndeficiencia\nde\nlas\ngl\u00e1ndulas\nlacrimales,\nobstrucci\u00f3n\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \nconductos.\nPuede\nestar\ninducida\npor\nf\u00e1rmacos,\nconservantes\no\nprocedimientos\n \n \n \n \n \n \n \n \n \nquir\u00fargicos.\n \n\u25cf\nEOS\nevaporativa:\nes\nm\u00e1s\nfrecuente\ny\nest\u00e1\nocasionada\npor\ntrastornos\nde\nlos\np\u00e1rpados\n \n \n \n \n \n \n \n \n \n \n \n \n \no\nde\nla\nsuperficie\nocular.\nPuede\ntener\nun\norigen\nintr\u00ednseco\npor\ndisfunci\u00f3n\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ngl\u00e1ndulas\nde\nMeibomio,\ntrastornos\nen\nla\napertura\nde\nlos\np\u00e1rpados\no\nbaja\nfrecuencia\n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nparpadeo.\nLa\nEOS\nevaporativa\nextr\u00ednseca\nest\u00e1\noriginada\npor\nalteraciones\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \nsuperficie\nocular\na\nconsecuencia\nde\nf\u00e1rmacos,\nuso\nde\nlentes\nde\ncontacto,\n \n \n \n \n \n \n \n \n \n \n \nhipervitaminosis o alergias.\n \n \n \n \n \n \n \n \n \n \n \n \n \nFig. 1. Clasificaci\u00f3n del Ojo Seco (5).\n \n \n \n34\n \n \nTratamiento\n \nSustitutos lagrimales\n \nEl\npilar\ndel\ntratamiento\nde\nla\nEOS\nse\nbasa\nen\nel\nuso\nde\nl\u00e1grimas\nartificiales.\nEn\nsu\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncomposici\u00f3n\npodemos\nencontrar\nalcohol\npolivin\u00edlico,\nhipromelosa,\ncarmelosa,\n \n \n \n \n \n \n \nhidroxipropilguar, trehalosa, povidona o \u00e1cido hialur\u00f3nico.\n \nLas\nl\u00e1grimas\nartificiales\nhan\ndemostrado\nser\nun\ntratamiento\neficaz\ny\nseguro\npara\nla\nEOS.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nNo\nhay\nbuenos\nestudios\nde\nsuperioridad\npara\ndiscernir\ncu\u00e1les\nson\nlos\nactivos\ncon\nmayor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \neficacia,\npor\nlo\nque\nlas\ndiferentes\nl\u00e1grimas\nartificiales\nse\nconsideran\nigual\nde\nefectivas.\nSe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnecesitan nuevos ensayos espec\u00edficos para aclarar esta cuesti\u00f3n (10).\n \nPara\nescoger\nla\nl\u00e1grima\nartificial\n\u00f3ptima\npara\ncada\npaciente\nhabr\u00eda\nque\ntener\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \nconsideraci\u00f3n,\nm\u00e1s\nque\nel\nprincipio\nactivo,\ncaracter\u00edsticas\ncomo\nla\nviscosidad\nde\nla\nmisma,\nsi\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nestamos\nante\nun\nojo\nseco\nevaporativo\no\nacuodeficiente\ny\nla\npresencia\nde\nsustancias\n \n \n \n \n \n \n \n \n \n \n \n \n \nconservantes.\nLa\nviscosidad\nde\nla\nl\u00e1grima\nartificial\nafecta\na\ndos\nfactores:\nla\nduraci\u00f3n\n(a\nmayor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nviscosidad,\nmayor\nduraci\u00f3n\nde\nlos\nefectos)\ny\nla\nvisi\u00f3n\n(a\nmayor\nviscosidad,\nmayor\np\u00e9rdida\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncapacidad\nvisual).\nPor\nlo\ntanto,\nse\npodr\u00eda\nemplear\nuna\nl\u00e1grima\nmuy\nl\u00edquida\nsi\nel\npaciente\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npuede\nestar\nus\u00e1ndola\nde\ncontinuo,\nsi\nbien\nesta\nopci\u00f3n\nes\npoco\neficaz\nya\nque\nencarecer\u00eda\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\ny\ndificultar\u00eda\nla\nadhesi\u00f3n.\nPor\nello,\nla\nelecci\u00f3n\nde\nla\nl\u00e1grima\na\nusar\ndepende\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntambi\u00e9n\nde\nla\nopini\u00f3n\nsubjetiva\nde\ncada\npaciente,\nencontrado\naquella\nque\nle\npermita\ntener\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nel m\u00e1ximo beneficio con la mayor comodidad posible.\n \nOtro\npunto\nmuy\nimportante\na\nla\nhora\nde\nelegir\nuna\nl\u00e1grima\nartificial\nes\nbuscar\nuna\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nest\u00e9\nexenta\nde\nconservantes\nque\npuedan\nda\u00f1ar\nal\nojo\no\nla\npel\u00edcula\nlagrimal\n(11).\nSustancias\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nlos\nfosfatos\npueden\nprecipitar\nal\nformar\ncomplejos\ncon\nel\ncalcio,\nda\u00f1ando\nla\nsuperficie\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nocular.\n \nSuero aut\u00f3logo\n \nLas\ngotas\noculares\nde\nsuero\naut\u00f3logo,\nhechas\na\npartir\nde\nla\npropia\nsangre\ndel\npaciente,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntienen\nventaja\npotencial\nfrente\na\nlos\ntratamientos\nconvencionales\nya\nque,\nadem\u00e1s\nde\nactuar\n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nun\nsustituto\nde\nla\nl\u00e1grima,\ncontiene\notros\ncomponentes\nbioqu\u00edmicos\nque\nimitan\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \n \nfielmente\nlas\nl\u00e1grimas\nnaturales\ny\nque\npodr\u00edan\npresentar\npropiedades\nreparadoras.\nLa\n \n \n \n \n \n \n \n \n \n \n \naplicaci\u00f3n\nde\nsuero\naut\u00f3logo\nen\nel\ntratamiento\nde\nla\nEOS\nha\nganado\npopularidad\ncomo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nde\nsegunda\nl\u00ednea\ny\nlos\nestudios\npublicados\nmuestran\nque\npodr\u00eda\nser\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nefectivo\npara\nel\nojo\nseco.\nSin\nembargo,\nen\ncomparaci\u00f3n\ncon\nlas\nl\u00e1grimas\n \n \n \n \n \n \n \n \n \n \n \n \n \nartificiales\nconvencionales,\nlas\ngotas\noculares\nde\nsuero\naut\u00f3logo\nno\nhan\nproporcionado\n \n \n \n \n \n \n \n \n \n \n \nefectos\nbeneficiosos\nadicionales\nseg\u00fan\notras\nevaluaciones\ncl\u00ednicas\nde\nla\nsuperficie\nocular.\nSe\n \n \n \n \n \n \n \n \n \n \n \n \nrequiere\nla\nrealizaci\u00f3n\nde\nnuevos\nensayos\ncl\u00ednicos\naleatorios\nbien\nplanificados,\ncon\nmayor\n \n \n \n \n \n \n \n \n \n \n \n \nn\u00famero\nde\nmuestra\ny\nde\nalta\ncalidad,\nsobre\nel\nojo\nseco\nde\ndiferentes\ngravedades\npoder\npara\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nevaluar el efecto beneficioso del tratamiento con suero aut\u00f3logo (12).\n \n \n \n35\n \n Oclusi\u00f3n puntual\n \nLos\ntapones\npuntuales\nse\ninsertan\nen\nlos\nconductos\nlagrimales\npara\nbloquear\nel\ndrenaje\n \n \n \n \n \n \n \n \n \n \n \n \n \nlagrimal\ny\npueden\nusarse\ncomo\ntratamiento\nde\nla\nEOS.\nUna\nrevisi\u00f3n\nde\nla\noclusi\u00f3n\npuntual\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nencontr\u00f3\nque\nno\nmejoran\nde\nmanera\nconcluyente\nlos\ns\u00edntomas\nde\nojo\nseco\nen\ncomparaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncon\notros\ntratamientos\ncomo\nlas\nl\u00e1grimas\nartificiales.\nAdem\u00e1s,\nsu\nuso\nse\nha\nrelacionado\ncon\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nun ligero aumento de efectos secundarios como lagrimeo o infecciones (13).\n \n\u00c1cidos grasos omega-3\n \nLa\ncomposici\u00f3n\nlip\u00eddica\nde\nla\nl\u00e1grima\npuede\nverse\nalterada\ny\nello\nconlleva\nel\ndesarrollo\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nuna\nEOS\nevaporativa.\nLa\nsuplementaci\u00f3n\ndiet\u00e9tica\ncon\n\u00e1cidos\ngrasos\nomega-3\nha\nsido\n \n \n \n \n \n \n \n \n \n \n \n \nrecomendada\npor\nel\n\u200b\nInternational\nDry\nEye\nWorkshop\n(14)\ny\nun\nestudio\nretrospectivo\nha\n \n \n \n \n \n \n \n \n \n \n \n \n \nrelacionado\nel\nconsumo\nhabitual\nde\npescado\nazul\nrico\nen\nomega-3\ncon\nla\ndisminuci\u00f3n\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nriesgo\nde\nEOS\n(15).\nExisten\nvarios\nestudios\nque\nparecen\nconfirmar\nla\neficacia\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnutrac\u00e9uticos\ncon\n\u00e1cido\neicosapentaenoico\ny\ndocosahexaenoico\nextra\u00eddos\nde\naceite\nde\n \n \n \n \n \n \n \n \n \n \npescado\nen\nel\ntratamiento\nde\nla\nEOS\n(16,\n17);\nsin\nembargo,\nestudios\nm\u00e1s\nrecientes\ny\ncon\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmejor\ncalidad\nmetodol\u00f3gica,\ncomo\nel\nestudio\nDREAM\n(18),\nno\nhan\nhallado\nmayor\neficacia\n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nel\nplacebo\nen\nestos\nsuplementos.\nA\nd\u00eda\nde\nhoy,\nno\nhay\nsuficiente\nevidencia\npara\npoder\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndemostrar la eficacia de los suplementos de omega-3 en el tratamiento de la EOS.\n \nHigiene palpebral\n \nSe\nconsidera\nque\nla\nhigiene\npalpebral\nconstante\ny\nrealizada\ncorrectamente,\ncon\ntoallitas\n \n \n \n \n \n \n \n \n \n \n \n \nu\notros\nproductos\nespec\u00edficos,\npuede\nayudar\na\naliviar\nlos\ns\u00edntomas\nde\nla\nEOS.\nLas\ncarga\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nevidencia es limitada (19, 20).\n \nDEGENERACI\u00d3N MACULAR ASOCIADA A LA EDAD\n \nMart\u00ednez, G.\n \nLa\ndegeneraci\u00f3n\nmacular\nasociada\na\nla\nedad\n(DMAE)\nes\nla\ncausa\nm\u00e1s\ncom\u00fan\nde\nceguera\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen\npersonas\nmayores\nde\n60\na\u00f1os.\nAl\ncomienzo\nde\nla\npatolog\u00eda\npuede\nser\nasintom\u00e1tica,\npero\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconforme\navanza,\nlos\npacientes\nrefieren\ndificultad\nen\nla\nagudeza\nvisual\nque\npuede\nterminar\n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nuna\np\u00e9rdida\ntotal\ndel\ncampo\ncentral\nde\nvisi\u00f3n,\naunque\nel\ncampo\nperif\u00e9rico\nse\nconserva\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(3).\n \nTratamiento\n \nAunque\nen\nla\nactualidad\nno\nse\ndispone\nde\nning\u00fan\nestudio\nque\ndemuestre\nla\neficacia\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamientos\nfarmacol\u00f3gicos\npara\nla\nprevenci\u00f3n\nde\nla\nDMAE,\nse\nhan\ndesarrollado\nnumerosas\n \n \n \n \n \n \n \n \n \n \n \n \ninvestigaciones\npara\nprobar\nla\neficacia\nde\nla\ningesta\nde\ncarotenoides,\nvitaminas\ny\nminerales\n \n \n \n \n \n \n \n \n \n \n \n \n \nfrente al agravamiento de la enfermedad.\n \n \n \n36\n \n Betacaroteno, zinc y vitaminas E y C\n \n \nLos\nprimeros\nestudios\nrealizados\ncon\nla\nconjunci\u00f3n\nde\nestos\nnutrientes\nindicaban\nque\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \npodr\u00eda\nfrenar\nel\navance\nde\nla\nenfermedad.\nEn\nconcreto,\nel\nprincipal\nestudio\nen\nel\nque\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nintent\u00f3\ndemostrar\nla\nevidencia\ndel\nefecto\nbeneficioso\nde\nestos\nsuplementos\nfue\nel\nAREDS\n \n \n \n \n \n \n \n \n \n \n \n \n \n2001,\ncon\nun\nbuen\ndise\u00f1o\ny\nn\u00famero\nde\npacientes,\npero\nque\npresentaba\npeque\u00f1os\nsesgos\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncuyos\nresultados\ns\u00f3lo\ndemostraban\nun\ndesaceleramiento\nde\nla\nenfermedad\nen\nel\n25%\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npacientes (11).\n \nExisten\nen\nconcreto\ndos\nrevisiones\nexhaustivas\nde\nesta\nf\u00f3rmula,\nuna\nde\nellas\nla\ndefiende\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npara\nfrenar\nla\nprogresi\u00f3n\nde\nla\nDMAE\n(3)\ny\nla\notra\ndetalla\nno\ncontar\ncon\nevidencias\npara\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \navalarla,\nadem\u00e1s\nde\ninformar\nde\nun\nposible\ncrecimiento\nde\nla\nmortalidad\nasociada\na\nla\nmisma\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(1).\n \nSin\nembargo,\nnovedosos\nestudios\nfarmacogen\u00e9ticos\nhan\ndemostrado\nque\nel\nefecto\ntanto\n \n \n \n \n \n \n \n \n \n \n \nbeneficioso\ncomo\nperjudicial\nde\nla\nf\u00f3rmula\nde\nAREDS\ndepende\nde\ndeterminados\n \n \n \n \n \n \n \n \n \n \n \ncomponentes gen\u00e9ticos que presente el paciente (5, 13, 14).\n \nLute\u00edna y zeaxantina\n \nSe\nrealizaron\nensayos\ncon\naporte\nde\nlute\u00edna\ny\nzeaxantina\nen\nun\nsegundo\nestudio\nde\nARED\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(2),\npero,\nal\ncontrario\nque\ncon\nel\nprimero,\nse\ndetermin\u00f3\nque\nhubo\nuna\npeque\u00f1a\no\nnula\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nreducci\u00f3n\ndel\nriesgo\nen\nla\nprogresi\u00f3n\nde\nla\nDMAE\nque\nno\nfue\nestad\u00edsticamente\nsignificativa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(3).\nOtros\nensayos\nposteriores\ndemuestran\nque\nno\nexiste\nasociaci\u00f3n\nentre\nla\ningesta\nde\nestos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncarotenoides y la paralizaci\u00f3n de la enfermedad (3, 6-8).\n \n\u00c1cidos grasos omega-3\n \nLas\nrevisiones\nsobre\nel\npapel\nde\nlos\nomega-3\nen\nla\nprevenci\u00f3n\nde\nla\nDMAE\nno\nhan\npodido\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndemostrar una clara evidencia sobre la reducci\u00f3n del progreso de la enfermedad (9, 10, 12).\n \nAtenci\u00f3n farmac\u00e9utica\n \nEs\nnecesario\ntener\nen\ncuenta\nque\nel\nefecto\nbeneficioso\nde\nlos\nsuplementos\ncon\nvitamina\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nC,\nE,\nbetacaroteno\ny\nzinc\nno\nha\npodido\nser\nclaramente\ndemostrado\ny\nestar\u00eda\nsujeto\na\nfactores\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ngen\u00e9ticos,\npudiendo\nincluso\ntener\nefectos\nnegativos.\nPor\neste\nmotivo,\nlo\nm\u00e1s\ncorrecto\nser\u00eda\n \n \n \n \n \n \n \n \n \n \n \n \n \nexplic\u00e1rselo al paciente para que tambi\u00e9n lo valorara.\n \nRespecto\nal\nuso\nde\nsuplementos\nde\ncarotenoides\n(lute\u00edna\ny\nzeaxantina),\nas\u00ed\ncomo\nlos\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nomega-3,\nal\nno\nexistir\nevidencias\nclaras,\nlo\nm\u00e1s\napropiado\ncomo\nprofesionales\nsanitarios\n \n \n \n \n \n \n \n \n \n \n \n \nser\u00eda\nno\nrecomendarlos\nhasta\nque\nno\nse\nprueben\nlos\nbeneficios\nmediante\nun\nconsenso\n \n \n \n \n \n \n \n \n \n \n \n \n \ncient\u00edfico.\nDeberemos\naconsejar\na\nnuestros\npacientes\nh\u00e1bitos\nsaludables\ncomo\ndejar\nde\n \n \n \n \n \n \n \n \n \n \n \nfumar,\ncomer\nsano\npara\nprevenir\nla\nobesidad\ny\nproteger\nlos\nojos\nde\nla\nexposici\u00f3n\nexcesiva\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla\nluz\nsolar,\nya\nque\nse\nha\ncomprobado\nque\nestos\nson\nalgunos\nde\nlos\nfactores\nde\nriesgo\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndesarrollo de DMAE (4, 7, 15-18).\n \n \n \n \n37\n \n ACIDEZ DE EST\u00d3MAGO\n \nJusto Hern\u00e1ndez, A.\n \nLa\nacidez\nde\nest\u00f3mago\n(pirosis)\nse\ndescribe\ncomo\nuna\nsensaci\u00f3n\nde\nquemaz\u00f3n\ndolorosa\n \n \n \n \n \n \n \n \n \n \n \n \n \ndetr\u00e1s\ndel\nestern\u00f3n\nque\nsurge\ndel\nest\u00f3mago\ny\npuede\nirradiarse\ndesde\nla\nzona\ndel\nepigastrio\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(boca del est\u00f3mago) hasta la garganta.\n \n \nEl\nes\u00f3fago\nes\nun\ntubo\nmuscular\nque\nune\nla\nfaringe\ncon\nest\u00f3mago\ny\ncuyas\nfunciones\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nb\u00e1sicas\nconsisten\nen\ntransportar\nel\nbolo\nalimenticio\nhacia\nel\nest\u00f3mago\ny\nevitar\nel\npaso\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninverso\ndel\ncontenido\ng\u00e1strico.\nPara\nello\ndispone\nde\n2\nesf\u00ednteres:\nel\nsuperior\n(p\u00edloro),\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nimpide\nel\npaso\na\nv\u00edas\na\u00e9reas,\ny\nel\ninferior\n(cardias),\nsituado\nen\nla\nboca\ndel\nest\u00f3mago.\nEste\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\u00faltimo\nest\u00e1\nrevestido\nde\nuna\nmucosa\nque\nlo\nprotege\nfrente\na\nlos\n\u00e1cidos\ng\u00e1stricos\nsegregados\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npara\nfavorecer\nla\ndigesti\u00f3n\nde\nlos\nalimentos;\nsin\nembargo,\nel\nes\u00f3fago\nno\ndispone\nde\nesa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmucosa\nprotectora,\npor\nlo\nque,\nsi\nlos\njugos\ng\u00e1stricos\nrefluyen\nhacia\n\u00e9l,\nprovocan\nesa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsensaci\u00f3n\nde\nquemaz\u00f3n\nque\ncaracteriza\na\nla\npirosis.\nA\neste\nproceso\nse\nle\ndenomina\nreflujo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ngastroesof\u00e1gico\ny\nen\ncondiciones\nnormales\nno\ndeber\u00eda\nproducirse,\ndebido\na\nque\nel\nesf\u00ednter\n \n \n \n \n \n \n \n \n \n \n \n \n \nesof\u00e1gico inferior impide que los jugos g\u00e1stricos refluyan hacia el es\u00f3fago.\n \nLa\npirosis\nno\nconstituye\nen\ns\u00ed\nmisma\nuna\nenfermedad,\npero\nsi\nse\nrepite\nmuy\na\nmenudo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npuede\nocasionar\nimportantes\ntrastornos.\nAparece\nespor\u00e1dicamente\nen\npersonas\nsanas,\npero\n \n \n \n \n \n \n \n \n \n \ncuando\nsu\nfrecuencia\no\nintensidad\naumentan\nsuele\nindicar\nuna\ndisfunci\u00f3n\nesof\u00e1gica.\nEs\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntoma\nm\u00e1s\ncom\u00fan\nde\nla\nERGE\n(enfermedad\npor\nreflujo\ngastroesof\u00e1gico),\naunque\npuede\n \n \n \n \n \n \n \n \n \n \n \n \nrelacionarse\ntambi\u00e9n\ncon\nenfermedades\nde\notros\n\u00f3rganos,\nafecciones\nsist\u00e9micas\ny\nconsumo\n \n \n \n \n \n \n \n \n \n \n \nde\nf\u00e1rmacos\no\nalcohol.\nPuede\naparecer\nen\ncualquier\nmomento,\naunque\nnormalmente\nlo\nhace\n \n \n \n \n \n \n \n \n \n \n \n \n \n30-60 min despu\u00e9s de la ingesta de alimentos (1).\n \nLa\nacidez\npuede\nser\nconsecuencia\nde\nvarios\nfactores\nentre\nlos\nque\nse\nencuentran\ndiversos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntrastornos\ndigestivos\n(dispepsia,\nERGE,\ngastritis,\n\u00falcera\np\u00e9ptica,\ninfecci\u00f3n\npor\n\u200b\nHelicobacter\n \n \n \n \n \n \n \n \n \n \npylori\n\u200b\n,\nhernia\nde\nhiato)\no\nsituaciones\nespeciales.\nPor\nejemplo,\nla\npirosis\nes\nespecialmente\n \n \n \n \n \n \n \n \n \n \n \n \n \nfrecuente\nen\nlas\nmujeres\ndurante\nla\ngestaci\u00f3n\ndebido\na\nque\nla\nprogesterona\nrelaja\n \n \n \n \n \n \n \n \n \n \n \n \n \nsustancialmente\nla\nmusculatura,\nincluyendo\nel\ncardias.\nAdem\u00e1s,\ndebido\nal\nincremento\ndel\n \n \n \n \n \n \n \n \n \n \n \ntama\u00f1o\ndel\n\u00fatero,\nse\nproduce\nun\naumento\nde\nla\npresi\u00f3n\nintraabdominal\nque\ntambi\u00e9n\nafecta\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nal\nest\u00f3mago.\nTambi\u00e9n\naumenta\nla\npresi\u00f3n\nabdominal\nen\npacientes\nobesos,\nlo\nque\nhace\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nel\ncontenido\ndel\nest\u00f3mago\npase\nal\nes\u00f3fago.\nOtros\nfactores\nque\ninfluyen\nen\nla\nacidez\nson\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncomidas\ncopiosas\ny\nlos\nalimentos\nque\nirritan\nel\nest\u00f3mago\n(caf\u00e9,\ntomate,\nc\u00edtricos,\nalimentos\n \n \n \n \n \n \n \n \n \n \n \n \n \npicantes),\nas\u00ed\ncomo\nlos\nalimentos\nque\ndisminuyen\nel\ntono\ndel\nesf\u00ednter\n(chocolate,\ncebolla,\n \n \n \n \n \n \n \n \n \n \n \n \n \najo,\nalcohol,\nalimentos\ngrasos).\nEl\ntabaco\ndisminuye\nla\nsalivaci\u00f3n\ny\ndificulta\nel\naclaramiento\n \n \n \n \n \n \n \n \n \n \n \n \n \nesof\u00e1gico;\nadem\u00e1s,\nproduce\nun\nmenor\ncontenido\nde\nbicarbonato\nen\nel\nbolo\nalimenticio,\nlo\n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nafecta\nnegativamente\na\nsu\ncapacidad\npara\nneutralizar\nel\n\u00e1cido.\nPor\n\u00faltimo,\nalgunos\n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\npueden\nreducir\nel\ntono\ndel\nesf\u00ednter,\npor\nejemplo:\nbarbit\u00faricos,\ndopamina,\n \n \n \n \n \n \n \n \n \n \n \nmorfina,\nprogesterona\no\ndiazepam.\nOtros\nson\nirritantes\ndirectos\ndel\nest\u00f3mago,\ncomo\n \n \n \n \n \n \n \n \n \n \n \nclopidogrel,\ndigoxina,\nAINE,\n\u00e1cido\nacetilsalic\u00edlico,\ncorticoides,\nantagonistas\nde\nlos\ncanales\nde\n \n \n \n \n \n \n \n \n \n \n \ncalcio, eritromicina, hierro, teofilina o tetraciclinas.\n \n38\n \n Tratamiento no farmacol\u00f3gico\n \nSe\nrecomienda\nevitar\nlas\ncomidas\ncopiosas,\nmasticar\nbien\nlos\nalimentos\ny\nevitar\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \nalimentos\ndemasiado\ncalientes\ny\nlos\nque\nel\npaciente\ndetecte\nque\nle\nproducen\nm\u00e1s\nacidez.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nOtras\nmedidas\nrecomendables:\nevitar\nacostarse,\nagacharse\no\nhacer\nejercicio\ninmediatamente\n \n \n \n \n \n \n \n \n \n \ndespu\u00e9s\nde\ncomer,\nacostarse\npreferiblemente\nsobre\nel\nlado\nizquierdo\ndel\ncuerpo,\nelevar\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \ncabecera\nde\nla\ncama\nunos\n15-30\ncm,\ncontrolar\nel\nestr\u00e9s,\nevitar\nel\ntabaco\ny\nel\nalcohol.\nEn\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npacientes\ncon\nsobrepeso\nse\nrecomienda\nadem\u00e1s\nperder\npeso\ny\npracticar\nejercicio\nf\u00edsico\n \n \n \n \n \n \n \n \n \n \n \n \nmoderado.\nTodas\nestas\nrecomendaciones\ntienen\nevidencia\ncient\u00edfica,\nexcepto\neliminar\nde\nla\n \n \n \n \n \n \n \n \n \n \n \ndieta\nciertos\nalimentos\nasociados\nal\nreflujo,\ncomo\ncafe\u00edna,\nc\u00edtricos,\nbebidas\ncarbonatadas\no\n \n \n \n \n \n \n \n \n \n \n \n \ngrasas (2, 3).\n \nTratamiento farmacol\u00f3gico\n \nAnti\u00e1cidos\n \nSon\nlos\nf\u00e1rmacos\nm\u00e1s\nempleados\npara\ntratar\nla\nacidez\ng\u00e1strica.\nEficaces\npara\nla\nacidosis\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nocasional,\nno\nhay\nevidencia\nque\napoye\nsu\nuso\ncr\u00f3nico\n(2).\nPresentan\nuna\nr\u00e1pida\nacci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npara\naliviar\nlos\ns\u00edntomas,\npero\nno\nde\nforma\nprolongada\nni\ncontribuyen\na\nla\ncuraci\u00f3n\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nerosi\u00f3n\nde\nla\nmucosa\n(3).\nPresentan\nun\nefecto\ndoble\nneutralizando\nel\n\u00e1cido\nclorh\u00eddrico\n \n \n \n \n \n \n \n \n \n \n \n \n \ndel\nest\u00f3mago\ntras\nreaccionar\ncon\n\u00e9l\nen\nla\nluz\ng\u00e1strica,\ncon\nlo\nque\nreducen\nla\nacidez,\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \naumentando\nla\npresi\u00f3n\ndel\ncardias\ndebido\na\nuna\nmayor\nsecreci\u00f3n\nde\ngastrina.\nAdem\u00e1s,\n \n \n \n \n \n \n \n \n \n \n \n \n \npueden\nabsorber\nla\npepsina\ny\notros\nenzimas\nproteol\u00edticos,\ndisminuyendo\nla\nagresividad\n \n \n \n \n \n \n \n \n \n \n \nenzim\u00e1tica\nsobre\nla\nmucosa\ndigestiva.\nEn\nfunci\u00f3n\nde\nsu\ncapacidad\npara\nser\nabsorbidos,\n \n \n \n \n \n \n \n \n \n \n \n \n \ncabe distinguir 2 tipos:\n \n\u25cf\nSist\u00e9micos.\nReaccionan\nde\nforma\nr\u00e1pida\ne\nirreversible\ncon\nel\n\u00e1cido\nclorh\u00eddrico,\n \n \n \n \n \n \n \n \n \n \n \ndisminuyendo\nel\ndolor\nen\nun\ncorto\nespacio\nde\ntiempo,\npero\nsu\nacci\u00f3n\nes\npoco\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nduradera\ny\npuede\nproducir\nefecto\nrebote.\nSu\nprincipal\nrepresentante\nes\nel\n \n \n \n \n \n \n \n \n \n \n \nbicarbonato\ns\u00f3dico,\nque\nen\nocasiones\nse\nusa\nasociado\na\nun\nanti\u00e1cido\nno\nsist\u00e9mico\n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nel\ncarbonato\nc\u00e1lcico.\nEst\u00e1n\nindicados\nen\nel\ntratamiento\na\ncorto\nplazo\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nmolestias\ngastrointestinales\nasociadas\na\nhiperacidez.\nPueden\nproducir\nhipernatremia\n \n \n \n \n \n \n \n \ny\ndeben\nadministrarse\ncon\nprecauci\u00f3n\na\npacientes\nhipertensos,\nas\u00ed\ncomo\na\npersonas\n \n \n \n \n \n \n \n \n \n \n \n \ncon\ninsuficiencia\ncardiaca\no\nrenal.\nTambi\u00e9n\npueden\ndesencadenar\nalcalosis\nsi\nse\n \n \n \n \n \n \n \n \n \n \n \nutilizan\nen\nperiodos\nprolongados\ndebido\na\nque\nla\nparte\ncati\u00f3nica\nde\nla\nmol\u00e9cula\nsufre\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nabsorci\u00f3n sist\u00e9mica.\n \n \n \n39\n \n \u25cf\nNo\nsist\u00e9micos.\nLa\nparte\ncati\u00f3nica\nde\nla\nmol\u00e9cula\nreacciona\ncon\nel\n\u00e1cido\nclorh\u00eddrico\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nest\u00f3mago\nformando\nuna\nsal\nque\nno\nse\nabsorbe.\nPresentan\nuna\nacci\u00f3n\nm\u00e1s\nlenta\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsostenida\nen\ncomparaci\u00f3n\ncon\nlos\nanteriores,\npor\nlo\nque\ntienen\nla\nventaja\nde\nque\nrara\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nvez\nproducen\nefecto\nrebote.\nLas\nreacciones\nadversas\nque\ngeneran\nsuelen\nser\nleves.\n \n \n \n \n \n \n \n \n \n \n \n \nEn este grupo se incluyen los siguientes compuestos:\n \no\nSales\nde\naluminio\n(algeldrato:\nhidr\u00f3xido\nde\naluminio).\nSu\nuso\ncontinuado\n \n \n \n \n \n \n \n \n \n \npuede\ninterferir\nen\nel\nmetabolismo\ndel\ncalcio,\nincrementando\nel\nriesgo\nde\n \n \n \n \n \n \n \n \n \n \n \nosteomalacia y osteoporosis.\n \no\nSales\nde\nmagnesio\n(hidr\u00f3xido\nde\nmagnesio,\ncarbonato\nde\nmagnesio).\nSi\nse\nusa\n \n \n \n \n \n \n \n \n \n \n \n \nde forma continuada puede ocasionar un cuadro de hipermagnesemia.\n \no\nSales\nde\ncalcio\n(carbonato\nc\u00e1lcico).\nSu\nuso\nprolongado\npuede\ndar\nlugar\na\n \n \n \n \n \n \n \n \n \n \n \n \nc\u00e1lculos renales o incluso a calcificaci\u00f3n tisular.\n \no\nComplejos\nde\naluminio-magnesio\n(almagato,\ncarbonato\ncomplejo\nde\naluminio\n \n \n \n \n \n \n \n \ny\nmagnesio,\ny\nmagaldrato,\nsulfato\ncomplejo\nde\naluminio\ne\nhidr\u00f3xido\n \n \n \n \n \n \n \n \n \n \nmagn\u00e9sico\ndihidratado).\nExcepcionalmente\npueden\ninducir\nhipofosfatemia\nen\n \n \n \n \n \n \n \npacientes con dietas bajas en fosfatos (1).\n \nLos\nalginatos\ncombinados\ncon\nanti\u00e1cidos\nhan\ndemostrado\nser\nm\u00e1s\neficaces\nque\nel\n \n \n \n \n \n \n \n \n \n \n \n \nplacebo\no\nlos\nanti\u00e1cidos\nsolos\npara\nel\ncontrol\npuntual\nde\nlos\ns\u00edntomas\nleves.\nNo\nexiste\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nevidencia\nde\nsu\neficacia\npara\nla\nresoluci\u00f3n\nde\nla\nesofagitis.\nAlgunos\nestudios\nhan\n \n \n \n \n \n \n \n \n \n \n \n \n \nevaluado\nsu\neficacia\npara\nmejorar\nlos\ns\u00edntomas\nresiduales\nen\npacientes\ntratados\ncon\n \n \n \n \n \n \n \n \n \n \n \n \ninhibidores\nde\nla\nbomba\nde\nprotones\n(IBP),\ndemostrando\nque\nel\nalginato\nes\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \n \neficaz\nque\nel\nplacebo\npara\naliviar\ndichos\ns\u00edntomas.\nSin\nembargo,\nen\notro\nestudio\nno\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nencontraron diferencias significativas entre ambos tratamientos (3).\n \nEstos\nanti\u00e1cidos\npresentan\nuna\nserie\nde\nefectos\nsobre\nla\nmotilidad\nintestinal.\nAs\u00ed,\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \nsales\nde\naluminio\ny\ncalcio\nson\nastringentes,\nmientras\nque\nlas\nde\nmagnesio\nson\n \n \n \n \n \n \n \n \n \n \n \n \n \nlaxantes\n(tienden\na\nproducir\ndiarrea\nosm\u00f3tica).\nPara\nevitar\nestas\nsituaciones,\nla\n \n \n \n \n \n \n \n \n \n \n \nmayor\u00eda\nde\nlos\npreparados\ncomerciales\nse\npresentan\ncomo\nmezclas\nde\nsales\nde\n \n \n \n \n \n \n \n \n \n \n \n \naluminio\ny\nde\nmagnesio,\nproduciendo\nun\nefecto\nsobre\nla\nmotilidad\nintestinal\ndif\u00edcil\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \npredecir.\n \nEn\ngeneral,\nlos\nanti\u00e1cidos\nutilizados\na\nlas\ndosis\nconvencionales\nson\nf\u00e1rmacos\nseguros\n \n \n \n \n \n \n \n \n \n \n \n \ny\neficaces.\nSe\nrecomienda\nsu\nadministraci\u00f3n\n30-60\nmin\ndespu\u00e9s\nde\nlas\ncomidas\npara\n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nsu\nefecto\nse\nprolongue\ndurante\nunas\n3\nhoras,\npuesto\nque\nsi\nse\ntoman\nen\nayunas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nson\nefectivos\ntan\nsolo\ndurante\n20-60\nmin.\nInterfieren\ncon\nla\nabsorci\u00f3n\ndigestiva\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\ncomo\ntetraciclinas,\ndigoxina,\nhierro,\n\u00e1cido\nacetilsalic\u00edlico\no\nisoniazida,\n \n \n \n \n \n \n \n \n \npor\nlo\nque\nse\nrecomienda\nseparar\nal\nmenos\n2\nhoras\nde\nla\nadministraci\u00f3n\ncon\nestos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nf\u00e1rmacos.\n \n \n \n40\n \n Antisecretores\n \nSe\nreservan\npara\ncuando\nla\nacidosis\ntiene\nlugar\nm\u00e1s\nde\ndos\nveces\na\nla\nsemana.\nSe\ntrata\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nf\u00e1rmacos\nque\ninhiben\nla\nsecreci\u00f3n\n\u00e1cida\nen\nel\nest\u00f3mago.\nAunque\nmuchos\npacientes\n \n \n \n \n \n \n \n \n \n \n \n \nobtienen\nun\nalivio\nduradero\nde\nla\nsintomatolog\u00eda,\nincluso\ndespu\u00e9s\nde\nhaber\nacabado\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento,\nuna\nproporci\u00f3n\nimportante\nde\nellos\nvolver\u00e1\na\npresentar\nalg\u00fan\nepisodio\nde\n \n \n \n \n \n \n \n \n \n \n \n \npirosis\nque\nhar\u00e1\naconsejable\nun\ntratamiento\nintermitente,\najustando\nla\ndosis\ny\nsu\n \n \n \n \n \n \n \n \n \n \n \n \nduraci\u00f3n a las necesidades individuales.\n \n\u25cf\nAntihistam\u00ednicos\nH2\n(AH2):\nfamotidina\ny\nranitidina.\nSon\nf\u00e1rmacos\nque\ncompiten\ncon\n \n \n \n \n \n \n \n \n \n \n \nla\nhistamina\ny\nbloquean\nde\nforma\nreversible\nsus\nreceptores\nH2\nsituados\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nmembrana\nde\nlas\nc\u00e9lulas\nparietales\ng\u00e1stricas,\nprovocando\nuna\ninhibici\u00f3n\ny\n \n \n \n \n \n \n \n \n \n \ndisminuci\u00f3n\ndel\nvolumen\nde\nsecreci\u00f3n\n\u00e1cida.\nSon\nantagonistas\nmuy\nespec\u00edficos\ny\nno\n \n \n \n \n \n \n \n \n \n \n \n \npresentan\nefectos\nanticolin\u00e9rgicos\n(1).\nNo\ndeben\nser\nusados\ncomo\ntratamiento\nde\n \n \n \n \n \n \n \n \n \n \n \nprimera\nl\u00ednea,\nsino\ncomo\nauxiliares\nen\nel\nmanejo\ncon\nIBP\n(2).\nSon\nm\u00e1s\neficaces\nque\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nplacebo\npara\naliviar\nlos\ns\u00edntomas\nde\nla\nERGE\ny\npara\nla\ncuraci\u00f3n\nde\nla\nesofagitis,\npero\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nclaramente\ninferiores\na\nlos\nIBP\n(3).\nEn\nla\nERGE\npueden\nser\n\u00fatiles\nen\nla\npr\u00e1ctica\ncl\u00ednica\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen\ntres\nsituaciones:\ncomo\ntratamiento\nsintom\u00e1tico\npuntual\npara\nel\nalivio\nr\u00e1pido\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas,\nen\npautas\nde\ntratamiento\ndescendente\npara\nsuspender\nlos\nIBP\ny\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento del escape \u00e1cido nocturno (3).\n \nLas\nindicaciones\nque\ntienen\nson:\ndispepsia\nfuncional,\nERGE,\nerradicaci\u00f3n\nde\n\u200b\nH.\npylori\n\u200b\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \nprevenci\u00f3n\nde\nlesiones\ngastrointestinales\ninducidas\npor\nAINE.\nEn\nla\ndispepsia\n \n \n \n \n \n \n \n \n \n \nfuncional\nel\ntratamiento\nm\u00e1s\nrecomendado\ncon\ncl\u00ednica\nde\ntipo\nulceroso,\nes\nun\nAH2\n \n \n \n \n \n \n \n \n \n \n \n \n \ncon\nun\nIBP,\npero\nno\nhay\nevidencia\nde\nsuperioridad\ndel\nIBP\nfrente\na\nAH2.\nEn\nel\nreflujo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ngastroesof\u00e1gico,\nlos\nAH2\nno\nson\ntan\nefectivos\ncomo\nlos\nIBP,\npero\ns\u00ed\nque\nson\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsuperiores\na\nplacebo\ny\npueden\nser\nuna\nbuena\nalternativa\nen\npacientes\nque\nno\nhayan\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrespondido\na\nIBP.\nPara\nla\nerradicaci\u00f3n\nde\n\u200b\nH.\npylori\n\u200b\n,\nla\nranitidina\npuede\nser\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nalternativa\nen\npacientes\nal\u00e9rgicos\na\nIBP.\nPor\n\u00faltimo,\nlas\ndosis\nest\u00e1ndares\nde\nAH2\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nson\nefectivas\npara\nreducir\nel\nriesgo\nde\n\u00falceras\ng\u00e1stricas\ninducidas\npor\nAINE,\npero\ndosis\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndobles de AH2 s\u00ed han demostrado ser efectivas (4).\n \nLos\nantihistam\u00ednicos\npueden\ngenerar\nefectos\nadversos\nleves\ncomo\ncefaleas,\nmareos,\n \n \n \n \n \n \n \n \n \n \ndiarrea\ny\nestre\u00f1imiento.\nSu\nmayor\ninconveniente\nes\nel\ndesarrollo\nde\ntaquifilaxia\ncon\n \n \n \n \n \n \n \n \n \n \n \n \nel\nuso\nprolongado,\nnormalmente\ndespu\u00e9s\nde\n7\nd\u00edas\n(2).\nPueden\ndisminuir\nla\n \n \n \n \n \n \n \n \n \n \n \n \nabsorci\u00f3n\nde\nf\u00e1rmacos\ncomo\nel\nketoconazol\ne\nitraconazol\n(necesitan\npH\n\u00e1cido\npara\nsu\n \n \n \n \n \n \n \n \n \n \n \n \n \nabsorci\u00f3n).\nAdem\u00e1s\nde\nlos\ncasos\nde\nhipersensibilidad,\nsolo\nest\u00e1\ncontraindicado\nel\nuso\n \n \n \n \n \n \n \n \n \n \n \n \nde\nranitidina\nen\npacientes\ncon\nporfiria.\nSon\nbastante\nseguros\npara\nsu\nuso\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nembarazo\n(categor\u00eda\nB)\ny\nla\nfamotidina\nse\nconsidera\ncompatible\ncon\nla\nlactancia.\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \nranitidina est\u00e1 indicada tambi\u00e9n en ni\u00f1os.\n \n \n \n41\n \n \u25cf\nInhibidores\nde\nla\nbomba\nde\nprotones\n(IBP):\nesomeprazol,\nlansoprazol,\nomeprazol,\n \n \n \n \n \n \n \n \n \n \npantoprazol\ny\nrabeprazol.\nAct\u00faan\ninhibiendo\nde\nforma\nirreversible\nla\nbomba\nde\n \n \n \n \n \n \n \n \n \n \n \nprotones\nATPasa\nH\n\u200b\n+\n\u200b\n/K\n\u200b\n+\nde\nla\nc\u00e9lula\nparietal\ng\u00e1strica,\npor\nlo\nque\nimpiden\nla\nproducci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\n\u00e1cido\ng\u00e1strico\ninducido\npor\nacetilcolina,\ngastrina\no\nhistamina.\nLa\nc\u00e9lula\nparietal\n \n \n \n \n \n \n \n \n \n \n \n \nsolo\nrecupera\nla\nactividad\nsecretora\nmediante\nla\ns\u00edntesis\nde\nnuevas\nmol\u00e9culas\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nbomba,\npor\neste\nmotivo\nla\nduraci\u00f3n\nde\nlos\nefectos\npuede\nser\nde\nhasta\n4\nd\u00edas\ntras\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nadministraci\u00f3n de una dosis \u00fanica (1).\n \nLos\nIBP\nse\nhan\nmostrado\neficaces\ncontra\nla\nERGE\ny\nm\u00e1s\neficaces\nque\nel\nplacebo\ny\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\nantagonistas\nH2\npara\nla\nremisi\u00f3n\nde\nlos\ns\u00edntomas\na\ncorto\nplazo\ny\nen\nla\ncuraci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla\nesofagitis,\ncon\nunas\nrespuestas\ndel\n70-75%.\nTambi\u00e9n\nse\nhan\nmostrado\neficaces\n \n \n \n \n \n \n \n \n \n \n \n \npara\nmantener\nla\nremisi\u00f3n\nde\nlos\ns\u00edntomas\nen\ntratamientos\nde\nmantenimiento\na\n \n \n \n \n \n \n \n \n \n \n \n \nlargo plazo (3).\n \nSon\nf\u00e1rmacos\nbien\ntolerados\ny\nsus\nreacciones\nadversas\nsuelen\nser\nleves\ny\ntransitorias.\n \n \n \n \n \n \n \n \n \n \n \n \n \nEs\ncom\u00fan\nla\naparici\u00f3n\nde\ncefalea\ny\ntrastornos\ngastrointestinales\ncomo\ndiarrea,\n \n \n \n \n \n \n \n \n \n \n \nestre\u00f1imiento, dolor abdominal, n\u00e1useas, v\u00f3mitos o flatulencia.\n \nSe\nmetabolizan\na\ntrav\u00e9s\ndel\ncitocromo\nP450,\nas\u00ed\nque\npueden\nprolongar\nla\nvida\nmedia\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\notros\nf\u00e1rmacos\nque\nse\neliminan\npor\noxidaci\u00f3n\nhep\u00e1tica\ncomo\ndiazepam,\nfenito\u00edna\n \n \n \n \n \n \n \n \n \n \n \n \ny\nanticoagulantes\norales.\nTambi\u00e9n\npueden\ndisminuir\nla\nabsorci\u00f3n\nde\ninhibidores\nde\n \n \n \n \n \n \n \n \n \n \n \nproteasas,\nketoconazol\ne\nitraconazol.\nNo\nse\nrecomienda\ntomar\nomeprazol\ncon\nginkgo\n \n \n \n \n \n \n \n \n \n \n \no\nhip\u00e9rico\nporque\nse\nha\nvisto\nque\npueden\ndisminuir\nsus\nniveles\nplasm\u00e1ticos.\n \n \n \n \n \n \n \n \n \n \n \n \nEsomeprazol,\nlansoprazol\ny\npantoprazol\npresentan\nmenos\ninteracciones\nsignificativas\n \n \n \n \n \n \n \n \ncon\nlos\nf\u00e1rmacos\nque\nse\nmetabolizan\npor\nesta\nv\u00eda,\nlo\nque\nrepresenta\nuna\nventaja\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \naquellos\ncasos\npacientes\npolimedicados.\nAparte\nde\nlos\ncasos\nde\nhipersensibilidad\na\n \n \n \n \n \n \n \n \n \n \n \neste\ngrupo\nde\nf\u00e1rmacos,\nla\n\u00fanica\ncontraindicaci\u00f3n\nes\nel\nuso\nde\nlansoprazol\nen\ncasos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\ninsuficiencia\nrenal\ngrave.\nSe\nclasifican\nen\nla\ncategor\u00eda\nB\npara\nsu\nuso\nen\nembarazo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(excepto el omeprazol, que pertenece a la C) (1).\n \nConclusiones\n \nLos\nIBP\nson\nm\u00e1s\nefectivos\nque\nlos\nantagonistas\nde\nlos\nreceptores\nH2\npara\naliviar\nla\npirosis.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nLos\npacientes\ncon\npirosis\nleve\no\nintermitente\npueden\nobtener\nalivio\ndurante\nun\nperiodo\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntiempo\ncon\nlas\nmodificaciones\ndel\nestilo\nde\nvida\ny\nlos\nanti\u00e1cidos.\nA\ncorto\nplazo,\nlos\nIBP\nalivian\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla\npirosis\nmejor\nque\nlos\nAH2\nen\nlos\npacientes\ntratados\nsin\nun\nexamen\ndiagn\u00f3stico\nespec\u00edfico\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprevio\ny,\naunque\nla\ndiferencia\nes\nm\u00e1s\npeque\u00f1a,\ntambi\u00e9n\nla\nalivian\nen\nlos\npacientes\ncon\nERGE\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\ntienen\nuna\nendoscopia\nsuperior\nnormal\n(5).\nLos\nIBP\nson\nlos\nf\u00e1rmacos\nm\u00e1s\neficaces\ntanto\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nel\ntratamiento\ninicial\ncomo\na\nlargo\nplazo,\ny\nofrecen\nel\nmejor\nperfil\nde\ncoste-eficacia.\nEn\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconcreto\nesomeprazol\nse\nha\nmostrado\nligeramente\nsuperior\nal\nresto\nen\nlos\nestudios\n \n \n \n \n \n \n \n \n \n \n \n \ncontrolados\ndisponibles,\nno\nhabi\u00e9ndose\nobservado\ndiferencias\nsignificativas\nen\ncuanto\na\n \n \n \n \n \n \n \n \n \n \neficacia\nentre\nlos\nrestantes\nf\u00e1rmacos\nde\neste\ngrupo.\nEl\nuso\nde\nIBP\nasociado\na\nanti\u00e1cidos\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndemanda\n(terapia\ncombinada)\nconsigue\naumentar\nla\nrapidez\nen\nel\ncontrol\nde\nla\nsecreci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\u00e1cida\ng\u00e1strica\npara\nuna\nmejora\ngeneral\nde\nla\nenfermedad,\nde\nlos\ns\u00edntomas\ny\nde\nlos\nepisodios\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde pirosis nocturna, evitando as\u00ed un incremento de la dosis est\u00e1ndar de IBP (6).\n \n42\n \n N\u00c1USEAS Y V\u00d3MITOS\n \nJusto Hern\u00e1ndez, A.\n \nSe\ndefine\ncomo\n\u00abn\u00e1usea\u00bb\na\nla\nsensaci\u00f3n\nde\nvomitar,\nlocalizada\nvagamente\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \nepigastrio\no\nla\ngarganta\ny\nque\npuede\no\nno\nculminar\nen\nv\u00f3mito.\nEl\nv\u00f3mito\nes\nla\nexpulsi\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrepentina\ny\nbrusca\ndel\ncontenido\ng\u00e1strico.\nObedece\na\nun\nmecanismo\nmotor\ncomplejo\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \ncoordinado\nque\nincluye\nel\ndescenso\nde\nlos\ndiafragmas\nacompa\u00f1ado\nde\ncontracciones\n \n \n \n \n \n \n \n \n \n \n \nintensas\ny\nmantenidas\nde\nla\nmusculatura\nabdominal\nque\nelevan\nla\npresi\u00f3n\nintrag\u00e1strica.\nTodo\n \n \n \n \n \n \n \n \n \n \n \n \n \nello\npermite\nla\neyecci\u00f3n\ndel\ncontenido\ng\u00e1strico\nque\nes\nexpulsado\npor\nla\nboca\n(1).\nNo\nes\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nenfermedad\ncomo\ntal,\nsino\nun\ns\u00edntoma\nproducido\npor\ndiferentes\ncausas,\nsiendo\nlas\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \n \nfrecuentes:\ninfecci\u00f3n\ngastrointestinal\nv\u00edrica\no\nbacteriana,\nembarazo,\nintoxicaci\u00f3n\nalimentaria\n \n \n \n \n \n \n \n \n \no\nalcoh\u00f3lica,\nmareo\npor\nmovimiento\n(cinetosis),\nmedicamentos\no\ndiversas\nenfermedades.\n \n \n \n \n \n \n \n \n \n \nLos\nmedicamentos\nm\u00e1s\nasociados\ncon\nlos\nv\u00f3mitos\nson:\ncitot\u00f3xicos,\nantiparkinsonianos\n \n \n \n \n \n \n \n \n \n \n(levodopa),\ncardiovasculares\n(digoxina,\nantiarr\u00edtmicos\ny\nantihipertensivos),\nantibi\u00f3ticos\n \n \n \n \n \n \n \n(eritromicina,\ntetraciclinas,\nsulfonamidas),\nopioides,\nantidiab\u00e9ticos\n(metformina),\n \n \n \n \n \n \nantiasm\u00e1ticos\n(teofilina),\nanest\u00e9sicos\ny\nanticonvulsionantes\n(fenito\u00edna,\ncarbamacepina),\n \n \n \n \n \n \n \nentre\notros.\nLas\nenfermedades\nque\ncursan\ncon\nv\u00f3mitos\nson\nsobre\ntodo\nc\u00f3lico\nnefr\u00edtico,\n \n \n \n \n \n \n \n \n \n \n \n \n \n\u00falcera p\u00e9ptica, enfermedad inflamatoria intestinal, migra\u00f1a y jaqueca.\n \nTratamiento\n \nEl\ntratamiento\nde\nlas\nn\u00e1useas\ny\nv\u00f3mitos\ndebe\ncumplir\ntres\nobjetivos:\ncorregir\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \ndisturbios\nhidroelectrol\u00edticos\ny\nel\nestado\nde\nmalnutrici\u00f3n\nresultantes\ndel\ns\u00edndrome,\n \n \n \n \n \n \n \n \n \n \nidentificar\ny\ntratar\nla\ncausa\nsubyacente,\ncuando\nsea\nposible,\ny\nconseguir\nel\nalivio\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas (1).\n \n\u25cf\nEl\ntratamiento\nde\nelecci\u00f3n\nde\nprimera\nl\u00ednea\nes\nla\nrehidrataci\u00f3n\noral\ncon\nagua,\nglucosa\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nelectrolitos\npara\nevitar\nla\ndeshidrataci\u00f3n\ny\nmantener\nel\nequilibrio\nhidroel\u00e9ctrico.\nSe\n \n \n \n \n \n \n \n \n \n \n \nrecomiendan\ndos\ntipos\nde\nsales\nde\nrehidrataci\u00f3n\noral\n(SRO),\nuna\npara\nla\nhidrataci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \ninicial\ncon\nconcentraciones\nde\nsodio\nde\n75-90mmol/L\ny\notra\npara\nmantenimiento\n(40-60\n \n \n \n \n \n \n \n \n \n \n \n \nmmol/L).\nSe\ndeben\nemplear\nsiempre\nSRO\ncon\nestas\nconcentraciones\ny\nno\nsustituirlas\npor\n \n \n \n \n \n \n \n \n \n \n \n \n \nbebidas isot\u00f3nicas, que no cumplen estos requisitos (2).\n \n\u25cf\nAntagonistas\nde\nla\nserotonina:\nondansetr\u00f3n.\nIndicado\nen\nquimioterapia\ny\ncuando\nlos\n \n \n \n \n \n \n \n \n \n \n \nv\u00f3mitos\nno\nremiten\nen\ncaso\nde\nuna\ngastroenteritis\naguda,\ndebido\na\nque\nlas\nn\u00e1useas\nson\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndebidas\na\nla\nestimulaci\u00f3n\nvisceral\nmediada\nsobre\ntodo\npor\nserotonina.\nSe\nemplea\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \ngastroenteritis\nespecialmente\ncuando\nhay\nriesgo\nde\ndeshidrataci\u00f3n\no\nno\nse\nha\ntolerado\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nrehidrataci\u00f3n\noral\n(3).\nHay\nevidencia\ncient\u00edfica\nsuficiente\n(2B)\nde\nque\nuna\nsola\ndosis\noral\no\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nintravenosa\ncontrola\nv\u00f3mitos\ny\nreduce\nhospitalizaciones\n(4).\nEl\nempleo\nde\n4-8\nmg\n \n \n \n \n \n \n \n \n \n \n \n \nintravenosos\ntiene\nevidencia\n1A\npara\nreducir\nlas\nn\u00e1useas\ny\nv\u00f3mitos\npostoperatorios\n(5).\n \n \n \n \n \n \n \n \n \n \n \n \nNo existe evidencia suficiente para usar otros antiem\u00e9ticos en gastroenteritis aguda.\n \n \n \n \n43\n \n \u25cf\nAntagonistas\ndopamin\u00e9rgicos.\nIndicados\nen\nv\u00f3mitos\ninducidos\npor\nf\u00e1rmacos\ny\nmigra\u00f1as,\n \n \n \n \n \n \n \n \n \n \nya\nque\nla\ndopamina\nes\nel\nmediador\nprimario\n(3).\nSe\nutiliza\ndomperidona,\nmetoclopramida\n \n \n \n \n \n \n \n \n \n \n \n \n \ny\nclorpromazina.\nPueden\nproducir\nefectos\nextrapiramidales,\ncomo\ninquietud,\n \n \n \n \n \n \n \n \nhipotensi\u00f3n, sedaci\u00f3n y letargia (5).\n \n\u25cf\nAntihistam\u00ednicos\nH1\n(AH1).\nLa\nsensaci\u00f3n\nde\nmareo\no\nv\u00e9rtigo\nasociada\nal\nmovimiento\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \nmodulada\npor\nreceptores\nvestibulares\nhistamin\u00e9rgicos\ny\nmuscar\u00ednicos,\nde\nah\u00ed\nque\nlos\n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas\npuedan\nprevenirse\no\ntratarse\ncon\nantihistam\u00ednicos.\nEl\ndimenhidrinato\nest\u00e1\n \n \n \n \n \n \n \n \n \n \nindicado\nen\nn\u00e1useas\nsecundarias\na\nv\u00e9rtigo\ny\ncinetosis\ncon\nevidencia\nnivel\nC\n(3).\nLos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nestudios\ncl\u00ednicos\npublicados\naportan\nevidencia\nacerca\nde\nla\neficacia\ny\nseguridad\nde\n \n \n \n \n \n \n \n \n \n \n \n \ndimenhidrinato\nen\nla\nprofilaxis\ny\nel\ntratamiento\nde\nla\ncinetosis,\nas\u00ed\ncomo\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\ndel\nv\u00e9rtigo\ny\nen\nla\nprofilaxis\nde\nla\nemesis\nen\nel\npostoperatorio\n(7).\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndoxilamina\nes\nel\ntratamiento\nde\nelecci\u00f3n\nen\nn\u00e1useas\nproducidas\nen\nel\nembarazo.\nAct\u00faa\n \n \n \n \n \n \n \n \n \n \n \n \n \naumentando\nel\numbral\nde\nexcitaci\u00f3n\nde\nlas\nneuronas\ndel\ncentro\nregulador\ndel\nv\u00f3mito,\nlo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nexplica\nel\nefecto\nantiem\u00e9tico\n(7).\nDiversos\nestudios\nrealizados\nhan\ndemostrado\n \n \n \n \n \n \n \n \n \n \n \neficacia\ny\nseguridad\npara\nel\nfeto\n(8).\nSin\nembargo,\nse\nhan\nhecho\nestudios\ncompar\u00e1ndolo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncon\nondansetr\u00f3n,\nen\ncaso\nde\nque\nel\nuso\nde\ndoxilamina\nfuera\nineficaz,\ncon\nel\nresultado\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nondansetr\u00f3n\nes\nm\u00e1s\neficaz\nque\ndoxilamina\nen\nn\u00e1useas\nde\nembarazo\n(9).\nHabr\u00eda\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nseguir\nrealizando\nestudios\nen\ncuanto\na\nseguridad\npara\nel\nfeto\ny\nlimitar\nsu\nuso\nen\n\u00e1mbitos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nhospitalarios,\npues\nes\ncategor\u00eda\nB\nde\nla\nFDA,\nmientras\nque\nla\ndoxilamina\nes\ncategor\u00eda\nA\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(10).\n \n\u25cf\nAnticolin\u00e9rgicos:\nescopolamina.\nIndicada\npara\natenuar\nespasmos\ngastrointestinales,\n \n \n \n \n \n \n \ntambi\u00e9n para n\u00e1useas y v\u00f3mitos por cinetosis. Evidencia tipo C (3).\n \n\u25cf\nFitoterapia.\nMuchos\nremedios\nherbales\nse\nemplean\ncomo\nantiem\u00e9ticos,\nespecialmente\n \n \n \n \n \n \n \n \n \ndurante\nel\nembarazo.\nA\npesar\nde\nsu\nuso\ngeneralizado,\nexisten\nmuy\npocas\ninvestigaciones\n \n \n \n \n \n \n \n \n \n \n \n \n \ncl\u00ednicas\nal\nrespecto,\nsalvo\nsobre\nel\nextracto\nde\njengibre.\nSu\nuso\ncomo\nantiem\u00e9tico\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprometedor,\npero\nla\nevidencia\nde\nsu\nefectividad\nes\nd\u00e9bil\ny\npoco\nconsistente.\nSon\n \n \n \n \n \n \n \n \n \n \n \n \n \nnecesarios\nmejores\nestudios\npara\nestablecer\nsu\nlugar\nen\nla\ncl\u00ednica.\nDado\nsu\nbuen\nperfil\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nseguridad, puede ser una opci\u00f3n v\u00e1lida (12, 13).\n \nPor\nnorma\ngeneral,\nlos\nmedicamentos\npara\nel\ncontrol\nde\nv\u00f3mitos\nen\nurgencias\nno\nson\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnecesarios,\nya\nque\nsuelen\ndurar\npoco\ntiempo.\nNo\nexisten\npruebas\ndefinitivas\npara\napoyar\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsuperioridad\nde\nning\u00fan\nf\u00e1rmaco\nsobre\notro,\nni\nla\nsuperioridad\nde\nning\u00fan\nf\u00e1rmaco\nsobre\n \n \n \n \n \n \n \n \n \n \n \n \n \nplacebo.\nNormalmente,\nla\ngravedad\nde\nlas\nn\u00e1useas\ntiende\na\ndisminuir\ndesde\nel\npunto\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nvista\ncl\u00ednico\na\nlos\n30\nminutos,\nindependientemente\nde\nsi\nse\nadministra\nun\nf\u00e1rmaco\n \n \n \n \n \n \n \n \n \n \n \n \n \nantiem\u00e9tico\no\nun\nplacebo\nsalino.\nEsto\nhace\nque\nla\nelecci\u00f3n\ndel\nf\u00e1rmaco\nen\nocasiones\nsea\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nbase al estado del paciente o al perfil de efectos adversos (11).\n \n \n \n44\n \n DIARREA AGUDA\n \nJusto Hern\u00e1ndez, A.\n \nLa\ndiarrea\nse\ndefine\ncomo\nla\ndisminuci\u00f3n\nde\nla\nconsistencia\no\nel\naumento\nde\nla\nfrecuencia\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nlas\nevacuaciones\nintestinales,\nal\nmenos\nm\u00e1s\nde\n3\ndiarias.\nLas\ndiarreas\npueden\nser\nagudas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(< 4 semanas) o cr\u00f3nicas (1). Entre las causas m\u00e1s frecuentes de diarrea aguda encontramos:\n \n \n\u25cf\nDiarrea infecciosa\n \no\nBacteriana:\n\u200b\nentre\nlos\nagentes\ncausales\nm\u00e1s\nhabituales\nse\nencuentran\n \n \n \n \n \n \n \n \n \nCampylobacter, Salmonella, Shigella \n\u200b\ny \n\u200b\nEscherichia coli \n\u200b\n(diarrea del viajero).\n \no\nViral:\n\u200b\nNorovirus\ny\nCitomegalovirus\nson\nlos\nm\u00e1s\ncomunes.\nEn\nni\u00f1os\nlos\nvirus\nson\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncausa m\u00e1s frecuente de diarrea, especialmente Rotavirus.\n \no\nParasitaria:\nlos\npar\u00e1sitos\nm\u00e1s\nrelacionados\ncon\ndiarrea\nen\nnuestro\nmedio\nson\n \n \n \n \n \n \n \n \n \n \n \nGiardia lamblia\n\u200b\n y \n\u200b\nCrytosporidium\n\u200b\n sp.\n \n\u25cf\nDiarrea\npor\nintoxicaci\u00f3n\no\ntoxiinfecci\u00f3n\nalimentaria:\nconsumo\nde\nalimentos\nque\n \n \n \n \n \n \n \n \n \n \ncontienen bacterias, par\u00e1sitos, virus o toxinas.\n \n\u25cf\nDiarrea\npor\nmedicamentos.\nEl\ntratamiento\ncon\nantibi\u00f3ticos\npuede\nalterar\nel\nequilibrio\n \n \n \n \n \n \n \n \n \n \n \nde\nlos\nmicroorganismos\nque\nhabitan\nnormalmente\nen\nel\nintestino,\npudiendo\nprovocar\n \n \n \n \n \n \n \n \n \n \n \ndiarrea.\n\u200b\nClostridium\ndifficile\nes\nun\nmicroorganismo\nque\npuede\nproducir\ninfecci\u00f3n\n \n \n \n \n \n \n \n \n \n \nintestinal\ncuando\nse\nha\nalterado\nla\nmicrobiota\nnormal.\nEs\nla\nprimera\ncausa\n \n \n \n \n \n \n \n \n \n \n \n \nidentificable de diarrea en pacientes hospitalizados (3, 5).\n \n\u25cf\nDiarrea por intolerancia alimentaria: a la lactosa, al gluten, etc.\n \n\u25cf\nDiarrea por alergia alimentaria: a prote\u00ednas de leche de vaca, soja, etc.\n \nTratamiento\n \n \nTratamiento no farmacol\u00f3gico\n \nComo\ntratamiento\nno\nfarmacol\u00f3gico\nel\npaciente\ndebe\ntomar\ndesde\nel\nprimer\nmomento\n \n \n \n \n \n \n \n \n \n \n \n \n \nsoluciones\nde\nrehidrataci\u00f3n\noral\ncon\nagua,\nglucosa\ny\nsales.\nEsto\nno\nacorta\nla\nduraci\u00f3n\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndiarrea,\npero\nevita\nla\ndeshidrataci\u00f3n\ny\nmantiene\nel\nequilibrio\nelectrol\u00edtico.\nLas\nsoluciones\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nrehidrataci\u00f3n\noral\n(SRO)\naceptadas\npor\nla\nOMS\nse\nhan\nido\nadaptando\nprogresivamente\na\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncaracter\u00edsticas\nde\nlas\ndiarreas\nagudas\ny\ndeshidrataciones\nen\nlas\npoblaciones\noccidentales.\n \n \n \n \n \n \n \n \n \n \n \nActualmente\nen\nEspa\u00f1a\nse\npreconiza\nmayoritariamente\nel\nuso\nde\nSRO\nhipot\u00f3nicas\nen\nni\u00f1os,\n \n \n \n \n \n \n \n \n \n \n \n \n \nya\nque,\nen\ngeneral,\nel\nobjetivo\nprincipal\nes\nmantener\nun\ncorrecto\nestado\nde\nhidrataci\u00f3n\ny,\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nalgunos\ncasos,\ncorregir\ndeshidrataciones\nleves\no\nmoderadas.\nAdem\u00e1s,\nlos\npat\u00f3genos\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \nfrecuentes\nresponsables\nde\ngastroenteritis\naguda\n(GEA)\nsuelen\nproducir\ndiarrea\ncon\nuna\n \n \n \n \n \n \n \n \n \n \n \np\u00e9rdida moderada de electrolitos (6).\n \nDe\nforma\nrutinaria\nse\nrecomienda\nseguir\nuna\ndieta\nblanda;\nsin\nembargo,\nesta\nmedida\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nest\u00e1 respaldada por estudios de eficacia cl\u00ednica (2).\n \n45\n \n  \n \n46\n \n Tratamiento farmacol\u00f3gico\n \nEl tratamiento farmacol\u00f3gico actualmente se clasifica de la siguiente manera:\n \n\u25cf\nInhibidores\nde\nla\nmotilidad\nintestinal.\nEst\u00e1n\ncontraindicados\nen\ndiarrea\ninfecciosa;\nse\n \n \n \n \n \n \n \n \n \n \n \nrecomiendan\nen\ndiarrea\npor\nintoxicaci\u00f3n.\nEs\nm\u00e1s\nempleado\nes\nla\nloperamida.\n \n \n \n \n \n \n \n \n \n \n \nDisminuye\nla\nmotilidad\ndel\nest\u00f3mago,\nretrasa\nel\nvaciado\ng\u00e1strico\ny\ndisminuye\nel\n \n \n \n \n \n \n \n \n \n \n \n \nperistaltismo\nintestinal.\nAsimismo,\nfacilita\nla\nabsorci\u00f3n\nde\nagua\ny\nelectrolitos.\nA\nd\u00eda\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nhoy,\nla\nloperamida\nes\nla\nposolog\u00eda\nrecomendada\n(2\nmg\ndespu\u00e9s\nde\ncada\ndeposici\u00f3n),\n \n \n \n \n \n \n \n \n \n \n \n \n \npero\nse\nnecesita\nm\u00e1s\nestudios\npara\ncomprobar\nla\nevidencia\ncient\u00edfica.\nEn\nalgunos\n \n \n \n \n \n \n \n \n \n \n \n \nestudios\nno\npresenta\nuna\neficacia\nsuperior\na\nla\ndel\nplacebo\nen\ncuanto\na\nla\nduraci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla\ndiarrea\nse\nrefiere\ny\ntampoco\nimpide\nla\ndeshidrataci\u00f3n.\nSin\nembargo,\nen\notros\n \n \n \n \n \n \n \n \n \n \n \n \n \nestudios\nse\nha\ncomparado\nen\n7\nd\u00edas\ncon\nplacebo\ny\nracecadotrilo\n(inhibidor\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsecreci\u00f3n)\ny\nse\nha\nvisto\nque\nambos\nmedicamentos\nson\nm\u00e1s\nefectivos\nque\nel\nplacebo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npara\nreducir\nla\nfrecuencia\ny\nla\nduraci\u00f3n\n(2).\nTiene\nun\nnivel\nde\nevidencia\n4,\ngrado\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomendaci\u00f3n D (4).\n \n\u25cf\nInhibidor\nde\nla\nsecreci\u00f3n\nintestinal:\nracecadotrilo.\nEs\nun\ninhibidor\nselectivo\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \nencefalinasa\nintestinal,\nenzima\nresponsable\nde\nla\ndegradaci\u00f3n\nde\nlas\nencefalinas\n \n \n \n \n \n \n \n \n \n \nintestinales,\nque\nregulan\nla\nsecreci\u00f3n\nde\nagua\ny\nelectrolitos.\nSu\nacci\u00f3n\nes\n \n \n \n \n \n \n \n \n \n \n \n \nexclusivamente\nperif\u00e9rica,\npor\nlo\nque\nsus\nefectos\ncolaterales\nson\nescasos.\nM\u00faltiples\n \n \n \n \n \n \n \n \n \n \n \nestudios\nhan\ndemostrado\nsu\nefectividad\nen\nel\nmanejo\nde\nla\ndiarrea\naguda\nen\nni\u00f1os\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nadultos.\nSe\nha\ndemostrado\nque\nla\nadministraci\u00f3n\nde\n100-200\nmg\n3\nveces\nal\nd\u00eda\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nreduce\nen\nm\u00e1s\nde\nun\ntercio\nel\ngasto\nfecal.\nTiene\nun\nnivel\nde\nevidencia\n2,\ngrado\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomendaci\u00f3n C (4).\n \n\u25cf\nProbi\u00f3ticos:\nson\nmicroorganismos\nvivos\n(bacterias\no\nlevaduras)\nque,\ningeridos\nde\n \n \n \n \n \n \n \n \n \n \nforma\nadecuada,\nejercen\nefectos\nbeneficiosos\npara\nla\nsalud.\nEl\nuso\nde\nprobi\u00f3ticos\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \ndiarrea\nes\nhoy\nen\nd\u00eda\nla\nindicaci\u00f3n\nde\nla\nque\nse\ndispone\nde\nmejor\nevidencia\ncient\u00edfica\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(3).\nSe\nha\ndemostrado\nque\ndisminuyen\nla\nduraci\u00f3n\nde\nlos\nepisodios\nen\nun\nd\u00eda\ny\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nn\u00famero\nde\ndeposiciones\nal\nsegundo\nd\u00eda\nde\ntratamiento.\nLas\nsiguientes\ncepas\nse\nhan\n \n \n \n \n \n \n \n \n \n \n \n \n \nestudiado\npor\nseparado\ny\nexiste\nevidencia\nsuficiente\ncomo\npara\nrecomendarlas\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nde\nla\ndiarrea\naguda,\nincluso\nen\nni\u00f1os:\n\u200b\nSacchromyces\nboulardii\n(250mg\nen\n \n \n \n \n \n \n \n \n \n \n \n \ndesayuno\ny\ncena),\n\u200b\nLactobacillus\nrhamnosus\nGG\n(1010\nUFC\nen\ndesayuno\ny\ncena).\nCon\n \n \n \n \n \n \n \n \n \n \n \n \n \nambos\nhay\nreducci\u00f3n\nsignificativa\nde\nla\nduraci\u00f3n\ndel\nproceso\ndiarreico,\ndisminuci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \ndel\nriesgo\nde\nprolongaci\u00f3n\nde\ndiarrea\naguda\ny\nreducci\u00f3n\ndel\nriesgo\nde\ndiarrea\n \n \n \n \n \n \n \n \n \n \n \n \n \nasociada\na\nantibi\u00f3ticos\n\u200b\n.\n\u200b\nExiste\nevidencia\nmoderada\ncon\nLactobacillus\nrhamnosus\nGG\n \n \n \n \n \n \n \n \n \n \nen\nla\nreducci\u00f3n\nde\nriesgo\nde\ndiarrea\nnosocomial\n(7).\nNo\nexiste\nevidencia\nsuficiente\n \n \n \n \n \n \n \n \n \n \n \n \n \npara\nrecomendar\n\u200b\nBifidobacterium\nlactis\n\u200b\nni\n\u200b\nLactobacillus\nacidophilus\ny\nse\ndesaconseja\n \n \n \n \n \n \n \n \n \n \nel\nuso\nde\nla\ncepa\nEnterococcus\nfaecium\n(2).\nEn\nla\ndiarrea\nasociada\na\nantibi\u00f3ticos,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nexiste\nevidencia\ncuando\nse\nasocian\nal\ntratamiento\nantimicrobiano\nde\nbase\ncomo\n \n \n \n \n \n \n \n \n \n \n \ncoadyuvantes\n(3,\n8).\nEl\nuso\na\ncorto\nplazo\nde\nprobi\u00f3ticos\nparece\nser\nseguro\ny\nefectivo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncuando\nse\nadministran\njunto\ncon\nantibi\u00f3ticos\nen\npacientes\nque\nno\nest\u00e1n\ngravemente\n \n \n \n \n \n \n \n \n \n \n \n \ndebilitados ni inmunocomprometidos (5, 8).\n \n47\n \n \u25cf\nAdsorbentes\nintestinales:\ncarb\u00f3n\nactivo,\nmetilcelulosa.\nNo\nexisten\nestudios\nque\n \n \n \n \n \n \n \n \n \ndemuestren su utilidad. No existe evidencia para recomendarlos (4).\n \n\u25cf\nAntibi\u00f3ticos:\nel\nuso\nde\nantibi\u00f3ticos\nno\nest\u00e1\nindicado\nde\nforma\nrutinaria\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nde\nla\ndiarrea\naguda,\ns\u00f3lo\nest\u00e1\njustificado\nen\ncaso\nde\ndiarrea\nbacteriana\n \n \n \n \n \n \n \n \n \n \n \n \n \ncausada\npor\n\u200b\nShigella\nsp.,\n\u200b\nE.\ncoli\nenteroinvasiva\ny\nenteropat\u00f3gena,\n\u200b\nClostridium\ndifficile\n\u200b\n,\n \n \n \n \n \n \n \n \n \n \n \nEntamoeba\nhistolytica,\nGiardia\nlamblia\no\nVibrio\ncholerae.\nEn\nel\ncaso\nconcreto\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n\u00abdiarrea\ndel\nviajero\u00bb,\nde\norigen\nbacteriano,\nen\ncasos\nleves\nno\nser\u00e1\nnecesario\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nantibi\u00f3tico,\nque\nse\nasocia\ncon\nuna\nmenor\nduraci\u00f3n\nde\nla\ndiarrea\npero\n \n \n \n \n \n \n \n \n \n \n \n \n \ntambi\u00e9n\ncon\nuna\nincidencia\nm\u00e1s\nalta\nde\nefectos\nsecundarios\n(9).\nLa\nrifaximina\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \naconseja\ns\u00f3lo\npara\nla\nprofilaxis\nantibi\u00f3tica\nen\nviajeros\ncon\nalto\nriesgo\nde\nsufrir\n \n \n \n \n \n \n \n \n \n \n \n \n \ncomplicaciones\ndebidas\na\nla\ndiarrea\n(grado\nde\nrecomendaci\u00f3n\nfuerte),\nla\nazitromicina\n \n \n \n \n \n \n \n \n \n \n \nes\nde\nelecci\u00f3n\npara\nlas\nformas\ngraves\n(grado\nde\nrecomendaci\u00f3n\nfuerte)\ny\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \nfluoroquinolonas est\u00e1n desaconsejadas como tratamiento profil\u00e1ctico (10).\n \n\u25cf\nZinc:\nel\nzinc\nes\nun\nmicronutriente\nimplicado\nen\nlos\nprocesos\ndiarreicos.\nLa\n \n \n \n \n \n \n \n \n \n \n \n \nsuplementaci\u00f3n\noral\ncon\nzinc\nreduce\nla\nduraci\u00f3n\ny\nla\ngravedad\nde\nla\ndiarrea.\nLa\nOMS\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomienda tratar con zinc a los ni\u00f1os con diarrea en pa\u00edses en desarrollo (11).\n \n \nConclusi\u00f3n\n \nEn\nla\nmayor\u00eda\nde\nocasiones\nla\ndiarrea\naguda\nes\nun\nproceso\nautolimitado\nque\nno\nrequiere\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nun\ntratamiento\nespec\u00edfico.\nEl\nuso\nde\nsoluciones\nde\nrehidrataci\u00f3n\nest\u00e1\naconsejado\nen\ntodos\n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\ntipos\nde\ndiarrea\ny\nes\nefectivo\na\nla\nhora\nde\nprevenir\ncomplicaciones.\nEn\ncaso\nde\nque\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nduraci\u00f3n\nde\nla\ndiarrea\nsea\nexcesiva\no\ninterfiera\ncon\nlos\nh\u00e1bitos\ndel\npaciente,\nexisten\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamientos eficaces como la loperamida, el rodecadotrilo y algunas cepas de probi\u00f3ticos.\n \n \n \n48\n \n ESTRE\u00d1IMIENTO\n \nJusto Hern\u00e1ndez, A.\n \nEs\ndif\u00edcil\ndefinir\ncon\nexactitud\nel\nestre\u00f1imiento,\npues\nes\nuna\nalteraci\u00f3n\ndel\nh\u00e1bito\n \n \n \n \n \n \n \n \n \n \n \n \n \nintestinal,\nel\ncual\nvar\u00eda\nde\nuna\npersona\na\notra.\nComo\nnorma\ngeneral\nse\nconsidera\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nestre\u00f1imiento\ncuando\nse\nproducen\ntres\nevacuaciones\no\nmenos\na\nla\nsemana,\ncon\nheces\nduras\n \n \n \n \n \n \n \n \n \n \n \n \n \n \no\nsecas,\ncon\nesfuerzo\npara\ndefecar\no\nsensaci\u00f3n\nde\nevacuaci\u00f3n\nincompleta\n(tenesmo).\n \n \n \n \n \n \n \n \n \n \n \n \nTambi\u00e9n\nse\npuede\ndefinir\ncomo\nretraso\no\ndificultad\nen\nla\ndefecaci\u00f3n\nque\nest\u00e1\npresente\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndurante\nal\nmenos\ndos\nsemanas\ny\nque\ntiene\nla\nintensidad\nsuficiente\ncomo\npara\nprovocar\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmalestar\nsignificativo\nen\nel\npaciente\n(1).\nSe\ndiferencia\nentre\nestre\u00f1imiento\nfuncional\n(tr\u00e1nsito\n \n \n \n \n \n \n \n \n \n \n \n \nintestinal\nlento)\ny\nestre\u00f1imiento\npor\nbloqueo\n(retraso\nen\nel\nvaciamiento\nde\nla\nampolla\nrectal)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(8).\n \nLas\ncausas\ndel\nestre\u00f1imiento\npueden\nser\ndiversas:\ndieta\npobre\nen\nfibra\ny\nen\ningesta\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nl\u00edquidos,\nescasa\nactividad\nf\u00edsica,\nembarazo,\nuso\nfrecuente\no\nexcesivo\nde\nlaxantes,\n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\ny\ndiversas\nenfermedades.\nLos\nmedicamentos\nm\u00e1s\nasociados\nal\nestre\u00f1imiento\n \n \n \n \n \n \n \n \n \n \nson:\nsales\nde\nhierro,\nopi\u00e1ceos,\nbenzodiacepinas,\nantidepresivos,\nantiparkinsonianos,\n \n \n \n \n \n \n \n \nantihipertensivos, antagonistas de calcio, diur\u00e9ticos, bifosfonatos e IBP, entre otros (2).\n \nTratamiento no farmacol\u00f3gico\n \n\u25cf\nAumentar\nla\nactividad\nf\u00edsica.\nAunque\nhay\nestudios\nepidemiol\u00f3gicos\nque\ndemuestran\nque\n \n \n \n \n \n \n \n \n \n \n \nel\nestre\u00f1imiento\nes\nm\u00e1s\nprevalente\nen\npacientes\ncon\nvida\nsedentaria,\nno\nhay\nevidencias\n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nque\nel\nejercicio\nf\u00edsico\nsea\n\u00fatil\nen\npacientes\ncon\nestre\u00f1imiento\ncr\u00f3nico.\nSin\nembargo,\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nincremento\nde\nla\nactividad\nf\u00edsica\nes\nrecomendable,\ndado\nque\nproduce\nmejor\u00eda\nen\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas asociados al estre\u00f1imiento (distensi\u00f3n abdominal y meteorismo) (2).\n \n\u25cf\nDieta\nadecuada:\nsuplementos\nde\nfibra\ny\naumentar\nla\ningesta\nde\nl\u00edquidos\ny\nverduras.\n \n \n \n \n \n \n \n \n \n \n \n \n \nAunque\nexisten\ndatos\ninsuficientes\nsobre\nel\nimpacto\nde\nlos\nl\u00edquidos\ny\nde\nla\nfibra\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nalimentos\ncompletos\nen\nla\nevoluci\u00f3n\ndel\nestre\u00f1imiento,\nse\ndeber\u00e1\nindicar\nun\naporte\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nfibra\ndiet\u00e9tica\ny\nde\nagua\nen\ncantidad\nsuficiente\npara\ncubrir\nlas\nrecomendaciones\nacordes\n \n \n \n \n \n \n \n \n \n \n \n \n \na la edad y sexo (3, 4).\n \n\u25cf\nRespetar el tiempo de la defecaci\u00f3n, no retras\u00e1ndolo cuando se sienta la necesidad.\n \n \nTodos\nlos\ntratamientos\nno\nfarmacol\u00f3gicos\ntienen\nun\nnivel\nde\nevidencia\n4\ny\ngrado\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomendaci\u00f3n D.\n \n \n \n49\n \n Tratamiento farmacol\u00f3gico\n \n\u25cf\nLaxantes\nformadores\nde\nmasa:\nconsisten\nfundamentalmente\nen\nsuplementos\nde\nfibra\n \n \n \n \n \n \n \n \n \n \nque\naumentan\nla\nmasa\nfecal.\nDeben\nir\nsiempre\nacompa\u00f1ados\npor\nuna\ningesta\nabundante\n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nagua.\nLa\nfibra\nabsorbe\nel\nagua\ny\nmodifica\nla\nconsistencia\nde\nlas\nheces.\nEl\nefecto\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nacci\u00f3n\nno\nes\ninmediato;\npuede\ntardar\nentre\n72\nhoras\ny\nsemanas\nen\nresultar\ncl\u00ednicamente\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nefectivo.\nUno\nde\nlos\nprincipales\nproblemas\nque\nproducen\nes\nla\nsensaci\u00f3n\nde\ndistensi\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \nabdominal\ny\nflatulencia,\nque\nse\ndeben\na\nla\nfermentaci\u00f3n\n(con\nformaci\u00f3n\nde\ngas)\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfibra\nen\nel\ncolon,\npues\nno\nse\nabsorbe\nen\nel\nintestino\ndelgado.\nLa\nmayor\u00eda\nde\ngu\u00edas\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npr\u00e1ctica\ncl\u00ednica\nindican\nque\nun\nincremento\nde\ningesta\nde\nfibra\ndiet\u00e9tica\no\nfibra\ncomercial\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndebe\nser\nla\nprimera\nmedida\nterap\u00e9utica\nen\npacientes\ncon\nestre\u00f1imiento\ncr\u00f3nico\n \n \n \n \n \n \n \n \n \n \n \nfuncional sin s\u00edntomas de s\u00edndrome de intestino irritable (6).\n \no\nFibra\ndiet\u00e9tica.\nEn\ngeneral,\nla\nfibra\ndiet\u00e9tica\nutilizada\ncomo\nlaxante\nes\ninsoluble\n \n \n \n \n \n \n \n \n \n \n \n \n(salvado),\naunque\nalgunas\nverduras\ny\nfrutas\nllevan\nfibra\nsoluble.\nSe\nha\nobservado\n \n \n \n \n \n \n \n \n \n \n \n \nque\nla\ningesta\nde\nsalvado\nde\ntrigo\ny\nde\npan\nde\ncenteno\nincrementa\nla\nfrecuencia\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nlas\ndefecaciones\ny\ndisminuye\nla\ndificultad\ndefecatoria.\nLa\neficacia\ndel\nsalvado\n \n \n \n \n \n \n \n \n \n \n \n \nde\ntrigo\nes\nmayor\nsi\nse\nasocia\na\nuna\ningesta\nm\u00ednima\nde\n2\nlitros\nde\nagua.\nTiene\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnivel de evidencia 3 y nivel de recomendaci\u00f3n C.\n \no\nFibra\nsoluble.\nHay\npocos\nensayos\ncl\u00ednicos\nrandomizados\nque\nanalicen\nel\nefecto\nde\n \n \n \n \n \n \n \n \n \n \n \n \nla\nfibra\nsoluble\nen\npacientes\ncon\nestre\u00f1imiento\ncr\u00f3nico\nfuncional.\nEl\npsylium\n \n \n \n \n \n \n \n \n \n \n \n(\n\u200b\nPlantago\novata\n\u200b\n)\nes\nla\nfibra\nmejor\nevaluada;\nen\ndos\nensayos\ncl\u00ednicos\nse\nobserv\u00f3\n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nera\nsuperior\nal\nplacebo\nen\nincrementar\nla\nfrecuencia\nde\nlas\ndeposiciones\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \ndisminuir\nla\nconsistencia\nde\nlas\nheces.\nTiene\nun\nnivel\nde\nevidencia\n2\ny\ngrado\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomendaci\u00f3n B.\n \n\u25cf\nLaxantes\nosm\u00f3ticos:\nlactulosa\ny\npolietilenglicol\n(PEG).\nAtraen\nagua\nhacia\nel\ninterior\n \n \n \n \n \n \n \n \n \n \n \nintestinal,\naumentando\nas\u00ed\nel\nvolumen\nde\nlas\nheces.\nSe\nha\ncomprobado\nque\nel\nPEG\nda\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmejores\nresultados\nque\nla\nlactulosa\nen\ncuanto\na\nresultados\nde\nla\nfrecuencia\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndeposiciones\npor\nsemana,\nforma\nde\nlas\nheces,\nalivio\ndel\ndolor\nabdominal\ny\nnecesidad\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nproductos\nadicionales,\nas\u00ed\ncomo\nmenos\nefectos\nsecundarios.\nPor\nlo\ntanto,\nse\ndebe\ndar\n \n \n \n \n \n \n \n \n \n \n \n \n \npreferencia\na\nla\nadministraci\u00f3n\nde\nPEG\nen\nlugar\nde\nlactulosa\npara\nel\ntratamiento\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nestre\u00f1imiento\ncr\u00f3nico\n(5).\nEl\nPEG\ntiene\nun\nnivel\nde\nevidencia\n1\ny\ngrado\nde\nrecomendaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nA\ny\nla\nlactulosa\nnivel\nde\nevidencia\n2\ny\ngrado\nde\nrecomendaci\u00f3n\nB.\nEl\nhidr\u00f3xido\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmagnesio\ntambi\u00e9n\nes\nun\nlaxante\nosm\u00f3tico,\naunque\nmenos\nutilizado.\nTiene\nun\nnivel\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nevidencia 3 y un grado de recomendaci\u00f3n C2.\n \n\u25cf\nLubrificantes,\nemolientes:\naceite\nde\nparafina,\nglicerina.\nEl\nefecto\nlaxante\nse\ndebe\na\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \nproducen\nuna\nemulsi\u00f3n\nde\nheces\ncon\nl\u00edpidos\ny\nagua.\nNo\nhay\nensayos\ncl\u00ednicos\ncon\neste\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntipo\nde\nlaxantes,\naunque\nse\nusan\nen\nla\npr\u00e1ctica\ncl\u00ednica\ncon\nprecauci\u00f3n.\nNo\nest\u00e1\nclaro\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nc\u00f3mo\nact\u00faan\nlos\nsupositorios\nde\nglicerina;\nposiblemente\nse\nasocie\nel\nefecto\nestimulante\n \n \n \n \n \n \n \n \n \n \n \n \nde\nsentir\nun\ncuerpo\nextra\u00f1o\nen\nel\nrecto\na\nla\nirritaci\u00f3n\ny\ncontracciones\nrectales,\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfavorecen\nla\ndefecaci\u00f3n.\nEl\naceite\nde\nparafina\ntiene\nun\nnivel\nde\nevidencia\n3\ny\ngrado\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomendaci\u00f3n C.\n \n50\n \n \u25cf\nEstimulantes.\nSu\nefecto\nde\nacci\u00f3n\nse\nbasa\nen\nla\nestimulaci\u00f3n\ndirecta\nde\nlos\nmovimientos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nintestinales,\ninduciendo\nla\nactividad\nmotora\ndel\ncolon\n(6).\nLos\nm\u00e1s\nutilizados\nson\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \npicosulfato\ns\u00f3dico\ny\nel\nbisacodilo.\nEstos\nf\u00e1rmacos\nse\nhan\nutilizado\ngen\u00e9ricamente\ncomo\n \n \n \n \n \n \n \n \n \n \n \n \nlaxante\nde\nrescate\nen\nensayos\ncl\u00ednicos\nde\notros\nlaxantes\ny\nen\nla\npr\u00e1ctica\ncl\u00ednica\ntambi\u00e9n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npueden\nser\nutilizados\ncon\neste\nfin\ncuando\nun\npaciente\nno\nresponde\nal\ntratamiento\ny\nest\u00e1\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndos\no\nm\u00e1s\nd\u00edas\nsin\ndefecar.\nEl\nbisacodilo\ny\nel\npicosulfato\ns\u00f3dico\nson\nm\u00e1s\neficaces\nque\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nplacebo\nen\nincrementar\nla\nfrecuencia\ndefecatoria,\ndisminuir\nla\nconsistencia\nde\nlas\nheces\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \nmejorar\nlos\ns\u00edntomas\ndel\nestre\u00f1imiento.\nConstituyen\nuna\nbuena\nalternativa\na\npacientes\n \n \n \n \n \n \n \n \n \n \n \nque\nno\nresponden\no\nno\ntoleran\nel\ntratamiento\ncon\nlaxantes\nosm\u00f3ticos\nni\nformadores\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmasa.\n \n\u25cf\nDerivados\nhidroxiantrac\u00e9nicos\nnaturales:\nsen,\nc\u00e1scara\nsagrada,\nfr\u00e1ngula\no\naloe.\nA\npesar\n \n \n \n \n \n \n \n \n \n \n \nde\nsu\nuso\ncom\u00fan\ny\nsu\npopularidad,\nla\nEuropean\nFood\nSafety\nAuthority\n(EFSA)\nha\nemitido\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nun\ncomunicado\nrelacionando\nsu\nuso\ncon\nefectos\ngenot\u00f3xicos\ny\ncarcinog\u00e9nicos\n(9).\nEs\n \n \n \n \n \n \n \n \n \n \n \n \nimportante recordar que natural nunca es sin\u00f3nimo de inocuo.\n \n \n\u25cf\nProbi\u00f3ticos.\nAunque\ntienen\nun\nefecto\npositivo\ndisminuyendo\nel\ntiempo\nde\ntr\u00e1nsito\n \n \n \n \n \n \n \n \n \n \n \ncol\u00f3nico,\nla\nfrecuencia\nde\nla\ndefecaci\u00f3n\ny\nsu\nconsistencia,\na\u00fan\nhay\npocos\nestudios\npara\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndeterminar\nsu\nutilidad\ncl\u00ednica\ncon\ncerteza.\nSe\nhan\nestudiado\ndiferentes\nespecies\nde\n \n \n \n \n \n \n \n \n \n \n \n \nLactobacillus\ny\n\u200b\nBifidobacterium\n(\n\u200b\nB.\nlactis,\nB.\nbifidum,\nB.\ninfants,\nB.\nlongum,\nL.\ncasei,\nL.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nplantarum,\nL.\nparacasei\ny\n\u200b\nL.\nrhamnosus\n\u200b\n),\npero\nuna\nrevisi\u00f3n\nsistem\u00e1tica\ndemuestra\nque\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \ndatos\npublicados\nhasta\nel\nmomento\nno\nson\nsuficientes\npara\napoyar\nuna\nrecomendaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \ngeneral\ndel\nuso\nde\nprobi\u00f3ticos\nen\nel\ntratamiento\ndel\nestre\u00f1imiento\nfuncional.\nSon\n \n \n \n \n \n \n \n \n \n \n \n \nnecesarios\nnuevos\nestudios\nque\nincluyan\nun\nn\u00famero\nadecuado\nde\npacientes\ny\ncon\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \nduraci\u00f3n\nde\ntratamiento\nprolongada\npara\ndefinir\nel\npapel\nde\nlos\nprobi\u00f3ticos\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\ndel\nestre\u00f1imiento\ncr\u00f3nico\nfuncional.\nNivel\nde\nevidencia\n3,\ngrado\nde\n \n \n \n \n \n \n \n \n \n \n \nrecomendaci\u00f3n D (3).\n \n\u25cf\nEnemas.\nEl\nmecanismo\nde\nacci\u00f3n\nes\nel\nest\u00edmulo\ndel\nperistaltismo\nsecundario\na\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \ndistensi\u00f3n\ndel\ncolon\njunto\na\nla\nacci\u00f3n\nespec\u00edfica\ndel\nproducto\nadministrado\n(8).\nAlgunos\n \n \n \n \n \n \n \n \n \n \n \n \n \npacientes\nson\nresistentes\na\ncualquier\nmedida\nterap\u00e9utica\noral\ny\ntras\nvarios\nd\u00edas\nsin\n \n \n \n \n \n \n \n \n \n \n \n \n \ndefecar\ny,\ncon\nel\nfin\nde\nevitar\nla\nimpactaci\u00f3n\nde\nheces\nen\nel\ncolon,\nprecisan\ntratamiento\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncon\nenemas\nde\nlimpieza\n(1500\nml\nde\nagua\nen\n25\nminutos)\no\nenemas\ncomerciales\n(140-\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n250\nml\nde\nenemas\nsalinos\no\nminerales).\nHay\nque\ntener\nprecauci\u00f3n\nen\nel\nuso\nde\nenemas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nfosfato\ns\u00f3dico,\ndado\nque\nse\nhan\ndescrito\ncasos\nde\nhiperfosfatemia\n(2).\nEl\nabuso\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nutilizaci\u00f3n\nde\nenemas\npuede\nllevar\na\nsobrecarga\nde\nl\u00edquidos,\nirritaci\u00f3n\ny\np\u00e9rdida\nde\ntono\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmuscular del intestino y del esf\u00ednter anal. Tienen un nivel de evidencia 4 (7).\n \n \n \n51\n \n INSUFICIENCIA VENOSA: VARICES EXTERNAS Y HEMORROIDES\n \nLafuente G\u00f3mez, N.\n \nLa\ninsuficiencia\nvenosa\nes\nuna\npatolog\u00eda\nque\nse\ncaracteriza\nporque\nel\nretorno\nvenoso\nest\u00e1\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndificultado.\nUna\nde\nlas\nposibles\nmanifestaciones\nes\nla\npresencia\nde\nvarices,\nque\nson\nvenas\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsistema\nvenoso\nsuperficial\nque\nest\u00e1n\ndilatadas\ny\nson\ntortuosas,\nsiendo\nm\u00e1s\ncomunes\nen\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nextremidades\ninferiores\n(1,\n2).\nSe\nestima\nque\nun\n25%\nde\nmujeres\ny\nun\n15%\nde\nhombres\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nadultos\nlas\npadecen\n(3,\n4),\nde\nah\u00ed\nla\nimportancia\nde\nun\ncorrecto\nabordaje\nterap\u00e9utico\ndesde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla farmacia comunitaria.\n \nTratamiento de la insuficiencia venosa\n \nTratamiento no farmacol\u00f3gico\n \n\u25cf\nMedidas\nhigi\u00e9nicas,\ndiet\u00e9ticas\ny\nposturales:\na\ntodos\nlos\npacientes\nque\nacudan\na\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nfarmacia\nse\nles\ndebe\naconsejar\nmantener\nlas\npiernas\nelevadas\ncuando\nsea\nposible,\n \n \n \n \n \n \n \n \n \n \n \n \nmantenerse\nen\nmovimiento,\nusar\ncompresas\nde\nfr\u00edo\ny\ncalor\nalternadas\nen\nla\nzona\n \n \n \n \n \n \n \n \n \n \n \n \n \nafectada\ne\nhidratar\nbien\nla\npiel\npara\nevitar\nla\naparici\u00f3n\nde\n\u00falceras.\nTodo\nello\nest\u00e1\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nenfocado a favorecer el retorno venoso (5, 6).\n \n\u25cf\nTerapia\ncompresiva:\nse\nrecomienda\nusar\nmedias\nde\ncompresi\u00f3n\nde\n20-30\nmmHg\n \n \n \n \n \n \n \n \n \n \n \n(clase\nII)\nque\nabarquen\ntoda\nla\nzona\nafectada,\nsiempre\nque\nno\nexista\nninguna\n \n \n \n \n \n \n \n \n \n \n \n \n \ncontraindicaci\u00f3n\n(6,\n7,\n8).\nUna\nrevisi\u00f3n\nCochrane\nde\n2013\nlleg\u00f3\na\nla\nconclusi\u00f3n\nde\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nno\nhay\nsuficientes\npruebas\nde\nalta\ncalidad\npara\ndeterminar\nsi\nlas\nmedias\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \ncompresi\u00f3n\nson\nefectivas\ncomo\ntratamiento\n\u00fanico\ne\ninicial\nde\nlas\nvenas\nvaricosas\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \npacientes\nsin\n\u00falceras\nvenosas.\nEstas\nconclusiones\nse\ndebieron\nfundamentalmente\na\nla\n \n \n \n \n \n \n \n \n \n \n \nfalta\nde\nensayos\nde\ncalidad\nen\neste\nasunto\n(9).\nPor\notro\nlado,\notra\nrevisi\u00f3n\nCochrane\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlleg\u00f3\na\nla\nconclusi\u00f3n\nde\nque\nel\nuso\nde\ncompresi\u00f3n\nmejoraba\nsignificativamente\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncura\nde\nlas\nvarices\ncon\n\u00falceras\n(10).\nAdem\u00e1s,\nun\nensayo\ndoble\nciego\nde\n2018\ncon\n30\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npacientes\ndonde\nla\nmitad\nutilizaron\nunas\nmedias\nde\n18-21\nmmHg\ny\nel\nresto\nunas\nde\n0\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmmHg\n(placebo)\ndemostr\u00f3\nque\nel\nuso\nde\nla\nterapia\ncompresiva\ndisminuy\u00f3\nlos\n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas\nasociados\na\nla\npresencia\nde\nvarices\n(11).\nEl\nprincipal\nproblema\nasociado\nal\n \n \n \n \n \n \n \n \n \n \n \n \n \nuso\nde\nmedias\ncompresivas\nes\nla\nfalta\nde\nadherencia\na\neste\ntratamiento\npor\nmuchos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npacientes debido a la incomodidad que les causa (12).\n \nTratamiento t\u00f3pico\n \n\u25cf\nUso\nde\nAINE\nt\u00f3picos.\nHay\ntrabajos\nque\nafirman\nque\nlos\nAINE\nt\u00f3picos\nreducen\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas\nlocales\nde\ndolor\ne\ninflamaci\u00f3n\nasociados\na\nla\ntromboflebitis\nsuperficial\nen\n \n \n \n \n \n \n \n \n \n \n \n \nlas\npiernas,\nque\nse\nrelaciona\ncon\nla\naparici\u00f3n\nde\nvarices\n(5,\n13).\nSe\nha\ndemostrado\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nel\nuso\nde\nantiinflamatorios\nt\u00f3picos\ncomo\ndiclofenaco\nparece\nreducir\n \n \n \n \n \n \n \n \n \nsignificativamente la cl\u00ednica (6, 14, 15).\n \n\u25cf\nLa\neficacia\nde\nderivados\nvenot\u00f3nicos\no\nflebot\u00f3nicos\ny\nheparinoides\nt\u00f3picos\nno\nest\u00e1\n \n \n \n \n \n \n \n \n \n \n \n \nclaramente\ndemostrada.\nDe\nhecho,\nse\ncree\nque\nel\nmasaje\nque\nse\nrealiza\ncon\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \naplicaci\u00f3n\nde\nestos\nproductos\nde\nmanera\nascendente\nes\nel\nque\notorga\nde\ncierto\nalivio\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npor\nla\nmejora\nde\nla\ncirculaci\u00f3n\nsangu\u00ednea\n(2).\nEs\nespecialmente\nrelevante\nel\nuso\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n52\n \n Thrombocid\u00ae\n(pentosano\npolisulfato\nde\nsodio)\ne\nHirudoid\u00ae\n(condroitina\nsulfato\nde\n \n \n \n \n \n \n \n \n \n \nsodio)\nen\npacientes\nafectados\ncon\nvarices.\nSin\nembargo,\nno\nse\ncontempla\nsu\nuso\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlas gu\u00edas cl\u00ednicas por la falta de estudios cl\u00ednicos que confirmen su eficacia (16).\n \n\u25cf\nLa\nasociaci\u00f3n\nde\ndermatolog\u00eda\njaponesa\nengloba\ntodos\nlos\ntratamientos\nt\u00f3picos\nde\n \n \n \n \n \n \n \n \n \n \n \neste estilo con un nivel de recomendaci\u00f3n C1 (17).\n \nTratamientos orales\n \n\u25cf\nEs\nespecialmente\nrelevante\nel\nuso\nde\nc\u00e1psulas\nde\ncasta\u00f1o\nde\nindias\n(\n\u200b\nAesculus\n \n \n \n \n \n \n \n \n \n \n \n \nhippocastanum\n\u200b\n).\nSe\nconsidera\nque\ntiene\nuna\nevidencia\n2B\n(16).\nEn\nseis\nestudios\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nescina\n(principio\nactivo\ndel\ncasta\u00f1o\nde\nindias)\nfrente\na\nplacebo\nsobre\npersonas\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \nsufren\nde\ninsuficiencia\nvenosa\ncr\u00f3nica,\nse\ndemostr\u00f3\nque\ntomando\nlas\nc\u00e1psulas\n \n \n \n \n \n \n \n \n \n \n \ndurante\n16\nsemanas\nse\nreduc\u00eda\nel\ndolor,\nel\nedema\ny\nel\npicor\nasociados.\nOtros\nestudios\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\nhan\ncomparado\neste\nprincipio\nactivo\nfrente\na\nrut\u00f3sidos\n(de\n\u200b\nAesculus\n \n \n \n \n \n \n \n \n \n \n \nhippocastanum\n\u200b\n),\npicnogenol\n(de\n\u200b\nPinus\npinaster\n\u200b\n)\ny\nmedias\nde\ncompresi\u00f3n\nhan\n \n \n \n \n \n \n \n \n \n \ndemostrado\nque\nno\nexisten\ndiferencias\nen\nla\nefectividad\nde\nlos\ntratamientos\n(18).\n \n \n \n \n \n \n \n \n \n \n \n \nOtros\nderivados\nde\nsaponinas,\ncomo\nFabroven\u00ae\n(ruscus,\nhesperidina\ny\n\u00e1cido\n \n \n \n \n \n \n \n \n \n \nasc\u00f3rbico), tienen evidencia moderada 2B (16).\n \n\u25cf\nDentro\nde\nlos\nflavonoides,\nla\nfracci\u00f3n\nflavonoica\npurificada\ny\nmicronizada\n(FFPM)\n \n \n \n \n \n \n \n \n \n \n \n(Daflon\u00ae:\n90%\ndiosmina\ny\n10%\nflavonoides\nexpresados\nen\nhesperidina):\ntiene\n \n \n \n \n \n \n \n \n \n \nevidencia\nde\ngrado\n1B\npara\nel\ntratamiento\nde\nlos\ns\u00edntomas\nde\nla\nenfermedad\nvenosa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncr\u00f3nica\n(16,\n19).\nSobre\nlas\ndiosminas\nno\nmicronizadas\no\nsint\u00e9ticas\n(Diosmina\u00ae,\n \n \n \n \n \n \n \n \n \n \n \nVenosmil\u00ae)\nno\nhay\nmuchos\ndatos\ndisponibles\ny\nse\nconsidera\nque\ntienen\nuna\nevidencia\n \n \n \n \n \n \n \n \n \n \n \n \n \n2C\n(16).\nLa\nfamilia\nde\nlos\nrut\u00f3sidos,\nque\nincluye\nrutina,\ntroxerutina,\noxerutinas\n \n \n \n \n \n \n \n \n \n \n \n \n(Esveriven\u00ae, Venoruton\u00ae), etc., presenta un nivel de evidencia 2B (16, 19).\n \n\u25cf\nOtros\nextractos\nde\nplantas,\ncomo\nlas\nantocianinas\n(\n\u200b\nVaccinium\nmyrtillus)\ny\nla\n \n \n \n \n \n \n \n \n \n \n \nproantocianidina\n(\n\u200b\nVitis\nvinifera\n\u200b\n)\nposeen\nun\nnivel\nde\nevidencia\n2B\n(19),\nmientras\nque\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \nextracto de Ginkgo (\n\u200b\nGinkgo biloba\n\u200b\n) no tiene ensayos que respalden su eficacia (20).\n \n\u25cf\nDentro\ndel\ntratamiento\noral\ncon\nprincipios\nactivos\nsint\u00e9ticos\ndestacan\nel\ndobesilato\n \n \n \n \n \n \n \n \n \n \n \nde\ncalcio\n(Doxium\u00ae)\ny\nel\nsulodexide\n(Dovida\u00ae),\nambos\ncon\nevidencia\nmoderada\n2B\n \n \n \n \n \n \n \n \n \n \n \n \n(16, 19), y benzarone y naftazon, sin informaci\u00f3n disponible (20).\n \nEn\nuna\nrevisi\u00f3n\nCochrane\ndonde\nse\nestudi\u00f3\nel\nuso\nde\ndistintos\nvenot\u00f3nicos\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \nobserv\u00f3 que los principales efectos adversos asociados eran gastrointestinales (21).\n \n \n\u25cf\nLos\nAINE\nse\nutilizan\npara\neliminar\nel\ndolor\nagudo\nasociado\na\nla\ninflamaci\u00f3n.\n \n \n \n \n \n \n \n \n \n \n \n \n \nFundamentalmente\nse\nusa\nibuprofeno,\ndiclofenaco,\nketoprofeno\ny\nnaproxeno\ncon\n \n \n \n \n \n \n \n \n \nuna duraci\u00f3n recomendada de 7 a 14 d\u00edas. En embarazas se dar\u00eda paracetamol (6).\n \n\u25cf\nEl\nuso\nde\nanticoagulantes\norales\no\ninyectados,\nbajo\ncriterio\nm\u00e9dico,\npuede\nestar\n \n \n \n \n \n \n \n \n \n \n \n \njustificado\ncuando\nla\ninsuficiencia\nvenosa\ndel\npaciente\nlo\nrequiera.\nEn\ncasos\ngraves\n \n \n \n \n \n \n \n \n \n \n \n \nincluso puede llegar a ser necesaria la cirug\u00eda vascular (20).\n \n \n \n \n53\n \n Hemorroides\n \nLas\nhemorroides\nson\nuna\nde\nlas\npatolog\u00edas\nanorrectales\nbenignas\nm\u00e1s\ncomunes\ny\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \nmanifiestan\ncon\ns\u00edntomas\ncomo\nsangrado,\ndolor,\npicor\ne\nhinchaz\u00f3n.\nSe\nestima\nque\nafecta\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nalrededor\nde\nun\n4%\nde\nla\npoblaci\u00f3n,\naunque\nse\npiensa\nque\nest\u00e1\ninfradiagnosticada\ndebido\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque muchos pacientes no informan de estos s\u00edntomas (22, 23).\n \nTratamiento\n \nLas\nposibilidades\nde\ntratamiento\nvar\u00edan\nen\nfunci\u00f3n\ndel\ngrado\nde\ngravedad\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \nhemorroides.\n \n\u25cf\nMedidas\nhigi\u00e9nico-diet\u00e9ticas.\nEl\nestre\u00f1imiento\njuega\nun\npapel\nfundamental\nen\nel\n \n \n \n \n \n \n \n \n \n \ndesarrollo\nde\nhemorroides,\npor\nlo\nque\nes\ndeseable\nmantener\nunos\nh\u00e1bitos\n \n \n \n \n \n \n \n \n \n \n \nintestinales\nregulares.\nSe\nrecomienda\nuna\ndieta\ncon\nalto\ncontenido\nen\nfibra\ny\nl\u00edquidos.\n \n \n \n \n \n \n \n \n \n \n \n \n \nEn\nensayos\ndonde\nse\nha\nevaluado\nc\u00f3mo\nafecta\nel\nconsumo\nde\nfibra\na\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nhemorroides,\nse\nha\nconcluido\nque\nsu\nconsumo\ntiene\nun\nefecto\nbeneficioso\npara\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento de los s\u00edntomas con una evidencia 1B (24, 25).\n \n\u25cf\nLos\nvenot\u00f3nicos\no\nflebot\u00f3nicos\nhan\nmostrado\nun\nbeneficio\nsignificativo\nen\nel\nalivio\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\ns\u00edntomas\nde\nlas\nhemorroides,\nespecialmente\nen\nlas\nque\ncursan\ncon\nsangrado.\nSe\n \n \n \n \n \n \n \n \n \n \n \n \n \nconsidera\nque\nsu\nuso\ntiene\nun\nnivel\nde\nevidencia\n1B\npor\nadministraci\u00f3n\noral\n(22).\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSociedad\nFrancesa\nde\nColoproctolog\u00eda\nconsidera\nque\nsu\nuso\nreduce\nel\nriesgo\nde\n \n \n \n \n \n \n \n \n \n \n \n \nrecurrencia\nde\nlos\ns\u00edntomas\nen\n6\nmeses\ny\nrecomienda\nsu\nuso\ncuando\nlas\nhemorroides\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncursen\ncon\nsangrado\ny\ndolor,\ncon\nun\nnivel\nde\nevidencia\n1A.\nSin\nembargo,\nadmiten\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsu\neficacia\npuede\nestar\nsobreestimada\npor\nla\nausencia\nde\npublicaciones\ncon\n \n \n \n \n \n \n \n \n \n \n \nresultados negativos (26).\n \n \n\u25cf\nEn\nel\ncaso\nde\nmujeres\nembarazas\nque\ntengan\nhemorroides,\nlos\nrut\u00f3sidos\nhan\n \n \n \n \n \n \n \n \n \n \n \n \ndemostrado ser efectivos en la reducci\u00f3n de los s\u00edntomas (27).\n \n \n\u25cf\nA\ntiempos\ncortos,\nlos\ntratamientos\nt\u00f3picos\nmejoran\nlos\ns\u00edntomas,\npero\nsu\nbeneficio\na\n \n \n \n \n \n \n \n \n \n \n \n \n \nlargo\nplazo\nno\nha\nsido\ndemostrado.\nSe\nrecomienda\nsu\nuso\ncon\nlas\nmanifestaciones\n \n \n \n \n \n \n \n \n \n \n \n \n \nagudas. El nivel de evidencia se considera que es 2B (26).\n \n \n\u25cf\nNo\nhay\ndatos\ncient\u00edficos\nsobre\nel\nuso\nde\nAINE,\ncorticoides\ny\notros\nanalg\u00e9sicos,\npero\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomiendan cuando las hemorroides se asocien a dolor (26).\n \n \n \n54\n \n INSOMNIO\n \nMu\u00f1oz Mu\u00f1oz, N.\n \nEl\ninsomnio\nes\nun\ntrastorno\ndel\nsue\u00f1o\nque\nocasiona\ndificultad\npara\nconciliar\no\nmantener\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nel\nsue\u00f1o,\no\nla\nsensaci\u00f3n\nde\nno\nhaber\ntenido\nun\nsue\u00f1o\nreparador.\nTambi\u00e9n\npodr\u00eda\ndefinirse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nla\ninsatisfacci\u00f3n\ncon\nla\ncantidad\no\nla\ncalidad\ndel\nsue\u00f1o.\nSe\ntrata,\npor\ntanto,\nde\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntrastorno\ncon\nun\nalto\ncomponente\nsubjetivo.\nEs\nel\ntrastorno\ndel\nsue\u00f1o\nm\u00e1s\nfrecuente\ny\nsolo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nse\nconsiderar\u00e1\ncl\u00ednicamente\nrelevante\nsi\nocasiona\ndisfunci\u00f3n\ndurante\nel\nd\u00eda\n(somnolencia,\n \n \n \n \n \n \n \n \n \n \n \nestr\u00e9s, cansancio, etc.) (1).\n \n \nLas\nmanifestaciones\nm\u00e1s\ncaracter\u00edsticas\ndel\ninsomnio\nson\nla\ndificultad\npara\niniciar\ny\n \n \n \n \n \n \n \n \n \n \n \n \nmantener\nel\nsue\u00f1o\ny\nel\ndespertar\nfinal\nadelantado;\naunque,\ncomo\ndemuestran\nalgunos\n \n \n \n \n \n \n \n \n \n \n \n \nestudios\nepidemiol\u00f3gicos,\nlas\npersonas\nque\nrefieren\npadecer\nestas\ndificultades\nno\nreconocen\n \n \n \n \n \n \n \n \n \n \n \nnecesariamente\npadecer\ninsomnio.\nLos\npacientes\nque\nconsultan\npor\ninsomnio\nse\nquejan\n \n \n \n \n \n \n \n \n \n \n \nadem\u00e1s\nde\notros\ns\u00edntomas\ndurante\nel\nd\u00eda,\ncomo\nalteraciones\ndel\nhumor\n(por\nejemplo\napat\u00eda),\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncansancio,\ndificultad\npara\nrealizar\nlas\ntareas\ncotidianas,\nd\u00e9ficit\ncognitivos,\nsomnolencia\ny\n \n \n \n \n \n \n \n \n \n \n \notros (2).\n \nConstituye\nun\nproblema\nde\nsalud\np\u00fablica\nque\nafecta\na\nmillones\nde\npersonas\nen\nlos\npa\u00edses\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nindustrializados,\nsiendo\nuno\nde\nlos\nprincipales\ns\u00edntomas\nde\nconsulta\nen\natenci\u00f3n\nprimaria.\nSe\n \n \n \n \n \n \n \n \n \n \n \n \n \nrelaciona\ncon\nun\nincremento\nde\nla\nmorbimortalidad\nen\ngeneral\ny\ncon\nun\nmayor\nconsumo\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\nrecursos\nsanitarios\ny\ndisminuye\nla\ncalidad\nde\nvida\ndel\npaciente\nya\nque\ninterfiere\nen\nsu\nvida\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlaboral, social y familiar (2).\n \nDebe\ntenerse\nen\ncuenta\nque\nla\nmodificaci\u00f3n\nen\nla\nestructura\ny\nel\npatr\u00f3n\ndel\nsue\u00f1o\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \naparece\nfisiol\u00f3gicamente\ncon\nla\nedad\ny\nno\ndebe\nconfundirse\ncon\nun\ntrastorno\ndel\nsue\u00f1o.\nEl\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninsomnio\npuede\ndeberse\na\nsituaciones\npuntuales\nde\nestr\u00e9s,\nal\nconsumo\nde\nalgunas\n \n \n \n \n \n \n \n \n \n \n \n \nsustancias,\na\nenfermedades\nsubyacentes\no\na\nsus\ntratamientos.\nSe\nconsidera\ninsomnio\n \n \n \n \n \n \n \n \n \n \n \nprimario cuando no se relaciona con ninguna situaci\u00f3n de las descritas.\n \nEl\ntratamiento\ndel\ninsomnio\nen\nAtenci\u00f3n\nPrimaria\ntiene\ncomo\nobjetivo\nprincipal\nmejorar\n \n \n \n \n \n \n \n \n \n \n \n \nel\nnivel\nde\nsatisfacci\u00f3n\nrespecto\nal\nsue\u00f1o,\ncentr\u00e1ndose\nen\nintervenciones\nque\nlo\npromuevan\n \n \n \n \n \n \n \n \n \n \n \n \n \npositivamente.\nSe\ndebe\nconsiderar\nun\nabordaje\nterap\u00e9utico\nintegral,\nen\nel\nque\nse\ntengan\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncuenta\ntodos\nlos\nfactores\ncontribuyentes.\nSon\nnecesarias\nestrategias\nde\nmodificaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \nconductas\ny\ncambios\nde\nestilo\nde\nvida\na\nlos\nque\nse\nasociar\u00e1\ntratamiento\nfarmacol\u00f3gico\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncuando\nsea\nnecesario\n(1).\nSe\nconseguir\u00e1\nas\u00ed\nmejorar\nla\ncalidad\ny\nla\ncantidad\nde\nsue\u00f1o\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nreducir\nla\nlatencia\nde\nsue\u00f1o\ny\nlos\ndespertares\nnocturnos,\nadem\u00e1s\nde\naumentar\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \nfuncionamiento\ndiurno.\nEl\nabordaje\ndel\ninsomnio\ndebe\nrealizarse\npor\nvarios\nfrentes:\nhigiene\n \n \n \n \n \n \n \n \n \n \n \n \ndel sue\u00f1o, terapias conductuales y tratamiento farmacol\u00f3gico.\n \n \n \n55\n \n Tratamiento\n \nHigiene del sue\u00f1o\n \n\u25cf\nHorarios\nregulares:\ndespertarse\ny\nacostarse\ntodos\nlos\nd\u00edas\nm\u00e1s\no\nmenos\na\nla\nmisma\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nhora (3).\n \n\u25cf\nMantener\ncondiciones\nambientales\nadecuadas\npara\ndormir:\ntemperatura\ntemplada\n \n \n \n \n \n \n \n \n(alrededor de los 18\u00ba C), ausencia de ruidos y luz, colch\u00f3n adecuado al gusto, etc.\n \n\u25cf\nComer\na\nhoras\nregulares\ny\nevitar\ncomidas\ncopiosas\ncerca\nde\nla\nhora\nde\nacostarse.\nNo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nes\nconveniente\nirse\na\nla\ncama\ncon\nhambre.\nTomar\nalgo\nligero\nantes,\ncomo\nun\npoco\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nleche tibia o un yogur, es muy conveniente.\n \n\u25cf\nLimitar\nla\ningesta\nde\nsustancias\ncon\nefecto\nestimulante,\ncomo\ncaf\u00e9,\nt\u00e9\no\ncola,\nsobre\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntodo\na\npartir\nde\nlas\n17\nhoras.\nTambi\u00e9n\nes\nconveniente\nlimitar\nel\nconsumo\nde\nalcohol,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsobre\ntodo\npor\nla\nnoche;\nno\nes\nrecomendable\nutilizar\nel\nalcohol\ncomo\nhipn\u00f3tico.\n \n \n \n \n \n \n \n \n \n \n \n \n \nLimitar o reducir el consumo de tabaco, ya que la nicotina es estimulante.\n \n\u25cf\nPermanecer\nen\nla\ncama\nentre\nsiete\ny\nocho\nhoras:\nreducir\nel\ntiempo\nde\npermanencia\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nla\ncama\nmejora\nel\nsue\u00f1o,\nmientras\nque\npermanecer\nen\nla\ncama\ndurante\nmucho\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntiempo\npuede\nproducir\nun\nsue\u00f1o\nfragmentado\ny\nligero.\nConviene\nirse\na\nla\ncama\nsolo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncuando se tenga sue\u00f1o.\n \n\u25cf\nEvitar\nsiestas\nlargas\ndurante\nel\nd\u00eda\ny\nlas\nsituaciones\nque\nlas\npropicien.\nEn\ncasos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconcretos,\nse\npuede\npermitir\nuna\nsiesta\ndespu\u00e9s\nde\ncomer,\nde\nduraci\u00f3n\nno\nsuperior\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n30 minutos.\n \n\u25cf\nRealizar\nejercicio\nf\u00edsico\nde\nmanera\nregular\ndurante\nel\nd\u00eda.\nEl\nejercicio\ndebe\nser\nsuave\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(como\npasear,\nnadar\no\nir\nen\nbicicleta)\ndurante\nal\nmenos\nuna\nhora,\ncon\nluz\nsolar\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsiempre\nal\nmenos\ntres\nhoras\nantes\nde\nir\na\ndormir.\nSe\ndebe\nevitar\nrealizar\nejercicio\npor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla noche por su efecto estimulante.\n \n\u25cf\nEvitar\nactividades\nexcitantes\nen\nlas\nhoras\nprevias\na\nacostarse.\nNo\ndeben\nrealizarse\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \nla\ncama\nactividades\ntales\ncomo\nver\nla\ntelevisi\u00f3n,\njugar\ncon\ntabletas\nu\notros\n \n \n \n \n \n \n \n \n \n \n \n \n \ndispositivos\nm\u00f3viles,\nhablar\npor\ntel\u00e9fono,\ndiscutir,\netc.\nEste\npunto\nes\nimportante,\n \n \n \n \n \n \n \n \n \n \n \nsobre\ntodo\nen\nadolescentes.\nNuestro\ncerebro\nnecesita\nasociar\nel\ndormitorio\ny\nla\ncama\n \n \n \n \n \n \n \n \n \n \n \n \n \na\ndormir.\nCuando\nen\nese\nlugar\nse\nrealizan\notro\ntipo\nde\nactividades,\nel\ncerebro\nrecibe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nun doble mensaje y se confunde.\n \n\u25cf\nRepetir\ncada\nnoche\nuna\nrutina\nde\nacciones\nque\nnos\nayuden\na\nprepararnos\nmental\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nf\u00edsicamente\npara\nir\na\nla\ncama:\nlavarse\nlos\ndientes,\nponerse\nel\npijama,\npreparar\nla\nropa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndel d\u00eda siguiente, etc.\n \n\u25cf\nPracticar\nrutinas\nde\nrelajaci\u00f3n\nantes\nde\nacostarse\npuede\ncontribuir\na\nque\nse\nduerma\n \n \n \n \n \n \n \n \n \n \n \n \n \nmejor, por ejemplo, realizar una respiraci\u00f3n lenta y relajada.\n \n \n \n56\n \n Psicoterapia\n \nOtro\ntipo\nde\nintervenci\u00f3n\nes\nla\npsicoterap\u00e9utica,\na\ntrav\u00e9s\nde\nlas\nterapias\nconductuales\n \n \n \n \n \n \n \n \n \n \n \n \n \n(relajaci\u00f3n\ny\nrespiraci\u00f3n,\ncontrol\nde\nest\u00edmulos,\nrestricci\u00f3n\ndel\ntiempo\nen\nla\ncama)\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \ncognitivo-conductuales.\nEste\ntipo\nde\nterapias\nno\nson\ndemasiado\nutilizadas\nen\nnuestro\nmedio,\n \n \n \n \n \n \n \n \n \n \n \n \na\npesar\nde\nque\ncuentan\ncon\nevidencia\ndisponible\nque\nlas\nrespalda\n(2).\nEn\nlas\ngu\u00edas\neuropeas\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \namericanas\nde\ntratamiento\ndel\ninsomnio,\nestas\nterapias\nse\nconsideran\nla\nprimera\nelecci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \ndebido al alto grado de evidencia cient\u00edfica (4,5).\n \nTratamiento farmacol\u00f3gico\n \nEl\ntratamiento\nfarmacol\u00f3gico,\nen\ncaso\nde\nser\nnecesario,\nse\ndeber\u00eda\na\u00f1adir\na\nlas\nterapias\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nanteriores.\nLos\nhipn\u00f3ticos\n(benzodiazep\u00ednicos\no\nno)\nson\nlos\nf\u00e1rmacos\nde\nelecci\u00f3n.\nUn\n \n \n \n \n \n \n \n \n \n \n \n \npar\u00e1metro\nque\nse\nha\nincluido\nrecientemente\npara\nvalorar\nla\neficacia\nde\nlos\nf\u00e1rmacos\n \n \n \n \n \n \n \n \n \n \n \n \n \nhipn\u00f3ticos\nes\nla\ncapacidad\nde\nincrementar\nel\ntiempo\ntotal\nde\nsue\u00f1o\ny\naumentar\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfuncionamiento\ndiurno\n(3).\nLos\nhipn\u00f3ticos\nse\ndeben\nseleccionar\nen\nfunci\u00f3n\ndel\npaciente,\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \nmonoterapia,\ny\ncon\nuna\nduraci\u00f3n\nno\nsuperior\na\n14\nd\u00edas\nincluyendo\nel\nperiodo\nde\nretirada,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\ndebe\nser\npaulatina\npara\nevitar\nel\ninsomnio\nde\nrebote.\nEste\nfen\u00f3meno\nsuele\npresentarse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncuando\nla\nadministraci\u00f3n\nde\nlas\nbenzodiacepinas\nse\ninterrumpe\nde\nmanera\nabrupta,\nincluso\n \n \n \n \n \n \n \n \n \n \n \n \ndespu\u00e9s\nde\nuna\na\ndos\nsemanas\nde\niniciado\nel\ntratamiento\n(6).\nEl\nriesgo\nde\ndependencia\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nbenzodiacepinas\naumenta\ncon\nla\nduraci\u00f3n\nprolongada\ndel\ntratamiento\n(superior\na\n3\nmeses),\n \n \n \n \n \n \n \n \n \n \n \n \nlas\ndosis\nelevadas\ny\nel\nuso\nde\nbenzodiacepinas\nde\nvida\nmedia\ncorta\n(alprazolam,\nlorazepam,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmidazolam) y de elevada potencia ansiol\u00edtica (alprazolam, lorazepam, etc.) (1).\n \n\u25cf\nAntihistam\u00ednicos\nH1.\nLa\ndifenhidramina\ny\nla\ndoxilamina,\naprobados\nen\nEspa\u00f1a\ncomo\n \n \n \n \n \n \n \n \n \n \n \nhipn\u00f3ticos\nque\nno\nnecesitan\nprescripci\u00f3n,\npresentan\npropiedades\nantihistam\u00ednicas\n \n \n \n \n \n \n \n \nprimarias,\npor\nlo\nque\npueden\ntener\nun\npapel\nen\nel\ntratamiento\na\ncorto\nplazo\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninsomnio\nen\nadultos\nj\u00f3venes,\naunque\nse\ndesarrolla\ntolerancia\nr\u00e1pidamente.\nSe\n \n \n \n \n \n \n \n \n \n \nadministran\nunos\n30\nminutos\nantes\nde\nacostarse\ny\nla\nduraci\u00f3n\ndel\ntratamiento\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \ndebe\npasar\nde\nlos\n7\nd\u00edas,\nya\nque\nsu\nefecto\ndisminuye\nr\u00e1pidamente.\nNo\nse\nrecomienda\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsu\nuso\nen\nancianos\npor\nsu\nacci\u00f3n\nanticolin\u00e9rgica,\npredisponiendo\na\ncuadros\n \n \n \n \n \n \n \n \n \n \n \ndelirantes, retenci\u00f3n urinaria, estre\u00f1imiento y otros efectos secundarios.\n \n\u25cf\nMelatonina.\nLa\nmelatonina\nes\nuna\nhormona\nnatural\nproducida\npor\nla\ngl\u00e1ndula\npineal\n \n \n \n \n \n \n \n \n \n \n \n \nen\nlas\nhoras\nnocturnas,\nya\nque\nsu\nsecreci\u00f3n\nse\ninhibe\npor\nefecto\nde\nla\nluz\nsolar.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nRegula\nel\nritmo\ncircadiano\nde\nsue\u00f1o-vigilia,\npor\nlo\nque\nse\nconsidera\nun\ncronobi\u00f3tico.\n \n \n \n \n \n \n \n \n \n \n \n \n \nTambi\u00e9n\nse\nasocia\na\nun\nefecto\nhipn\u00f3tico\ny\na\nuna\nmayor\npropensi\u00f3n\nal\nsue\u00f1o.\nHay\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nalgunas\nsustancias\ncomo\nel\ntabaco,\nel\nalcohol\ny\nalgunos\nf\u00e1rmacos\nque\ndisminuyen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nproducci\u00f3n\nde\nmelatonina.\nLa\nsecreci\u00f3n\nde\nmelatonina\ndisminuye\ncon\nla\nedad\ny\n \n \n \n \n \n \n \n \n \n \n \n \npuede\ncontribuir,\nparcialmente,\nen\nla\netiolog\u00eda\nde\nlos\ntrastornos\ndel\nsue\u00f1o\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \npersonas\nmayores\n(2).\nEn\nEspa\u00f1a\nla\nmelatonina\nest\u00e1\ncomercializada\ncomo\n \n \n \n \n \n \n \n \n \n \nsuplemento\ndiet\u00e9tico\npara\nreducir\nla\nlatencia\ndel\ninicio\ndel\nsue\u00f1o.\nExisten\n \n \n \n \n \n \n \n \n \n \n \npreparaciones\nde\nmelatonina\nde\nliberaci\u00f3n\ninmediata\ncon\nalta\nvariabilidad\nen\ncuanto\n \n \n \n \n \n \n \n \n \n \n \na\ncontenido,\ncalidad,\npureza,\ndosificaci\u00f3n\ny\nformulaci\u00f3n\n(c\u00e1psulas,\ncomprimidos\n \n \n \n \n \n \n \n \n \nsublinguales,\nparches,\npreparados\nde\nadministraci\u00f3n\nintravenosa),\nlo\nque\ndificulta\nsu\n \n \n \n \n \n \n \n \n \n \nvaloraci\u00f3n\ncomo\nhipn\u00f3tico\n(2).\nHay\npublicado\nun\nmetan\u00e1lisis\nsobre\nla\neficacia\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n57\n \n melatonina\ncomparada\ncon\nplacebo\nen\nel\ntratamiento\nde\nlos\ntrastornos\nprimarios\ndel\n \n \n \n \n \n \n \n \n \n \n \n \nsue\u00f1o\nen\nadultos\ny\nni\u00f1os\n(19\nensayos\ncon\n1683\npacientes).\nLos\nestudios\neran\nmuy\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndiversos\nen\ncuanto\nla\nedad\nde\nlos\nparticipantes,\nlas\ndosis\nutilizadas\ny\nel\ndise\u00f1o.\nLos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nresultados\nconcluyeron\nque\nla\nmelatonina\nera\neficaz\nen\nreducir\nla\nlatencia\ndel\nsue\u00f1o\n \n \n \n \n \n \n \n \n \n \n \n \n \nrespecto\na\nplacebo\n7\nminutos\n(4-10\nmin),\naumentar\nla\nduraci\u00f3n\ndel\nsue\u00f1o\n8\nminutos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(2-15\nmin)\ny\nmejorar\nla\ncalidad\ndel\nsue\u00f1o.\nLa\nrelevancia\ncl\u00ednica\nde\nestos\nefectos\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmuy\nescasa,\naunque\nse\nconsidera\nun\nf\u00e1rmaco\nseguro\n(4,\n9).\nAdem\u00e1s,\nla\nmelatonina\n \n \n \n \n \n \n \n \n \n \n \n \n \nparece\ntener\nevidencia\nsu\nuso\nen\nla\nmejora\ndel\ninsomnio\ntipo\n\u200b\njet\nlag\nen\nviajeros\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncruzan\nvarias\nzonas\nhorarias\n(7).\nPor\notro\nlado,\nexiste\nun\nmedicamento\ncon\n2\nmg\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmelatonina\nde\nliberaci\u00f3n\nprolongada,\ncon\nla\nindicaci\u00f3n\nautorizada\nde\ntratamiento\nen\n \n \n \n \n \n \n \n \n \n \n \nmonoterapia,\na\ncorto\nplazo,\ndel\ninsomnio\nprimario\ncaracterizado\npor\nun\nsue\u00f1o\nde\n \n \n \n \n \n \n \n \n \n \n \n \nmala\ncalidad\nen\npacientes\nmayores\nde\n55\na\u00f1os\n(2).\nMantiene\nniveles\nsimilares\na\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfisiol\u00f3gicos\ndurante\ntoda\nla\nnoche,\nimitando\nas\u00ed\nlos\npatrones\nde\nla\nsecreci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nmelatonina\nend\u00f3gena.\nRequiere\nprescripci\u00f3n\nm\u00e9dica\ny\nno\nest\u00e1\nfinanciado\npor\nel\n \n \n \n \n \n \n \n \n \n \n \nSistema Nacional de Salud.\n \nLa\nmelatonina\ndebe\ntomarse\nentre\n0,5-2\nhoras\nantes\nde\nacostarse\ny\nse\ndebe\n \n \n \n \n \n \n \n \n \n \n \n \n \nmantener\nel\ntratamiento\nun\ncierto\ntiempo;\nno\nest\u00e1\nindicado\nsu\nuso\npuntual.\nSe\n \n \n \n \n \n \n \n \n \n \n \n \n \ndesconocen\nlos\nefectos\na\nlargo\nplazo\nde\nesta\nsustituci\u00f3n\nhormonal,\npor\nlo\nque\nno\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomienda\nsu\nuso\nen\nperiodos\nmuy\nprolongados.\nLa\nindicaci\u00f3n\noficial\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \nmelatonina\nde\nliberaci\u00f3n\nprolongada\nse\nlimita\na\n13\nsemanas\n(3\nmeses),\npor\nser\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntiempo recogido en los estudios oficiales de registro.\n \n\u25cf\nFitoterapia.\nTradicionalmente\nse\nhan\nusado\nextractos\nde\nplantas\npor\nla\npoblaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \npara\nel\ntratamiento\ndel\ninsomnio,\nsiendo\nla\nvaleriana\nel\nproducto\nm\u00e1s\nempleado,\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \nforma\nde\npolvo\ny\ntambi\u00e9n\nde\nextracto\nacuoso\no\nalcoh\u00f3lico.\nEl\nm\u00e9todo\nde\npreparaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npuede\ninfluir\nen\nlos\ncomponentes\nactivos,\npor\nlo\nque\nes\ndif\u00edcil\nla\ncomparaci\u00f3n\nentre\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\ndistintos\nestudios.\nLa\nrevisi\u00f3n\nde\nlos\nestudios\nno\nmuestra\nevidencia\ncl\u00ednica\ncon\n \n \n \n \n \n \n \n \n \n \n \n \n \nsuficiente\nrelevancia,\npor\nlo\nque\nno\nser\u00eda\n\u00fatil\nen\nel\ntratamiento\ndel\ninsomnio\nprimario.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDisminuye\nel\ntiempo\nde\nlatencia\ndel\nsue\u00f1o,\npero\nno\nde\nforma\nsignificativa\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninsomnio\nocasional,\nsiendo\nen\ncombinaciones\ncon\nl\u00fapulo\ncuando\nse\nobtienen\n \n \n \n \n \n \n \n \n \n \nresultados\nalgo\nmejores,\naunque\nno\nsignificativos\ncl\u00ednicamente\n(8,10).\nSe\nnecesitan\n \n \n \n \n \n \n \n \n \n \nensayos\ncl\u00ednicos\naleatorizados\nque\nincluyan\nmuestras\nm\u00e1s\ngrandes\ny\nque\ncomparen\nla\n \n \n \n \n \n \n \n \n \n \n \n \nvaleriana\ncon\nel\nplacebo\nu\notras\nintervenciones\nutilizadas\npara\ntratar\nel\ninsomnio.\n \n \n \n \n \n \n \n \n \n \n \n \nTambi\u00e9n\nse\nnecesita\ndeterminar\ncu\u00e1les\nde\nlas\npresentaciones\nque\nhay\nen\nel\nmercado\n \n \n \n \n \n \n \n \n \n \n \n \n \npodr\u00edan\nser\neficaces,\ntanto\na\nnivel\nde\nla\ndosis\nde\nvaleriana\ncomo\nde\nsus\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncombinaciones\ncon\nplantas\nsedantes\ncomo\npasiflora,\namapola\nde\nCalifornia,\nlavanda,\n \n \n \n \n \n \n \n \n \n \nmelisa y tilo (2).\n \nEl\nresto\nde\nintervenciones,\ncomo\nla\nacupuntura\no\nla\nmoxibusti\u00f3n,\nno\ntienen\nestudios\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncalidad que permitan evaluarlas.\n \n \n \n \n58\n \n CEFALEA\n \nBaquero Navarro, R.\n \nLa\ncefalea\nes\nun\ns\u00edntoma\nque\nhace\nreferencia\na\ncualquier\ntipo\nde\ndolor\nlocalizado\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncabeza.\nExisten\nm\u00e1s\nde\n150\ntipos,\npero\nse\npueden\ndividir\na\ngrandes\nrasgos\nen\ndos\ncategor\u00edas:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncefaleas\nprimarias\ny\nsecundarias\n(1).\nLas\ncefaleas\nprimarias\nrepresentan\nel\n90%\ndel\ntotal\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nson\naquellas\nen\nlas\nque\nel\ndolor\nde\ncabeza\ntiene\nunos\ncriterios\ny\ncaracter\u00edsticas\npropias.\nEl\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndolor\nde\ncabeza\nconstituye\npor\ns\u00ed\nmismo\nla\nenfermedad,\ndada\nsu\ngravedad\no\nrecurrencia.\nEn\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlas\ncefaleas\nsecundarias,\nla\ncefalea\nno\nes\nla\nenfermedad\nprincipal,\nsino\nque\naparece\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntranscurso de una determinada enfermedad o proceso patol\u00f3gico (1).\n \nLa\ncefalea\npresenta\nuna\nalta\nprevalencia,\nde\nhasta\nel\n90%\nen\nel\ncaso\nde\nlas\nmujeres,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsiendo\norigen\ndel\n2%\nde\nlas\nconsultas\nde\nurgencias\n(2)\ny\nocasionando\nun\nimportante\ngasto\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npor\nincapacidad\nlaboral\n(3).\nLa\ncefalea\nque\nse\npresenta\ndurante\n15\nd\u00edas\no\nm\u00e1s\ncada\nmes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nafecta\nde\nun\n1,7%\na\nun\n4%\nde\nla\npoblaci\u00f3n\nadulta\nen\nel\nmundo\n(1).\nA\npesar\nde\nalgunas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nvariaciones\nregionales,\nla\ncefalea\nes\nun\nproblema\nque\nafecta\na\npersonas\nde\ntodas\nlas\nedades,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrazas,\nniveles\nde\ningresos\ny\nzonas\ngeogr\u00e1ficas.\nSeg\u00fan\nun\nestudio\nde\nla\nOrganizaci\u00f3n\nMundial\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nla\nSalud\n(Global\nBarden\nof\nDesease\nSud\n2015),\nlas\ncefaleas\nson\nla\nsexta\ncausa\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndiscapacidad\nen\nel\nmundo\n(1).\nLa\nmigra\u00f1a\n(un\ntipo\nde\ncefalea\nque\nveremos\nm\u00e1s\nadelante)\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla tercera en personas de menos de 50 a\u00f1os (1).\n \nTipos de cefaleas\n \n\u25cf\nCefalea\ntensional:\nes\nla\nm\u00e1s\nfrecuente\n(1).\nEst\u00e1\ncausada\npor\ntensi\u00f3n\nmuscular\ny\nsuele\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncoincidir\ncon\nperiodos\nde\nestr\u00e9s.\nEste\ntipo\nde\ncefalea\nse\nmanifiesta\ncomo\nuna\ntensi\u00f3n\no\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npresi\u00f3n\nconstante,\na\nmodo\nde\ncasco,\nen\nambos\nlados\nde\nla\ncabeza\ncon\npredominio\nen\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfrente y la nuca.\n \n\u25cf\nMigra\u00f1a\no\njaqueca:\nse\ncaracteriza\npor\nepisodios\nrepetidos\no\nrecurrentes\nde\ndolor\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \ncabeza.\nLa\nintensidad\nes\nvariable\nen\nlos\ndiferentes\nepisodios,\npero\npuede\nser\nelevada.\nEl\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndolor\nse\ninicia\ngeneralmente\nen\nun\nlado\nde\nla\ncabeza\n(hemicraneal)\ny\nse\nextiende\na\ntoda\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nla\ncabeza,\nsuele\nser\npuls\u00e1til\n(como\nsi\nse\nnotara\nel\nlatido\ndel\ncoraz\u00f3n)\ny\npuede\nir\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nacompa\u00f1ada\nde\nn\u00e1useas\ny\nv\u00f3mitos\ny\nun\nmalestar\nque\nempeora\ncon\nla\nluz\n(fotofobia),\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nruidos\n(fonofobia)\no\nlos\nolores\n(osmofobia).\nSe\ndistingue\nentre\nmigra\u00f1a\ncon\naura\n \n \n \n \n \n \n \n \n \n \n \n \n(s\u00edntomas\nvisuales,\nsensitivos,\nde\nlenguaje\no\nmotores)\ny\nmigra\u00f1a\nsin\naura\n(80%).\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \nmigra\u00f1a\nes\nla\ncefalea\nm\u00e1s\nimportante\ne\nincapacitante,\ntiene\nun\ncomponente\nhereditario\n \n \n \n \n \n \n \n \n \n \n \n \n(el\n80%\nde\nlos\npacientes\ntienen\npadres\no\nhermanos\ncon\nmigra\u00f1a)\ny\nes\nm\u00e1s\ncom\u00fan\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npersonas\nj\u00f3venes\ny\nen\nmujeres\n(1).\nEst\u00e1\nligada\nal\nestr\u00e9s\ny\nal\nconsumo\nde\ndeterminados\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nalimentos\nque\ncontengan\ntiramina\no\nglutamato\nmonos\u00f3dico\n(cacao,\nvainilla,\npl\u00e1tano,\n \n \n \n \n \n \n \n \n \n \nfrutos\nsecos,\nc\u00edtricos,\nsalchichas,\nquesos\nfermentados,\npicantes)\n(1).\nEl\nalcohol,\nlos\n \n \n \n \n \n \n \n \n \n \n \ncambios\nhormonales\no\nlos\nf\u00e1rmacos\n(p.\nej.:\nciertos\nvasodilatadores\no\nlos\nnitritos)\npueden\n \n \n \n \n \n \n \n \n \n \n \n \n \ndesencadenar tambi\u00e9n un ataque de migra\u00f1a.\n \n\u25cf\nCefaleas\ntrig\u00e9mino-auton\u00f3micas:\nest\u00e1\nimplicado\nel\nnervio\ntrig\u00e9mino.\nUn\ntipo\nde\nellas\nes\n \n \n \n \n \n \n \n \n \n \n \n \nla cefalea en racimo, que es la m\u00e1s frecuente de este tipo.\n \n59\n \n \u25cf\nEntre\notras\ncefaleas\nprimarias\npodemos\nencontrar\nalgunas\ncausadas\npor\nla\ntos,\npor\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \nesfuerzo\nf\u00edsico\nmuy\nintenso,\npor\ncrioest\u00edmulo\n(p.\nej.:\nal\ncomer\nun\nhelado\nmuy\nfr\u00edo)\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntambi\u00e9n la neuralgia del trig\u00e9mino, que curso con dolor en uno de los lados de la cara.\n \n\u25cf\nLas\ncefaleas\nsecundarias\npueden\ndeberse\na\nun\ntraumatismo,\npatolog\u00eda\nvascular,\nconsumo\n \n \n \n \n \n \n \n \n \n \n \no\nabstinencia\nde\nsustancias\ncomo\nel\nalcohol\n(resaca),\nalteraciones\nmetab\u00f3licas,\nauditivas,\n \n \n \n \n \n \n \n \n \n \n \noculares, etc.\n \nProfilaxis\n \nEl\nobjetivo\ndel\ntratamiento\npreventivo\nes\nconseguir\nuna\nreducci\u00f3n\nen\nla\nfrecuencia\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncrisis\nde\nal\nmenos\nun\n50%\n(2).\nSe\npersigue\nque\nla\nmigra\u00f1a\nno\npase\nde\nepis\u00f3dica\na\ncr\u00f3nica,\nas\u00ed\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nprevenir\nalgunas\ncomplicaciones\nevolutivas\nde\nla\nmigra\u00f1a\n(como\npuede\nser\nel\nictus,\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncasos de riesgo) y tambi\u00e9n prevenir las migra\u00f1as por abuso de medicaci\u00f3n (2).\n \nLos\nf\u00e1rmacos\nm\u00e1s\nutilizados\nen\nla\nprevenci\u00f3n\nson\nbetabloqueantes,\ncalcioantagonistas,\n \n \n \n \n \n \n \n \n \n \nantidepresivos\ntric\u00edclicos,\nneuromoduladores\ny\nasociaciones\nde\nbetabloqueantes\ncon\n \n \n \n \n \n \n \n \namitriptilina\no\nbetabloqueantes\ncon\nneuromoduladores\n(2).\nNo\nnos\ndetendremos\nmucho\nen\n \n \n \n \n \n \n \n \n \n \n \nellos\nporque\nno\nson\nel\nobjeto\nde\neste\nart\u00edculo,\nya\nque\nnos\ncentraremos\nm\u00e1s\nen\naquellos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nque\nson\nobjeto\nde\nindicaci\u00f3n\nfarmac\u00e9utica.\nS\u00f3lo\ndecir\nque\nel\npropanolol\nes\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nrecomendado\nde\nprimera\nl\u00ednea\npara\nla\nprofilaxis\nde\nla\nmigra\u00f1a,\ncon\nnivel\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nevidencia\nA\n(4).\nEn\ncuanto\na\nlos\nantiepil\u00e9pticos,\nel\ntopiramato\ny\nel\nvalproato\ns\u00f3dico\nest\u00e1n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomendados\npara\nreducir\nla\nfrecuencia\ny\ngravedad\nde\nlas\nmigra\u00f1as\n(nivel\nevidencia\nA).\nLa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecomendaci\u00f3n\nde\nla\ngabapentina\ntiene\nun\nnivel\nde\nevidencia\nC\n(4).\nAlgunos\nantidepresivos\n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nlos\nISRS\nno\nest\u00e1n\nrecomendados\nen\nel\ntratamiento\nprofil\u00e1ctico\nde\nla\nmigra\u00f1a\n(nivel\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nevidencia\nB).\nLa\namitriptilina\nse\nrecomienda\ncon\nnivel\nde\nrecomendaci\u00f3n\nB.\nLa\nvenlafaxina\n \n \n \n \n \n \n \n \n \n \n \n \n \npuede\nser\nuna\nalternativa\neficaz\na\nlos\nantidepresivos\ntric\u00edclicos,\ncon\nnivel\nde\nevidencia\nB\n(4).\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nLos\nbeneficios\ncl\u00ednicos\nde\nlos\ntratamientos\npreventivos\nse\nobservan\ndespu\u00e9s\nde\ndos\nmeses\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento.\n \nTratamiento farmacol\u00f3gico\n \nEl\ntratamiento\nagudo\nse\ndebe\niniciar\nel\ntratamiento\nlo\nm\u00e1s\npronto\nposible,\nsobre\ntodo\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nel\ncaso\nde\nla\nmigra\u00f1a,\nporque\nlas\nn\u00e1useas\ny\nlos\nv\u00f3mitos\nque\npueden\nacompa\u00f1arla\nvan\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nretrasar\nel\ninicio\nde\nacci\u00f3n\ndel\nf\u00e1rmaco\nal\nno\npoder\nabsorberse\ncorrectamente.\nPara\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\ntanto\nde\nla\ncefalea\ntensional\ny\nde\nla\nmigra\u00f1a\nse\npueden\nemplear\nAINE\ncomo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nibuprofeno,\nnaproxeno,\nparacetamol\no\n\u00e1cido\nacetilsalic\u00edlico\n(2).\nEn\nel\ntratamiento\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \nmigra\u00f1a\nse\npueden\ncombinar,\nen\nfunci\u00f3n\nde\nla\nrespuesta,\ncon\ntriptanes\n(almotript\u00e1n,\n \n \n \n \n \n \n \n \n \n \n \n \nsumatript\u00e1n,\neletript\u00e1n,\nfrovatript\u00e1n,\nnaratript\u00e1n,\nrizatrpt\u00e1n\ny\nzolimitript\u00e1n).\nNo\nhay\n \n \n \n \n \n \n \n \n \nevidencias\nclaras\nde\nsuperioridad\nde\nun\ntript\u00e1n\nsobre\nel\nresto\n(3).\nLos\nderivados\nerg\u00f3ticos,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nla\nergotamina\ny\ndihidroergotamina,\nse\nemplean\npara\nel\ntratamiento\nde\nla\nmigra\u00f1a\npero\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nest\u00e1n\nen\ndesuso\npor\nsu\nelevado\nabanico\nde\nefectos\nadversos\ny\nsobre\ntodo\nporque\nel\nabuso\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nlos\nmismos\ncausa\ncefalea\n\u00abde\nrebote\u00bb\n(2).\nEste\nefecto\nse\nve\npotenciado\nadem\u00e1s\npor\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncafe\u00edna\nque\nsuele\nacompa\u00f1ar\na\nestos\nprincipios\nactivos\nen\nlos\npreparados\ncomercializados\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \nnuestro pa\u00eds.\n \n60\n \n El\nfarmac\u00e9utico\ntiene\na\nsu\ndisposici\u00f3n\nuna\nserie\nde\nf\u00e1rmacos\nque\nhan\ndemostrado\nsu\n \n \n \n \n \n \n \n \n \n \n \n \n \n \neficacia\nen\ndiferentes\ntipos\nde\ncefaleas\ny\nque\nno\nrequieren\nprescripci\u00f3n\nm\u00e9dica\npara\nsu\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndispensaci\u00f3n. Ser\u00e1n de aplicaci\u00f3n para el caso de cefaleas leves-moderadas.\n \n\u25cf\nParacetamol.\nSu\neficacia\nen\nel\ntratamiento\nde\nla\ncefalea\naguda\nmoderada-grave\nha\n \n \n \n \n \n \n \n \n \n \n \n \nsido\nclaramente\nestablecido\n(5,\n7).\nLas\nprincipales\nreacciones\nadversas\nson\n \n \n \n \n \n \n \n \n \n \nalteraciones\nhematol\u00f3gicas,\nerupci\u00f3n\ncut\u00e1nea,\nreacciones\nde\nhipersensibilidad\ny\n \n \n \n \n \n \n \n \nriesgo\nde\nsobredosificaci\u00f3n\no\nintoxicaci\u00f3n.\nHa\nde\nemplearse\ncon\nprecauci\u00f3n\nen\n \n \n \n \n \n \n \n \n \n \n \nenfermos renales y hep\u00e1ticos. Dosis (adultos): 650-1000 mg/4-6 h; m\u00e1ximo 4 g/d\u00eda.\n \n\u25cf\n\u00c1cido\nacetilsalic\u00edlico\n(AAS).La\ncalidad\nde\nlas\npruebas\nde\nla\nutilidad\ncl\u00ednica\ndel\nAAS\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlas\ncefaleas\nes\nm\u00e1s\nlimitada\nque\nlas\nde\notros\nf\u00e1rmacos;\nsin\nembargo,\nparece\nque\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndosis\n\u00fanica\nde\n500-1000\nmg\nconsigue\nciertos\nbeneficios\nen\ncuanto\na\nreducci\u00f3n\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicaci\u00f3n\nde\nrescate\ny\nsatisfacci\u00f3n\nde\nlos\npacientes\nrespecto\na\nplacebo\nen\nadultos\n \n \n \n \n \n \n \n \n \n \n \n \n \ncon\ncefalea\ntensional\nde\nintensidad\nmoderada\no\ngrave\n(5,8).\nLas\nreacciones\nadversas\n \n \n \n \n \n \n \n \n \n \n \n \nm\u00e1s\nfrecuentes\nson\nproblemas\ngastrointestinales\npor\naumento\nde\nla\nacidez\n \n \n \n \n \n \n \n \n \n \ngastrointestinal\nen\npersonas\npredispuestas.\nCon\nmenor\nfrecuencia\npuede\naparecer\n \n \n \n \n \n \n \n \n \nurticaria,\nerupci\u00f3n,\nedema,\nespasmo\nbronquial,\ndisnea.\nDebe\nusarse\ncon\nprecauci\u00f3n\n \n \n \n \n \n \n \n \n \n \nen\ncaso\nde\nasma,\ndiabetes,\ngota,\nhipertensi\u00f3n,\ninsuficiencia\nhep\u00e1tica\no\nrenal.\nEl\nAAS\n \n \n \n \n \n \n \n \n \n \n \n \n \nest\u00e1\ncontraindicado\nen\ncaso\nde\nalergia\na\nsalicilatos,\nhistorial\nde\nbroncoespasmo,\n \n \n \n \n \n \n \n \n \n \n \n\u00falcera\ngastroduodenal\no\nproblemas\nen\nla\ncoagulaci\u00f3n\ny\nen\nni\u00f1os.\nSe\nrecomienda\n \n \n \n \n \n \n \n \n \n \n \n \nadministrarlo junto con alimentos.\n \n\u25cf\nIbuprofeno.\nA\ndosis\nde\n400\nmg\nha\ndemostrado\nun\nefecto\nbeneficioso\nsobre\nel\nalivio\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndel\ndolor\nen\nla\ncefalea\ntensional\nepis\u00f3dica;\nsin\nembargo,\nlos\nestudio\nse\u00f1alan\nque\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntodos\nlos\npacientes\nde\nbenefician\nde\ntal\nefecto\n(5,\n9).\nSu\nuso\ncr\u00f3nico\npuede\noriginar\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nvisi\u00f3n\nborrosa,\nreacciones\nhematol\u00f3gicas,\nalteraciones\ng\u00e1stricas,\nretenci\u00f3n\nde\nsodio\no\n \n \n \n \n \n \n \n \n \n \nproblemas\nbronquiales.\nDebe\nusarse\ncon\nprecauci\u00f3n\nen\ncasos\nde\nasma,\n\u00falcera,\n \n \n \n \n \n \n \n \n \n \n \nenfermedad renal o pacientes hipertensos.\n \nTratamiento no farmacol\u00f3gico\n \n\u25cf\nH\u00e1bitos\nbeneficiosos.\nDurante\nla\ncrisis\nes\nrecomendable\nel\nreposo\nen\nun\nambiente\n \n \n \n \n \n \n \n \n \n \n \n \ntranquilo,\nsin\nruidos,\nni\nolores\ny\ncon\nuna\niluminaci\u00f3n\ntenue.\nAunque\nen\nla\nmayor\u00eda\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncasos\nse\nprefiere\nestar\ntumbado,\nen\notros\nresulta\nm\u00e1s\neficaz\nel\nestar\nsimplemente\n \n \n \n \n \n \n \n \n \n \n \n \n \nsentado.\nPuede\naplicarse\nfr\u00edo\nlocal,\nsin\nque\n\u00e9ste\nsea\nmuy\nintenso,\npero\nes\nimportante\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsea mantenido.\n \n\u25cf\nToxina\nbotul\u00ednica.\nLas\ninyecciones\nde\nesta\ntoxina\nse\nemplean\npara\nel\ntratamiento\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmigra\u00f1a\ncr\u00f3nica.\nSe\nha\nvisto\ncierta\nmejor\u00eda\nen\ncuanto\na\nla\nreducci\u00f3n\ndel\nn\u00famero\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nepisodios\nanuales,\npero\nno\nse\nha\nestablecido\nsuperioridad\nrespecto\nde\notros\n \n \n \n \n \n \n \n \n \n \n \ntratamientos\nexistentes.\nEn\nel\ncaso\nde\nla\nmigra\u00f1a\nocasional,\nla\nevidencia\ndisponible\nes\n \n \n \n \n \n \n \n \n \n \n \n \n \nescasa (13).\n \n\u25cf\nOxigenoterapia.\nLa\nrespiraci\u00f3n\nde\noxigeno\npuro\nmediante\nun\nm\u00e1scara\no\ndentro\nde\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \nc\u00e1mara\nhiperb\u00e1rica,\na\npesar\nde\nsu\nuso\nrelativamente\nextendido,\nno\nha\nconseguido\n \n \n \n \n \n \n \n \n \n \n \n \nestablecer claramente su efectividad (12).\n \n61\n \n \u25cf\nAcupuntura.\nConsiste\nen\nla\naplicaci\u00f3n\nde\nagujas\nen\nciertas\nzonas\nde\nla\nsuperficie\ncorporal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nencaminadas\na\nllegar\na\ninteractuar\ncon\ndeterminados\nmeridianos\nque\natravesar\u00edan\ntodas\n \n \n \n \n \n \n \n \n \n \n \nlas\nzonas\nde\nnuestro\ncuerpo\ny\nde\nello\nse\nderivar\u00eda\nla\nmejora\no\nla\nresoluci\u00f3n\nde\ninfinidad\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nproblemas\nde\nsalud.\nEl\nmecanismo\nde\nacci\u00f3n\nde\nla\nacupuntura\nnunca\nha\npodido\nser\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndemostrado.\nLos\nmeridianos\ny\npuntos\nde\nacupuntura\nno\nse\ncorresponden\ncon\nninguna\n \n \n \n \n \n \n \n \n \n \n \n \nestructura\nbiol\u00f3gica.\nEn\nel\ncaso\nque\nnos\nocupa,\nla\ncefalea\ntensional,\nhay\nensayos\ncl\u00ednicos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrealizados\nque\nmuestran\nun\nbeneficio\npr\u00e1cticamente\nigual\nal\nque\nse\nconsigue\ncon\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \nacupuntura\n\u00abplacebo\u00bb,\nen\nla\nque\nno\nse\naplican\nverdaderas\nagujas,\nsino\nque\nson\nsimuladas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \no\nbien\nse\naplican\nlas\nagujas\nen\nzonas\nque\nno\nse\ncorresponden\na\nlos\nmeridianos\ncitados.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAdem\u00e1s,\ncuanto\nmayor\nes\nla\ncantidad\ny\nla\ncalidad\nde\nlos\nensayos\ncl\u00ednicos\nrealizados,\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nse\nva\nviendo\nque\nla\neficacia\natribuida\na\nesta\nterapia\nva\ndisminuyendo\n(10,11).\nA\npesar\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsu amplia utilizaci\u00f3n, la acupuntura sigue siendo considerada una pseudoterapia.\n \n \nConclusiones\n \nEl\nfarmac\u00e9utico\npuede\nactuar\nbien\ncomo\nfiltro\npara\nderivar\nal\npaciente\nen\nbusca\natenci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nm\u00e9dica\no\naportando\nsoluciones\neficaces\n\u00e9l\nmismo\nen\nlos\ncasos\nde\ncefalea\nleve-moderada\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nno\nprecisen\nde\ntal\nderivaci\u00f3n.\nCausas\nde\nremisi\u00f3n\nal\nm\u00e9dico:\ncefalea\ncr\u00f3nica\nque\ncambia\nsus\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncaracter\u00edsticas,\ncefalea\nde\ninicio\nbrusco,\npresencia\nde\naura,\ndolor\nde\ncabeza\nasociado\na\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntraumatismo,\ndolor\nagudo\nen\nla\nparte\nposterior\nde\nla\ncabeza\ncon\nrigidez\nde\ncuello\ny\nnuca\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nv\u00f3mitos,\ndolor\nde\ncabeza\ncon\ns\u00edntomas\nasociados\ncomo\ncongesti\u00f3n\nnasal,\nenrojecimiento\n \n \n \n \n \n \n \n \n \n \n \nocular,\np\u00e9rdida\nde\nmemoria,\nvisi\u00f3n\nborrosa,\nfiebre,\nalteraci\u00f3n\ndel\nsue\u00f1o,\netc.\nEn\nel\ncaso\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nni\u00f1os\ny\npersonas\nmuy\nancianas\ntambi\u00e9n\ncomo\nprecauci\u00f3n\ngeneral\ndeberemos\nde\nremitirlos\n \n \n \n \n \n \n \n \n \n \n \n \nal m\u00e9dico ante la presencia de una cefalea anormal o inesperada.\n \nLas\ncefaleas\nleves-moderadas\nde\ntipo\ntensional\nque\nno\nprecisen\nderivaci\u00f3n\nal\nm\u00e9dico\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \npueden\ntratar\ncon\nanalg\u00e9sicos\nque\nno\nprecisan\nreceta\nm\u00e9dica:\nparacetamol,\n\u00e1cido\n \n \n \n \n \n \n \n \n \n \n \nacetilsalic\u00edlico o ibuprofeno (5).\n \n \n \n62\n \n BIBLIOGRAF\u00cdA\n \n \nAcn\u00e9\n \n1)\nKnutsen-Larson,\nS.;\net\nal.\nAcne\nVulgaris:\nPathogenesis,\nTreatment,\nand\nNeeds\nAssessment.\n \n \n \n \n \n \n \n \n \n \n \nDermatol. Clin. 2012, 30 (1), 99\u2013106, viii\u2013ix.\n \n2)\nOlutunmbi,\nY.;\nPaley,\nK.;\nEnglish,\nJ.\nC.\nAdolescent\nFemale\nAcne:\nEtiology\nand\nManagement.\nJ.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPediatr. Adolesc. Gynecol. 2008, 21 (4), 171\u2013176.\n \n \n3)\nNast,\nA.;\net\nal.\nEuropean\nEvidence-Based\n(S3)\nGuidelines\nfor\nthe\nTreatment\nof\nAcne.\nJ.\nEur.\nAcad.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDermatology Venereol. 2012, 26, 1\u201329.\n \n \n4)\nStringer,\nT.;\nNagler,\nA.;\nOrlow,\nS.\nJ.;\nOza,\nV.\nS.\nClinical\nEvidence\nfor\nWashing\nand\nCleansers\nin\nAcne\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nVulgaris: A Systematic Review. J. Dermatolog. Treat. 2018, 29 (7), 688\u2013693.\n \n \n5)\nMagin,\nP.;\nPond,\nD.;\nSmith,\nW.;\nWatson,\nA.\nA\nSystematic\nReview\nof\nthe\nEvidence\nfor\n\u201cmyths\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nMisconceptions\u201d\nin\nAcne\nManagement:\nDiet,\nFace-Washing\nand\nSunlight.\nFam.\nPract.\n2004,\n22\n \n \n \n \n \n \n \n \n \n \n \n \n(1), 62\u201370.\n \n6)\nHaider, A.; Shaw, J. C. Treatment of Acne Vulgaris. JAMA 2004, 292 (6), 726.\n \n \n7)\nThielitz,\nA.;\nAbdel-Naser,\nM.\nB.;\nFluhr,\nJ.\nW.;\nZouboulis,\nC.\nC.;\nGollnick,\nH.\nTopical\nRetinoids\nin\nAcne\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n-\nan\nEvidence-Based\nOverview.\nJ.\nder\nDtsch.\nDermatologischen\nGesellschaft\n2008,\n6\n(12),\n \n \n \n \n \n \n \n \n \n \n \n \n1023\u20131031.\n \n \n8)\nSimonart,\nT.;\nDramaix,\nM.\nTreatment\nof\nAcne\nwith\nTopical\nAntibiotics:\nLessons\nfrom\nClinical\n \n \n \n \n \n \n \n \n \n \n \n \n \nStudies. Br. J. Dermatol. 2005, 153 (2), 395\u2013403.\n \n9)\nAdler,\nB.\nL.;\nKornmehl,\nH.;\nArmstrong,\nA.\nW.\nAntibiotic\nResistance\nin\nAcne\nTreatment.\nJAMA\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDermatology 2017, 153 (8), 810.\n \n10)\nSinnott,\nS.-J.;\nBhate,\nK.;\nMargolis,\nD.\nJ.;\nLangan,\nS.\nM.\nAntibiotics\nand\nAcne:\nAn\nEmerging\nIceberg\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nof Antibiotic Resistance? Br. J. Dermatol. 2016, 175 (6), 1127\u20131128.\n \n11)\nBienenfeld,\nA.;\nNagler,\nA.\nR.;\nOrlow,\nS.\nJ.\nOral\nAntibacterial\nTherapy\nfor\nAcne\nVulgaris:\nAn\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nEvidence-Based Review. Am. J. Clin. Dermatol. 2017, 18 (4), 469\u2013490.\n \n12)\nLeyden,\nJ.\nCurrent\nIssues\nin\nAntimicrobial\nTherapy\nfor\nthe\nTreatment\nof\nAcne.\nJ.\nEur.\nAcad.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDermatology Venereol. 2001, 15, 51\u201355.\n \n13)\nTan,\nJ.\nHormonal\nTreatment\nof\nAcne:\nReview\nof\nCurrent\nBest\nEvidence.\nJ.\nCutan.\nMed.\nSurg.\n2005,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n8 (S4), 11\u201315.\n \n14)\nArowojolu,\nA.\nO.;\nGallo,\nM.\nF.;\nLopez,\nL.\nM.;\nGrimes,\nD.\nA.\nCombined\nOral\nContraceptive\nPills\nfor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTreatment\nof\nAcne.\nIn\nCochrane\nDatabase\nof\nSystematic\nReviews;\nArowojolu,\nA.\nO.,\nEd.;\nJohn\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nWiley & Sons, Ltd: Chichester, UK, 2012.\n \n15)\nCosta,\nC.\nS.;\nBagatin,\nE.;\nMartimbianco,\nA.\nL.\nC.;\nda\nSilva,\nE.\nM.;\nL\u00facio,\nM.\nM.;\nMagin,\nP.;\nRiera,\nR.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nOral Isotretinoin for Acne. Cochrane Database Syst. Rev. 2018, No. 11.\n \n16)\nTan,\nJ.;\nKnezevic,\nS.;\nBoyal,\nS.;\nWaterman,\nB.;\nJanik,\nT.\nEvaluation\nof\nEvidence\nfor\nAcne\nRemission\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nWith\nOral\nIsotretinoin\nCumulative\nDosing\nof\n120-150\nMg/Kg.\nJ.\nCutan.\nMed.\nSurg.\n2016,\n20\n(1),\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n13\u201320.\n \n17)\nMunavalli,\nG.\nS.;\nWeiss,\nR.\nA.\nEvidence\nfor\nLaser-\nand\nLight-Based\nTreatment\nof\nAcne\nVulgaris.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSemin. Cutan. Med. Surg. 2008, 27 (3), 207\u2013211.\n \n18)\nZheng,\nW.;\nWu,\nY.;\nXu,\nX.;\nGao,\nX.;\nChen,\nH.-D.;\nLi,\nY.\nEvidence-Based\nReview\nof\nPhotodynamic\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTherapy in the Treatment of Acne. Eur. J. Dermatol. 2014, 24(4), 444\u201356.\n \n19)\nBoen,\nM.;\nBrownell,\nJ.;\nPatel,\nP.;\nTsoukas,\nM.\nM.\nThe\nRole\nof\nPhotodynamic\nTherapy\nin\nAcne:\nAn\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nEvidence-Based Review. Am. J. Clin. Dermatol. 2017, 18 (3), 311\u2013321.\n \n63\n \n 20)\nTong,\nL.\nX.;\nBrauer,\nJ.\nA.\nLasers,\nLight,\nand\nthe\nTreatment\nof\nAcne:\nA\nComprehensive\nReview\nof\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nLiterature. J. Drugs Dermatol. 2017, 16 (11), 1095\u20131102.\n \n21)\nH\u00e6dersdal,\nM.;\nTogsverd-Bo,\nK.;\nWulf,\nH.\nEvidence-Based\nReview\nof\nLasers,\nLight\nSources\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \nPhotodynamic\nTherapy\nin\nthe\nTreatment\nof\nAcne\nVulgaris.\nJ.\nEur.\nAcad.\nDermatology\nVenereol.\n \n \n \n \n \n \n \n \n \n \n \n \n \n2008, 22 (3), 267\u2013278.\n \n22)\nCao,\nH.;\nYang,\nG.;\nWang,\nY.;\nLiu,\nJ.\nP.;\nSmith,\nC.\nA.;\nLuo,\nH.;\nLiu,\nY.\nComplementary\nTherapies\nfor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAcne Vulgaris. Cochrane Database Syst. Rev. 2015.\n \n23)\nIngram,\nJ.\nR.;\nGrindlay,\nD.\nJ.\nC.;\nWilliams,\nH.\nC.\nManagement\nof\nAcne\nVulgaris:\nAn\nEvidence-Based\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nUpdate. Clin. Exp. Dermatol. 2010, 35 (4), 351\u2013354.\n \n24)\nStrauss,\nJ.\nS.\net\nal.\nGuidelines\nof\nCare\nfor\nAcne\nVulgaris\nManagement.\nJ.\nAm.\nAcad.\nDermatol.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2007, 56 (4), 651\u2013663.\n \n25)\nWebster,\nG.\nEvidence-Based\nReview:\nFixed-Combination\nTherapy\nand\nTopical\nRetinoids\nin\nthe\n \n \n \n \n \n \n \n \n \n \n \nTreatment of Acne. J. Drugs Dermatol. 2011, 10 (6), 636\u2013644.\n \n26)\nEichenfield,\nL.\nF.;\net\nal.\nEvidence-Based\nRecommendations\nfor\nthe\nDiagnosis\nand\nTreatment\nof\n \n \n \n \n \n \n \n \n \n \n \n \n \nPediatric Acne. Pediatrics 2013, 131 (Supplement), S163\u2013S186.\n \n27)\nde\nVries,\nF.\nM.\nC.;\nMeulendijks,\nA.\nM.;\nDriessen,\nR.\nJ.\nB.;\nvan\nDooren,\nA.\nA.;\nTjin,\nE.\nP.\nM.;\nvan\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nKerkhof,\nP.\nC.\nM.\nThe\nEfficacy\nand\nSafety\nof\nNon-Pharmacological\nTherapies\nfor\nthe\nTreatment\nof\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAcne\nVulgaris:\nA\nSystematic\nReview\nand\nBest-Evidence\nSynthesis.\nJ.\nEur.\nAcad.\nDermatology\n \n \n \n \n \n \n \n \n \n \n \n \nVenereol. 2018, 32 (7), 1195\u20131203.\n \n28)\nChien,\nA.\nL.;\nQi,\nJ.;\nRainer,\nB.;\nSachs,\nD.\nL.;\nHelfrich,\nY.\nR.\nTreatment\nof\nAcne\nin\nPregnancy.\nJ.\nAm.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nBoard Fam. Med. 2016, 29 (2), 254\u2013262.\n \n29)\nGollnick,\nH.\nP.;\net\nal.\nA\nConsensus-Based\nPractical\nand\nDaily\nGuide\nfor\nthe\nTreatment\nof\nAcne\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPatients. J. Eur. Acad. Dermatology Venereol. 2016, 30 (9), 1480\u20131490.\n \n30)\nNast,\nA.;\net\nal.\nEuropean\nEvidence-Based\n(S3)\nGuideline\nfor\nthe\nTreatment\nof\nAcne.\nJ.\nEur.\nAcad.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDermatology Venereol. 2016, 30 (8), 1261\u20131268.\n \n31)\nNast,\nA.;\nRosumeck,\nS.;\nErdmann,\nR.;\nAlsharif,\nU.;\nDressler,\nC.;\nWerner,\nR.\nN.\nMethods\nReport\non\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nthe\nDevelopment\nof\nthe\nEuropean\nEvidence-Based\n(S3)\nGuideline\nfor\nthe\nTreatment\nof\nAcne.\nJ.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nEur. Acad. Dermatology Venereol. 2016, 30 (8), e1\u2013e28.\n \n \n \n \n64\n \n Herpes labial\n \n1)\nMurray\nP.R.,\nRosenthal\nK.S.,\nPfaller\nM.A.\nMicrobiolog\u00eda\nm\u00e9dica.\n8a\nEdici\u00f3n.\nBarcelona:\nEditorial\n \n \n \n \n \n \n \n \n \n \n \n \nElsevier; 2017.\n \n \n2)\nMedline\nPlus.\nHerpes\n\u2013\noral.\n[Internet].\n[Consultado\n29\nAgo\n2019].\nDisponible\nen:\n \n \n \n \n \n \n \n \n \n \n \n \nhttps://medlineplus.gov/spanish/ency/article/000606.htm\n \n \n3)\nMensa\nJ.,\nSoriano\nA.\net\nal.\nGu\u00eda\nde\nterap\u00e9utica\nantimicrobiana\n2019.\nBarcelona:\nEditorial\nAntares;\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2019.\n \n4)\nInformedHealth.org\n[Internet].\nCologne,\nGermany:\nInstitute\nfor\nQuality\nand\nEfficiency\nin\nHealth\n \n \n \n \n \n \n \n \n \n \n \nCare\n(IQWiG);\n2006-.\nHow\neffective\nare\ncreams\nand\ntablets\nfor\nthe\ntreatment\nof\ncold\nsores?\n12\nJul\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2018\n \n5)\nAgencia\nEspa\u00f1ola\nde\nMedicamentos\ny\nProductos\nSanitarios\n[Internet].\nZovicrem.\nFicha\nt\u00e9cnica\ndel\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamento.\n \n \n6)\nAgencia\nEspa\u00f1ola\nde\nMedicamentos\ny\nProductos\nSanitarios\n[Internet].\nZoviduo.\nFicha\nt\u00e9cnica\ndel\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamento.\n \n \n7)\nHull\nC.M.,\nHarmenberg\nJ.,\nArlander\nE.,\nAoki\nF.,\nBring\nJ.,\nDarp\u00f6\nB.\net\nal.\nEarly\ntreatment\nof\ncold\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsores\nwith\ntopical\nME-609\ndecreases\nthe\nfrequency\nof\nulcerative\nlesions:\na\nrandomized,\ndouble-\n \n \n \n \n \n \n \n \n \n \n \n \n \nblind,\nplacebo-controlled,\npatient-initiated\nclinical\ntrial.\nJ\nAm\nAcad\nDermatol\n[Internet].\n2011\nAbr;\n \n \n \n \n \n \n \n \n \n \n \n \n64(4).\n \n \n8)\nArain\nN.,\nParavastu\nS.C.,\nArain\nM.A.\nEffectiveness\nof\ntopical\ncorticosteroids\nin\naddition\nto\nantiviral\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntherapy\nin\nthe\nmanagement\nof\nrecurrent\nherpes\nlabialis:\na\nsystematic\nreview\nand\nmeta-\nanalysis.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nBMC Infect Dis [Internet]. 2015 Feb 21; 15:82.\n \n9)\nWorrall G. Herpes labialis. BMJ Clin Evid [Internet]. 2009: 1704.\n \n10)\nMcKeough\nM.B.,\nSpruance\nS.L.\nComparison\nof\nnew\ntopical\ntreatments\nfor\nherpes\nlabialis:\nefficacy\n \n \n \n \n \n \n \n \n \n \n \n \n \nof penciclovir cream, acyclovir cream, and n-docosanol cream against experimental\n \n \n11)\nCutaneous\nherpes\nsimplex\nvirus\ntype\n1\ninfection.\nArch\nDermatol\n[Internet].\n2001\nSep\n \n \n \n \n \n \n \n \n \n \n \n \n137(9):1153-8.\n \n12)\nAgencia\nEspa\u00f1ola\nde\nMedicamentos\ny\nProductos\nSanitarios\n[Internet].\nFenivir.\nFicha\nt\u00e9cnica\ndel\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamento.\n \n \n13)\nAgencia\nEspa\u00f1ola\nde\nMedicamentos\ny\nProductos\nSanitarios\n[Internet].\nErazaban.\nFicha\nt\u00e9cnica\ndel\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamento.\n \n \n14)\nSociedad Espa\u00f1ola de Medicina Interna. Herpes z\u00f3ster.\n \n \n15)\nArens\nM.,\nTravis\nS.\nZinc\nSalts\nInactivate\nClinical\nIsolates\nof\nHerpes\nSimplex\nVirus\nIn\nVitro.\nJ\nClin\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nMicrobiol 2000 May\n \n16)\nAmerican Sexual Health Association. Herpes treatment. [Internet].\n \n \n \n \n65\n \n Estomatitis aftosa\n \n1)\nSchemel-Su\u00e1rez\nM,\nL\u00f3pez-L\u00f3pez\nJ,\nChimenos-K\u00fcstner\nE.\n\u00dalceras\nOrales:\nDiagn\u00f3stico\nDiferencial\nY\n \n \n \n \n \n \n \n \n \n \n \nTratamiento. Med Clin (Barc) [Internet]. 2015;145(11):499-503.\n \n2)\nEscudero N. Profesi\u00f3n Lesiones orales y cuidado bucal. 2019;14-6.\n \n3)\nFalg\u00e1s Franco J, Parram\u00f3n Cuadrado V. Patolog\u00eda bucal. Pediatr Integr. 2007;11(1):33-41.\n \n4)\nRioboo\nM,\nBascones\nA.\nAftas\nde\nla\nmucosa\noral.\nAv\nOdontoestomatol\n[Internet].\n \n \n \n \n \n \n \n \n \n \n \n \n2011;27(2):63-74.\n \n5)\nRodr\u00edguez-Archilla\nA,\nRaissouni\nT.\nEnsayo\ncl\u00ednico\naleatorizado\nsobre\nla\nefectividad\nde\ntratamientos\n \n \n \n \n \n \n \n \n \n \n \n \nalternativos\nen\nla\nestomatitis\naftosa\nrecurrente.\nMed\nClin\n(Barc)\n[Internet].\n21\nde\njulio\nde\n2017\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n[citado 2 de mayo de 2019];149(2):55-60.\n \n6)\nLi\nC-L,\nHuang\nH-L,\nHua\nH,\nWang\nW-C.\nEfficacy\nand\nsafety\nof\ntopical\nherbal\nmedicine\ntreatment\non\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrecurrent\naphthous\nstomatitis:\na&amp;nbsp;systemic\nreview.\nDrug\nDes\nDevel\nTher\n[Internet].\n \n \n \n \n \n \n \n \n \n \ndiciembre de 2015 [citado 26 de marzo de 2019];10:107.\n \n7)\nHamedi\nS,\nSadeghpour\nO,\nShamsardekani\nMR,\nAmin\nG,\nHajighasemali\nD,\nFeyzabadi\nZ.\nThe\nMost\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCommon\nHerbs\nto\nCure\nthe\nMost\nCommon\nOral\nDisease:\nStomatitis\nRecurrent\nAphthous\nUlcer\n \n \n \n \n \n \n \n \n \n \n \n \n \n(RAU). Iran Red Crescent Med J [Internet]. 13 de febrero de 2016 [citado 26 de marzo de 2019]\n \n8)\nLalla\nR\nV,\nChoquette\nLE,\nFeinn\nRS,\nZawistowski\nH,\nLatortue\nMC,\nKelly\nET,\net\nal.\nMultivitamin\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntherapy\nfor\nrecurrent\naphthous\nstomatitis:\na\nrandomized,\ndouble-masked,\nplacebo-controlled\n \n \n \n \n \n \n \n \n \ntrial. J Am Dent Assoc [Internet]. 2012;143(4):370\u20136.\n \n9)\nEdgar\nNR,\nSaleh\nD,\nMiller\nRA.\nRecurrent\nAphthous\nStomatitis:\nA\nReview.\n\u200b\nJ\nClin\nAesthet\nDermatol\n\u200b\n.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2017;10(3):26\u201336.\n \n10)\nMar\u00eda\nAng\u00e9lica\nMarinovic.\nRecurrent\noral\nthrush:\ndifferential\ndiagnosis\nand\nmanagement.\n \n \n \n \n \n \n \n \n \n \nMedwave\n\u200b\n 2009 Feb;9(2):e3773 doi: 10.5867/medwave.2009.02.3773.\n \n \n \n \n66\n \n Faringoamigdalitis aguda\n \n1)\nVan\nDriel\nML,\nDe\nSutter\nAIM,\nHabraken\nH,\nThorning\nS,\nChristiaens\nT.\nDifferent\nantibiotic\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntreatments for group A streptococcal pharyngitis.\n \n \n2)\nPierce\nCA.\nEficacia\ny\nseguridad\ndel\nibuprofeno\ny\nel\nparacetamol\nen\nni\u00f1os\ny\nadultos:\nun\nmetan\u00e1lisis\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ny una revisi\u00f3n cualitativa. \n\u200b\nAnn Pharmacother. \n\u200b\n2010; 44: 489-506.\n \n3)\nBisno AL. Acute pharyngitis. \n\u200b\nN Engl J Med.\n\u200b\n 2001;344:201-211.\n \n4)\nHayward\nG,\nThompson\nM,\nPerera\nR,\nGlasziou\nP,\nDel\nMar\nC,\nHeneghan\nC.\nCorticosteroides\ncomo\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nindependiente\no\ncomplementario\npara\nla\nfaringitis.\nCochrane\nDatabase\nof\nSystematic\n \n \n \n \n \n \n \n \n \n \n \nReviews 2012.\n \n5)\nRelief\nof\nsore\nthroat\nwith\nthe\nanti-inflammatory\nthroat\nlozenge\nflurbiprofen\n8.75\nmg:\na\n \n \n \n \n \n \n \n \n \n \n \n \n \nrandomised,\ndouble-blind,\nplacebo-controlled\nstudy\nof\nefficacy\nand\nsafety.\nWatson\nN,\nNimmo\n \n \n \n \n \n \n \n \n \n \n \nWS, Christian J, Charlesworth A, Speight J, Miller K.\n \n6)\nClinical studies on Frubienzyme in a controlled double-blind trial. Raus I.\n \n7)\nEfficacy\nand\nsafety\nof\na\ntriple\nactive\nsore\nthroat\nlozenge\nin\nthe\ntreatment\nof\npatients\nwith\nacute\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npharyngitis:\nResults\nof\na\nmulti-centre,\nrandomised,\nplacebo-controlled,\ndouble-blind,\n \n \n \n \n \n \n \n \nparallel-group\ntrial\n(DoriPha).\nPalm\nJ,\nFuchs\nK,\nStammer\nH,\nSchumacher-Stimpfl\nA,\nMilde\nJ;\n \n \n \n \n \n \n \n \n \n \n \n \n \nDoriPha investigators.\n \n8)\nEctoine\nlozenges\nin\nthe\ntreatment\nof\nacute\nviral\npharyngitis:\na\nprospective\nactive\ncontrolled\n \n \n \n \n \n \n \n \n \n \n \n \n \nclinical study. Dao VA, Overhagen S, Bilstein A, Kolot C, Sonnemann U, M\u00f6sges R.\n \n9)\nEfficacy\nand\ntolerability\nof\nambroxol\nhydrochloride\nlozenges\nin\nsore\nthroat.\nRandomised,\n \n \n \n \n \n \n \n \n \n \n \ndouble-blind,\nplacebo-controlled\ntrials\nregarding\nthe\nlocal\nanaesthetic\nproperties.\nFischer\nJ,\n \n \n \n \n \n \n \n \n \n \nPschorn U, Vix JM, Peil H, Aicher B, M\u00fcller A, de Mey C.\n \n10)\nBrinckmann\nJ,\nSigwart\nH,\nvan\nHouten\nL\nTaylor.\nSafety\nand\nefficacy\nof\na\ntraditional\nherbal\nmedicine\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(Throat\nCoat)\nin\nsymptomatic\ntemporary\nrelief\nof\npain\nin\npatients\nwith\nacute\npharyngitis:\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmulticenter,\nprospective,\nrandomized,\ndouble-blinded,\nplacebo-controlled\nstudy.\n\u200b\nJ\nAltern\n \n \n \n \n \n \n \n \nComplement Med.\n\u200b\n2 03\n \n11)\nWonnemann\nM,\nHelm\nI,\nStrauss-Grabo\nM,\net\nal.\nLidocaine\n8\nmg\nsore\nthroat\nlozenges\nin\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntreatment\nof\nacute\npharyngitis.\nA\nnew\ntherapeutic\noption\ninvestigated\nin\ncomparison\nto\nplacebo\n \n \n \n \n \n \n \n \n \n \n \n \n \ntreatment. \n\u200b\nArznelmittelforschung.\n\u200b\n2007\n \n12)\nShi\nY,\nGu\nR,\nLiu\nC,\net\nal.\nChinese\nmedicinal\nherbs\nfor\nsore\nthroat.\n\u200b\nCochrane\nDatabase\nSyst\nRev.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2010\n \n13)\nSamet\nN,\nLaurent\nC,\nSusarla\nSM,\nSamet-Rubinsteen\nN.Effect\nof\nTopical\nPropolis\non\nWound\n \n \n \n \n \n \n \n \n \n \n \n \n \nHealing Process After Tonsillectomy: Randomized Controlled Study.\n \n \n14)\nChen\nH,\nZhuo\nQ,\nYuan\nW,\nWang\nJ,\nWu\nT.\nVitamina\nA\npara\nla\nprevenci\u00f3n\nde\nlas\ninfecciones\nagudas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde las v\u00edas respiratorias inferiores en los ni\u00f1os de hasta siete a\u00f1os de edad.\n \n \n \n67\n \n Tos aguda\n \n1)\nYvonne\nCM\nDuijvestijn,\nNadjette\nMourdi,\nJohn\nSmucny,\nG\u00e9rard\nPons,\nMartin\nChalumeau.\n \n \n \n \n \n \n \n \n \n \n \nAcetilciste\u00edna\ny\ncarbociste\u00edna\npara\nlas\ninfecciones\nagudas\nde\nlas\nv\u00edas\na\u00e9reas\nsuperiores\ne\ninferiores\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen pacientes pedi\u00e1tricos sin enfermedad broncopulmonar cr\u00f3nica.\n \n2)\nSmith\nSM,\nSchroeder\nK,\nFahey\nT.\nOver-the-counter\nmedications\nfor\nacute\ncough\nin\nchildren\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nadults in ambulatory settings. Cochrane Database Syst Rev. 2008;(1):CD001831.\n \n3)\nDuijvestijn\nYC,\nMourdi\nN,\nSmucny\nJ,\nPons\nG,\nChalumeau\nM.\nAcetylcysteine\nand\ncarbocysteine\nfor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nacute\nupper\nand\nlower\nrespiratory\ntract\ninfections\nin\npaediatric\npatients\nwithout\nchronic\n \n \n \n \n \n \n \n \n \n \n \n \nbroncho-pulmonary disease. Cochrane Database Syst Rev. 2009;(1):CD003124.\n \n4)\nCodeine and cough: an ineffective gold standard. Donald C. Bolser and Paul W. Davenport\n \n5)\nThe\neffect\nof\ncodeine\non\nthe\nUrge-to-Cough\nresponse\nto\ninhaled\ncapsaicin.\nDavenport\nPW1,\n \n \n \n \n \n \n \n \n \n \n \n \n \nBolser DC, Vickroy T, Berry RB, Martin AD, Hey JA, Danzig M.\n \n6)\nCodeine for acute cough in children. Goldman RD\n \n \n7)\nTo\ncompare\nthe\neffect\nof\ndextromethorphan,\npromethazine\nand\nplacebo\non\nnocturnal\ncough\nin\n \n \n \n \n \n \n \n \n \n \n \n \n \nchildren\naged\n1-12\ny\nwith\nupper\nrespiratory\ninfections:\na\nrandomized\ncontrolled\ntrial.\n \n \n \n \n \n \n \n \n \n \n \n \nBhattacharya M1, Joshi N, Yadav S.\n \n8)\nEficacia\ndel\nuso\nde\ndextrometorfano\npara\nel\ntratamiento\nde\nla\ntos\nen\npediatr\u00eda:\nRevisi\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsistem\u00e1tica.\nAna\nPaula\nEleno\nBeierbacha\n,\nMar\u00eda\nFlorencia\nLucanoa\n,\ny\nMar\u00eda\nde\nla\nPaz\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nJaureguizarb.\n \n \n9)\nPharmacological\nand\nclinical\noverview\nof\ncloperastine\nin\ntreatment\nof\ncough.\nMaria\nAntonietta\n \n \n \n \n \n \n \n \n \n \n \n \nCatania and Salvatore Cuzzocrea.\n \n \n10)\nAntihistam\u00ednicos\npara\nla\ntos\ninespec\u00edfica\nprolongada\nen\nni\u00f1os.\nAnne\nB\nChang,\nJane\nPeake,\n \n \n \n \n \n \n \n \n \n \n \n \n \nMargaret S McElrea. Revisi\u00f3n sistem\u00e1tica Cochrane.\n \n \n11)\nSmucny J, Becker L, Glazier R. Agonistas beta2 para la bronquitis aguda (Revisi\u00f3n Cochrane).\n \n \n12)\nLevodropropizine\nfor\ntreating\ncough\nin\nadult\nand\nchildren:\na\nmeta-analysis\nof\npublished\nstudies.\n \n \n \n \n \n \n \n \n \n \n \n \n \nAlessandro\nZanasi,\nLuigi\nLanata,\nGiovanni\nFontana,\nFederico\nSaibene,\nPeter\nDicpinigaitis,and\n \n \n \n \n \n \n \n \n \n \nFrancesco De Blasio\n \n13)\nEfficacy\nand\nTolerability\nof\nLevodropropizine\nand\nDropropizine\nin\nChildren\nwith\nNon-Productive\n \n \n \n \n \n \n \n \n \n \n \nCough. G.Banderali, E.Riva, A.Fiocchi\n \n14)\nInfant Deaths Associated with Cough and Cold Medications. FDA, 2005\n \n15)\nSmith\nSM,\nSchroeder\nK,\nFahey\nT.\nOver-the-counter\n(OTC)\nmedications\nfor\nacute\ncough\nin\nchildren\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nand\nadults\nin\ncommunity\nsettings.\nCochrane\nDatabase\nof\nSystematic\nReviews\n2014,\nIssue\n11.\nArt.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nNo.: CD001831.\n \n16)\nOduwole\nO,\nUdoh\nEE,\nOyo-Ita\nA,\nMeremikwu\nMM.\nHoney\nfor\nacute\ncough\nin\nchildren.\nCochrane\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDatabase of Systematic Reviews 2018, Issue 4. Art. No.: CD007094.\n \n17)\nEffect\nof\nhoney\non\nnocturnal\ncough\nand\nsleep\nquality:\na\ndouble-blind,\nrandomized,\n \n \n \n \n \n \n \n \n \n \n \n \nplacebo-controlled\nstudy.\nCohen\nHA1,\nRozen\nJ,\nKristal\nH,\nLaks\nY,\nBerkovitch\nM,\nUziel\nY,\nKozer\nE,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPomeranz A, Efrat H.\n \n18)\nSystematic\nReview\nof\nClinical\nTrials\nAssessing\nthe\nEffectiveness\nof\nIvy\nLeaf\n(Hedera\nHelix)\nfor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAcute Upper Respiratory Tract Infections. Felix Holzinger and Jean-Fran\u00e7ois Chenot.\n \n \n \n68\n \n Congesti\u00f3n nasal\n \n1)\nCorboz\nMR,\nMutter\nJC,\nRivelli\nMA,\net\nal.\nAlpha2-adrenoceptor\nagonists\nas\nnasal\ndecongestants.\n \n \n \n \n \n \n \n \n \n \n \n \n \nPulm Pharmacol Ther. 2007;20(2):149\u2013156.\n \n2)\nG\u00f3mez Ayala, A.M. Congesti\u00f3n nasal. Farmacia Profesional 2006;25(1):48-54\n \n3)\nCorey\nJP,\nHouser\nSM,\nNg\nBA.\nNasal\ncongestion:\na\nreview\nof\nits\netiology,\nevaluation,\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntreatment. Ear Nose Throat J. 2000;79(9):690\u2013698\n \n4)\nNaclerio,\nRobert\nM\net\nal.\n\u00abFisiopatolog\u00eda\nde\nla\ncongesti\u00f3n\nnasal\u00bb.\n\u200b\nRevista\ninternacional\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicina general\n\u200b\n vol. 3 47-57. 8 de abril de 2010\n \n5)\nBened\u00ed J, Romero C. Descongestivos nasales. Farmacia Profesional 2006;20(9):58-61\n \n6)\nDeckx\nL,\nDe\nSutter\nAIM,\nGuo\nL,\nMir\nNA,\nvan\nDriel\nML.\nNasal\ndecongestants\nin\nmonotherapy\nfor\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncommon cold. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD009612.\n \n7)\nConnell\nJ.T.,\nand\nLinzmayer\nM.I.:\nComparison\nof\nnasal\nairway\npatency\nchanges\nafter\ntreatment\n \n \n \n \n \n \n \n \n \n \n \n \n \nwith oxymetazoline and pseudoephedrine. Am J Rhinol 1987; 1: pp. 87-94\n \n8)\nMandell, Douglas y Bennett. Enfermedades infecciosas. Principios y pr\u00e1ctica, 58, 775-779\n \n9)\nGoldman-Cecil. Tratado de medicina interna, 361, 2185-2187\n \n10)\nG.\nMortuaire,\nL.\nde\nGabory,\nM.\nFran\u00e7ois,\nG.\nMass\u00e9,\nF.\nBloch,\nN.\nBrion,\nR.\nJankowski,\nE.\nSerrano.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nEffet\nrebond\net\nrhinite\naux\nvasoconstricteurs\nnasaux\nen\npratique\nclinique.\nRevue\ncritique\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlitt\u00e9rature\npar\nun\ngroupe\nd\u2019experts.\nAnnales\nfran\u00e7aises\nd'Oto-rhino-laryngologie\net\nde\nPathologie\n \n \n \n \n \n \n \n \n \n \n \nCervico-faciale, Vol 130, Issue 3, June 2013, pp. 140-143.\n \n11)\nDivins MJ. Descongestivos nasales t\u00f3picos. Farmacia Profesional. 2003;17(2):28-35\n \n12)\nDe\nSutter\nAIM,\nSaraswat\nA,\nvan\nDriel\nML.\nAntihistamines\nfor\nthe\ncommon\ncold.\nCochrane\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDatabase of Systematic Reviews 2015, Issue 11. Art. No.: CD009345.\n \n13)\nDe\nSutter\nAIM,\nvan\nDriel\nML,\nKumar\nAA,\nLesslar\nO,\nSkrt\nA.\nOral\n \n \n \n \n \n \n \n \n \n \n \n \n \nantihistamine-decongestant-analgesic\ncombinations\nfor\nthe\ncommon\ncold.\nCochrane\nDatabase\nof\n \n \n \n \n \n \n \n \n \nSystematic Reviews 2012, Issue 2. Art. No.: CD004976.\n \n14)\nRey\nD,\nMitchell\nB,\nWilliams\nCP,\nSpurling\nGKP.\nIrrigaci\u00f3n\nnasal\nsalina\npara\ninfecciones\nagudas\ndel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntracto\nrespiratorio\nsuperior.\nBase\nde\nDatos\nCochrane\nde\nRevisiones\nSistem\u00e1ticas\n2015,\nN\u00famero\n4.\n \n \n \n \n \n \n \n \n \n \n \n \n \nArt. No .: CD006821.\n \n15)\nChirico\nG,\nQuartarone\nG,\nMallefet\nP.\nNasal\ncongestion\nin\ninfants\nand\nchildren:\na\nliterature\nreview\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \non\nefficacy\nand\nsafety\nof\nnon-pharmacological\ntreatments.\nMinerva\nPediatr.\n2014\n \n \n \n \n \n \n \n \n \n \nDec;66(6):549-57\n \n16)\nBhattacharyya N. Clinical presentation, diagnosis, and treatment of nasal obstruction.\n \n17)\nLieberman P. Chronic nonallergic rhinitis.\n \n18)\nPynnonen\nMA,\nMukerji\nSS,\nKim\nHM,\nAdams\nME,\nTerrell\nJE.\nNasal\nSaline\nfor\nChronic\nSinonasal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSymptoms:\nA\nRandomized\nControlled\nTrial.\nArch\nOtolaryngol\nHead\nNeck\nSurg.\n \n \n \n \n \n \n \n \n \n \n2007;133(11):1115\u20131120.\n \n \n19)\nRuoling\nGuo,\nPeter\nH.\nCanter,\nEdzard\nErnst.\nHerbal\nmedicines\nfor\nthe\ntreatment\nof\nrhinosinusitis:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nA\nsystematic\nreview,\nOtolaryngology\n-\nHead\nand\nNeck\nSurgery,\nVolume\n135,\nIssue\n4,\n2006,\nPages\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n496-506\n \n20)\nhttps://www.ema.europa.eu/en/documents/herbal-summary/eucalyptus-leaf-summary-public_e\ns.pdf\n \n \n \n69\n \n Rinitis al\u00e9rgica\n \n1)\nFokkens\nW,\nLund\nV,\nMullol\nJ\non\nbehalf\nof\nthe\nEuropean\nPosition\nPaper\non\nRhinosinusitis\nand\nNasal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPolyp\nGroup.\nEuropean\nposition\npaper\non\nrhinosinusitis\nand\nnasal\npolyps.\nRhinology.\n2007;\nSuppl\n \n \n \n \n \n \n \n \n \n \n \n \n \n20: 1-136.\n \n2)\nV.\nBauchau,\nS.R.\nDurham.Prevalence\nand\nrate\nof\ndiagnosis\nof\nallergic\nrhinitis\nin\nEurope.\nEur\nRespir\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nJ, 24 (2004), pp. 758-764\n \n3)\nA.\nTogias.\nRhinitis\nand\nasthma;\nevidence\nfor\nrespiratory\nsystem\nintegration.J\nAllergy\nClin\n \n \n \n \n \n \n \n \n \n \n \n \nImmunol, 111 (2003), pp. 1171-1183\n \n4)\nGarde\nJM,\nGarc\u00eda\nAvil\u00e9s\nB,\nMarco\nN,\nMontahud\nC,\nPerona\nJ.\nRinoconjuntivitis\nal\u00e9rgica.\nProtoc\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndiagn ter pediatr. 2013;1:157-75.\n \n5)\nBousquet\nJ,\nKhaltaev\nN,\nCruz\nAA,\nDenburg\nJ,\nFokkens\nWJ,\nTogias\nA,\net\nal.\nAllergic\nRhinitis\nand\nits\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nImpact\non\nAsthma\n(ARIA)\n2008\nUpdate\n(in\ncollaboration\nwith\nthe\nWorld\nHealth\nOrganization,\n \n \n \n \n \n \n \n \n \n \n \n \n \nGA2LEN* and AllerGen**). Allergy. 2008; 63(s86): 8-160.\n \n6)\nSheikh A, Panesar SS, Dhami S. Seasonal allergic rhinitis. BMJ Clinical Evidence 2003.\n \n7)\nHan\nD,\nChen\nL,\nCheng\nL,\nLiu\nS,\nFu\nZ,\nZhang\nW,\nWang\nC,\nXi\nL,\nZhang\nL.\nA\nmulticenter\nrandomized\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndouble-blind\n2-week\ncomparison\nstudy\nof\nazelastine\nnasal\nspray\n0.1%\nversus\nlevocabastine\nnasal\n \n \n \n \n \n \n \n \n \n \n \n \nspray\n0.05%\nin\npatients\nwith\nmoderate-to-severe\nallergic\nrhinitis.\nOtorhinolaryngol\nRelat\nSpec.\n \n \n \n \n \n \n \n \n \n \n \n2011;73(5):260-5.\n \n8)\nCorren\nJ,\nStorms\nW,\nBernstein\nJ,\nBerger\nW,\nNayak\nA,\nSacks\nH,\nEffectiveness\nof\nazelastine\nnasal\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nspray\ncompared\nwith\noral\ncetirizine\nin\npatients\nwith\nseasonal\nallergic\nrhinitis.\nAzelastine\nCetirizine\n \n \n \n \n \n \n \n \n \n \n \n \n \nTrial No. 1 (ACT 1) Study Group..Clin Ther. 2005 May; 27(5):543-53..\n \n9)\nNasser\nM,\nFedorowicz\nZ,\nAljufairi\nH,\nMcKerrow\nW.\nAntihistam\u00ednicos\ncomo\ncomplemento\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \nesteroides\nnasales\nt\u00f3picos\npara\nla\nrinitis\nal\u00e9rgica\nintermitente\ny\npersistente\nen\nni\u00f1os.\nCochrane\n \n \n \n \n \n \n \n \n \n \n \n \n \nDatabase of Systematic Reviews 2010 Issue 7. Art. No.: CD006989.\n \n10)\nKetan\nSheth.\nEvaluaci\u00f3n\nde\nla\nseguridad\nde\nlos\nesteroides\nintranasales\nen\nel\ntratamiento\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrinitis al\u00e9rgica. Alergia Asma Clin Immunol . 2008; 4 (3): 125-129.\n \n11)\nSchenkel\nEJ\net\nal.\nAusencia\nde\nretraso\nen\nel\ncrecimiento\nen\nni\u00f1os\ncon\nrinitis\nal\u00e9rgica\nperenne\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndespu\u00e9s\nde\nun\na\u00f1o\nde\ntratamiento\ncon\nmometasona\nfuroato\nnasal\nacuoso\nen\nspray.\nPediatr\u00eda.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2000 febrero; 105 (2): E22.\n \n12)\nWeiner\nJM,\nAbramson\nMJ,\nPuy\nRM.\nIntranasal\ncorticosteroids\nversus\noral\nH1\nreceptor\nantagonists\n \n \n \n \n \n \n \n \n \n \n \n \n \nin allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998;317:1624-9.\n \n13)\nSeidman\nM,\nGurgel\nR,\nNnacheta\nL\ny\ncolaboradores.\nSeidman\nM,\nGurgel\nR,\nNnacheta\nL\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ncolaboradores. Otolaryngology-Head and Neck Surgery 152(1S):28-29, 2015.\n \n14)\nHead\nK,\nSnidvongs\nK,\nGlew\nS,\nScadding\nG,\nSchilder\nAGM,\nPhilpott\nC,\nHopkins\nC.\nSaline\nirrigation\nfor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nallergic rhinitis. Cochrane Database of Systematic Reviews 2018, Issue 6. Art. No.: CD012597.\n \n15)\nSheikh A, Panesar SS, Dhami S. Seasonal allergic rhinitis. BMJ Clinical Evidence 2007\n \n16)\nGlenis\nK\nScadding.Optimal\nmanagement\nof\nallergic\nrhinitis.\nArch\nDis\nChild.\n2015\nJun;\n100(6):\n \n \n \n \n \n \n \n \n \n \n \n \n \n576\u2013582.\n \n17)\nKarpova\nEP\net\nal.\nAbout\nthe\nsafety\nof\napplication\nof\nnasal\ndecongestants\nin\nthe\npractice\nof\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npediatricians. Vestn Otorinolaringol. 2018;83(2):46-50.\n \n18)\nCalderon\nMA,\nAlves\nB,\nJacobson\nM,\nHurwitz\nB,\nSheikh\nA,\nDurham\nS.\nLa\nBiblioteca\nCochrane\nPlus.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nThe Cochrane Library.\n \n \n \n70\n \n Conjuntivitis\n \n1)\nPeterson\nDW.\nOjo\nrojo.\nEn:\nTaylor\nRB,\neditor.\nMedicina\nde\nfamilia.\nPrincipios\ny\npr\u00e1ctica.\n6.\u00aa\ned.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nBarcelona: Elsevier; 2003. p. 635-9.\n \n2)\nFitch\nCP,\nRapoza\nPA,\nOwens\nS,\net\nal.\nEpidemiology\nand\ndiagnosis\nof\nacute\nconjunctivitis\nat\nan\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ninner-city hospital. Ophthalmology 1989; 96:1215.\n \n3)\nMartin Bun M, Carre\u00f1o Freire P, Saniger Herrera JM. Conjuntivitis. FMC 209;16(2):106-10.\n \n4)\nFriedlaender\nMH.\nA\nreview\nof\nthe\ncauses\nand\ntreatment\nof\nbacterial\nand\nallergic\nconjunctivitis.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nClin Ther 1995; 17:800.\n \n5)\nSheikh\nA,\nHurwitz\nB,\nvan\nSchayck\nC,\nMcLean\nS,\nNurmatov\nU.\nAntibi\u00f3ticos\nversus\nplacebo\npara\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconjuntivitis\nbacteriana\naguda.\nCochrane\nDatabase\nof\nSystematic\nReviews\n2012\nIssue\n9.\nArt.\nNo.:\n \n \n \n \n \n \n \n \n \n \n \n \n \nCD001211.\n \n6)\nJacobs DS. Conjunctivitis. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2018.\n \n7)\nPaduch\nR,\nWo\n\u017a\nniak\nA,\nNiedziela\nP,\nRejdak\nR.\nAssessment\nof\neyebright\n(euphrasia\nofficinalis\nL.)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nextract\nactivity\nin\nrelation\nto\nhuman\ncorneal\ncells\nusing\nin\nvitro\ntests.\n\u200b\nBalkan\nMed\nJ\n\u200b\n.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2014;31(1):29\u201336.\n \n \n \nBlefaritis\n \n1)\nAmerican Academy of Ophthalmology. Blepharitis: Preferred Practice Pattern. 2018\n \n2)\nLee\nC\n,\nChen\nH\n,\nLin\nH\n,\ny\notros\nLa\nblefaritis\ncomo\nun\nsigno\ntemprano\nde\ns\u00edndrome\nmetab\u00f3lico:\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nestudio\nbasado\nen\nla\npoblaci\u00f3n\na\nnivel\nnacional.\nBritish\nJournal\nof\nOphthalmology\n2018;\n102:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n1283-1287.\n \n3)\nLuo\nX,\nLi\nJ,\nChen\nC,\nTseng\nS,\nDemodicosis\nocular\nde\nLiang\nL.\ncomo\ncausa\npotencial\nde\ninflamaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nla\nsuperficie\nocular.\nC\u00f3rnea\n.\n2017;\n36\nSuppl\n1\n(Suppl\n1):\nS9\n\u2013\nS14.\nDoi:\n10.1097\n/\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nICO.0000000000001361\n \n4)\nLindsley\nK,\nMatsumura\nS,\nHatef\nE,\nAkpek\nEK.\nInterventions\nfor\nchronic\nblepharitis.\nCochrane\n \n \n \n \n \n \n \n \n \n \n \n \n \nDatabase\nof\nSystematic\nReviews\n2012,\nIssue\n5.\nArt.\nNo.:\nCD005556.\nDOI:\n \n \n \n \n \n \n \n \n \n \n \n10.1002/14651858.CD005556.pub2\n \n5)\nDuncan\nK,\nJeng\nBH.\nMedical\nmanagement\nof\nblepharitis.\nCurr\nOpin\nOphthalmol.\n2015\n \n \n \n \n \n \n \n \n \n \n \n \nJul;26(4):289-94. doi: 10.1097/ICU.0000000000000164. Review.\n \n6)\nGeerling\nG,\nTauber\nJ,\nBaudouin\nC,\net\nal.\nEl\ntaller\ninternacional\nsobre\nla\ndisfunci\u00f3n\nde\nla\ngl\u00e1ndula\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmeibomiana:\ninforme\ndel\nsubcomit\u00e9\nsobre\nel\nmanejo\ny\ntratamiento\nde\nla\ndisfunci\u00f3n\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ngl\u00e1ndula meibomiana. Invertir Oftalmol Vis Sci . 2011; 52 (4): 2050\u20132064.\n \n7)\nMaguire\nMG,\nAsbell\nPA,\nDREAM\nStudy\nResearch\nGroup.\nN-3\nFatty\nAcid\nSupplementation\nfor\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntreatment of Dry Eye Disease. N Engl J Med 2018;378:1681- 1690. DOI: 10.1056/NEJMoa1709691\n \n8)\nSantaella\nR,\nFraunfelder\nF.\nOcular\nAdverse\nEffects\nAssociated\nwith\nSystemic\nMedications.\nDrugs.\n \n \n \n \n \n \n \n \n \n \n \n \n2007;67(1):75-93.\n \n9)\nLam,\nN.,\nLong,\nX.,\nGriffin,\nR.,\nChen,\nM.,\n&\nDoery,\nJ.\n(2018).\nCan\nthe\ntea\ntree\noil\n(Australian\nnative\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nplant:\nMelaleuca\nalternifolia\nCheel)\nbe\nan\nalternative\ntreatment\nfor\nhuman\ndemodicosis\non\nskin?\n \n \n \n \n \n \n \n \n \n \n \n \n \nParasitology,145(12), 1510-1520. doi:10.1017/S0031182018000495\n \n10)\nTighe\nS,\nGao\nYY,\nTseng\nSC.\nTerpinen-4-ol\nes\nel\ningrediente\nm\u00e1s\nactivo\ndel\naceite\nde\n\u00e1rbol\nde\nt\u00e9\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npara matar a los \u00e1caros Demodex . Transl Vis Sci Technol. 2013; 2 (7): 2. doi: 10.1167 / tvst.2.7.2\n \n \n \n71\n \n Orzuelo\n \n1)\nParima\nHirunwiwatkul,\nKanitta\nWachirasereechai,\nMayuree\nKhantipong,\nAnan\nChongthaleong,\n \n \n \n \n \n \n \n \nIdentifications\nof\nhordeolum\npathogens\nand\nits\nsusceptibility\nto\nantimicrobial\nagents\nin\ntopical\n \n \n \n \n \n \n \n \n \n \n \n \nand oral medications, 2017.\n \n2)\nEstilita Esteva, Infecciones oculares, 2006.\n \n3)\nMerc\u00e8\nPiera\nFern\u00e1ndez,\nPeque\u00f1as\nafecciones\ny\nurgencias\noftalmol\u00f3gicas.\nActuaci\u00f3n\ninmediata\n,\n \n \n \n \n \n \n \n \n \n \n \n2001.\n \n4)\nKimberly P. Cockerham, MD, FACS, Christ Haggarty, Lids, 2006.\n \n5)\nKristina\nLindsley,\nJason\nJ\nNichols,\nKay\nDickersin,\nNon-surgical\ninterventions\nfor\nacute\ninternal\n \n \n \n \n \n \n \n \n \n \n \n \nhordeolum, 2017.\n \n6)\nPhillips Thygeson, Terramycin in Ocular Infections.\n \n \n \n72\n \n Ojo seco\n \n1)\nCraig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017.\n \n2)\nZhang\nX,\nZhao\nl,\nDeng\nS,\nSun\nX,\nWang\nN.\nDry\neye\nsyndrome\nin\npatients\nwith\ndiabetes\nmellitus:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprevalence, etiology, and clinical characteristics. J Ophthalmology. 2016;2016:1-7.\n \n3)\nKawashima\nM,\nUchino\nM,\nYokoi\nN\net\nal.\nThe\nassociation\nof\nsleep\nquality\nwith\ndry\neye\ndisease:\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nOsaka study. Clin Ophthalmol. 2016 10: 1015-1021.\n \n4)\nFacts\nabout\ndry\neye\n|\nNational\nEye\nInstitute\n[internet].\nnei.nih.gov.\n2017\n[cited\n9\nmarch\n2017].\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \navailable from: \n\u200b\nhttps://nei.nih.gov/health/dryeye/dryeye\n \n5)\nKantor\nA.Actualizaci\u00f3n\nen\nojo\nseco\npara\nel\nm\u00e9dico\nno\noftalm\u00f3logo.\nRev\nMed\nClin\nCondes\n2010;\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n21(6):883-890.\n \n6)Barbero Gonz\u00e1lez A. i-VALOR. 1st ed. Tecnolog\u00eda y ediciones del conocimiento; 2014.\n \n7)\nAslan\nBayhan\nS,\nBayhan\nH,\n\u00c7\u00f6lge\u00e7en\nE,\nG\u00fcrdal\nC.\nEffects\nof\ntopical\nacne\ntreatment\non\nthe\nocular\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsurface in patients with acne vulgaris. Contact Lens and Anterior Eye. 2016;39(6):431-434.\n \n8)\nMu\u00f1oz-Hern\u00e1ndez\nAM,\nGalbis-Estrada\nC,\nSantos-Bueso\nE,\net\nal.\nMetabol\u00f3mica\nde\nla\nl\u00e1grima.\nArch\n \n \n \n \n \n \n \n \n \n \n \n \n \nSoc Esp Oftalmol. 2016;91(4):157-159.\n \n9)\nBron\nAJ,\nde\nPaiva\nCS,\nChauhan\nSK,\net\nal.\nTFOS\nDEWS\nII\npathophysiology\nreport.\nOcul\nSurf.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2017;15(3):438-510.\n \n10)\nPucker\nAD,\nNg\nSM,\nNichols\nJJ.\nOver\nthe\ncounter\n(OTC)\nartificial\ntear\ndrops\nfor\ndry\neye\nsyndrome.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCochrane Database of Systematic Reviews 2016.\n \n11)\nDe\nSaint\nJean\nM.,\net\nal.\n\u201cEffects\nof\nbenzalkonium\nchloride\non\ngrowth\nand\nsurvival\nof\nChang\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconjunctival cells\u201d. Investigative Ophthalmology and Visual Science 3 (1999): 619-630.\n \n12)\nPan\nQ,\nAngelina\nA,\nMarrone\nM,\nStark\nWJ,\nAkpek\nEK.\nAutologous\nserum\neye\ndrops\nfor\ndry\neye.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCochrane Database of Systematic Reviews 2017\n \n13)\nErvin\nA,\nLaw\nA,\nPucker\nAD.\nPunctal\nocclusion\nfor\ndry\neye\nsyndrome.\nCochrane\nDatabase\nof\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSystematic Reviews 2017.\n \n14)\nDe\nSaint\nJean\nM.,\net\nal.\n\u201cEffects\nof\nbenzalkonium\nchloride\non\ngrowth\nand\nsurvival\nof\nChang\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nconjunctival cells\u201d. Investigative Ophthalmology and Visual Science 3 (1999): 619-630.\n \n15)\nThe\ndefinition\nand\nclassification\nof\ndry\neye\ndisease:\nreport\nof\nthe\nInternational\nDry\nEye\nWorkshop.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nOcul Surf. 2007;5:65\u2013204.\n \n16)\nMiljanovic\nB.,\nTrivedi\nK.A.,\nDana\nM.R.,\nGilbard\nJ.P.,\nBuring\nJ.E.,\nSchaumberg\nD.A.\nRelation\nbetween\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndietary\nn-3\nand\nn-6\nfatty\nacids\nand\nclinically\ndiagnosed\ndry\neye\nsyndrome\nin\nwomen.\nAm\nJ\nClin\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nNutr. 2005;82:887\u2013893.\n \n17)\nBrignole-Baudouin\nF,\nBaudouin\nC,\nAragona\nP,\net\nal.\nA\nmulticentre,\ndouble-masked,\nrandomized,\n \n \n \n \n \n \n \n \n \n \n \n \ncontrolled\ntrial\nassessing\nthe\neffect\nof\noral\nsupplementation\nof\nomega-3\nand\nomega-6\nfatty\nacids\n \n \n \n \n \n \n \n \n \n \n \n \n \n \non\na\nconjunctival\ninflammatory\nmarker\nin\ndry\neye\npatients.\nActa\nOphthalmol.\n \n \n \n \n \n \n \n \n \n \n \n2011;89(7):e591\u2013e597.\n \n18)\nMaguire\nMG,\nAsbell\nPA,\nDREAM\nStudy\nResearch\nGroup.\nN-3\nFatty\nAcid\nSupplementation\nfor\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntreatment of Dry Eye Disease. N Engl J Med 2018;378:1681- 1690.\n \n19)\nAlghamdi\nYA,\nCamp\nA,\nFeuer\nW,\nKarp\nCL,\nWellik\nS,\nGalor\nA.\nCompliance\nand\nSubjective\nPatient\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nResponses to Eyelid Hygiene. Eye Contact Lens. 2017;43(4):213-217.\n \n20)\nTanabe\nH.,\nKaido\nM,\nKawashima\nM,\nIshida\nR,\nAyaki\nM,\nTsubota\nK.\nEffect\nof\nEyelid\nHygiene\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDetergent on Obstructive Meibomian Gland Dysfunction.\n \n \n \n73\n \n Degeneraci\u00f3n macular asociada a la edad\n \n1)\nBjelakovic\nG,\nNikolova\nD,\nGluud\nLL,\nSimonetti\nRG,\nGluud\nC.\n,\nAntioxidant\nsupplements\nfor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprevention of mortality in healthy participants and patients with various diseases, 2012.\n \n2)\nThe\nAge-Related\nEye\nDisease\nStudy\n2\n(AREDS2)\nResearch\nGroup,\nLutein\n+\nZeaxanthin\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \nOmega-3\nFatty\nAcids\nfor\nAge-Related\nMacular\nDegeneration:\nThe\nAge-Related\nEye\nDisease\nStudy\n \n \n \n \n \n \n \n \n \n \n \n \n2 (AREDS2) Randomized Clinical Trial, 2013.\n \n3)\nEvans\nJR,\nLawrenson\nJG,\nAntioxidant\nvitamin\nand\nmineral\nsupplements\nfor\nslowing\nthe\n \n \n \n \n \n \n \n \n \n \n \n \nprogression of age-related macular degeneration.\n \n4)\nQian-Yu Zhang et al. Overweight, Obesity, and Risk of Age-Related Macular Degeneration, 2016.\n \n5)\nVavvas\nDG,\nSmall\nKW,\nAwh\nCC,\nZanke\nBW,\nTibshirani\nRJ,\nKustra\nR.,\nCFH\nand\nARMS2\ngenetic\nrisk\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndetermines\nprogression\nto\nneovascular\nage-related\nmacular\ndegeneration\nafter\nantioxidant\nand\n \n \n \n \n \n \n \n \n \n \nzinc supplementation., 2018.\n \n6)\nKorobelnik\nJF,\nRougier\nMB,\nDelyfer\nMN,\nBron\nA,\nMerle\nBMJ,\nSavel\nH,\nCh\u00eane\nG,,\nDelcourt\nC,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCreuzot-Garcher\nC.,\nEffect\nof\nDietary\nSupplementation\nWith\nLutein,Zeaxanthin,\nand\n\u03c9\n-3\non\n \n \n \n \n \n \n \n \n \n \n \nMacular Pigment: A Randomized Clinical Trial, 2017.\n \n7)\nManeli\nMozaffarieh,\nStefan\nSacu\nand\nAndreas\nWedrich,\nThe\nrole\nof\nthe\ncarotenoids,\nlutein\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nzeaxanthin,\nin\nprotecting\nagainst\nage-related\nmacular\ndegeneration:\nA\nreview\nbased\non\n \n \n \n \n \n \n \n \n \n \n \ncontroversial evidence, 2003.\n \n8)\nLe\nMa,\nHong-Liang\nDou,\nYi-Qun\nWu,\nYang-Mu\nHuang,\nYu-Bei\nHuang,\nXian-Rong\nXu,Zhi-Yong\nZou,\n \n \n \n \n \n \n \n \n \n \n \n \n \nXiao-Ming\nLin,\nLutein\nand\nzeaxanthin\nintake\nand\nthe\nrisk\nof\nage-related\nmacular\ndegeneration:\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsystematic review and meta-analysis, 2012.\n \n9)\nLawrenson\nJG,\nEvans\nJR.,\nOmega\n3\nfatty\nacids\nfor\npreventing\nor\nslowing\nthe\nprogression\nof\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nage-related macular degeneration, 2015.\n \n10)\nHodge\nWG,\nBarnes\nD,\nSchachter\nHM,\nPan\nYI,\nLowcock\nEC,\nZhang\nL,\nSampson\nM,\nMorrison\nA,Tran\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nK,\nMiguelez\nM,\nLewin\nG.,\nEvidence\nfor\nthe\neffect\nof\nomega-3\nfatty\nacids\non\nprogression\nof\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nage-related macular degeneration: a systematic review, 2007.\n \n11)\nAge-Related\nEye\nDisease\nStudy\nResearch\nGroup,\nA\nRandomized,\nPlacebo-Controlled,\nClinical\nTrial\n \n \n \n \n \n \n \n \n \n \n \nof\nHigh-Dose\nSupplementation\nWith\nVitamins\nC\nand\nE,\nBeta\nCarotene,\nand\nZinc\nfor\nAge-Related\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nMacular Degeneration and Vision Loss.\n \n12)\nMeng,\nYan,\nMB\net\nal.\nOmega-3\nand\nranibizumab\nfor\nage-related\nmacular\ndegeneration.\nA\n \n \n \n \n \n \n \n \n \n \n \n \n \nsystematic review protocol, 2019.\n \n13)\nSeddon\nJM,\nSilver\nRE,\nRosner\nB,\nResponse\nto\nAREDS\nsupplements\naccording\nto\ngenetic\nfactors:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsurvival analysis approach using the eye as the unit of analysis, 2016.\n \n14)\nAwh\nCC,\nHawken\nS,\nZanke\nBW,\nTreatment\nresponse\nto\nantioxidants\nand\nzinc\nbased\non\nCFH\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nARMS2 genetic risk allele number in the Age-Related Eye Disease Study, 2015.\n \n15)\nSchick,\nTina\nMD\net\nal.\nHistory\nof\nsunlight\nexposure\nis\na\nrisk\nfactor\nfor\nage-related\nmacular\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndegeneration, 2016.\n \n16)\nBuitendijk\nGHS\net\nal.\nPrediction\nof\nage-related\nmacular\ndegeneration\nin\nthe\ngeneral\npopulation:\n \n \n \n \n \n \n \n \n \n \n \n \n \nthe Three Continent AMD Consortium, 2014.\n \n17)\nSeddon,\nJohanna\nM.\net\nal.,\nRisk\nModels\nfor\nProgression\nto\nAdvanced\nAge-Related\nMacular\n \n \n \n \n \n \n \n \n \n \n \n \n \nDegeneration Using Demographic, Environmental, Genetic, and Ocular Factors, 2011.\n \n18)\nMyers,\nChelsea\nE.\net\nal.,\nCigarette\nSmoking\nand\nthe\nNatural\nHistory\nof\nAge-Related\nMacular\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDegeneration, 2014.\n \n \n \n74\n \n Acidez de est\u00f3mago\n \n1)\nP\u00e9rez\nRoncero,\nL.\n(2016).\nCurso\nb\u00e1sico\nsobre\npatolog\u00edas\ndigestivas,\npirosis.\nFarmacia\nprofesional,\n \n \n \n \n \n \n \n \n \n \n \n \nVol 30, n\u00fam 2 (p\u00e1ginas 5-16).\n \n \n2)\nHuerta-Iga,\nF;\nBielsa-Fern\u00e1ndez,\nV;\nremes-Troche,\nJ.M;\nValdovinos-D\u00edaz,\nM.A\ny\nTamayo\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \nCuesta,\nJ.L.\n(2015).Diagnosis\nand\ntreatment\nof\ngastroesophageal\nreflux\ndisease:\n \n \n \n \n \n \n \n \n \nrecommendations\nof\nthe\nAsociaci\u00f3n\nMexicana\nde\nGastroenterolog\u00eda.\nRevista\nde\n \n \n \n \n \n \n \n \n \ngastroenterolog\u00eda de M\u00e9xico. Vulume 81, Issue 2, Oct\u2013Dec 2016, Pages 208-222.\n \n \n3)\nAlcedo,\nJ;\nBalboa,\nA;\nCiriza,\nC;\nEstremera,\nF;\nGuarner-Argente,\nC;\nMas,\nP;\nMearin,\nF;\nM\u00ednguez,\nM;\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nMontoro,\nM;\nMurzi-Pulgar,\nM;\nRey,\nE\ny\nSerra,\nJ.\n(2019).\nDocumento\nde\nactualizaci\u00f3n\nde\nla\ngu\u00eda\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npr\u00e1ctica cl\u00ednica sobre la enfermedad por reflujo gastroesof\u00e1gico en el adulto.\n \n4)\nTroncoso\nMari\u00f1o,\nA\n(2012).\nEvidencia\ncient\u00edfica\nen\nque\nse\nbasan\nlos\nindicadores\nde\nprescripci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfarmac\u00e9utica\nen\nel\ninstituto\ncatal\u00e1n\nde\nsalud:\nAINE,\nanti\u00e1cidos\ny\nantidepresivos.\nBolet\u00edn\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \ninformaci\u00f3n terap\u00e9utica, vol 23, n\u00fam 3.\n \n5)\nVan\nPinxteren\nB,\nSigterman\nKE,\nBonis\nP,\nLau\nJ,\nNumans\nME.\nShort-term\ntreatment\nwith\nproton\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npump\ninhibitors,\nH2-receptor\nantagonists\nand\nprokinetics\nfor\ngastro-oesophageal\nreflux\n \n \n \n \n \n \n \n \n \ndisease-like\nsymptoms\nand\nendoscopy\nnegative\nreflux\ndisease.\nCochrane\nDatabase\nof\nSystematic\n \n \n \n \n \n \n \n \n \n \n \nReviews 2006, Issue 3. Art. No.: CD002095. DOI: 10.1002/14651858.CD002095.pub3.\n \n6)\nArin,\nA;\nIglesias,\nMR.\nEnfermedad\npor\nreflujo\ngastroesof\u00e1gico.\nAnales\nSis\nSan\nNavarra\n[online].\n \n \n \n \n \n \n \n \n \n \n \n \n \n2003, vol.26, n.2 [citado 2019-07-23], pp.251-268.\n \n \n \n \n75\n \n N\u00e1useas y v\u00f3mitos\n \n1)\nMontoro,\nM\nA;\nLera,\nI\ny\nDucons\nJ.\nN\u00e1usea\ny\nV\u00f3mitos.\nS\u00edntomas\ngastrointestinales\nfrecuentes.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nExtra\u00eddo\nde:\n \n \nhttps://www.aegastro.es/sites/default/files/archivos/ayudas-practicas/02_Nauseas_y_vomitos.p\ndf\n \n2)\nMEJIA\nSALAS,\nH.\nSales\nde\nRehidrataci\u00f3n\nOral:\nde\nosmolaridad\nreducida\ny\notras\nSales\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nRehidrataci\u00f3n.\nRev.\nbol.\nped.\n[online].\n2006,\nvol.45,\nn.3\n[citado\n2019-06-15],\npp.\n201-205.\n \n \n \n \n \n \n \n \n \n \n \n \nDisponible\n \nen:O<http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1024-06752006000300012&l\nng=es&nrm=iso>. ISSN 1024-0675.\n \n3)\nBenedetti,L\n(2015).\nAntiespasm\u00f3dicos,\nantiem\u00e9ticos\ny\nantidiarreicos,\n\u00bfpueden\nemplearse\nen\n \n \n \n \n \n \n \n \n \nni\u00f1os?\n \n4)\nFedorowicz,\nZ;\nJagannath,\nVA\ny\nCarter\nB.\nAntiemetics\nfor\nreducing\nvomiting\nrelated\nto\nacute\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ngastroenteritis\nin\nchildren\nand\nadolescents.\nCochrane\nDatabase\nof\nSystematic\nReviews\n2011,\nIssue\n \n \n \n \n \n \n \n \n \n \n \n \n9. Art. No.: CD005506.\n \n5)\nGomez-Arnau,\nJ.\nI.\ny\ngrupo\nde\ntrabajo\nde\nnvpo\nde\nla\nsociedad\nespanola\nde\nanestesiologia,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nreanimacion\ny\nterapeutica\ndel\ndolor\net\nal.\nRecomendaciones\nde\nprevenci\u00f3n\ny\ntratamiento\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nn\u00e1useas\ny\nv\u00f3mitos\npostoperatorios\no\nasociados\na\nlas\ninfusiones\nde\nopioides.\nRev.\nSoc.\nEsp.\nDolor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2011, vol.18, n.1, pp.24-42. ISSN 1134-8046.\n \n6)\nBorja,J\ny\nCapdevila,G\n(2003).\nEficacia\ncl\u00ednica\ny\nseguridad\ndel\ndimenhidrinato.\nFarmacia\n \n \n \n \n \n \n \n \n \n \n \nprofesional. Vol 17, N\u00fam 9 (pag 7-91).\n \n \n7)\nArias\nRico,\nJ;\nBermejo\nS\u00e1nchez,\nE;\nFern\u00e1ndez,\nP\ny\nMart\u00ednez\nFr\u00edas,\nM\nL.\n(2011)\nConsumption\nof\nH1\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nantihistamines\nduring\nthe\nfirst\ntrimester\nof\npregnancy\nin\nSpain,\nand\nestimation\nof\nthe\noverall\nrisk\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfor\ncongenital\ndefects\nin\nthe\nnewborn.\nRevista\nde\ndismorfolog\u00eda\ny\nepidemiolog\u00eda.\nSerie\nVI,\n \n \n \n \n \n \n \n \n \n \n \n \n \nn\u00famero 1\n \n8)\nGutierrez-Castrellon,\nP\net\nal.\nRevisi\u00f3n\nsistem\u00e1tica\nde\nla\nseguridad\ny\neficacia\nde\nla\ncombinaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndoxilamina\n+\npiridoxina\npara\nel\ntratamiento\nde\nla\nn\u00e1usea\ny\nel\nv\u00f3mito\ndurante\nel\nembarazo.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPerinatol. Reprod. Hum\n\u200b\n 2012, vol.26, n.4, pp.158-166.\n \n9)\nFerrer\nMarquez,\nF\ny\nCarvajal\nC,\nJ\nA.\nComparaci\u00f3n\nentre\nOndansetr\u00f3n\ny\nDoxilamina\nm\u00e1s\nPiridoxina\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npara\nel\ntratamiento\nde\nlas\nn\u00e1useas\nen\nel\nembarazo.\nOliveira\nLG,\nCapp\nSM,\nYou\nWB,\nRiffenburgh\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nRH, Carstairs SD.\n\u200b\n Rev. chil. obstet. Ginecol \n\u200b\n2015, vol.80, n.2, pp.191-193.\n \n \n10)\nMolina\nGiraldo,\nS;\nV\u00e1squez\nAwad,\nD;\nBenavides\nSerralde\n,J\nA;\nAramendiz,\nJ\nM,\nV\u00e1squez\nZapata,\nG\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nA y Buitrago Lea, M (2016) .Manejo de las n\u00e1useas y v\u00f3mitos en el embarazo.\n \n \n11)\nFuryk,\nJS;\nMeek,\nRA\ny\nEgerton-Warburton,\nD.\nDrugs\nfor\nthe\ntreatment\nof\nnausea\nand\nvomiting\nin\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nadults\nin\nthe\nemergency\ndepartment\nsetting.\nCochrane\nDatabase\nof\nSystematic\nReviews\n2015,\n \n \n \n \n \n \n \n \n \n \n \n \nIssue 9. Art. No.: CD010106\n \n12)\nMatthews\nA,\nHaas\nDM,\nO'Math\u00fana\nDP,\nDowswell\nT,\nDoyle\nM.\nIntervenciones\npara\nlas\nn\u00e1useas\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nv\u00f3mitos\nen\nel\nembarazo\ntemprano.\nBase\nde\nDatos\nCochrane\nde\nRevisiones\nSistem\u00e1ticas\n2014,\n \n \n \n \n \n \n \n \n \n \n \n \n \nN\u00famero 3. Art. No .: CD007575.\n \n13)\nG.\nDante,\nG.\nPedrielli,\nE.\nAnnessi\n&\nF.\nFacchinetti\n(2013)\nHerb\nremedies\nduring\npregnancy:\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsystematic\nreview\nof\ncontrolled\nclinical\ntrials,\nThe\nJournal\nof\nMaternal-Fetal\n&\nNeonatal\nMedicine,\n \n \n \n \n \n \n \n \n \n \n \n \n \n26:3, 306-312\n \n \n \n76\n \n Diarrea aguda\n \n1)\nRuiz Rodr\u00edguez, A. (2003) Manual de farmacia pr\u00e1ctica, cap\u00edtulo 30, 543- 545\n \n2)\nCielo,\nA\n(2001).\nManagement\nof\nacute\ndiarrheic\nsyndrome\nin\nadults.\nRevista\nchilena\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \ninfectolog\u00eda, 18 (2). DOI: 10.4067/S0716-10182001000200005\n \n \n3)\nD\u00edaz\nMart\u00edn,\nJ.J\ny\nNavas\nL\u00f3pez,\nV.M\n(2015).\nEmpleo\nde\nprobi\u00f3ticos\nen\nprocesos\ndiarreicos.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nContiuum, el portal de formaci\u00f3n de la AE.\n \n \n4)\nRemes\nTroche,\nJ.M,\nSagols\nM\u00e9ndez\nG.A\ny\nTrujenque\nFranco,\nM.A\n(2010).\nClinical\nguidelines\nfor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndiagnosis\nand\ntreatment\nof\nchronic\ndiarrhea.\nApproach\nof\nthe\npatient\nwith\nchronic\ndiarrhea\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nspecial situations. Revista de gastroenterolog\u00eda de M\u00e9xico, 75(2), 133-246.\n \n5)\nGoldenberg\nJZ,\nYap\nC,\nLytvyn\nL,\nLo\nCKF,\nBeardsley\nJ,\nMertz\nD,\nJohnston\nBC.\nProbiotics\nfor\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprevention\nof\nClostridium\ndifficile-associated\ndiarrhea\nin\nadults\nand\nchildren.\nCochrane\nDatabase\n \n \n \n \n \n \n \n \n \n \n \nof\nSystematic\nReviews\n2017,\nIssue\n12.\nArt.\nNo.:\nCD006095.\nDOI:\n \n \n \n \n \n \n \n \n \n \n10.1002/14651858.CD006095.pub4.\n \n6)\nSu\u00e1rez\nCortina\nL,\nCano\nGuti\u00e9rrez\nB.\nCurrent\nmanagement\nof\nacute\ngastroenteritis\n(AGE)\nwith\noral\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nrehydration solutions.\n \n \n7)\nPosada\nBustos,\nS;\nVera\nChamorro,\nJF.\nProbi\u00f3ticos\nen\ndiarrea\naguda,\nasociada\na\nantibi\u00f3ticos\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnosocomial:\nevidencia\nen\npediatr\u00eda.\nRevista\nColombiana\ndeGastroenterolog\u00eda,\n[S.l.],\nv.\n33,\nn.\n1,\np.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n41 - 48, apr. 2018. ISSN 2500-7440.\n \n8)\nGuo\nQ,\nGoldenberg\nJZ,\nHumphrey\nC,\nEl\nDib\nR,\nJohnston\nBC.\nProbiotics\nfor\nthe\nprevention\nof\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npediatric\nantibiotic-associated\ndiarrhea.\nCochrane\nDatabase\nof\nSystematic\nReviews\n2019,\nIssue\n4.\n \n \n \n \n \n \n \n \n \n \n \nArt. No.: CD004827. DOI: 10.1002/14651858.CD004827.pub5\n \n9)\nDe\nBruyn\nG,\nHahn\nS,\nBorwick\nA.\nAntibiotic\ntreatment\nfor\ntravellers'\ndiarrhoea.\nCochrane\nDatabase\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nof Systematic Reviews 2000, Issue 3. Art. No.: CD002242. DOI: 10.1002/14651858.CD002242\n \n10)\nRiddle\nMS,\nConnor\nBA,\nBeeching\nNJ,\nDuPont\nHL,\nHamer\nDH,\nKozarsky\nP,\nLibman\nM,\nSteffen\nR,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTaylor\nD,\nTribble\nDR,\nVila\nJ,\nZanger\nP,\nEricsson\nCD.\nGuidelines\nfor\nthe\nprevention\nand\ntreatment\nof\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntravelers'\ndiarrhea:\na\ngraded\nexpert\npanel\nreport.\nJ\nTravel\nMed.\n24(suppl_1):S57-S74.\ndoi:\n \n \n \n \n \n \n \n \n \n \n \n \n10.1093/jtm/tax026.\nEpub\n2017\nApr\n29.\nPubMed\nPMID:\n28521004;\nPubMed\nCentral\nPMCID:\n \n \n \n \n \n \n \n \n \n \n \nPMC5731448.\n \n11)\nWHO/UNICEF\nJoint\nStatement:\nClinical\nManagement\nof\nAcute\nDiarrhea.\nThe\nUnited\nNations\n \n \n \n \n \n \n \n \n \n \n \nChildren\u2019s Fund/World Health Organization, 2004. WHO/FCH/CAH/04.7.\n \n \n \n77\n \n Estre\u00f1imiento\n \n1)\nOrtega\nP\u00e1ez\nE.\n(2015).\nEstre\u00f1imiento\nfuncional\nen\nel\nni\u00f1o\n(2015).\nGu\u00eda\nde\nAlgoritmos\nen\nPediatr\u00eda\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde Atenci\u00f3n Primaria.\n \n2)\nM\u00ednguez\nP\u00e9rez,\nM;\nGarrigues\nGil,V;\nMas\nMercader,\nP\ny\nMora\nMiguel,\nF.\n(2013).\nGu\u00eda\npr\u00e1ctica\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nactuaci\u00f3n diagn\u00f3stico-terap\u00e9utica en estre\u00f1imiento cr\u00f3nico.\n \n3)\nRemes\nTroche\nJ.M,\nCh\u00e1vez\nBarrera\nJ.A,\nGonz\u00e1lez\nOrt\u00edz\nB,\nHeller\nRouassant\nS,\nMontijo\nBarrios\nE,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nVelasco\nLav\u00edn\nM.R,\nWorona\nDibner\nL.B\n(2011).\nGuidelines\nfor\ndiagnosis\nand\ntreatment\nof\n \n \n \n \n \n \n \n \n \n \n \n \n \nconstipation\nin\nMexico.\nEvaluation\nand\ntreatment\nof\nconstipation\nin\npediatric\npopulation.\nRevista\n \n \n \n \n \n \n \n \n \n \n \n \nde gastroenterolog\u00eda de M\u00e9xico. Vol 76, N 2, pag 79-189.\n \n \n4)\nCarbajo\nFerreira,\nA.J\n(2018).\nEstre\u00f1imiento,\ngastroenterolog\u00eda\npedi\u00e1trica.\nGrupo\nde\n \n \n \n \n \n \n \n \n \ngastroenterolog\u00eda y nutrici\u00f3n de la AEPap.\n \n \n5)\nLee-Robichaud\nH,\nThomas\nK,\nMorgan\nJ,\nNelson\nRL.\nLactulose\nversus\nPolyethylene\nGlycol\nfor\n \n \n \n \n \n \n \n \n \n \n \n \n \nChronic\nConstipation.\nCochrane\nDatabase\nof\nSystematic\nReviews\n2010,\nIssue\n7.\nArt.\nNo.:\n \n \n \n \n \n \n \n \n \n \n \n \nCD007570.\n \n6)\nCarretero\nRib\u00f3n,\nC.\nTratamiento\nfarmacol\u00f3gico\ndel\nestre\u00f1imiento.\nFundaci\u00f3n\nespa\u00f1ola\ndel\n \n \n \n \n \n \n \n \n \n \naparato digestivo.\n \n7)\nAguilera\nPe\u00f1a,\nF;\nCarri\u00f3n\nMu\u00f1oz,\nF;\nFlorez\nAlmonacid,\nC.I;\nGalv\u00e1n\nLedesma,\nJ;\nRold\u00e1n\nCano,\nB;\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nRomero\nBravo,\nA;\nRubio\nMellado,\nA.\n(2010).\nAdministraci\u00f3n\nde\nenemas.\nManual\nde\nprotocolos\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprocedimientos generales de enfermer\u00eda.\n \n \n8)\nMascar\u00f3 J y Formiga F. Valoraci\u00f3n y tratamiento del estre\u00f1imiento en el anciano.\n \n \n9)\nEuropean Food Safety Autority: Safety of hidroxanthracene derivatives for use in food.\n \n \nInsuficiencia venosa: varices y hemorroides\n \n1)\nLozano\nF,\nJim\u00e9nez-Coss\u00edo\nJ,\nUlloa\nJ.,\nRelief\nG.\nLa\ninsuficiencia\nvenosa\ncr\u00f3nica\nen\nEspa\u00f1a.\nEstudio\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nepidemiol\u00f3gico RELIEF. Angiolog\u00eda. 2001;53(1):5-16.\n \n2)\nAzcona L. Insuficiencia venosa: prevenci\u00f3n y tratamiento. Farm Profesional. 2008; 22(10):36-40.\n \n3)\nDePopas\nE,\nBrown\nM.\nVaricose\nVeins\nand\nLower\nExtremity\nVenous\nInsufficiency.\nSemin\nIntervent\n \n \n \n \n \n \n \n \n \n \n \n \n \nRadiol. 2018;35:56-61.\n \n4)\nFan\nC-M.\nEpidemiology\nand\npathophysiology\nof\nvaricose\nveins.\nTech\nVasc\nInterv\nRadiol.\n2003;\n \n \n \n \n \n \n \n \n \n \n \n \n \n6(3): 108-110.\n \n5)\nFr\u00edas\nVargas\nM\net\nal.\nDocumento\nde\nconsenso\nde\nla\nSociedad\nEspa\u00f1ola\nde\nM\u00e9dicos\nde\nAtenci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPrimaria\ny\nCap\u00edtulo\nEspa\u00f1ol\nde\nFlebolog\u00eda\ny\nLinfolog\u00eda\nde\nla\nSociedad\nEspa\u00f1ola\nde\nAngiolog\u00eda\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCirug\u00eda\nVascular:\ntrombosis\nvenosa\nsuperficial\nde\nmiembros\ninferiores\nen\nAtenci\u00f3n\nPrimaria.\n \n \n \n \n \n \n \n \n \n \n \nMedicina de Familia SEMERGEN. 2018;45(3):187-196.\n \n6)\nBrenes Artavia M. Tromboflebitis Superficial. Revista M\u00e9dica Sinergia. 2019;4(3):50-57.\n \n7)\nBozkurt,\nK\net\nal.\nInsuficiencia\nvenosa\ncr\u00f3nica:\nmanejo\ny\ntratamiento.\nEMH\nDermatol.\n2017;\n \n \n \n \n \n \n \n \n \n \n \n \n \n5[Suppl 3]: 2-14.\n \n8)\nNicolaides,\nA\net\nal.\nManagement\nof\nchronic\nvenous\ndisorders\nof\nthe\nlower\nlimbs.\nGuidelines\n \n \n \n \n \n \n \n \n \n \n \n \n \n \naccording to scientific evidence. Int Angiol. 2014;33(2):87-208.\n \n9)\nShingler\nS,\nRobertson\nL,\nBoghossian\nS,\nStewart\nM.\nCompression\nstockings\nfor\nthe\ninitial\ntreatment\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nof\nvaricose\nveins\nin\npatients\nwithout\nvenous\nulceration.\nCochrane\nDatabase\nof\nSystematic\n \n \n \n \n \n \n \n \n \n \n \n \nReviews. 2013; Issue 12. Art. No.: CD008819.\n \n78\n \n 10)\nO'Meara\nS,\nCullum\nN,\nNelson\nE,\nDumville\nJ.\nCompression\nfor\nvenous\nleg\nulcers.\nCochrane\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDatabase of Systematic Reviews. 2012; Issue 11. Art. No.: CD000265.\n \n11)\nKakkos\nS\net\nal.\nAcute\nEffects\nof\nGraduated\nElastic\nCompression\nStockings\nin\nPatients\nwith\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nSymptomatic\nVaricose\nVeins:\nA\nRandomised\nDouble\nBlind\nPlacebo\nControlled\nTrial.\nEuropean\n \n \n \n \n \n \n \n \n \n \n \nJournal of Vascular and Endovascular Surgery. 2018;55(1):118-125.\n \n12)\nKhetarpal A, Sydnor M. Varicose Veins. IR Playbook. 2018;177-184.\n \n13)\nDi\nNisio\nM,\nWichers\nIM,\nMiddeldorp\nS.\nTreatment\nfor\nsuperficial\nthrombophlebitis\nof\nthe\nleg\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(Review). Cochrane Database of Systematic Reviews. 2018; Issue 2. Art. No.: CD004982.\n \n14)\nScovell S. Phlebitis and thrombosis of the superficial lower extremity veins.\n \n15)\nDi\nNisio\nM,\nPeinemann\nF,\nPorreca\nE,\nRutjes\nA.\nTreatment\nfor\nsuperficial\ninfusion\nthrombophlebitis\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nof\nthe\nupper\nextremity.\nCochrane\nDatabase\nof\nSystematic\nReviews.\n2015;\nIssue\n11.\nArt.\nNo.:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCD011015.\n \n16)\nCarrasco\nCarrasco\nE,\nD\u00edaz\nS\u00e1nchez\nS.\nRecomendaciones\npara\nel\nmanejo\nde\nla\nEnfermedad\nVenosa\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCr\u00f3nica en Atenci\u00f3n Primaria. 2015.\n \n17)\nIto\nT\net\nal.\nThe\nwound/burn\nguidelines.\nGuidelines\nfor\nthe\nmanagement\nof\nlower\nleg\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nulcers/varicose veins. The Journal of Dermatology. 2016;43(8):853-868.\n \n18)\nPittler\nMH,\nErnst\nE.\nHorse\nchestnut\nseed\nextract\nfor\nchronic\nvenous\ninsufficiency\n(Review).\n \n \n \n \n \n \n \n \n \n \n \n \n \nCochrane Database of Systematic Reviews. 2012; Issue 11. Art. No.: CD003230.\n \n19)\nManagement\nof\nchronic\nvenous\ndisorders\nof\nthe\nlower\nlimbs-guidelines\naccording\nto\nscientific\n \n \n \n \n \n \n \n \n \n \n \n \nevidence.\nDocument\ndeveloped\nunder\nthe\nauspices\nof\nThe\nEuropean\nVenous\nForum,\nThe\n \n \n \n \n \n \n \n \n \n \n \n \nInternational\nUnion\nof\nAngiology,\nThe\nCardiovascularm\nDisease\nEducational\nand\nResearch\nTrust\n \n \n \n \n \n \n \n \n \n \n \n(UK), Union Internationale de Phlebologie. Int Angiol. 2014;33:87-208.\n \n20)\nMiquel\nAbbad\nC,\nRial\nHorcajo\nR,\nBallesteros\nOrtega\nM,\nGarc\u00eda\nMadrid\nC.\nGu\u00eda\nde\npr\u00e1ctica\ncl\u00ednica\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nenfermedad\nvenosa\ncr\u00f3nica\ndel\nCap\u00edtulo\nde\nFlebolog\u00eda\ny\nLinfolog\u00eda\nde\nla\nSociedad\nEspa\u00f1ola\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAngiolog\u00eda y Cirug\u00eda Vascular. Angiolog\u00eda. 2015;68(1):55-62.\n \n21)\nMartinez-Zapata\nMJ\net\nal.\nPhlebotonics\nfor\nvenous\ninsufficiency.\nCochrane\nDatabase\nof\n \n \n \n \n \n \n \n \n \n \n \nSystematic Reviews 2016, Issue 4. Art. No.: CD003229.\n \n22)\nPerera\nN,\nLiolitsa\nD,\nIype\nS,\nCroxford\nA,\nYassin\nM,\nLang\nP,\nUkaegbu\nO,\nvan\nIssum\nC.\nPhlebotonics\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfor haemorrhoids. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD004322.\n \n23)\nGralnek\nIM,\nRon-Tal\nFisher\nO,\nHolub\nJL,\nEisen\nGM.\nThe\nrole\nof\ncolonoscopy\nin\nevaluating\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nhematochezia:\na\npopulationbased\nstudy\nin\na\nlarge\nconsortium\nof\nendoscopy\npractices.\n \n \n \n \n \n \n \n \n \n \n \nGastrointest Endosc. 2013;77:410-418.\n \n24)\nTrompetto\nM,\nClerico\nG,\nCocorullo\nG,\nGiordano\nP,\nMarino\nF,\nMartellucci\nJ\net\nal.\nEvaluation\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmanagement\nof\nhemorrhoids:\nItalian\nsociety\nof\ncolorectal\nsurgery\n(SICCR)\nconsensus\nstatement.\n \n \n \n \n \n \n \n \n \n \n \nTechniques in Coloproctology. 2015;19(10):567-575.\n \n25)\nAlonso-Coello\nP,\nMills\nE,\nHeels-Ansdell\nD,\nLopez-Yarto\nM,\nZhou\nQ,\nJohanson\nJ\net\nal.\nFiber\nfor\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTreatment\nof\nHemorrhoids\nComplications:\nA\nSystematic\nReview\nand\nMeta-Analysis.\nThe\nAmerican\n \n \n \n \n \n \n \n \n \n \n \nJournal of Gastroenterology. 2006;101(1):181-188.\n \n26)\nHiguero\nT,\nAbramowitz\nL,\nCastinel\nA,\nFathallah\nN,\nHemery\nP,\nLaclotte\nDuhoux\nC\net\nal.\nGuidelines\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfor the treatment of hemorrhoids (short report). Journal of Visceral Surgery. 2016;153,213-218.\n \n27)\nQuijano\nCE,\nAbalos\nE.\nConservative\nmanagement\nof\nsymptomatic\nand/or\ncomplicated\n \n \n \n \n \n \n \n \n \n \nhaemorrhoids\nin\npregnancy\nand\nthe\npuerperium.\nCochrane\nDatabase\nof\nSystematic\nReviews.\n \n \n \n \n \n \n \n \n \n \n \n2005. Issue 3. Art. No.: CD004077.\n \n \n \n79\n \n Insomnio\n \n1)\nL\u00f3pez\nde\nCastro,F,\nFern\u00e1ndez\nRodr\u00edguez,\nO,\nMareque\nOrtega,\nMA,\nFern\u00e1ndez\nAg\u00fcero,L.\nAbordaje\n \n \n \n \n \n \n \n \n \n \n \n \nterap\u00e9utico\ndel\ninsomnio,\nSEMERGEN\n-\nMedicina\nde\nFamilia,\nVolume\n38,\nIssue\n4\n2012,\nPages\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n233-240\n \n2)\nGrupo\nde\nTrabajo\nde\nla\nGu\u00eda\nde\nPr\u00e1ctica\nCl\u00ednica\npara\nel\nManejo\nde\nPacientes\ncon\nInsomnio\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAtenci\u00f3n\nPrimariaPlan\nde\nCalidad\npara\nel\nSistema\nNacional\nde\nSalud\ndel\nMinisterio\nde\nSanidad\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPol\u00edtica\nSocial.\nUnidad\nde\nEvaluaci\u00f3n\nde\nTecnolog\u00edas\nSanitarias.\nAgencia\nLa\u00edn\nEntralgo.\nComunidad\n \n \n \n \n \n \n \n \n \n \n \n \nde Madrid; 2009. Gu\u00edas de Pr\u00e1ctica Cl\u00ednica en el SNS: UETS N\u00ba 2007/5-1.\n \n3)\nTer\u00e1n\nSantos,\nJ;\nRomero\nSanto-Tom\u00e1s,\nO;\nP\u00e9rez\nD\u00edaz,\nH;\nMart\u00edn\n\u00c1gueda,\nB;\nCa\u00f1ellas\nDols,\nF;\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAlonso\n\u00c1lvarez,\nML;\n\u00c1lamo\nGonz\u00e1lez,\nC.\nPautas\nde\nActuacion\ny\nSeguimiento.\nInsomnio\n \n \n \n \n \n \n \n \n \n \n \n \nInternational Marketing & Communication, S.A. (IM&C) ISBN: 978-84-7867-352-0\n \n4)\nGuia\neuropea:\nRiemann,\nD.\n,\nBaglioni,\nC.\n,\nBassetti,\nC.\n,\nBjorvatn,\nB.\n,\nDolenc\nGroselj,\nL.\n,\nEllis,\nJ.\nG.,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nEspie,\nC.\nA.,\nGarcia-Borreguero,\nD.\n,\nGjerstad,\nM.\n,\nGon\u00e7alves,\nM.\n,\nHertenstein,\nE.\n,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nJansson-Fr\u00f6jmark,\nM.\n,\nJennum,\nP.\nJ.,\nLeger,\nD.\n,\nNissen,\nC.\n,\nParrino,\nL.\n,\nPaunio,\nT.\n,\nPevernagie,\nD.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n,\nVerbraecken,\nJ.\n,\nWee\u00df,\nH.\n,\nWichniak,\nA.\n,\nZavalko,\nI.\n,\nArnardottir,\nE.\nS.,\nDeleanu,\nO.\n,\nStrazisar,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nB.\n,\nZoetmulder,\nM.\nand\nSpiegelhalder,\nK.\n(2017),\nEuropean\nguideline\nfor\nthe\ndiagnosis\nand\n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntreatment of insomnia. J Sleep Res, 26: 675-700.\n \n5)\nGuia\namericana\nconducta:\nSchutte-Rodin\nS,\nBroch\nL,\nBuysse\nD\net\nal.\nClinical\nguideline\nfor\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nevaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008; 4:487-504\n \n6)\nMedina-Ch\u00e1vez,\nJuan\nHumberto,\nFuentes-Alexandro,\nSalvador\nAmadeo,\nGil-Palafox,\nIrwin\n \n \n \n \n \n \n \n \nBernardo,\nAdame-Galv\u00e1n,\nLorena,\nSol\u00eds-Lam,\nFernando,\nS\u00e1nchez-Herrera,\nLuc\u00eda\nYveth,\n \n \n \n \n \n \n \n \nS\u00e1nchez-Narv\u00e1ez,\nFrancisco,\nGu\u00eda\nde\npr\u00e1ctica\ncl\u00ednica.\nDiagn\u00f3stico\ny\ntratamiento\ndel\ninsomnio\nen\n \n \n \n \n \n \n \n \n \n \n \n \nel\nadulto\nmayor.\nRevista\nM\u00e9dica\ndel\nInstituto\nMexicano\ndel\nSeguro\nSocial\n[en\nlinea]\n2014,\n52\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n[Fecha\nde\nconsulta:\n21\nde\njunio\nde\n2019]\nDisponible\n \n \n \n \n \n \n \n \n \nen:<http://www.redalyc.org/articulo.oa?id=457745480022> ISSN 0443-5117\n \n \n7)\nHerxheimer\nA,\nPetrie\nKJ.\nMelatonin\nfor\nthe\nprevention\nand\ntreatment\nof\njet\nlag.\nCochrane\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nDatabase of Systematic Reviews 2002, Issue 2. Art. No.: CD001520\n \n8)\nGuia\nAmericana\nfarmacos:\nSateia\nMJ,\nBuysse\nDJ,\nKrystal\nAD,\nNeubauer\nDN,\nHeald\nJL.\nClinical\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npractice\nguideline\nfor\nthe\npharmacologic\ntreatment\nof\nchronic\ninsomnia\nin\nadults:\nan\nAmerican\n \n \n \n \n \n \n \n \n \n \n \n \n \nAcademy of Sleep Medicine clinical practice guideline. \n\u200b\nJ Clin Sleep Med.\n\u200b\n 2017;13(2):307\u2013349.\n \n9)\nFerracioli-Oda,\nEduardo\net\nal.\n\u201cMeta-analysis:\nmelatonin\nfor\nthe\ntreatment\nof\nprimary\nsleep\n \n \n \n \n \n \n \n \n \n \n \n \ndisorders.\u201d \n\u200b\nPloS one\n\u200b\n vol. 8,5 e63773. 17 May. 2013, doi:10.1371/journal.pone.0063773\n \n10)\nCulpepper,\nLarry,\nand\nMark\nA\nWingertzahn.\n\u201cOver-the-Counter\nAgents\nfor\nthe\nTreatment\nof\n \n \n \n \n \n \n \n \n \n \n \n \nOccasional\nDisturbed\nSleep\nor\nTransient\nInsomnia:\nA\nSystematic\nReview\nof\nEfficacy\nand\nSafety.\u201d\n \n \n \n \n \n \n \n \n \n \n \n \n \nThe primary care companion for CNS disorders\n\u200b\nvol. 17,6 10.4088/PCC.15r01798. 31 Dec. 2015.\n \n \n \n80\n \n Cefalea\n \n1)\nGu\u00eda oficial de pr\u00e1ctica cl\u00ednica en cefaleas. Sociedad Espa\u00f1ola de Neurolog\u00eda. 2015\n \n2)\nCurso\nb\u00e1sico\nsobre\ndolor.\nTema\n2.\nCefaleas\nGoiuri\nUribe\nBengoa\na\nIrantzu\nGandarias\nZ\u00e1rraga\na\na.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nFarmac\u00e9uticas\ncomunitarias\nen\nLasarte-Oria.\nMiembros\ndel\ngrupo\nde\ntrabajo\nGaur\ndel\nCOFBi.\nRev.\n \n \n \n \n \n \n \n \n \n \n \n \n \nFarmacia Profesional Vol. 29 Num. 2P\u00e1ginas 36-46. 2015\n \n3)\nVicente-Herreroa,\nTerradillos\nGarc\u00eda.\nEl\ncoste\nde\nla\nincapacidad\ntemporal\npor\ncefaleas\nen\nEspa\u00f1a.\n \n \n \n \n \n \n \n \n \n \n \n \n \nNeurolog\u00eda Argentina. Volume 6, Issue 4, Oct\u2013Dec 2014, pp. 199-206.\n \n4)\nCurso\nb\u00e1sico\nsobre\ndolor.\nTema\n2.\nCefaleas\nGoiuri\nUribe\nBengoa\na\nIrantzu\nGandarias\nZ\u00e1rraga\na\na.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nFarmac\u00e9uticas\ncomunitarias\nen\nLasarte-Oria.\nMiembros\ndel\ngrupo\nde\ntrabajo\nGaur\ndel\nCOFBi.\nRev.\n \n \n \n \n \n \n \n \n \n \n \n \n \nFarmacia Profesional Vol. 29 Num. 2P\u00e1ginas 36-46. 2015.\n \n5)\nCefaleas y migra\u00f1as. BTA. A\u00f1o 2017; 32(3)\n \n6)\nBanco\nde\nPreguntas\nPreevid.\nTratamiento\nfarmacol\u00f3gico\nm\u00e1s\neficaz\npara\nla\nprevenci\u00f3n\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \ncrisis migra\u00f1osas. Murciasalud, 2010.\n \n7)\nCefaleas\nEst\u00edbaliz\nB\u00f3veda\na,\nBlanca\nD\u00edez\na,\nM\u00f3nica\nFern\u00e1ndez\na,\nPatricia\nFern\u00e1ndez\na,\nEdurne\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nHidalgo\na,\nEst\u00edbaliz\nSalinas\na\na\nFarmac\u00e9uticas.\nGrupo\nde\ntrabajo\ndel\nColegio\nOficial\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nFarmac\u00e9uticos de Bizkaia. Rev. Farmacia Profesional Vol. 17. Num. 1. P\u00e1ginas 46-55. 2003\n \n8)\nProtocolos\nde\nIndicaci\u00f3n\nFarmac\u00e9utica\ny\nCriterios\nde\nDerivaci\u00f3n\nal\nM\u00e9dico\nen\nS\u00edntomas\nMenores:\n \n \n \n \n \n \n \n \n \n \n \n \n \nsemFYC, Sefac, grupo de AF de la Universidad de Granada y Fundaci\u00f3n Abbott\n \n \n9)\nStephens\nG,\nDerry\nS,\nMoore\nR.\nParacetamol\n(acetaminophen)\nfor\nacute\ntreatment\nof\nepisodic\n \n \n \n \n \n \n \n \n \n \n \n \n \ntension-type\nheadache\nin\nadults.\nCochrane\nDatabase\nof\nSystematic\nReviews\n2016,\nIssue\n6.\nArt.\n \n \n \n \n \n \n \n \n \n \n \n \n \nNo.: CD011889.\n \n \n10)\nDerry\nS,\nWiffen\nPJ,\nMoore\nR.\nAspirin\nfor\nacute\ntreatment\nof\nepisodic\ntension-type\nheadache\nin\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nadults. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD011888.\n \n11)\nDerry\nS,\nWiffen\nPJ,\nMoore\nR,\nBendtsen\nL.\nIbuprofen\nfor\nacute\ntreatment\nof\nepisodic\ntension-type\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nheadache in adults. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD011474.\n \n12)\nKlaus\nLinde,\nGianni\nAllais,\nBenno\nBrinkhaus,\nEric\nManheimer,\nAndrew\nVickers,\nAdrian\nR\nWhite.\n \n \n \n \n \n \n \n \n \n \n \n \n \nAcupuntura\npara\nla\ncefalea\nde\ntipo\ntensional\n(Revision\nCochrane\ntraducida).\nEn:\nBiblioteca\n \n \n \n \n \n \n \n \n \n \n \n \nCochrane Plus 2009 N\u00famero 2. Oxford: Update Software Ltd.\n \n13)\nLinde\nK,\nAllais\nG,\nBrinkhaus\nB,\nFei\nY,\nMehring\nM,\nShin\nB,\nVickers\nA,\nWhite\nAR.\nAcupuncture\nfor\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nprevention\nof\ntension-type\nheadache.\nCochrane\nDatabase\nof\nSystematic\nReviews\n2016,\nIssue\n4.\n \n \n \n \n \n \n \n \n \n \n \n \nArt. No.: CD007587.\n \n14)\nBennett\nMH,\nFrench\nC,\nSchnabel\nA,\nWasiak\nJ,\nKranke\nP,\nWeibel\nS.\nNormobaric\nand\nhyperbaric\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \noxygen\ntherapy\nfor\nthe\ntreatment\nand\nprevention\nof\nmigraine\nand\ncluster\nheadache.\nCochrane\n \n \n \n \n \n \n \n \n \n \n \n \n \nDatabase of Systematic Reviews 2015, Issue 12. Art. No.: CD005219.\n \n15)\nHerd\nCP,\nTomlinson\nCL,\nRick\nC,\nScotton\nWJ,\nEdwards\nJ,\nIves\nN,\nClarke\nCE,\nSinclair\nA.\nBotulinum\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ntoxins\nfor\nthe\nprevention\nof\nmigraine\nin\nadults.\nCochrane\nDatabase\nof\nSystematic\nReviews\n2018,\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nIssue 6. Art. No.: CD011616.\n \n81\n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}